[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fmLxkPSOalnd8QkBpdeCIcVZG9k675Bxl58avHr770_M":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":37,"phaseBuckets":86,"rows":93},"University of Oxford",[4],803,false,141,51,19884279,123,394,[14,17,20,23,26,29,32,35],{"name":15,"count":16},"Malaria",60,{"name":18,"count":19},"Tuberculosis",31,{"name":21,"count":22},"Depression",29,{"name":24,"count":25},"Healthy",23,{"name":27,"count":28},"Malaria,Falciparum",15,{"name":30,"count":31},"Influenza",12,{"name":33,"count":34},"Plasmodium Falciparum Malaria",10,{"name":36,"count":34},"Stroke",[38,43,48,53,58,63,67,72,77,82],{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT01252953","REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification","2017-01-31","Anacetrapib",{"nctId":44,"briefTitle":45,"date":46,"intervention":47},"NCT00135226","ASCEND: A Study of Cardiovascular Events iN Diabetes","2018-03-12","Aspirin",{"nctId":49,"briefTitle":50,"date":51,"intervention":52},"NCT03782636","Interleukin-2 Therapy of Autoimmunity in Diabetes (ITAD)","2023-02-16","Aldesleukin",{"nctId":54,"briefTitle":55,"date":56,"intervention":57},"NCT04704830","R21\u002FMatrix-M in African Children Against Clinical Malaria","2023-03-21","R21\u002FMatrix-M",{"nctId":59,"briefTitle":60,"date":61,"intervention":62},"NCT06141057","A Study to Compare Two Dosing Regimens for a New Malaria Vaccine","2025-07","Matrix M with RH5.1",{"nctId":64,"briefTitle":65,"date":61,"intervention":66},"NCT06628154","Losartan and Emotional Learning","Losartan potassium 50mg",{"nctId":68,"briefTitle":69,"date":70,"intervention":71},"NCT06704516","COmmencing Menopausal HOrmone Replacement Therapy and the Effect on Metabolic-dysfunction Associated Steatotic Liver Disease: a Pilot Mechanistic Study","2025-08-05","Menopausal hormone therapy",{"nctId":73,"briefTitle":74,"date":75,"intervention":76},"NCT06557642","Nitrous Oxide and EMOtional Cognition","2025-08-15","Entonox",{"nctId":78,"briefTitle":79,"date":80,"intervention":81},"NCT06696482","Effort and Antidepressant Study Test","2025-09","Escitalopram 10mg",{"nctId":83,"briefTitle":84,"date":85,"intervention":66},"NCT06624904","Losartan and Social Processing","2025-10-01",[87,88,89,90,91,92],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[94,166,206,224,249,267,295,313,331,349,376,404,422,450,468,486,512,594,662,700,722,744,784,818,846,872,892,910,928,955,973,1001,1019,1037,1055,1073,1091,1109,1127,1145,1163,1181,1199,1217,1235,1253,1271,1336,1362,1409,1498,1540,1586,1608,1630,1652,1679,1715,1751,1790,1812,1834,1859,1877,1903,1921,1939,1957,1975,1993,2011,2029,2047,2065,2092,2114,2136,2154,2172,2190,2208,2226,2244,2262,2280,2298,2326,2349,2367,2385,2403,2421,2439,2457,2475,2493,2531,2558,2598,2618,2643,2670,2688,2711,2729,2747,2768,2794,2817,2840,2883,2933,3008,3038,3065,3083,3101,3123,3141,3167,3185,3203,3221,3239,3290,3318,3340,3362,3398,3434,3461,3500,3518,3536,3562,3587,3611,3636,3662,3680,3698,3723,3752,3770,3794,3812,3838,3856,3882,3907,3925,3948,3973,3991,4016,4034,4063,4087,4112,4138,4163,4188,4206,4232,4254,4279,4303,4330,4348,4366,4384,4409,4433,4457,4483,4501,4525,4591,4645,4685,4707,4729,4751,4782,4816,4838,4873,4895,4913,4937,4955,4973,4991,5017,5035,5053,5071,5089,5107,5125,5143,5161,5179,5197,5225,5243,5267,5285,5308,5326,5344,5362,5388,5406,5432,5450,5468,5486,5504,5522,5549,5567,5585,5603,5627,5653,5671,5699,5717,5735,5753,5777,5795,5818,5845,5863,5881,5899,5917,5935,5960,5978,5999,6138,6208,6257,6283,6333,6367,6389,6411,6438,6466,6488,6510,6534,6552,6570,6596,6614,6636,6654,6680,6702,6720,6738,6756,6774,6792,6810,6828,6846,6867,6892,6910,6928,6946,6970,6994,7022,7040,7058,7085,7103,7121,7139,7162,7187,7205,7230,7248,7273,7296,7320,7338,7361,7385,7409,7427,7445,7463,7481,7508,7526,7544,7562,7580,7604,7629,7647,7665,7689,7707,7725,7743,7769,7787,7805,7823,7841,7871,7889,7907,7925,7943,7961,7979,8002,8029,8047,8065,8089,8112,8136,8154,8178,8202,8220,8238,8266,8284,8308,8330,8348,8366,8384,8405,8427,8450,8473,8494,8512,8534,8552,8582,8600,8618,8636,8654,8672,8697,8715,8737,8755,8773,8797,8822,8840,8866,8884,8902,8920,8938,8956,8979,9005,9030,9053,9077,9099,9117,9143,9161,9179,9197,9257,9283,9305,9336,9368,9390,9420,9452,9480,9502,9529,9551,9574,9592,9610,9628,9646,9671,9689,9711,9729,9752,9770,9797,9815,9833,9851,9874,9892,9910,9934,9957,9985,10003,10021,10039,10057,10075,10093,10111,10129,10153,10176,10194,10218,10236,10257,10281,10299,10321,10345,10369,10387,10405,10428,10451,10476,10494,10515,10539,10557,10575,10593,10617,10635,10653,10678,10696,10714,10744,10762,10780,10798,10816,10834,10852,10870,10888,10906,10924,10946,10967,10990,11012,11030,11054,11072,11100,11118,11136,11154,11172,11190,11208,11232,11250,11268,11286,11309,11327,11353,11371,11389,11407,11425,11443,11461,11479,11505,11523,11541,11559,11577,11603,11621,11647,11665,11683,11705,11723,11741,11769,11787,11810,11833,11851,11869,11887,11910,11935,11953,11971,11994,12016,12048,12066,12084,12102,12120,12138,12156,12174,12192,12214,12232,12255,12278,12305,12323,12346,12369,12393,12416,12440,12463,12529,12585,12624,12658,12692,12733,12769,12809,12842,12871,12905,12927,12955,12986,13015,13037,13067,13093,13116,13140,13165,13183,13201,13225,13250,13280,13306,13329,13352,13375,13399,13421,13446,13464,13486,13507,13530,13554,13579,13597,13618,13641,13663,13686,13710,13731,13749,13767,13785,13808,13826,13844,13867,13890,13916,13934,13957,13978,14002,14020,14046,14064,14086,14113,14136,14159,14184,14202,14220,14238,14256,14280,14303,14326,14350,14368,14392,14416,14437],{"intervention":47,"totalTrials":95,"cells":96},3,{"EARLY_PHASE1":97,"PHASE1":100,"PHASE2":102,"PHASE3":104,"PHASE4":152,"NA":164},{"trials":98,"activeCount":99},[],0,{"trials":101,"activeCount":99},[],{"trials":103,"activeCount":99},[],{"trials":105,"activeCount":151,"soonestReadout":124},[106,119],{"nctId":107,"briefTitle":108,"status":109,"phases":110,"primaryCompletion":111,"completion":111,"start":112,"enrollment":113,"conditions":114,"interventions":117},"NCT00357682","A Phase III, Randomized, Study of Aspirin and Esomeprazole Chemoprevention in Barrett's Metaplasia","COMPLETED",[90],"2017-05-31","2005-03-10",2557,[115,116],"Esophageal Cancer","Precancerous Condition",[118,118,47],"Esomeprazole",{"nctId":120,"briefTitle":121,"status":122,"phases":123,"primaryCompletion":124,"completion":125,"start":126,"enrollment":127,"conditions":128,"interventions":130},"NCT04381936","Randomised Evaluation of COVID-19 Therapy","RECRUITING",[90],"2028-09-30","2038-09-30","2020-03-19",70000,[129],"Pneumonia",[131,132,133,134,135,136,137,138,47,139,140,141,142,143,144,145,146,147,148,149,150,150],"Lopinavir-Ritonavir","Corticosteroid","Hydroxychloroquine","Azithromycin","Convalescent plasma","Tocilizumab","Immunoglobulin","Synthetic neutralising antibodies","Colchicine","Baricitinib","Anakinra","Dimethyl fumarate","High Dose Corticosteroid","Empagliflozin","Sotrovimab","Molnupiravir","Paxlovid","Baloxavir Marboxil","Oseltamivir","Corticosteroids",1,{"trials":153,"activeCount":151,"soonestReadout":46},[154],{"nctId":44,"briefTitle":45,"status":155,"phases":156,"primaryCompletion":46,"completion":157,"start":158,"enrollment":159,"conditions":160,"interventions":162},"ACTIVE_NOT_RECRUITING",[91],"2037-07-31","2005-03",15480,[161],"Diabetes Mellitus",[47,163],"Omega-3 Ethyl Esters",{"trials":165,"activeCount":99},[],{"intervention":167,"totalTrials":168,"cells":169},"Tafenoquine",2,{"EARLY_PHASE1":170,"PHASE1":172,"PHASE2":174,"PHASE3":176,"PHASE4":178,"NA":204},{"trials":171,"activeCount":99},[],{"trials":173,"activeCount":99},[],{"trials":175,"activeCount":99},[],{"trials":177,"activeCount":99},[],{"trials":179,"activeCount":151,"soonestReadout":195},[180,191],{"nctId":181,"briefTitle":182,"status":183,"phases":184,"primaryCompletion":185,"completion":185,"start":186,"enrollment":99,"conditions":187,"interventions":189},"NCT04984759","Tafenoquine and Primaquine in Colostrum and Breast Milk","WITHDRAWN",[91],"2025-06-30","2023-07-01",[188],"Healthy Lactating Women",[190,167],"Primaquine",{"nctId":192,"briefTitle":193,"status":122,"phases":194,"primaryCompletion":195,"completion":196,"start":197,"enrollment":198,"conditions":199,"interventions":201},"NCT04704999","Southeast Asia Dose Optimization of Tafenoquine",[91],"2027-10-04","2028-02-07","2024-07-22",700,[200],"Plasmodium Vivax Malaria",[167,202,203],"Chloroquine","Artemether 20 mg-Lumefantrine 120 mg",{"trials":205,"activeCount":99},[],{"intervention":163,"totalTrials":151,"cells":207},{"EARLY_PHASE1":208,"PHASE1":210,"PHASE2":212,"PHASE3":214,"PHASE4":216,"NA":222},{"trials":209,"activeCount":99},[],{"trials":211,"activeCount":99},[],{"trials":213,"activeCount":99},[],{"trials":215,"activeCount":99},[],{"trials":217,"activeCount":151,"soonestReadout":46},[218],{"nctId":44,"briefTitle":45,"status":155,"phases":219,"primaryCompletion":46,"completion":157,"start":158,"enrollment":159,"conditions":220,"interventions":221},[91],[161],[47,163],{"trials":223,"activeCount":99},[],{"intervention":225,"totalTrials":151,"cells":226},"DHA\u002Fpiperaquine and a SLD-PQ",{"EARLY_PHASE1":227,"PHASE1":229,"PHASE2":231,"PHASE3":233,"PHASE4":235,"NA":247},{"trials":228,"activeCount":99},[],{"trials":230,"activeCount":99},[],{"trials":232,"activeCount":99},[],{"trials":234,"activeCount":99},[],{"trials":236,"activeCount":151,"soonestReadout":241},[237],{"nctId":238,"briefTitle":239,"status":122,"phases":240,"primaryCompletion":241,"completion":241,"start":242,"enrollment":243,"conditions":244,"interventions":245},"NCT06068530","Mass Vaccine and Drug Administration, Bangladesh",[91],"2028-02-01","2025-02-15",10000,[33],[225,246],"Study vaccine R21\u002FMatrix-M™",{"trials":248,"activeCount":99},[],{"intervention":246,"totalTrials":151,"cells":250},{"EARLY_PHASE1":251,"PHASE1":253,"PHASE2":255,"PHASE3":257,"PHASE4":259,"NA":265},{"trials":252,"activeCount":99},[],{"trials":254,"activeCount":99},[],{"trials":256,"activeCount":99},[],{"trials":258,"activeCount":99},[],{"trials":260,"activeCount":151,"soonestReadout":241},[261],{"nctId":238,"briefTitle":239,"status":122,"phases":262,"primaryCompletion":241,"completion":241,"start":242,"enrollment":243,"conditions":263,"interventions":264},[91],[33],[225,246],{"trials":266,"activeCount":99},[],{"intervention":268,"totalTrials":151,"cells":269},"10μg R21\u002F50μg Matrix-M",{"EARLY_PHASE1":270,"PHASE1":272,"PHASE2":274,"PHASE3":276,"PHASE4":278,"NA":293},{"trials":271,"activeCount":99},[],{"trials":273,"activeCount":99},[],{"trials":275,"activeCount":99},[],{"trials":277,"activeCount":99},[],{"trials":279,"activeCount":151,"soonestReadout":285},[280],{"nctId":281,"briefTitle":282,"status":283,"phases":284,"primaryCompletion":285,"completion":285,"start":286,"enrollment":287,"conditions":288,"interventions":290},"NCT07194668","R21\u002FMM Dosing, Presentations, and Preservatives","NOT_YET_RECRUITING",[91],"2026-12-31","2026-04-01",375,[33,15,289],"Vaccine Reaction",[268,291,292],"5μg R21\u002F50μg Matrix-M with adaptor preservative free","5μg R21\u002F50μg Matrix-M with 2PE preservative",{"trials":294,"activeCount":99},[],{"intervention":291,"totalTrials":151,"cells":296},{"EARLY_PHASE1":297,"PHASE1":299,"PHASE2":301,"PHASE3":303,"PHASE4":305,"NA":311},{"trials":298,"activeCount":99},[],{"trials":300,"activeCount":99},[],{"trials":302,"activeCount":99},[],{"trials":304,"activeCount":99},[],{"trials":306,"activeCount":151,"soonestReadout":285},[307],{"nctId":281,"briefTitle":282,"status":283,"phases":308,"primaryCompletion":285,"completion":285,"start":286,"enrollment":287,"conditions":309,"interventions":310},[91],[33,15,289],[268,291,292],{"trials":312,"activeCount":99},[],{"intervention":292,"totalTrials":151,"cells":314},{"EARLY_PHASE1":315,"PHASE1":317,"PHASE2":319,"PHASE3":321,"PHASE4":323,"NA":329},{"trials":316,"activeCount":99},[],{"trials":318,"activeCount":99},[],{"trials":320,"activeCount":99},[],{"trials":322,"activeCount":99},[],{"trials":324,"activeCount":151,"soonestReadout":285},[325],{"nctId":281,"briefTitle":282,"status":283,"phases":326,"primaryCompletion":285,"completion":285,"start":286,"enrollment":287,"conditions":327,"interventions":328},[91],[33,15,289],[268,291,292],{"trials":330,"activeCount":99},[],{"intervention":203,"totalTrials":151,"cells":332},{"EARLY_PHASE1":333,"PHASE1":335,"PHASE2":337,"PHASE3":339,"PHASE4":341,"NA":347},{"trials":334,"activeCount":99},[],{"trials":336,"activeCount":99},[],{"trials":338,"activeCount":99},[],{"trials":340,"activeCount":99},[],{"trials":342,"activeCount":151,"soonestReadout":195},[343],{"nctId":192,"briefTitle":193,"status":122,"phases":344,"primaryCompletion":195,"completion":196,"start":197,"enrollment":198,"conditions":345,"interventions":346},[91],[200],[167,202,203],{"trials":348,"activeCount":99},[],{"intervention":350,"totalTrials":151,"cells":351},"Daridorexant 50 mg",{"EARLY_PHASE1":352,"PHASE1":354,"PHASE2":356,"PHASE3":358,"PHASE4":360,"NA":374},{"trials":353,"activeCount":99},[],{"trials":355,"activeCount":99},[],{"trials":357,"activeCount":99},[],{"trials":359,"activeCount":99},[],{"trials":361,"activeCount":151,"soonestReadout":366},[362],{"nctId":363,"briefTitle":364,"status":122,"phases":365,"primaryCompletion":366,"completion":367,"start":85,"enrollment":368,"conditions":369,"interventions":373},"NCT07267559","Dual Orexin Antagonism and Emotion and Affective Processing Study",[91],"2026-09-01","2026-10-01",62,[370,371,372],"Learning","Cognitive Functioning","Emotional Processing",[350],{"trials":375,"activeCount":99},[],{"intervention":377,"totalTrials":151,"cells":378},"PCV15",{"EARLY_PHASE1":379,"PHASE1":381,"PHASE2":383,"PHASE3":385,"PHASE4":387,"NA":402},{"trials":380,"activeCount":99},[],{"trials":382,"activeCount":99},[],{"trials":384,"activeCount":99},[],{"trials":386,"activeCount":99},[],{"trials":388,"activeCount":151,"soonestReadout":393},[389],{"nctId":390,"briefTitle":391,"status":122,"phases":392,"primaryCompletion":393,"completion":394,"start":395,"enrollment":396,"conditions":397,"interventions":400},"NCT06731374","Carriage to Assess Protection of New Pneumococcal Vaccines - PCV15",[91],"2025-12","2026-12","2025-02-24",106,[398,399],"Pneumococcal Disease","Pneumococcal Carriage",[377,401],"Streptococcus pneumoniae serotype 3",{"trials":403,"activeCount":99},[],{"intervention":401,"totalTrials":151,"cells":405},{"EARLY_PHASE1":406,"PHASE1":408,"PHASE2":410,"PHASE3":412,"PHASE4":414,"NA":420},{"trials":407,"activeCount":99},[],{"trials":409,"activeCount":99},[],{"trials":411,"activeCount":99},[],{"trials":413,"activeCount":99},[],{"trials":415,"activeCount":151,"soonestReadout":393},[416],{"nctId":390,"briefTitle":391,"status":122,"phases":417,"primaryCompletion":393,"completion":394,"start":395,"enrollment":396,"conditions":418,"interventions":419},[91],[398,399],[377,401],{"trials":421,"activeCount":99},[],{"intervention":423,"totalTrials":151,"cells":424},"Doxycycline 7 days",{"EARLY_PHASE1":425,"PHASE1":427,"PHASE2":429,"PHASE3":431,"PHASE4":433,"NA":448},{"trials":426,"activeCount":99},[],{"trials":428,"activeCount":99},[],{"trials":430,"activeCount":99},[],{"trials":432,"activeCount":99},[],{"trials":434,"activeCount":151,"soonestReadout":439},[435],{"nctId":436,"briefTitle":437,"status":155,"phases":438,"primaryCompletion":439,"completion":440,"start":441,"enrollment":442,"conditions":443,"interventions":445},"NCT03083197","Scrub Typhus Antibiotic Resistance Trial",[91],"2026-10-31","2028-10","2017-10-15",177,[444],"Scrub Typhus",[423,446,447],"Doxycycline 3 days","Azithromycin 3 days",{"trials":449,"activeCount":99},[],{"intervention":446,"totalTrials":151,"cells":451},{"EARLY_PHASE1":452,"PHASE1":454,"PHASE2":456,"PHASE3":458,"PHASE4":460,"NA":466},{"trials":453,"activeCount":99},[],{"trials":455,"activeCount":99},[],{"trials":457,"activeCount":99},[],{"trials":459,"activeCount":99},[],{"trials":461,"activeCount":151,"soonestReadout":439},[462],{"nctId":436,"briefTitle":437,"status":155,"phases":463,"primaryCompletion":439,"completion":440,"start":441,"enrollment":442,"conditions":464,"interventions":465},[91],[444],[423,446,447],{"trials":467,"activeCount":99},[],{"intervention":447,"totalTrials":151,"cells":469},{"EARLY_PHASE1":470,"PHASE1":472,"PHASE2":474,"PHASE3":476,"PHASE4":478,"NA":484},{"trials":471,"activeCount":99},[],{"trials":473,"activeCount":99},[],{"trials":475,"activeCount":99},[],{"trials":477,"activeCount":99},[],{"trials":479,"activeCount":151,"soonestReadout":439},[480],{"nctId":436,"briefTitle":437,"status":155,"phases":481,"primaryCompletion":439,"completion":440,"start":441,"enrollment":442,"conditions":482,"interventions":483},[91],[444],[423,446,447],{"trials":485,"activeCount":99},[],{"intervention":487,"totalTrials":151,"cells":488},"Semaglutide Oral",{"EARLY_PHASE1":489,"PHASE1":491,"PHASE2":493,"PHASE3":495,"PHASE4":497,"NA":510},{"trials":490,"activeCount":99},[],{"trials":492,"activeCount":99},[],{"trials":494,"activeCount":99},[],{"trials":496,"activeCount":99},[],{"trials":498,"activeCount":151,"soonestReadout":503},[499],{"nctId":500,"briefTitle":501,"status":122,"phases":502,"primaryCompletion":503,"completion":504,"start":505,"enrollment":506,"conditions":507,"interventions":509},"NCT05441267","A Study of Cardiovascular Events iN Diabetes Plus",[91],"2028-08-17","2048-08-17","2023-03-13",20000,[508],"Diabetes Mellitus, Type 2",[487],{"trials":511,"activeCount":99},[],{"intervention":202,"totalTrials":513,"cells":514},7,{"EARLY_PHASE1":515,"PHASE1":517,"PHASE2":519,"PHASE3":521,"PHASE4":546,"NA":582},{"trials":516,"activeCount":99},[],{"trials":518,"activeCount":99},[],{"trials":520,"activeCount":99},[],{"trials":522,"activeCount":99},[523,535],{"nctId":524,"briefTitle":525,"status":109,"phases":526,"primaryCompletion":527,"completion":527,"start":528,"enrollment":529,"conditions":530,"interventions":532},"NCT01074905","Study on the Treatment of Vivax Malaria",[90],"2012-10","2010-05",655,[531],"Vivax Malaria",[533,202,534],"Artesunate","Chloroquine\u002FPrimaquine",{"nctId":536,"briefTitle":537,"status":109,"phases":538,"primaryCompletion":539,"completion":540,"start":541,"enrollment":542,"conditions":543,"interventions":544},"NCT01640574","Comparison Between 7 and 14 Day Primaquine Combined With Dihydroartemisinin-piperaquine or 3 Day Chloroquine Radical Cure of P. Vivax (BPD)",[90],"2015-07","2015-12","2012-02",680,[531],[545,545,202,202],"Dihydroartemisinin-Piperaquine",{"trials":547,"activeCount":151,"soonestReadout":195},[548,557,568,572],{"nctId":549,"briefTitle":550,"status":109,"phases":551,"primaryCompletion":552,"completion":552,"start":553,"enrollment":554,"conditions":555,"interventions":556},"NCT01178021","Estimating the Risk of Plasmodium Vivax Relapses in Afghanistan",[91],"2014-02","2009-08",593,[531],[202,534],{"nctId":558,"briefTitle":559,"status":109,"phases":560,"primaryCompletion":561,"completion":561,"start":562,"enrollment":563,"conditions":564,"interventions":565},"NCT02876549","G6PD Assessment Before Primaquine for Radical Treatment of Vivax Malaria",[91],"2018-11","2016-09-01",1000,[531],[202,566,567],"Primaquine 0.25 mg\u002Fkg\u002Fday","Primaquine 0.75 mg\u002Fkg weekly",{"nctId":192,"briefTitle":193,"status":122,"phases":569,"primaryCompletion":195,"completion":196,"start":197,"enrollment":198,"conditions":570,"interventions":571},[91],[200],[167,202,203],{"nctId":573,"briefTitle":574,"status":109,"phases":575,"primaryCompletion":576,"completion":576,"start":577,"enrollment":578,"conditions":579,"interventions":580},"NCT02192944","Comparison of the ECG Effects Related to Pharmacokinetic Profile of Chloroquine and Piperaquine",[91],"2015-09","2014-07",16,[24],[202,581],"Dihydroartemisinin-piperaquine",{"trials":583,"activeCount":99},[584],{"nctId":585,"briefTitle":586,"status":109,"phases":587,"primaryCompletion":588,"completion":589,"start":590,"enrollment":591,"conditions":592,"interventions":593},"NCT01546961","Chloroquine Population Pharmacokinetics in Pre and Post-partum Women",[92],"2016-11","2017-05","2011-06",49,[531],[202],{"intervention":146,"totalTrials":595,"cells":596},4,{"EARLY_PHASE1":597,"PHASE1":599,"PHASE2":601,"PHASE3":652,"PHASE4":658,"NA":660},{"trials":598,"activeCount":99},[],{"trials":600,"activeCount":99},[],{"trials":602,"activeCount":95,"soonestReadout":619},[603,615,636],{"nctId":604,"briefTitle":605,"status":122,"phases":606,"primaryCompletion":607,"completion":607,"start":608,"enrollment":563,"conditions":609,"interventions":612},"NCT06488300","Assessing Antiviral Treatments in Early Symptomatic RSV",[89],"2027-01-01","2024-07-25",[610,611],"Respiratory Syncytial Virus","Respiratory Syncytial Virus, Human",[613,146,614],"Ribavirin","Favipiravir",{"nctId":616,"briefTitle":617,"status":122,"phases":618,"primaryCompletion":619,"completion":619,"start":620,"enrollment":621,"conditions":622,"interventions":624},"NCT05041907","Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)",[89],"2027-01","2021-09-30",3800,[623],"COVID-19",[625,626,627,133,628,629,146,145,630,628,614,631,632,633,634,625,625,635],"Nirmatrelvir\u002Fritonavir","Nitazoxanide","Molnupiravir and nirmatrelvir\u002Fritonavir","Monoclonal antibodies","Fluoxetine","Ensitrelvir","Ivermectin","Remdesivir","Atilotrelvir\u002Fritonavir","Metformin","Nirmatrelvir",{"nctId":637,"briefTitle":638,"status":122,"phases":639,"primaryCompletion":607,"completion":607,"start":640,"enrollment":641,"conditions":642,"interventions":644},"NCT05648448","A Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic Influenza",[89],"2023-02-22",3000,[30,643],"Influenza, Human",[149,614,645,646,146,647,648,649,650,651],"Zanamivir","Baloxavir","Peramivir","Laninamivir","Oseltamivir and Baloxavir","Oseltamivir and Favipiravir","Favipiravir and Baloxavir",{"trials":653,"activeCount":151,"soonestReadout":124},[654],{"nctId":120,"briefTitle":121,"status":122,"phases":655,"primaryCompletion":124,"completion":125,"start":126,"enrollment":127,"conditions":656,"interventions":657},[90],[129],[131,132,133,134,135,136,137,138,47,139,140,141,142,143,144,145,146,147,148,149,150,150],{"trials":659,"activeCount":99},[],{"trials":661,"activeCount":99},[],{"intervention":149,"totalTrials":595,"cells":663},{"EARLY_PHASE1":664,"PHASE1":666,"PHASE2":668,"PHASE3":674,"PHASE4":688,"NA":698},{"trials":665,"activeCount":99},[],{"trials":667,"activeCount":99},[],{"trials":669,"activeCount":151,"soonestReadout":607},[670],{"nctId":637,"briefTitle":638,"status":122,"phases":671,"primaryCompletion":607,"completion":607,"start":640,"enrollment":641,"conditions":672,"interventions":673},[89],[30,643],[149,614,645,646,146,647,648,649,650,651],{"trials":675,"activeCount":151,"soonestReadout":124},[676,684],{"nctId":677,"briefTitle":678,"status":183,"phases":679,"primaryCompletion":680,"completion":680,"start":681,"enrollment":99,"conditions":682,"interventions":683},"NCT01546935","Oseltamivir for Influenza Lower Respiratory Tract Infection in Children Under One",[89,90],"2014-12","2012-12",[30],[149],{"nctId":120,"briefTitle":121,"status":122,"phases":685,"primaryCompletion":124,"completion":125,"start":126,"enrollment":127,"conditions":686,"interventions":687},[90],[129],[131,132,133,134,135,136,137,138,47,139,140,141,142,143,144,145,146,147,148,149,150,150],{"trials":689,"activeCount":99},[690],{"nctId":691,"briefTitle":692,"status":109,"phases":693,"primaryCompletion":681,"completion":681,"start":694,"enrollment":151,"conditions":695,"interventions":697},"NCT01443806","Characterisation of the Human Carboxylesterase 1 (CES1) Mutations in Thailand",[91],"2011-07",[696],"Metabolic Disease",[149],{"trials":699,"activeCount":99},[],{"intervention":133,"totalTrials":168,"cells":701},{"EARLY_PHASE1":702,"PHASE1":704,"PHASE2":706,"PHASE3":712,"PHASE4":718,"NA":720},{"trials":703,"activeCount":99},[],{"trials":705,"activeCount":99},[],{"trials":707,"activeCount":151,"soonestReadout":619},[708],{"nctId":616,"briefTitle":617,"status":122,"phases":709,"primaryCompletion":619,"completion":619,"start":620,"enrollment":621,"conditions":710,"interventions":711},[89],[623],[625,626,627,133,628,629,146,145,630,628,614,631,632,633,634,625,625,635],{"trials":713,"activeCount":151,"soonestReadout":124},[714],{"nctId":120,"briefTitle":121,"status":122,"phases":715,"primaryCompletion":124,"completion":125,"start":126,"enrollment":127,"conditions":716,"interventions":717},[90],[129],[131,132,133,134,135,136,137,138,47,139,140,141,142,143,144,145,146,147,148,149,150,150],{"trials":719,"activeCount":99},[],{"trials":721,"activeCount":99},[],{"intervention":145,"totalTrials":168,"cells":723},{"EARLY_PHASE1":724,"PHASE1":726,"PHASE2":728,"PHASE3":734,"PHASE4":740,"NA":742},{"trials":725,"activeCount":99},[],{"trials":727,"activeCount":99},[],{"trials":729,"activeCount":151,"soonestReadout":619},[730],{"nctId":616,"briefTitle":617,"status":122,"phases":731,"primaryCompletion":619,"completion":619,"start":620,"enrollment":621,"conditions":732,"interventions":733},[89],[623],[625,626,627,133,628,629,146,145,630,628,614,631,632,633,634,625,625,635],{"trials":735,"activeCount":151,"soonestReadout":124},[736],{"nctId":120,"briefTitle":121,"status":122,"phases":737,"primaryCompletion":124,"completion":125,"start":126,"enrollment":127,"conditions":738,"interventions":739},[90],[129],[131,132,133,134,135,136,137,138,47,139,140,141,142,143,144,145,146,147,148,149,150,150],{"trials":741,"activeCount":99},[],{"trials":743,"activeCount":99},[],{"intervention":745,"totalTrials":168,"cells":746},"CBD 100 mg\u002FmL Oral Solution",{"EARLY_PHASE1":747,"PHASE1":749,"PHASE2":751,"PHASE3":753,"PHASE4":780,"NA":782},{"trials":748,"activeCount":99},[],{"trials":750,"activeCount":99},[],{"trials":752,"activeCount":99},[],{"trials":754,"activeCount":168,"soonestReadout":759},[755,769],{"nctId":756,"briefTitle":757,"status":283,"phases":758,"primaryCompletion":759,"completion":760,"start":761,"enrollment":762,"conditions":763,"interventions":768},"NCT06778564","Stratification and Treatment in Early Psychosis Study - ENHANCE",[90],"2028-02","2029-02","2026-02",250,[764,765,766,767],"Psychosis","First Episode Psychosis","Psychotic Disorders","Psychotic Episode",[745],{"nctId":770,"briefTitle":771,"status":283,"phases":772,"primaryCompletion":773,"completion":774,"start":775,"enrollment":762,"conditions":776,"interventions":778},"NCT07326124","Stratification and Treatment in Early Psychosis Study -ASSIST",[90],"2028-09","2029-09","2026-06",[777,764],"Treatment Resistant Psychosis",[745,779],"Placeb",{"trials":781,"activeCount":99},[],{"trials":783,"activeCount":99},[],{"intervention":57,"totalTrials":168,"cells":785},{"EARLY_PHASE1":786,"PHASE1":788,"PHASE2":790,"PHASE3":804,"PHASE4":814,"NA":816},{"trials":787,"activeCount":99},[],{"trials":789,"activeCount":99},[],{"trials":791,"activeCount":99},[792],{"nctId":793,"briefTitle":794,"status":795,"phases":796,"primaryCompletion":797,"completion":797,"start":798,"enrollment":799,"conditions":800,"interventions":801},"NCT03947190","A Study to Determine if New Types of Malaria Vaccines Are Safe, Effective and Lead to Immunity in Kenyan Adults","TERMINATED",[89],"2023-02-26","2022-08-31",80,[27],[57,802,803],"ChAd63\u002FMVA ME-TRAP","intradermal injection (ID) or direct venous injection (DVI) of PfSPZ Challenge",{"trials":805,"activeCount":151,"soonestReadout":56},[806],{"nctId":54,"briefTitle":55,"status":155,"phases":807,"primaryCompletion":56,"completion":808,"start":809,"enrollment":810,"conditions":811,"interventions":812},[90],"2028-04","2021-04-29",4800,[15],[57,813],"Rabies vaccine, Hepatitis A vaccine or Meningococcal vaccine",{"trials":815,"activeCount":99},[],{"trials":817,"activeCount":99},[],{"intervention":134,"totalTrials":168,"cells":819},{"EARLY_PHASE1":820,"PHASE1":822,"PHASE2":824,"PHASE3":826,"PHASE4":842,"NA":844},{"trials":821,"activeCount":99},[],{"trials":823,"activeCount":99},[],{"trials":825,"activeCount":99},[],{"trials":827,"activeCount":151,"soonestReadout":124},[828,838],{"nctId":829,"briefTitle":830,"status":109,"phases":831,"primaryCompletion":832,"completion":833,"start":834,"enrollment":835,"conditions":836,"interventions":837},"NCT04381962","A Multicentre Open-label Two-arm Randomised Superiority Clinical Trial of Azithromycin Versus Usual Care In Ambulatory COVID19 (ATOMIC2)",[90],"2021-01-29","2021-04-20","2020-06-03",298,[623],[134],{"nctId":120,"briefTitle":121,"status":122,"phases":839,"primaryCompletion":124,"completion":125,"start":126,"enrollment":127,"conditions":840,"interventions":841},[90],[129],[131,132,133,134,135,136,137,138,47,139,140,141,142,143,144,145,146,147,148,149,150,150],{"trials":843,"activeCount":99},[],{"trials":845,"activeCount":99},[],{"intervention":847,"totalTrials":151,"cells":848},"Inclisiran",{"EARLY_PHASE1":849,"PHASE1":851,"PHASE2":853,"PHASE3":855,"PHASE4":868,"NA":870},{"trials":850,"activeCount":99},[],{"trials":852,"activeCount":99},[],{"trials":854,"activeCount":99},[],{"trials":856,"activeCount":151,"soonestReadout":861},[857],{"nctId":858,"briefTitle":859,"status":155,"phases":860,"primaryCompletion":861,"completion":862,"start":863,"enrollment":864,"conditions":865,"interventions":867},"NCT03705234","A Randomized Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Cardiovascular Disease",[90],"2026-10","2049-12","2018-10-30",16124,[866],"Atherosclerotic Cardiovascular Disease",[847],{"trials":869,"activeCount":99},[],{"trials":871,"activeCount":99},[],{"intervention":42,"totalTrials":151,"cells":873},{"EARLY_PHASE1":874,"PHASE1":876,"PHASE2":878,"PHASE3":880,"PHASE4":888,"NA":890},{"trials":875,"activeCount":99},[],{"trials":877,"activeCount":99},[],{"trials":879,"activeCount":99},[],{"trials":881,"activeCount":151,"soonestReadout":41},[882],{"nctId":39,"briefTitle":40,"status":155,"phases":883,"primaryCompletion":41,"completion":884,"start":590,"enrollment":885,"conditions":886,"interventions":887},[90],"2037-01-31",30449,[866],[42],{"trials":889,"activeCount":99},[],{"trials":891,"activeCount":99},[],{"intervention":813,"totalTrials":151,"cells":893},{"EARLY_PHASE1":894,"PHASE1":896,"PHASE2":898,"PHASE3":900,"PHASE4":906,"NA":908},{"trials":895,"activeCount":99},[],{"trials":897,"activeCount":99},[],{"trials":899,"activeCount":99},[],{"trials":901,"activeCount":151,"soonestReadout":56},[902],{"nctId":54,"briefTitle":55,"status":155,"phases":903,"primaryCompletion":56,"completion":808,"start":809,"enrollment":810,"conditions":904,"interventions":905},[90],[15],[57,813],{"trials":907,"activeCount":99},[],{"trials":909,"activeCount":99},[],{"intervention":779,"totalTrials":151,"cells":911},{"EARLY_PHASE1":912,"PHASE1":914,"PHASE2":916,"PHASE3":918,"PHASE4":924,"NA":926},{"trials":913,"activeCount":99},[],{"trials":915,"activeCount":99},[],{"trials":917,"activeCount":99},[],{"trials":919,"activeCount":151,"soonestReadout":773},[920],{"nctId":770,"briefTitle":771,"status":283,"phases":921,"primaryCompletion":773,"completion":774,"start":775,"enrollment":762,"conditions":922,"interventions":923},[90],[777,764],[745,779],{"trials":925,"activeCount":99},[],{"trials":927,"activeCount":99},[],{"intervention":929,"totalTrials":151,"cells":930},"Artemether-Lumefantrine-Amodiaquine",{"EARLY_PHASE1":931,"PHASE1":933,"PHASE2":935,"PHASE3":937,"PHASE4":951,"NA":953},{"trials":932,"activeCount":99},[],{"trials":934,"activeCount":99},[],{"trials":936,"activeCount":99},[],{"trials":938,"activeCount":151,"soonestReadout":943},[939],{"nctId":940,"briefTitle":941,"status":122,"phases":942,"primaryCompletion":943,"completion":943,"start":944,"enrollment":945,"conditions":946,"interventions":948},"NCT05951595","A Study to Find Out if a Combination of 3 Medicines for the Treatment of Malaria Works as Well and is as Safe and Tolerable as Combinations of 2 Medicines",[90],"2026-07-31","2025-09-11",1680,[947],"Uncomplicated Plasmodium Falciparum Malaria",[929,949,950],"Artemether-Lumefantrine","Artesunate-Amodiaquine",{"trials":952,"activeCount":99},[],{"trials":954,"activeCount":99},[],{"intervention":950,"totalTrials":151,"cells":956},{"EARLY_PHASE1":957,"PHASE1":959,"PHASE2":961,"PHASE3":963,"PHASE4":969,"NA":971},{"trials":958,"activeCount":99},[],{"trials":960,"activeCount":99},[],{"trials":962,"activeCount":99},[],{"trials":964,"activeCount":151,"soonestReadout":943},[965],{"nctId":940,"briefTitle":941,"status":122,"phases":966,"primaryCompletion":943,"completion":943,"start":944,"enrollment":945,"conditions":967,"interventions":968},[90],[947],[929,949,950],{"trials":970,"activeCount":99},[],{"trials":972,"activeCount":99},[],{"intervention":974,"totalTrials":151,"cells":975},"Cannabidiol",{"EARLY_PHASE1":976,"PHASE1":978,"PHASE2":980,"PHASE3":982,"PHASE4":997,"NA":999},{"trials":977,"activeCount":99},[],{"trials":979,"activeCount":99},[],{"trials":981,"activeCount":99},[],{"trials":983,"activeCount":151,"soonestReadout":988},[984],{"nctId":985,"briefTitle":986,"status":283,"phases":987,"primaryCompletion":988,"completion":989,"start":990,"enrollment":991,"conditions":992,"interventions":996},"NCT07434973","Stratification and Treatment in Early Psychosis Study - PROMOTE",[90],"2029-12-01","2031-12-01","2026-05-01",586,[993,994,995],"Clinical High Risk for Psychosis (CHR)","Clinical High Risk for Psychosis","Clinical High Risk for Developing Psychosis",[974],{"trials":998,"activeCount":99},[],{"trials":1000,"activeCount":99},[],{"intervention":131,"totalTrials":151,"cells":1002},{"EARLY_PHASE1":1003,"PHASE1":1005,"PHASE2":1007,"PHASE3":1009,"PHASE4":1015,"NA":1017},{"trials":1004,"activeCount":99},[],{"trials":1006,"activeCount":99},[],{"trials":1008,"activeCount":99},[],{"trials":1010,"activeCount":151,"soonestReadout":124},[1011],{"nctId":120,"briefTitle":121,"status":122,"phases":1012,"primaryCompletion":124,"completion":125,"start":126,"enrollment":127,"conditions":1013,"interventions":1014},[90],[129],[131,132,133,134,135,136,137,138,47,139,140,141,142,143,144,145,146,147,148,149,150,150],{"trials":1016,"activeCount":99},[],{"trials":1018,"activeCount":99},[],{"intervention":132,"totalTrials":151,"cells":1020},{"EARLY_PHASE1":1021,"PHASE1":1023,"PHASE2":1025,"PHASE3":1027,"PHASE4":1033,"NA":1035},{"trials":1022,"activeCount":99},[],{"trials":1024,"activeCount":99},[],{"trials":1026,"activeCount":99},[],{"trials":1028,"activeCount":151,"soonestReadout":124},[1029],{"nctId":120,"briefTitle":121,"status":122,"phases":1030,"primaryCompletion":124,"completion":125,"start":126,"enrollment":127,"conditions":1031,"interventions":1032},[90],[129],[131,132,133,134,135,136,137,138,47,139,140,141,142,143,144,145,146,147,148,149,150,150],{"trials":1034,"activeCount":99},[],{"trials":1036,"activeCount":99},[],{"intervention":135,"totalTrials":151,"cells":1038},{"EARLY_PHASE1":1039,"PHASE1":1041,"PHASE2":1043,"PHASE3":1045,"PHASE4":1051,"NA":1053},{"trials":1040,"activeCount":99},[],{"trials":1042,"activeCount":99},[],{"trials":1044,"activeCount":99},[],{"trials":1046,"activeCount":151,"soonestReadout":124},[1047],{"nctId":120,"briefTitle":121,"status":122,"phases":1048,"primaryCompletion":124,"completion":125,"start":126,"enrollment":127,"conditions":1049,"interventions":1050},[90],[129],[131,132,133,134,135,136,137,138,47,139,140,141,142,143,144,145,146,147,148,149,150,150],{"trials":1052,"activeCount":99},[],{"trials":1054,"activeCount":99},[],{"intervention":136,"totalTrials":151,"cells":1056},{"EARLY_PHASE1":1057,"PHASE1":1059,"PHASE2":1061,"PHASE3":1063,"PHASE4":1069,"NA":1071},{"trials":1058,"activeCount":99},[],{"trials":1060,"activeCount":99},[],{"trials":1062,"activeCount":99},[],{"trials":1064,"activeCount":151,"soonestReadout":124},[1065],{"nctId":120,"briefTitle":121,"status":122,"phases":1066,"primaryCompletion":124,"completion":125,"start":126,"enrollment":127,"conditions":1067,"interventions":1068},[90],[129],[131,132,133,134,135,136,137,138,47,139,140,141,142,143,144,145,146,147,148,149,150,150],{"trials":1070,"activeCount":99},[],{"trials":1072,"activeCount":99},[],{"intervention":137,"totalTrials":151,"cells":1074},{"EARLY_PHASE1":1075,"PHASE1":1077,"PHASE2":1079,"PHASE3":1081,"PHASE4":1087,"NA":1089},{"trials":1076,"activeCount":99},[],{"trials":1078,"activeCount":99},[],{"trials":1080,"activeCount":99},[],{"trials":1082,"activeCount":151,"soonestReadout":124},[1083],{"nctId":120,"briefTitle":121,"status":122,"phases":1084,"primaryCompletion":124,"completion":125,"start":126,"enrollment":127,"conditions":1085,"interventions":1086},[90],[129],[131,132,133,134,135,136,137,138,47,139,140,141,142,143,144,145,146,147,148,149,150,150],{"trials":1088,"activeCount":99},[],{"trials":1090,"activeCount":99},[],{"intervention":138,"totalTrials":151,"cells":1092},{"EARLY_PHASE1":1093,"PHASE1":1095,"PHASE2":1097,"PHASE3":1099,"PHASE4":1105,"NA":1107},{"trials":1094,"activeCount":99},[],{"trials":1096,"activeCount":99},[],{"trials":1098,"activeCount":99},[],{"trials":1100,"activeCount":151,"soonestReadout":124},[1101],{"nctId":120,"briefTitle":121,"status":122,"phases":1102,"primaryCompletion":124,"completion":125,"start":126,"enrollment":127,"conditions":1103,"interventions":1104},[90],[129],[131,132,133,134,135,136,137,138,47,139,140,141,142,143,144,145,146,147,148,149,150,150],{"trials":1106,"activeCount":99},[],{"trials":1108,"activeCount":99},[],{"intervention":139,"totalTrials":151,"cells":1110},{"EARLY_PHASE1":1111,"PHASE1":1113,"PHASE2":1115,"PHASE3":1117,"PHASE4":1123,"NA":1125},{"trials":1112,"activeCount":99},[],{"trials":1114,"activeCount":99},[],{"trials":1116,"activeCount":99},[],{"trials":1118,"activeCount":151,"soonestReadout":124},[1119],{"nctId":120,"briefTitle":121,"status":122,"phases":1120,"primaryCompletion":124,"completion":125,"start":126,"enrollment":127,"conditions":1121,"interventions":1122},[90],[129],[131,132,133,134,135,136,137,138,47,139,140,141,142,143,144,145,146,147,148,149,150,150],{"trials":1124,"activeCount":99},[],{"trials":1126,"activeCount":99},[],{"intervention":140,"totalTrials":151,"cells":1128},{"EARLY_PHASE1":1129,"PHASE1":1131,"PHASE2":1133,"PHASE3":1135,"PHASE4":1141,"NA":1143},{"trials":1130,"activeCount":99},[],{"trials":1132,"activeCount":99},[],{"trials":1134,"activeCount":99},[],{"trials":1136,"activeCount":151,"soonestReadout":124},[1137],{"nctId":120,"briefTitle":121,"status":122,"phases":1138,"primaryCompletion":124,"completion":125,"start":126,"enrollment":127,"conditions":1139,"interventions":1140},[90],[129],[131,132,133,134,135,136,137,138,47,139,140,141,142,143,144,145,146,147,148,149,150,150],{"trials":1142,"activeCount":99},[],{"trials":1144,"activeCount":99},[],{"intervention":141,"totalTrials":151,"cells":1146},{"EARLY_PHASE1":1147,"PHASE1":1149,"PHASE2":1151,"PHASE3":1153,"PHASE4":1159,"NA":1161},{"trials":1148,"activeCount":99},[],{"trials":1150,"activeCount":99},[],{"trials":1152,"activeCount":99},[],{"trials":1154,"activeCount":151,"soonestReadout":124},[1155],{"nctId":120,"briefTitle":121,"status":122,"phases":1156,"primaryCompletion":124,"completion":125,"start":126,"enrollment":127,"conditions":1157,"interventions":1158},[90],[129],[131,132,133,134,135,136,137,138,47,139,140,141,142,143,144,145,146,147,148,149,150,150],{"trials":1160,"activeCount":99},[],{"trials":1162,"activeCount":99},[],{"intervention":142,"totalTrials":151,"cells":1164},{"EARLY_PHASE1":1165,"PHASE1":1167,"PHASE2":1169,"PHASE3":1171,"PHASE4":1177,"NA":1179},{"trials":1166,"activeCount":99},[],{"trials":1168,"activeCount":99},[],{"trials":1170,"activeCount":99},[],{"trials":1172,"activeCount":151,"soonestReadout":124},[1173],{"nctId":120,"briefTitle":121,"status":122,"phases":1174,"primaryCompletion":124,"completion":125,"start":126,"enrollment":127,"conditions":1175,"interventions":1176},[90],[129],[131,132,133,134,135,136,137,138,47,139,140,141,142,143,144,145,146,147,148,149,150,150],{"trials":1178,"activeCount":99},[],{"trials":1180,"activeCount":99},[],{"intervention":143,"totalTrials":151,"cells":1182},{"EARLY_PHASE1":1183,"PHASE1":1185,"PHASE2":1187,"PHASE3":1189,"PHASE4":1195,"NA":1197},{"trials":1184,"activeCount":99},[],{"trials":1186,"activeCount":99},[],{"trials":1188,"activeCount":99},[],{"trials":1190,"activeCount":151,"soonestReadout":124},[1191],{"nctId":120,"briefTitle":121,"status":122,"phases":1192,"primaryCompletion":124,"completion":125,"start":126,"enrollment":127,"conditions":1193,"interventions":1194},[90],[129],[131,132,133,134,135,136,137,138,47,139,140,141,142,143,144,145,146,147,148,149,150,150],{"trials":1196,"activeCount":99},[],{"trials":1198,"activeCount":99},[],{"intervention":144,"totalTrials":151,"cells":1200},{"EARLY_PHASE1":1201,"PHASE1":1203,"PHASE2":1205,"PHASE3":1207,"PHASE4":1213,"NA":1215},{"trials":1202,"activeCount":99},[],{"trials":1204,"activeCount":99},[],{"trials":1206,"activeCount":99},[],{"trials":1208,"activeCount":151,"soonestReadout":124},[1209],{"nctId":120,"briefTitle":121,"status":122,"phases":1210,"primaryCompletion":124,"completion":125,"start":126,"enrollment":127,"conditions":1211,"interventions":1212},[90],[129],[131,132,133,134,135,136,137,138,47,139,140,141,142,143,144,145,146,147,148,149,150,150],{"trials":1214,"activeCount":99},[],{"trials":1216,"activeCount":99},[],{"intervention":147,"totalTrials":151,"cells":1218},{"EARLY_PHASE1":1219,"PHASE1":1221,"PHASE2":1223,"PHASE3":1225,"PHASE4":1231,"NA":1233},{"trials":1220,"activeCount":99},[],{"trials":1222,"activeCount":99},[],{"trials":1224,"activeCount":99},[],{"trials":1226,"activeCount":151,"soonestReadout":124},[1227],{"nctId":120,"briefTitle":121,"status":122,"phases":1228,"primaryCompletion":124,"completion":125,"start":126,"enrollment":127,"conditions":1229,"interventions":1230},[90],[129],[131,132,133,134,135,136,137,138,47,139,140,141,142,143,144,145,146,147,148,149,150,150],{"trials":1232,"activeCount":99},[],{"trials":1234,"activeCount":99},[],{"intervention":148,"totalTrials":151,"cells":1236},{"EARLY_PHASE1":1237,"PHASE1":1239,"PHASE2":1241,"PHASE3":1243,"PHASE4":1249,"NA":1251},{"trials":1238,"activeCount":99},[],{"trials":1240,"activeCount":99},[],{"trials":1242,"activeCount":99},[],{"trials":1244,"activeCount":151,"soonestReadout":124},[1245],{"nctId":120,"briefTitle":121,"status":122,"phases":1246,"primaryCompletion":124,"completion":125,"start":126,"enrollment":127,"conditions":1247,"interventions":1248},[90],[129],[131,132,133,134,135,136,137,138,47,139,140,141,142,143,144,145,146,147,148,149,150,150],{"trials":1250,"activeCount":99},[],{"trials":1252,"activeCount":99},[],{"intervention":150,"totalTrials":151,"cells":1254},{"EARLY_PHASE1":1255,"PHASE1":1257,"PHASE2":1259,"PHASE3":1261,"PHASE4":1267,"NA":1269},{"trials":1256,"activeCount":99},[],{"trials":1258,"activeCount":99},[],{"trials":1260,"activeCount":99},[],{"trials":1262,"activeCount":151,"soonestReadout":124},[1263],{"nctId":120,"briefTitle":121,"status":122,"phases":1264,"primaryCompletion":124,"completion":125,"start":126,"enrollment":127,"conditions":1265,"interventions":1266},[90],[129],[131,132,133,134,135,136,137,138,47,139,140,141,142,143,144,145,146,147,148,149,150,150],{"trials":1268,"activeCount":99},[],{"trials":1270,"activeCount":99},[],{"intervention":1272,"totalTrials":1273,"cells":1274},"Artemether-lumefantrine",5,{"EARLY_PHASE1":1275,"PHASE1":1277,"PHASE2":1292,"PHASE3":1305,"PHASE4":1323,"NA":1325},{"trials":1276,"activeCount":99},[],{"trials":1278,"activeCount":99},[1279],{"nctId":1280,"briefTitle":1281,"status":795,"phases":1282,"primaryCompletion":1283,"completion":1283,"start":1284,"enrollment":1285,"conditions":1286,"interventions":1289},"NCT04080895","Pharmacokinetic Study of Artemether-lumefantrine and Amodiaquine in Healthy Subjects",[88],"2025-04-01","2022-11-01",8,[1287,24,1288],"Pharmacokinetic","Drug Combination",[1272,1290,1272,1291],"Amodiaquine","Artemether-lumefantrine + Amodiaquine",{"trials":1293,"activeCount":99},[1294],{"nctId":1295,"briefTitle":1296,"status":795,"phases":1297,"primaryCompletion":1298,"completion":1298,"start":1299,"enrollment":1300,"conditions":1301,"interventions":1302},"NCT02696954","Study of Artemether-lumefantrine, Amodiaquine and Primaquine in Healthy Subjects",[88,89],"2019-03","2016-11-18",17,[1287,1288,24],[1272,1290,1272,1291,190,1303,1304,1303],"Artemether-lumefantrine + Primaquine","Artemether-lumefantrine + Amodiaquine + Primaquine",{"trials":1306,"activeCount":151,"soonestReadout":943},[1307,1319],{"nctId":1308,"briefTitle":1309,"status":109,"phases":1310,"primaryCompletion":1311,"completion":1311,"start":1312,"enrollment":1313,"conditions":1314,"interventions":1316},"NCT03452475","Comparison of Arterolane-piperaquine Versus Arterolane-piperaquine+Mefloquine Versus Artemether-lumefantrine in Kenyan Children",[90],"2019-06-03","2018-03-07",219,[1315],"Plasmodium Falciparum",[1317,1318,1272],"Arterolane-piperaquine","Arterolane-piperaquine+mefloquine",{"nctId":940,"briefTitle":941,"status":122,"phases":1320,"primaryCompletion":943,"completion":943,"start":944,"enrollment":945,"conditions":1321,"interventions":1322},[90],[947],[929,949,950],{"trials":1324,"activeCount":99},[],{"trials":1326,"activeCount":99},[1327],{"nctId":1328,"briefTitle":1329,"status":109,"phases":1330,"primaryCompletion":1331,"completion":1331,"start":1332,"enrollment":1333,"conditions":1334,"interventions":1335},"NCT04041973","Study to Assess Efficacy of Artemether-lumefantrine Prophylaxis Against Forest Malaria in Cambodia (PAL_Cambodia)",[92],"2021-03-17","2020-03-11",1480,[15],[1272],{"intervention":614,"totalTrials":95,"cells":1337},{"EARLY_PHASE1":1338,"PHASE1":1340,"PHASE2":1342,"PHASE3":1356,"PHASE4":1358,"NA":1360},{"trials":1339,"activeCount":99},[],{"trials":1341,"activeCount":99},[],{"trials":1343,"activeCount":95,"soonestReadout":619},[1344,1348,1352],{"nctId":604,"briefTitle":605,"status":122,"phases":1345,"primaryCompletion":607,"completion":607,"start":608,"enrollment":563,"conditions":1346,"interventions":1347},[89],[610,611],[613,146,614],{"nctId":616,"briefTitle":617,"status":122,"phases":1349,"primaryCompletion":619,"completion":619,"start":620,"enrollment":621,"conditions":1350,"interventions":1351},[89],[623],[625,626,627,133,628,629,146,145,630,628,614,631,632,633,634,625,625,635],{"nctId":637,"briefTitle":638,"status":122,"phases":1353,"primaryCompletion":607,"completion":607,"start":640,"enrollment":641,"conditions":1354,"interventions":1355},[89],[30,643],[149,614,645,646,146,647,648,649,650,651],{"trials":1357,"activeCount":99},[],{"trials":1359,"activeCount":99},[],{"trials":1361,"activeCount":99},[],{"intervention":629,"totalTrials":595,"cells":1363},{"EARLY_PHASE1":1364,"PHASE1":1366,"PHASE2":1368,"PHASE3":1374,"PHASE4":1376,"NA":1378},{"trials":1365,"activeCount":99},[],{"trials":1367,"activeCount":99},[],{"trials":1369,"activeCount":151,"soonestReadout":619},[1370],{"nctId":616,"briefTitle":617,"status":122,"phases":1371,"primaryCompletion":619,"completion":619,"start":620,"enrollment":621,"conditions":1372,"interventions":1373},[89],[623],[625,626,627,133,628,629,146,145,630,628,614,631,632,633,634,625,625,635],{"trials":1375,"activeCount":99},[],{"trials":1377,"activeCount":99},[],{"trials":1379,"activeCount":168,"soonestReadout":285},[1380,1388,1397],{"nctId":1381,"briefTitle":1382,"status":122,"phases":1383,"primaryCompletion":285,"completion":285,"start":85,"enrollment":799,"conditions":1384,"interventions":1387},"NCT07424781","Fluoxetine on Emotional Experience (FLEX) Study",[92],[1385,1386,21],"Depression - Major Depressive Disorder","Irritability",[629],{"nctId":1389,"briefTitle":1390,"status":109,"phases":1391,"primaryCompletion":1392,"completion":1392,"start":1393,"enrollment":1394,"conditions":1395,"interventions":1396},"NCT03436173","OxSYPan: Oxford Study With Young People on Antidepressants",[92],"2015-11-10","2012-05-23",32,[21],[629],{"nctId":1398,"briefTitle":1399,"status":283,"phases":1400,"primaryCompletion":1401,"completion":1402,"start":1403,"enrollment":799,"conditions":1404,"interventions":1408},"NCT07456501","Fluoxetine and Understanding Social Experiences",[92],"2027-07-20","2027-07-22","2026-03",[1405,1406,1407],"Depression in Adolescence","Antidepressant Activity in Healthy Volunteers","Healthy Adult Participants",[629],{"intervention":1410,"totalTrials":513,"cells":1411},"Rabies vaccine",{"EARLY_PHASE1":1412,"PHASE1":1414,"PHASE2":1428,"PHASE3":1492,"PHASE4":1494,"NA":1496},{"trials":1413,"activeCount":99},[],{"trials":1415,"activeCount":99},[1416],{"nctId":1417,"briefTitle":1418,"status":109,"phases":1419,"primaryCompletion":1420,"completion":1420,"start":1421,"enrollment":1422,"conditions":1423,"interventions":1424},"NCT03435874","Safety and Immunogenicity of ChAd63 RH5 and MVA RH5 in Adults, Young Children and Infants Living in Tanzania",[88],"2019-07-11","2018-04-12",63,[27],[1425,1426,1427],"ChAd63 RH5","MVA RH5","Rabies Vaccine",{"trials":1429,"activeCount":168,"soonestReadout":1444},[1430,1440,1452,1462,1473,1484],{"nctId":1431,"briefTitle":1432,"status":109,"phases":1433,"primaryCompletion":1434,"completion":1434,"start":1435,"enrollment":1436,"conditions":1437,"interventions":1438},"NCT01658696","Efficacy of Candidate Malaria Vaccines in Senegalese Adults",[89],"2013-02","2012-08",120,[15],[1439,1410],"ChAd63 ME-TRAP and MVA ME-TRAP",{"nctId":1441,"briefTitle":1442,"status":155,"phases":1443,"primaryCompletion":1444,"completion":1445,"start":1446,"enrollment":1447,"conditions":1448,"interventions":1450},"NCT06799234","Safety and Immunogenicity of a Candidate Rift Valley Fever Vaccine (RVF003)",[89],"2026-03-31","2027-03-31","2025-07-08",240,[1449],"Rift Valley Fever",[1451,1427],"ChAdOx1 RVF",{"nctId":1453,"briefTitle":1454,"status":109,"phases":1455,"primaryCompletion":1456,"completion":1457,"start":1458,"enrollment":1459,"conditions":1460,"interventions":1461},"NCT01635647","A Phase 1\u002F2b Study of an Investigational Malaria Vaccination Strategy in 5-17 Month Old Infants and Children in Burkina Faso",[88,89],"2014-08","2014-09","2012-11",730,[15],[1439,1410],{"nctId":1463,"briefTitle":1464,"status":109,"phases":1465,"primaryCompletion":1466,"completion":1466,"start":1467,"enrollment":1468,"conditions":1469,"interventions":1470},"NCT03896724","Safety, Immunogenicity and Efficacy of R21 Matrix-M in 5-17 Month Old Children in Nanoro, Burkina Faso",[88,89],"2023-07-07","2019-05-07",450,[27],[1471,1427,1472],"R21 adjuvanted with 25mcg Matrix-M","R21 adjuvanted with 50mcg Matrix-M",{"nctId":1474,"briefTitle":1475,"status":122,"phases":1476,"primaryCompletion":1477,"completion":1477,"start":1478,"enrollment":1479,"conditions":1480,"interventions":1481},"NCT05790889","A Study to Test Experimental Blood Stage Malaria Vaccine in Burkina Faso.",[88,89],"2026-05-30","2023-04-03",480,[27],[1410,1482,1483],"RH5.1 10μg adjuvated with 50μg Matrix-M","RH5.2 5μg adjuvated with 50μg Matrix-M",{"nctId":1485,"briefTitle":1486,"status":109,"phases":1487,"primaryCompletion":1435,"completion":1435,"start":1488,"enrollment":1436,"conditions":1489,"interventions":1490},"NCT01666925","Efficacy of Malaria Vaccines in Kenyan Adults",[89],"2012-03",[15],[1491,1410],"ChAd63 ME-TRAP \u002F MVA ME-TRAP prime-boost immunisation",{"trials":1493,"activeCount":99},[],{"trials":1495,"activeCount":99},[],{"trials":1497,"activeCount":99},[],{"intervention":1499,"totalTrials":95,"cells":1500},"Inactivated Rabies Vaccine",{"EARLY_PHASE1":1501,"PHASE1":1503,"PHASE2":1516,"PHASE3":1534,"PHASE4":1536,"NA":1538},{"trials":1502,"activeCount":99},[],{"trials":1504,"activeCount":99},[1505],{"nctId":1506,"briefTitle":1507,"status":795,"phases":1508,"primaryCompletion":1509,"completion":1509,"start":1510,"enrollment":1511,"conditions":1512,"interventions":1514},"NCT04162600","Safety and Immunogenicity of the Candidate Rabies Vaccine ChAdOx2 RabG",[88],"2024-07-10","2020-01-02",18,[1513],"Rabies",[1515,1499,1515,1515,1499,1499],"ChAdOx2 RabG",{"trials":1517,"activeCount":168,"soonestReadout":1403},[1518,1526],{"nctId":1519,"briefTitle":1520,"status":155,"phases":1521,"primaryCompletion":773,"completion":773,"start":1522,"enrollment":1523,"conditions":1524,"interventions":1525},"NCT04270838","A Phase Ib\u002FII Study of the Safety and Immunogenicity of the Candidate Rabies Vaccine ChAdOx2 RabG",[88,89],"2022-02-17",174,[1513],[1515,1499],{"nctId":1527,"briefTitle":1528,"status":283,"phases":1529,"primaryCompletion":1403,"completion":1403,"start":393,"enrollment":1530,"conditions":1531,"interventions":1532},"NCT07168018","Safety and Immunogenicity of Coadministration of the Candidate Rabies Vaccine ChAdOx2 RabG and Licensed Vaccine",[89],40,[1513],[1533,1499],"Coadministration of ChAdOx2 RabG and licensed inactivated rabies vaccine",{"trials":1535,"activeCount":99},[],{"trials":1537,"activeCount":99},[],{"trials":1539,"activeCount":99},[],{"intervention":1541,"totalTrials":95,"cells":1542},"R21",{"EARLY_PHASE1":1543,"PHASE1":1545,"PHASE2":1567,"PHASE3":1580,"PHASE4":1582,"NA":1584},{"trials":1544,"activeCount":99},[],{"trials":1546,"activeCount":151,"soonestReadout":861},[1547,1556],{"nctId":1548,"briefTitle":1549,"status":109,"phases":1550,"primaryCompletion":1551,"completion":1551,"start":1552,"enrollment":19,"conditions":1553,"interventions":1554},"NCT02572388","A Study to Assess the Safety and Immunogenicity of the Malaria Vaccine, R21, Administered With and Without Matrix-M1",[88],"2017-08-29","2015-10-15",[15],[1541,1555],"Matrix-M1",{"nctId":1557,"briefTitle":1558,"status":122,"phases":1559,"primaryCompletion":861,"completion":861,"start":1560,"enrollment":1561,"conditions":1562,"interventions":1563},"NCT06958198","A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 Combined With R21\u002FMatrix-M (a \"Multi-stage\" Malaria Vaccine)",[88],"2025-09-15",56,[27],[1541,1564,1565,1566],"RH5.1","R78C","Matrix-M™",{"trials":1568,"activeCount":151,"soonestReadout":394},[1569],{"nctId":1570,"briefTitle":1571,"status":155,"phases":1572,"primaryCompletion":394,"completion":394,"start":1573,"enrollment":1574,"conditions":1575,"interventions":1576},"NCT07183371","A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 With Matrix-M in Combination With R21\u002FMatrix-M",[89],"2025-12-15",360,[27],[1541,1564,1565,1566,1577,1578,1579],"Rabivax-S","Menveo","Avaxim 80",{"trials":1581,"activeCount":99},[],{"trials":1583,"activeCount":99},[],{"trials":1585,"activeCount":99},[],{"intervention":1564,"totalTrials":168,"cells":1587},{"EARLY_PHASE1":1588,"PHASE1":1590,"PHASE2":1596,"PHASE3":1602,"PHASE4":1604,"NA":1606},{"trials":1589,"activeCount":99},[],{"trials":1591,"activeCount":151,"soonestReadout":861},[1592],{"nctId":1557,"briefTitle":1558,"status":122,"phases":1593,"primaryCompletion":861,"completion":861,"start":1560,"enrollment":1561,"conditions":1594,"interventions":1595},[88],[27],[1541,1564,1565,1566],{"trials":1597,"activeCount":151,"soonestReadout":394},[1598],{"nctId":1570,"briefTitle":1571,"status":155,"phases":1599,"primaryCompletion":394,"completion":394,"start":1573,"enrollment":1574,"conditions":1600,"interventions":1601},[89],[27],[1541,1564,1565,1566,1577,1578,1579],{"trials":1603,"activeCount":99},[],{"trials":1605,"activeCount":99},[],{"trials":1607,"activeCount":99},[],{"intervention":1565,"totalTrials":168,"cells":1609},{"EARLY_PHASE1":1610,"PHASE1":1612,"PHASE2":1618,"PHASE3":1624,"PHASE4":1626,"NA":1628},{"trials":1611,"activeCount":99},[],{"trials":1613,"activeCount":151,"soonestReadout":861},[1614],{"nctId":1557,"briefTitle":1558,"status":122,"phases":1615,"primaryCompletion":861,"completion":861,"start":1560,"enrollment":1561,"conditions":1616,"interventions":1617},[88],[27],[1541,1564,1565,1566],{"trials":1619,"activeCount":151,"soonestReadout":394},[1620],{"nctId":1570,"briefTitle":1571,"status":155,"phases":1621,"primaryCompletion":394,"completion":394,"start":1573,"enrollment":1574,"conditions":1622,"interventions":1623},[89],[27],[1541,1564,1565,1566,1577,1578,1579],{"trials":1625,"activeCount":99},[],{"trials":1627,"activeCount":99},[],{"trials":1629,"activeCount":99},[],{"intervention":1566,"totalTrials":168,"cells":1631},{"EARLY_PHASE1":1632,"PHASE1":1634,"PHASE2":1640,"PHASE3":1646,"PHASE4":1648,"NA":1650},{"trials":1633,"activeCount":99},[],{"trials":1635,"activeCount":151,"soonestReadout":861},[1636],{"nctId":1557,"briefTitle":1558,"status":122,"phases":1637,"primaryCompletion":861,"completion":861,"start":1560,"enrollment":1561,"conditions":1638,"interventions":1639},[88],[27],[1541,1564,1565,1566],{"trials":1641,"activeCount":151,"soonestReadout":394},[1642],{"nctId":1570,"briefTitle":1571,"status":155,"phases":1643,"primaryCompletion":394,"completion":394,"start":1573,"enrollment":1574,"conditions":1644,"interventions":1645},[89],[27],[1541,1564,1565,1566,1577,1578,1579],{"trials":1647,"activeCount":99},[],{"trials":1649,"activeCount":99},[],{"trials":1651,"activeCount":99},[],{"intervention":631,"totalTrials":168,"cells":1653},{"EARLY_PHASE1":1654,"PHASE1":1656,"PHASE2":1658,"PHASE3":1664,"PHASE4":1666,"NA":1677},{"trials":1655,"activeCount":99},[],{"trials":1657,"activeCount":99},[],{"trials":1659,"activeCount":151,"soonestReadout":619},[1660],{"nctId":616,"briefTitle":617,"status":122,"phases":1661,"primaryCompletion":619,"completion":619,"start":620,"enrollment":621,"conditions":1662,"interventions":1663},[89],[623],[625,626,627,133,628,629,146,145,630,628,614,631,632,633,634,625,625,635],{"trials":1665,"activeCount":99},[],{"trials":1667,"activeCount":99},[1668],{"nctId":1669,"briefTitle":1670,"status":109,"phases":1671,"primaryCompletion":1672,"completion":1672,"start":1673,"enrollment":1674,"conditions":1675,"interventions":1676},"NCT03690453","Effect of Ivermectin Metabolites on Mosquito Survival",[91],"2022-04-05","2019-02-04",20,[24],[631],{"trials":1678,"activeCount":99},[],{"intervention":1451,"totalTrials":95,"cells":1680},{"EARLY_PHASE1":1681,"PHASE1":1691,"PHASE2":1703,"PHASE3":1709,"PHASE4":1711,"NA":1713},{"trials":1682,"activeCount":99},[1683],{"nctId":1684,"briefTitle":1685,"status":109,"phases":1686,"primaryCompletion":1687,"completion":1687,"start":1688,"enrollment":28,"conditions":1689,"interventions":1690},"NCT04754776","Safety and Immunogenicity of a Candidate RVFV Vaccine (RVF001)",[87],"2022-04-06","2021-06-11",[1449],[1451],{"trials":1692,"activeCount":99},[1693],{"nctId":1694,"briefTitle":1695,"status":109,"phases":1696,"primaryCompletion":1697,"completion":1697,"start":1698,"enrollment":1699,"conditions":1700,"interventions":1702},"NCT04672824","A Study to Assess the New Candidate Rift Valley Fever Virus Vaccine in Healthy Adults",[88],"2022-12-15","2022-05-31",30,[1701,1449],"RVF",[1451],{"trials":1704,"activeCount":151,"soonestReadout":1444},[1705],{"nctId":1441,"briefTitle":1442,"status":155,"phases":1706,"primaryCompletion":1444,"completion":1445,"start":1446,"enrollment":1447,"conditions":1707,"interventions":1708},[89],[1449],[1451,1427],{"trials":1710,"activeCount":99},[],{"trials":1712,"activeCount":99},[],{"trials":1714,"activeCount":99},[],{"intervention":1716,"totalTrials":168,"cells":1717},"R21\u002FMatrix-M1",{"EARLY_PHASE1":1718,"PHASE1":1720,"PHASE2":1722,"PHASE3":1745,"PHASE4":1747,"NA":1749},{"trials":1719,"activeCount":99},[],{"trials":1721,"activeCount":99},[],{"trials":1723,"activeCount":151,"soonestReadout":1737},[1724,1733],{"nctId":1725,"briefTitle":1726,"status":109,"phases":1727,"primaryCompletion":1728,"completion":1728,"start":1729,"enrollment":1730,"conditions":1731,"interventions":1732},"NCT02925403","A Study to Assess the Safety and Immunogenicity of the Malaria Vaccine, R21, With Matrix-M1 Adjuvant",[88,89],"2017-02-15","2016-08-26",13,[15],[1716],{"nctId":1734,"briefTitle":1735,"status":155,"phases":1736,"primaryCompletion":1737,"completion":1738,"start":1739,"enrollment":1740,"conditions":1741,"interventions":1743},"NCT06080243","Assessment of Safety, Immunogenicity and Efficacy of R21\u002FMatrix-M1 Malaria Vaccine in Healthy WOCBP in Mali",[89],"2027-09-01","2027-12-31","2025-03-19",330,[1742],"Healthy Women of Child Bearing Potential",[1716,1744],"Saline and R21\u002FMatrix-M1",{"trials":1746,"activeCount":99},[],{"trials":1748,"activeCount":99},[],{"trials":1750,"activeCount":99},[],{"intervention":1752,"totalTrials":168,"cells":1753},"ChAdOx1.tHIVconsv1",{"EARLY_PHASE1":1754,"PHASE1":1756,"PHASE2":1769,"PHASE3":1784,"PHASE4":1786,"NA":1788},{"trials":1755,"activeCount":99},[],{"trials":1757,"activeCount":99},[1758],{"nctId":1759,"briefTitle":1760,"status":109,"phases":1761,"primaryCompletion":1762,"completion":1762,"start":1763,"enrollment":1730,"conditions":1764,"interventions":1766},"NCT04586673","A Study to Assess Safety and Immunogenicity of Conserved Mosaic HIV-1 Vaccines",[88],"2022-08-03","2021-07-03",[1765],"HIV",[1752,1752,1767,1768],"MVA.tHIVconsv3","MVA.tHIVconsv4",{"trials":1770,"activeCount":151,"soonestReadout":1775},[1771],{"nctId":1772,"briefTitle":1773,"status":122,"phases":1774,"primaryCompletion":1775,"completion":1776,"start":1777,"enrollment":1778,"conditions":1779,"interventions":1780},"NCT07054931","Combination Vaccination and Broadly Neutralising Antibody Therapy in HIV",[89],"2027-10-31","2028-06-30","2025-09-05",48,[1765],[1752,1781,1768,1782,1783],"ChAdOx1.HIVconsv62","GS-5423","GS-2872",{"trials":1785,"activeCount":99},[],{"trials":1787,"activeCount":99},[],{"trials":1789,"activeCount":99},[],{"intervention":1768,"totalTrials":168,"cells":1791},{"EARLY_PHASE1":1792,"PHASE1":1794,"PHASE2":1800,"PHASE3":1806,"PHASE4":1808,"NA":1810},{"trials":1793,"activeCount":99},[],{"trials":1795,"activeCount":99},[1796],{"nctId":1759,"briefTitle":1760,"status":109,"phases":1797,"primaryCompletion":1762,"completion":1762,"start":1763,"enrollment":1730,"conditions":1798,"interventions":1799},[88],[1765],[1752,1752,1767,1768],{"trials":1801,"activeCount":151,"soonestReadout":1775},[1802],{"nctId":1772,"briefTitle":1773,"status":122,"phases":1803,"primaryCompletion":1775,"completion":1776,"start":1777,"enrollment":1778,"conditions":1804,"interventions":1805},[89],[1765],[1752,1781,1768,1782,1783],{"trials":1807,"activeCount":99},[],{"trials":1809,"activeCount":99},[],{"trials":1811,"activeCount":99},[],{"intervention":1515,"totalTrials":168,"cells":1813},{"EARLY_PHASE1":1814,"PHASE1":1816,"PHASE2":1822,"PHASE3":1828,"PHASE4":1830,"NA":1832},{"trials":1815,"activeCount":99},[],{"trials":1817,"activeCount":99},[1818],{"nctId":1506,"briefTitle":1507,"status":795,"phases":1819,"primaryCompletion":1509,"completion":1509,"start":1510,"enrollment":1511,"conditions":1820,"interventions":1821},[88],[1513],[1515,1499,1515,1515,1499,1499],{"trials":1823,"activeCount":151,"soonestReadout":773},[1824],{"nctId":1519,"briefTitle":1520,"status":155,"phases":1825,"primaryCompletion":773,"completion":773,"start":1522,"enrollment":1523,"conditions":1826,"interventions":1827},[88,89],[1513],[1515,1499],{"trials":1829,"activeCount":99},[],{"trials":1831,"activeCount":99},[],{"trials":1833,"activeCount":99},[],{"intervention":1835,"totalTrials":151,"cells":1836},"Malaria Vaccine",{"EARLY_PHASE1":1837,"PHASE1":1839,"PHASE2":1841,"PHASE3":1853,"PHASE4":1855,"NA":1857},{"trials":1838,"activeCount":99},[],{"trials":1840,"activeCount":99},[],{"trials":1842,"activeCount":151,"soonestReadout":1847},[1843],{"nctId":1844,"briefTitle":1845,"status":283,"phases":1846,"primaryCompletion":1847,"completion":1847,"start":607,"enrollment":1848,"conditions":1849,"interventions":1851},"NCT05380388","A Safety, Immunogenicity and Efficacy Study of PvRII\u002FMatrix-M in Healthy Thai Adults Living in Thailand ( MIST3 )",[89],"2027-12-30",36,[1850,1835],"Plasmodium Vivax Infection",[1835,1852],"HBV vaccine",{"trials":1854,"activeCount":99},[],{"trials":1856,"activeCount":99},[],{"trials":1858,"activeCount":99},[],{"intervention":1852,"totalTrials":151,"cells":1860},{"EARLY_PHASE1":1861,"PHASE1":1863,"PHASE2":1865,"PHASE3":1871,"PHASE4":1873,"NA":1875},{"trials":1862,"activeCount":99},[],{"trials":1864,"activeCount":99},[],{"trials":1866,"activeCount":151,"soonestReadout":1847},[1867],{"nctId":1844,"briefTitle":1845,"status":283,"phases":1868,"primaryCompletion":1847,"completion":1847,"start":607,"enrollment":1848,"conditions":1869,"interventions":1870},[89],[1850,1835],[1835,1852],{"trials":1872,"activeCount":99},[],{"trials":1874,"activeCount":99},[],{"trials":1876,"activeCount":99},[],{"intervention":1878,"totalTrials":151,"cells":1879},"5µg R21\u002F50µg Matrix-M",{"EARLY_PHASE1":1880,"PHASE1":1882,"PHASE2":1884,"PHASE3":1897,"PHASE4":1899,"NA":1901},{"trials":1881,"activeCount":99},[],{"trials":1883,"activeCount":99},[],{"trials":1885,"activeCount":151,"soonestReadout":1890},[1886],{"nctId":1887,"briefTitle":1888,"status":122,"phases":1889,"primaryCompletion":1890,"completion":1891,"start":1892,"enrollment":1530,"conditions":1893,"interventions":1895},"NCT07074665","Dose Finding Trial of R21\u002FMatrix-M in School Children",[89],"2026-04","2027-03","2026-02-18",[1894],"Malaria (Plasmodium Falciparum)",[1878,1896],"10µg R21\u002F50µg Matrix-M",{"trials":1898,"activeCount":99},[],{"trials":1900,"activeCount":99},[],{"trials":1902,"activeCount":99},[],{"intervention":1896,"totalTrials":151,"cells":1904},{"EARLY_PHASE1":1905,"PHASE1":1907,"PHASE2":1909,"PHASE3":1915,"PHASE4":1917,"NA":1919},{"trials":1906,"activeCount":99},[],{"trials":1908,"activeCount":99},[],{"trials":1910,"activeCount":151,"soonestReadout":1890},[1911],{"nctId":1887,"briefTitle":1888,"status":122,"phases":1912,"primaryCompletion":1890,"completion":1891,"start":1892,"enrollment":1530,"conditions":1913,"interventions":1914},[89],[1894],[1878,1896],{"trials":1916,"activeCount":99},[],{"trials":1918,"activeCount":99},[],{"trials":1920,"activeCount":99},[],{"intervention":625,"totalTrials":151,"cells":1922},{"EARLY_PHASE1":1923,"PHASE1":1925,"PHASE2":1927,"PHASE3":1933,"PHASE4":1935,"NA":1937},{"trials":1924,"activeCount":99},[],{"trials":1926,"activeCount":99},[],{"trials":1928,"activeCount":151,"soonestReadout":619},[1929],{"nctId":616,"briefTitle":617,"status":122,"phases":1930,"primaryCompletion":619,"completion":619,"start":620,"enrollment":621,"conditions":1931,"interventions":1932},[89],[623],[625,626,627,133,628,629,146,145,630,628,614,631,632,633,634,625,625,635],{"trials":1934,"activeCount":99},[],{"trials":1936,"activeCount":99},[],{"trials":1938,"activeCount":99},[],{"intervention":626,"totalTrials":151,"cells":1940},{"EARLY_PHASE1":1941,"PHASE1":1943,"PHASE2":1945,"PHASE3":1951,"PHASE4":1953,"NA":1955},{"trials":1942,"activeCount":99},[],{"trials":1944,"activeCount":99},[],{"trials":1946,"activeCount":151,"soonestReadout":619},[1947],{"nctId":616,"briefTitle":617,"status":122,"phases":1948,"primaryCompletion":619,"completion":619,"start":620,"enrollment":621,"conditions":1949,"interventions":1950},[89],[623],[625,626,627,133,628,629,146,145,630,628,614,631,632,633,634,625,625,635],{"trials":1952,"activeCount":99},[],{"trials":1954,"activeCount":99},[],{"trials":1956,"activeCount":99},[],{"intervention":627,"totalTrials":151,"cells":1958},{"EARLY_PHASE1":1959,"PHASE1":1961,"PHASE2":1963,"PHASE3":1969,"PHASE4":1971,"NA":1973},{"trials":1960,"activeCount":99},[],{"trials":1962,"activeCount":99},[],{"trials":1964,"activeCount":151,"soonestReadout":619},[1965],{"nctId":616,"briefTitle":617,"status":122,"phases":1966,"primaryCompletion":619,"completion":619,"start":620,"enrollment":621,"conditions":1967,"interventions":1968},[89],[623],[625,626,627,133,628,629,146,145,630,628,614,631,632,633,634,625,625,635],{"trials":1970,"activeCount":99},[],{"trials":1972,"activeCount":99},[],{"trials":1974,"activeCount":99},[],{"intervention":628,"totalTrials":151,"cells":1976},{"EARLY_PHASE1":1977,"PHASE1":1979,"PHASE2":1981,"PHASE3":1987,"PHASE4":1989,"NA":1991},{"trials":1978,"activeCount":99},[],{"trials":1980,"activeCount":99},[],{"trials":1982,"activeCount":151,"soonestReadout":619},[1983],{"nctId":616,"briefTitle":617,"status":122,"phases":1984,"primaryCompletion":619,"completion":619,"start":620,"enrollment":621,"conditions":1985,"interventions":1986},[89],[623],[625,626,627,133,628,629,146,145,630,628,614,631,632,633,634,625,625,635],{"trials":1988,"activeCount":99},[],{"trials":1990,"activeCount":99},[],{"trials":1992,"activeCount":99},[],{"intervention":630,"totalTrials":151,"cells":1994},{"EARLY_PHASE1":1995,"PHASE1":1997,"PHASE2":1999,"PHASE3":2005,"PHASE4":2007,"NA":2009},{"trials":1996,"activeCount":99},[],{"trials":1998,"activeCount":99},[],{"trials":2000,"activeCount":151,"soonestReadout":619},[2001],{"nctId":616,"briefTitle":617,"status":122,"phases":2002,"primaryCompletion":619,"completion":619,"start":620,"enrollment":621,"conditions":2003,"interventions":2004},[89],[623],[625,626,627,133,628,629,146,145,630,628,614,631,632,633,634,625,625,635],{"trials":2006,"activeCount":99},[],{"trials":2008,"activeCount":99},[],{"trials":2010,"activeCount":99},[],{"intervention":632,"totalTrials":151,"cells":2012},{"EARLY_PHASE1":2013,"PHASE1":2015,"PHASE2":2017,"PHASE3":2023,"PHASE4":2025,"NA":2027},{"trials":2014,"activeCount":99},[],{"trials":2016,"activeCount":99},[],{"trials":2018,"activeCount":151,"soonestReadout":619},[2019],{"nctId":616,"briefTitle":617,"status":122,"phases":2020,"primaryCompletion":619,"completion":619,"start":620,"enrollment":621,"conditions":2021,"interventions":2022},[89],[623],[625,626,627,133,628,629,146,145,630,628,614,631,632,633,634,625,625,635],{"trials":2024,"activeCount":99},[],{"trials":2026,"activeCount":99},[],{"trials":2028,"activeCount":99},[],{"intervention":633,"totalTrials":151,"cells":2030},{"EARLY_PHASE1":2031,"PHASE1":2033,"PHASE2":2035,"PHASE3":2041,"PHASE4":2043,"NA":2045},{"trials":2032,"activeCount":99},[],{"trials":2034,"activeCount":99},[],{"trials":2036,"activeCount":151,"soonestReadout":619},[2037],{"nctId":616,"briefTitle":617,"status":122,"phases":2038,"primaryCompletion":619,"completion":619,"start":620,"enrollment":621,"conditions":2039,"interventions":2040},[89],[623],[625,626,627,133,628,629,146,145,630,628,614,631,632,633,634,625,625,635],{"trials":2042,"activeCount":99},[],{"trials":2044,"activeCount":99},[],{"trials":2046,"activeCount":99},[],{"intervention":635,"totalTrials":151,"cells":2048},{"EARLY_PHASE1":2049,"PHASE1":2051,"PHASE2":2053,"PHASE3":2059,"PHASE4":2061,"NA":2063},{"trials":2050,"activeCount":99},[],{"trials":2052,"activeCount":99},[],{"trials":2054,"activeCount":151,"soonestReadout":619},[2055],{"nctId":616,"briefTitle":617,"status":122,"phases":2056,"primaryCompletion":619,"completion":619,"start":620,"enrollment":621,"conditions":2057,"interventions":2058},[89],[623],[625,626,627,133,628,629,146,145,630,628,614,631,632,633,634,625,625,635],{"trials":2060,"activeCount":99},[],{"trials":2062,"activeCount":99},[],{"trials":2064,"activeCount":99},[],{"intervention":2066,"totalTrials":151,"cells":2067},"Tebentafusp",{"EARLY_PHASE1":2068,"PHASE1":2070,"PHASE2":2072,"PHASE3":2086,"PHASE4":2088,"NA":2090},{"trials":2069,"activeCount":99},[],{"trials":2071,"activeCount":99},[],{"trials":2073,"activeCount":151,"soonestReadout":2078},[2074],{"nctId":2075,"briefTitle":2076,"status":155,"phases":2077,"primaryCompletion":2078,"completion":2079,"start":2080,"enrollment":2081,"conditions":2082,"interventions":2085},"NCT05315258","Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma",[89],"2026-12-30","2027-06-30","2022-07-25",850,[2083,2084],"Melanoma (Skin)","Melanoma, Uveal",[2066],{"trials":2087,"activeCount":99},[],{"trials":2089,"activeCount":99},[],{"trials":2091,"activeCount":99},[],{"intervention":52,"totalTrials":151,"cells":2093},{"EARLY_PHASE1":2094,"PHASE1":2096,"PHASE2":2098,"PHASE3":2108,"PHASE4":2110,"NA":2112},{"trials":2095,"activeCount":99},[],{"trials":2097,"activeCount":99},[],{"trials":2099,"activeCount":151,"soonestReadout":51},[2100],{"nctId":49,"briefTitle":50,"status":155,"phases":2101,"primaryCompletion":51,"completion":2102,"start":2103,"enrollment":2104,"conditions":2105,"interventions":2107},[89],"2026-09","2019-01-28",41,[2106],"Type1 Diabetes",[52],{"trials":2109,"activeCount":99},[],{"trials":2111,"activeCount":99},[],{"trials":2113,"activeCount":99},[],{"intervention":2115,"totalTrials":151,"cells":2116},"Pfs25-IMX313, Pfs48\u002F45",{"EARLY_PHASE1":2117,"PHASE1":2119,"PHASE2":2121,"PHASE3":2130,"PHASE4":2132,"NA":2134},{"trials":2118,"activeCount":99},[],{"trials":2120,"activeCount":99},[],{"trials":2122,"activeCount":151,"soonestReadout":2102},[2123],{"nctId":2124,"briefTitle":2125,"status":155,"phases":2126,"primaryCompletion":2102,"completion":2102,"start":2127,"enrollment":1561,"conditions":2128,"interventions":2129},"NCT06549257","Assessing the Safety, Immunogenicity and Ex-vivo Efficacy of Two Candidate Malaria Transmission Blocking Vaccines, Pfs25-IMX313 and Pfs45\u002F48 Administered Alone and in Combination, in Matrix-M Adjuvant",[88,89],"2025-07-07",[33],[2115],{"trials":2131,"activeCount":99},[],{"trials":2133,"activeCount":99},[],{"trials":2135,"activeCount":99},[],{"intervention":1482,"totalTrials":151,"cells":2137},{"EARLY_PHASE1":2138,"PHASE1":2140,"PHASE2":2142,"PHASE3":2148,"PHASE4":2150,"NA":2152},{"trials":2139,"activeCount":99},[],{"trials":2141,"activeCount":99},[],{"trials":2143,"activeCount":151,"soonestReadout":1477},[2144],{"nctId":1474,"briefTitle":1475,"status":122,"phases":2145,"primaryCompletion":1477,"completion":1477,"start":1478,"enrollment":1479,"conditions":2146,"interventions":2147},[88,89],[27],[1410,1482,1483],{"trials":2149,"activeCount":99},[],{"trials":2151,"activeCount":99},[],{"trials":2153,"activeCount":99},[],{"intervention":1483,"totalTrials":151,"cells":2155},{"EARLY_PHASE1":2156,"PHASE1":2158,"PHASE2":2160,"PHASE3":2166,"PHASE4":2168,"NA":2170},{"trials":2157,"activeCount":99},[],{"trials":2159,"activeCount":99},[],{"trials":2161,"activeCount":151,"soonestReadout":1477},[2162],{"nctId":1474,"briefTitle":1475,"status":122,"phases":2163,"primaryCompletion":1477,"completion":1477,"start":1478,"enrollment":1479,"conditions":2164,"interventions":2165},[88,89],[27],[1410,1482,1483],{"trials":2167,"activeCount":99},[],{"trials":2169,"activeCount":99},[],{"trials":2171,"activeCount":99},[],{"intervention":645,"totalTrials":151,"cells":2173},{"EARLY_PHASE1":2174,"PHASE1":2176,"PHASE2":2178,"PHASE3":2184,"PHASE4":2186,"NA":2188},{"trials":2175,"activeCount":99},[],{"trials":2177,"activeCount":99},[],{"trials":2179,"activeCount":151,"soonestReadout":607},[2180],{"nctId":637,"briefTitle":638,"status":122,"phases":2181,"primaryCompletion":607,"completion":607,"start":640,"enrollment":641,"conditions":2182,"interventions":2183},[89],[30,643],[149,614,645,646,146,647,648,649,650,651],{"trials":2185,"activeCount":99},[],{"trials":2187,"activeCount":99},[],{"trials":2189,"activeCount":99},[],{"intervention":646,"totalTrials":151,"cells":2191},{"EARLY_PHASE1":2192,"PHASE1":2194,"PHASE2":2196,"PHASE3":2202,"PHASE4":2204,"NA":2206},{"trials":2193,"activeCount":99},[],{"trials":2195,"activeCount":99},[],{"trials":2197,"activeCount":151,"soonestReadout":607},[2198],{"nctId":637,"briefTitle":638,"status":122,"phases":2199,"primaryCompletion":607,"completion":607,"start":640,"enrollment":641,"conditions":2200,"interventions":2201},[89],[30,643],[149,614,645,646,146,647,648,649,650,651],{"trials":2203,"activeCount":99},[],{"trials":2205,"activeCount":99},[],{"trials":2207,"activeCount":99},[],{"intervention":647,"totalTrials":151,"cells":2209},{"EARLY_PHASE1":2210,"PHASE1":2212,"PHASE2":2214,"PHASE3":2220,"PHASE4":2222,"NA":2224},{"trials":2211,"activeCount":99},[],{"trials":2213,"activeCount":99},[],{"trials":2215,"activeCount":151,"soonestReadout":607},[2216],{"nctId":637,"briefTitle":638,"status":122,"phases":2217,"primaryCompletion":607,"completion":607,"start":640,"enrollment":641,"conditions":2218,"interventions":2219},[89],[30,643],[149,614,645,646,146,647,648,649,650,651],{"trials":2221,"activeCount":99},[],{"trials":2223,"activeCount":99},[],{"trials":2225,"activeCount":99},[],{"intervention":648,"totalTrials":151,"cells":2227},{"EARLY_PHASE1":2228,"PHASE1":2230,"PHASE2":2232,"PHASE3":2238,"PHASE4":2240,"NA":2242},{"trials":2229,"activeCount":99},[],{"trials":2231,"activeCount":99},[],{"trials":2233,"activeCount":151,"soonestReadout":607},[2234],{"nctId":637,"briefTitle":638,"status":122,"phases":2235,"primaryCompletion":607,"completion":607,"start":640,"enrollment":641,"conditions":2236,"interventions":2237},[89],[30,643],[149,614,645,646,146,647,648,649,650,651],{"trials":2239,"activeCount":99},[],{"trials":2241,"activeCount":99},[],{"trials":2243,"activeCount":99},[],{"intervention":649,"totalTrials":151,"cells":2245},{"EARLY_PHASE1":2246,"PHASE1":2248,"PHASE2":2250,"PHASE3":2256,"PHASE4":2258,"NA":2260},{"trials":2247,"activeCount":99},[],{"trials":2249,"activeCount":99},[],{"trials":2251,"activeCount":151,"soonestReadout":607},[2252],{"nctId":637,"briefTitle":638,"status":122,"phases":2253,"primaryCompletion":607,"completion":607,"start":640,"enrollment":641,"conditions":2254,"interventions":2255},[89],[30,643],[149,614,645,646,146,647,648,649,650,651],{"trials":2257,"activeCount":99},[],{"trials":2259,"activeCount":99},[],{"trials":2261,"activeCount":99},[],{"intervention":650,"totalTrials":151,"cells":2263},{"EARLY_PHASE1":2264,"PHASE1":2266,"PHASE2":2268,"PHASE3":2274,"PHASE4":2276,"NA":2278},{"trials":2265,"activeCount":99},[],{"trials":2267,"activeCount":99},[],{"trials":2269,"activeCount":151,"soonestReadout":607},[2270],{"nctId":637,"briefTitle":638,"status":122,"phases":2271,"primaryCompletion":607,"completion":607,"start":640,"enrollment":641,"conditions":2272,"interventions":2273},[89],[30,643],[149,614,645,646,146,647,648,649,650,651],{"trials":2275,"activeCount":99},[],{"trials":2277,"activeCount":99},[],{"trials":2279,"activeCount":99},[],{"intervention":651,"totalTrials":151,"cells":2281},{"EARLY_PHASE1":2282,"PHASE1":2284,"PHASE2":2286,"PHASE3":2292,"PHASE4":2294,"NA":2296},{"trials":2283,"activeCount":99},[],{"trials":2285,"activeCount":99},[],{"trials":2287,"activeCount":151,"soonestReadout":607},[2288],{"nctId":637,"briefTitle":638,"status":122,"phases":2289,"primaryCompletion":607,"completion":607,"start":640,"enrollment":641,"conditions":2290,"interventions":2291},[89],[30,643],[149,614,645,646,146,647,648,649,650,651],{"trials":2293,"activeCount":99},[],{"trials":2295,"activeCount":99},[],{"trials":2297,"activeCount":99},[],{"intervention":2299,"totalTrials":151,"cells":2300},"RH5.1 and\u002For RH5.2-VLP with Matrix-M",{"EARLY_PHASE1":2301,"PHASE1":2303,"PHASE2":2305,"PHASE3":2320,"PHASE4":2322,"NA":2324},{"trials":2302,"activeCount":99},[],{"trials":2304,"activeCount":99},[],{"trials":2306,"activeCount":151,"soonestReadout":2311},[2307],{"nctId":2308,"briefTitle":2309,"status":155,"phases":2310,"primaryCompletion":2311,"completion":2312,"start":2313,"enrollment":2314,"conditions":2315,"interventions":2319},"NCT05978037","A Study to Assess the Safety and Effectiveness of Two Experimental Malaria Vaccines",[88,89],"2026-01-10","2026-03-10","2023-08-18",58,[15,27,2316,2317,2318],"Parasitic Disease","Vector Borne Diseases","Infections",[2299],{"trials":2321,"activeCount":99},[],{"trials":2323,"activeCount":99},[],{"trials":2325,"activeCount":99},[],{"intervention":81,"totalTrials":151,"cells":2327},{"EARLY_PHASE1":2328,"PHASE1":2330,"PHASE2":2332,"PHASE3":2343,"PHASE4":2345,"NA":2347},{"trials":2329,"activeCount":99},[],{"trials":2331,"activeCount":99},[],{"trials":2333,"activeCount":151,"soonestReadout":80},[2334],{"nctId":78,"briefTitle":79,"status":283,"phases":2335,"primaryCompletion":80,"completion":80,"start":2336,"enrollment":2337,"conditions":2338,"interventions":2342},[88,89],"2025-01",50,[2339,2340,2341],"Effort Based Decision Making","Prosocial Behavior","Apathy",[81],{"trials":2344,"activeCount":99},[],{"trials":2346,"activeCount":99},[],{"trials":2348,"activeCount":99},[],{"intervention":1533,"totalTrials":151,"cells":2350},{"EARLY_PHASE1":2351,"PHASE1":2353,"PHASE2":2355,"PHASE3":2361,"PHASE4":2363,"NA":2365},{"trials":2352,"activeCount":99},[],{"trials":2354,"activeCount":99},[],{"trials":2356,"activeCount":151,"soonestReadout":1403},[2357],{"nctId":1527,"briefTitle":1528,"status":283,"phases":2358,"primaryCompletion":1403,"completion":1403,"start":393,"enrollment":1530,"conditions":2359,"interventions":2360},[89],[1513],[1533,1499],{"trials":2362,"activeCount":99},[],{"trials":2364,"activeCount":99},[],{"trials":2366,"activeCount":99},[],{"intervention":1781,"totalTrials":151,"cells":2368},{"EARLY_PHASE1":2369,"PHASE1":2371,"PHASE2":2373,"PHASE3":2379,"PHASE4":2381,"NA":2383},{"trials":2370,"activeCount":99},[],{"trials":2372,"activeCount":99},[],{"trials":2374,"activeCount":151,"soonestReadout":1775},[2375],{"nctId":1772,"briefTitle":1773,"status":122,"phases":2376,"primaryCompletion":1775,"completion":1776,"start":1777,"enrollment":1778,"conditions":2377,"interventions":2378},[89],[1765],[1752,1781,1768,1782,1783],{"trials":2380,"activeCount":99},[],{"trials":2382,"activeCount":99},[],{"trials":2384,"activeCount":99},[],{"intervention":1782,"totalTrials":151,"cells":2386},{"EARLY_PHASE1":2387,"PHASE1":2389,"PHASE2":2391,"PHASE3":2397,"PHASE4":2399,"NA":2401},{"trials":2388,"activeCount":99},[],{"trials":2390,"activeCount":99},[],{"trials":2392,"activeCount":151,"soonestReadout":1775},[2393],{"nctId":1772,"briefTitle":1773,"status":122,"phases":2394,"primaryCompletion":1775,"completion":1776,"start":1777,"enrollment":1778,"conditions":2395,"interventions":2396},[89],[1765],[1752,1781,1768,1782,1783],{"trials":2398,"activeCount":99},[],{"trials":2400,"activeCount":99},[],{"trials":2402,"activeCount":99},[],{"intervention":1783,"totalTrials":151,"cells":2404},{"EARLY_PHASE1":2405,"PHASE1":2407,"PHASE2":2409,"PHASE3":2415,"PHASE4":2417,"NA":2419},{"trials":2406,"activeCount":99},[],{"trials":2408,"activeCount":99},[],{"trials":2410,"activeCount":151,"soonestReadout":1775},[2411],{"nctId":1772,"briefTitle":1773,"status":122,"phases":2412,"primaryCompletion":1775,"completion":1776,"start":1777,"enrollment":1778,"conditions":2413,"interventions":2414},[89],[1765],[1752,1781,1768,1782,1783],{"trials":2416,"activeCount":99},[],{"trials":2418,"activeCount":99},[],{"trials":2420,"activeCount":99},[],{"intervention":1744,"totalTrials":151,"cells":2422},{"EARLY_PHASE1":2423,"PHASE1":2425,"PHASE2":2427,"PHASE3":2433,"PHASE4":2435,"NA":2437},{"trials":2424,"activeCount":99},[],{"trials":2426,"activeCount":99},[],{"trials":2428,"activeCount":151,"soonestReadout":1737},[2429],{"nctId":1734,"briefTitle":1735,"status":155,"phases":2430,"primaryCompletion":1737,"completion":1738,"start":1739,"enrollment":1740,"conditions":2431,"interventions":2432},[89],[1742],[1716,1744],{"trials":2434,"activeCount":99},[],{"trials":2436,"activeCount":99},[],{"trials":2438,"activeCount":99},[],{"intervention":1577,"totalTrials":151,"cells":2440},{"EARLY_PHASE1":2441,"PHASE1":2443,"PHASE2":2445,"PHASE3":2451,"PHASE4":2453,"NA":2455},{"trials":2442,"activeCount":99},[],{"trials":2444,"activeCount":99},[],{"trials":2446,"activeCount":151,"soonestReadout":394},[2447],{"nctId":1570,"briefTitle":1571,"status":155,"phases":2448,"primaryCompletion":394,"completion":394,"start":1573,"enrollment":1574,"conditions":2449,"interventions":2450},[89],[27],[1541,1564,1565,1566,1577,1578,1579],{"trials":2452,"activeCount":99},[],{"trials":2454,"activeCount":99},[],{"trials":2456,"activeCount":99},[],{"intervention":1578,"totalTrials":151,"cells":2458},{"EARLY_PHASE1":2459,"PHASE1":2461,"PHASE2":2463,"PHASE3":2469,"PHASE4":2471,"NA":2473},{"trials":2460,"activeCount":99},[],{"trials":2462,"activeCount":99},[],{"trials":2464,"activeCount":151,"soonestReadout":394},[2465],{"nctId":1570,"briefTitle":1571,"status":155,"phases":2466,"primaryCompletion":394,"completion":394,"start":1573,"enrollment":1574,"conditions":2467,"interventions":2468},[89],[27],[1541,1564,1565,1566,1577,1578,1579],{"trials":2470,"activeCount":99},[],{"trials":2472,"activeCount":99},[],{"trials":2474,"activeCount":99},[],{"intervention":1579,"totalTrials":151,"cells":2476},{"EARLY_PHASE1":2477,"PHASE1":2479,"PHASE2":2481,"PHASE3":2487,"PHASE4":2489,"NA":2491},{"trials":2478,"activeCount":99},[],{"trials":2480,"activeCount":99},[],{"trials":2482,"activeCount":151,"soonestReadout":394},[2483],{"nctId":1570,"briefTitle":1571,"status":155,"phases":2484,"primaryCompletion":394,"completion":394,"start":1573,"enrollment":1574,"conditions":2485,"interventions":2486},[89],[27],[1541,1564,1565,1566,1577,1578,1579],{"trials":2488,"activeCount":99},[],{"trials":2490,"activeCount":99},[],{"trials":2492,"activeCount":99},[],{"intervention":634,"totalTrials":95,"cells":2494},{"EARLY_PHASE1":2495,"PHASE1":2497,"PHASE2":2509,"PHASE3":2515,"PHASE4":2517,"NA":2519},{"trials":2496,"activeCount":99},[],{"trials":2498,"activeCount":99},[2499],{"nctId":2500,"briefTitle":2501,"status":109,"phases":2502,"primaryCompletion":2503,"completion":2503,"start":2504,"enrollment":1674,"conditions":2505,"interventions":2507},"NCT02696941","SGLT2 Inhibitors and Metformin on Metabolism and Non-Alcoholic SteatoHepatitis",[88],"2018-04-01","2016-02",[2506],"Non-alcoholic Fatty Liver Disease",[634,2508],"SGLT2 inhibitor",{"trials":2510,"activeCount":151,"soonestReadout":619},[2511],{"nctId":616,"briefTitle":617,"status":122,"phases":2512,"primaryCompletion":619,"completion":619,"start":620,"enrollment":621,"conditions":2513,"interventions":2514},[89],[623],[625,626,627,133,628,629,146,145,630,628,614,631,632,633,634,625,625,635],{"trials":2516,"activeCount":99},[],{"trials":2518,"activeCount":99},[],{"trials":2520,"activeCount":99},[2521],{"nctId":2522,"briefTitle":2523,"status":109,"phases":2524,"primaryCompletion":2525,"completion":2525,"start":2526,"enrollment":2527,"conditions":2528,"interventions":2530},"NCT01046032","Metformin Treatment Before in Vitro Fertilization (IVF) in Women With Ultrasound Evidence of Polycystic Ovaries",[92],"2009-05","2005-12",134,[2529],"Polycystic Ovary Syndrome",[634],{"intervention":613,"totalTrials":168,"cells":2532},{"EARLY_PHASE1":2533,"PHASE1":2535,"PHASE2":2537,"PHASE3":2543,"PHASE4":2545,"NA":2547},{"trials":2534,"activeCount":99},[],{"trials":2536,"activeCount":99},[],{"trials":2538,"activeCount":151,"soonestReadout":607},[2539],{"nctId":604,"briefTitle":605,"status":122,"phases":2540,"primaryCompletion":607,"completion":607,"start":608,"enrollment":563,"conditions":2541,"interventions":2542},[89],[610,611],[613,146,614],{"trials":2544,"activeCount":99},[],{"trials":2546,"activeCount":99},[],{"trials":2548,"activeCount":99},[2549],{"nctId":2550,"briefTitle":2551,"status":795,"phases":2552,"primaryCompletion":2553,"completion":2553,"start":2554,"enrollment":168,"conditions":2555,"interventions":2557},"NCT03889106","Cardiovascular Function and Ribavirin Pharmacokinetics and Pharmacodynamics in Patients With Lassa Fever",[],"2020-10-01","2019-03-01",[2556],"Lassa Fever",[613],{"intervention":2559,"totalTrials":168,"cells":2560},"Piperaquine",{"EARLY_PHASE1":2561,"PHASE1":2563,"PHASE2":2577,"PHASE3":2592,"PHASE4":2594,"NA":2596},{"trials":2562,"activeCount":99},[],{"trials":2564,"activeCount":151,"soonestReadout":2569},[2565],{"nctId":2566,"briefTitle":2567,"status":283,"phases":2568,"primaryCompletion":2569,"completion":2570,"start":2571,"enrollment":2572,"conditions":2573,"interventions":2574},"NCT07470424","A Clinical Study of Piperaquine, Pyronaridine, and Artesunate Administered in Combination in Healthy Adults",[88],"2027-06-01","2027-08-01","2026-06-01",24,[15],[2559,2575,2576],"Artesunate-pyronaridine","Piperaquine and artesunate-pyronaridine",{"trials":2578,"activeCount":99},[2579],{"nctId":2580,"briefTitle":2581,"status":2582,"phases":2583,"primaryCompletion":393,"completion":2584,"start":2585,"enrollment":2586,"conditions":2587,"interventions":2588},"NCT04280692","Controlled Human Malaria Infection Transmission Model - Phase A","SUSPENDED",[88,89],"2026-08","2022-08-22",44,[27],[2589,2590,2559,2591,190],"PfSPZ Challenge","Sulfadoxine-Pyrimethamine","Artemether lumefantrine",{"trials":2593,"activeCount":99},[],{"trials":2595,"activeCount":99},[],{"trials":2597,"activeCount":99},[],{"intervention":62,"totalTrials":151,"cells":2599},{"EARLY_PHASE1":2600,"PHASE1":2602,"PHASE2":2610,"PHASE3":2612,"PHASE4":2614,"NA":2616},{"trials":2601,"activeCount":99},[],{"trials":2603,"activeCount":151,"soonestReadout":61},[2604],{"nctId":59,"briefTitle":60,"status":155,"phases":2605,"primaryCompletion":61,"completion":61,"start":2606,"enrollment":2572,"conditions":2607,"interventions":2609},[88],"2023-06-06",[15,27,2608,2316,2318,2317],"Protozoan Infections",[62],{"trials":2611,"activeCount":99},[],{"trials":2613,"activeCount":99},[],{"trials":2615,"activeCount":99},[],{"trials":2617,"activeCount":99},[],{"intervention":2619,"totalTrials":151,"cells":2620},"Omicron BA.5 SARS-CoV-2 challenge virus",{"EARLY_PHASE1":2621,"PHASE1":2623,"PHASE2":2635,"PHASE3":2637,"PHASE4":2639,"NA":2641},{"trials":2622,"activeCount":99},[],{"trials":2624,"activeCount":151,"soonestReadout":2629},[2625],{"nctId":2626,"briefTitle":2627,"status":155,"phases":2628,"primaryCompletion":2629,"completion":2629,"start":2630,"enrollment":2631,"conditions":2632,"interventions":2634},"NCT06478420","COVID-19 Omicron BA.5 Subvariant Dose Finding Infection Study",[88],"2028-10-31","2024-08-08",45,[2633],"SARS-CoV-2 Infection",[2619],{"trials":2636,"activeCount":99},[],{"trials":2638,"activeCount":99},[],{"trials":2640,"activeCount":99},[],{"trials":2642,"activeCount":99},[],{"intervention":2644,"totalTrials":151,"cells":2645},"Shigella sonnei 53G",{"EARLY_PHASE1":2646,"PHASE1":2648,"PHASE2":2662,"PHASE3":2664,"PHASE4":2666,"NA":2668},{"trials":2647,"activeCount":99},[],{"trials":2649,"activeCount":151,"soonestReadout":2654},[2650],{"nctId":2651,"briefTitle":2652,"status":122,"phases":2653,"primaryCompletion":2654,"completion":2655,"start":2656,"enrollment":2657,"conditions":2658,"interventions":2660},"NCT05959616","Shigella Sonnei 53G Human Infection Study in Kenyan Adults",[88],"2026-04-30","2027-08-30","2025-01-21",70,[2659],"Shigellosis",[2644,2661],"Ciprofloxacin 500 mg",{"trials":2663,"activeCount":99},[],{"trials":2665,"activeCount":99},[],{"trials":2667,"activeCount":99},[],{"trials":2669,"activeCount":99},[],{"intervention":2661,"totalTrials":151,"cells":2671},{"EARLY_PHASE1":2672,"PHASE1":2674,"PHASE2":2680,"PHASE3":2682,"PHASE4":2684,"NA":2686},{"trials":2673,"activeCount":99},[],{"trials":2675,"activeCount":151,"soonestReadout":2654},[2676],{"nctId":2651,"briefTitle":2652,"status":122,"phases":2677,"primaryCompletion":2654,"completion":2655,"start":2656,"enrollment":2657,"conditions":2678,"interventions":2679},[88],[2659],[2644,2661],{"trials":2681,"activeCount":99},[],{"trials":2683,"activeCount":99},[],{"trials":2685,"activeCount":99},[],{"trials":2687,"activeCount":99},[],{"intervention":2689,"totalTrials":151,"cells":2690},"R21\u002FMatrix M™",{"EARLY_PHASE1":2691,"PHASE1":2693,"PHASE2":2703,"PHASE3":2705,"PHASE4":2707,"NA":2709},{"trials":2692,"activeCount":99},[],{"trials":2694,"activeCount":151,"soonestReadout":775},[2695],{"nctId":2696,"briefTitle":2697,"status":155,"phases":2698,"primaryCompletion":775,"completion":2699,"start":2700,"enrollment":1848,"conditions":2701,"interventions":2702},"NCT06320535","A Phase 1 Study to Assess an Escalating Dose, Multi-prime Vaccination Schedule of R21\u002FMatrix-M™",[88],"2027-06","2024-03-25",[27],[2689,2689,2689],{"trials":2704,"activeCount":99},[],{"trials":2706,"activeCount":99},[],{"trials":2708,"activeCount":99},[],{"trials":2710,"activeCount":99},[],{"intervention":2575,"totalTrials":151,"cells":2712},{"EARLY_PHASE1":2713,"PHASE1":2715,"PHASE2":2721,"PHASE3":2723,"PHASE4":2725,"NA":2727},{"trials":2714,"activeCount":99},[],{"trials":2716,"activeCount":151,"soonestReadout":2569},[2717],{"nctId":2566,"briefTitle":2567,"status":283,"phases":2718,"primaryCompletion":2569,"completion":2570,"start":2571,"enrollment":2572,"conditions":2719,"interventions":2720},[88],[15],[2559,2575,2576],{"trials":2722,"activeCount":99},[],{"trials":2724,"activeCount":99},[],{"trials":2726,"activeCount":99},[],{"trials":2728,"activeCount":99},[],{"intervention":2576,"totalTrials":151,"cells":2730},{"EARLY_PHASE1":2731,"PHASE1":2733,"PHASE2":2739,"PHASE3":2741,"PHASE4":2743,"NA":2745},{"trials":2732,"activeCount":99},[],{"trials":2734,"activeCount":151,"soonestReadout":2569},[2735],{"nctId":2566,"briefTitle":2567,"status":283,"phases":2736,"primaryCompletion":2569,"completion":2570,"start":2571,"enrollment":2572,"conditions":2737,"interventions":2738},[88],[15],[2559,2575,2576],{"trials":2740,"activeCount":99},[],{"trials":2742,"activeCount":99},[],{"trials":2744,"activeCount":99},[],{"trials":2746,"activeCount":99},[],{"intervention":71,"totalTrials":151,"cells":2748},{"EARLY_PHASE1":2749,"PHASE1":2751,"PHASE2":2760,"PHASE3":2762,"PHASE4":2764,"NA":2766},{"trials":2750,"activeCount":99},[],{"trials":2752,"activeCount":151,"soonestReadout":70},[2753],{"nctId":68,"briefTitle":69,"status":122,"phases":2754,"primaryCompletion":70,"completion":2755,"start":2336,"enrollment":34,"conditions":2756,"interventions":2759},[88],"2026-01-01",[2757,2758],"Menopause","Metabolic Dysfunction Associated Steatotic Liver Disease",[71],{"trials":2761,"activeCount":99},[],{"trials":2763,"activeCount":99},[],{"trials":2765,"activeCount":99},[],{"trials":2767,"activeCount":99},[],{"intervention":66,"totalTrials":168,"cells":2769},{"EARLY_PHASE1":2770,"PHASE1":2784,"PHASE2":2786,"PHASE3":2788,"PHASE4":2790,"NA":2792},{"trials":2771,"activeCount":168,"soonestReadout":61},[2772,2777],{"nctId":64,"briefTitle":65,"status":122,"phases":2773,"primaryCompletion":61,"completion":61,"start":2774,"enrollment":16,"conditions":2775,"interventions":2776},[87],"2024-08-14",[372],[66],{"nctId":83,"briefTitle":84,"status":122,"phases":2778,"primaryCompletion":85,"completion":85,"start":2779,"enrollment":2780,"conditions":2781,"interventions":2783},[87],"2024-08-19",68,[2782],"Social Cognition",[66],{"trials":2785,"activeCount":99},[],{"trials":2787,"activeCount":99},[],{"trials":2789,"activeCount":99},[],{"trials":2791,"activeCount":99},[],{"trials":2793,"activeCount":99},[],{"intervention":2795,"totalTrials":151,"cells":2796},"Losartan with BA",{"EARLY_PHASE1":2797,"PHASE1":2807,"PHASE2":2809,"PHASE3":2811,"PHASE4":2813,"NA":2815},{"trials":2798,"activeCount":151,"soonestReadout":285},[2799],{"nctId":2800,"briefTitle":2801,"status":122,"phases":2802,"primaryCompletion":285,"completion":285,"start":1446,"enrollment":2803,"conditions":2804,"interventions":2806},"NCT07017023","Combined Blood Pressure Medication and Activity Scheduling for Low Mood",[87],76,[372,2805],"Mood",[2795],{"trials":2808,"activeCount":99},[],{"trials":2810,"activeCount":99},[],{"trials":2812,"activeCount":99},[],{"trials":2814,"activeCount":99},[],{"trials":2816,"activeCount":99},[],{"intervention":2818,"totalTrials":151,"cells":2819},"Matrix M with R78C and\u002For RH5.1",{"EARLY_PHASE1":2820,"PHASE1":2830,"PHASE2":2832,"PHASE3":2834,"PHASE4":2836,"NA":2838},{"trials":2821,"activeCount":151,"soonestReadout":1444},[2822],{"nctId":2823,"briefTitle":2824,"status":155,"phases":2825,"primaryCompletion":1444,"completion":1444,"start":2826,"enrollment":1848,"conditions":2827,"interventions":2829},"NCT05385471","A Phase Ia Clinical Trial to Assess the Safety and Immunogenicity of the Blood-stage Malaria Candidate Vaccines RH5.1 in Matrix-M and R78C in Matrix-M in Healthy UK Adults",[87],"2023-01-13",[2828],"Malaria, Falciparum",[2818],{"trials":2831,"activeCount":99},[],{"trials":2833,"activeCount":99},[],{"trials":2835,"activeCount":99},[],{"trials":2837,"activeCount":99},[],{"trials":2839,"activeCount":99},[],{"intervention":2841,"totalTrials":95,"cells":2842},"Losartan Potassium",{"EARLY_PHASE1":2843,"PHASE1":2854,"PHASE2":2856,"PHASE3":2858,"PHASE4":2860,"NA":2862},{"trials":2844,"activeCount":151,"soonestReadout":2849},[2845],{"nctId":2846,"briefTitle":2847,"status":122,"phases":2848,"primaryCompletion":2849,"completion":2849,"start":2850,"enrollment":16,"conditions":2851,"interventions":2852},"NCT06636812","Losartan and Emotional Processing in Young People",[87],"2025-12-31","2024-03-07",[372],[2853],"Losartan potassium",{"trials":2855,"activeCount":99},[],{"trials":2857,"activeCount":99},[],{"trials":2859,"activeCount":99},[],{"trials":2861,"activeCount":99},[],{"trials":2863,"activeCount":99},[2864,2874],{"nctId":2865,"briefTitle":2866,"status":109,"phases":2867,"primaryCompletion":2868,"completion":2868,"start":2869,"enrollment":2870,"conditions":2871,"interventions":2873},"NCT03763409","Losartan and Emotional Memory",[92],"2018-09-28","2018-03-01",53,[2872,370],"Memory",[2841],{"nctId":2875,"briefTitle":2876,"status":109,"phases":2877,"primaryCompletion":2878,"completion":2878,"start":2879,"enrollment":2104,"conditions":2880,"interventions":2882},"NCT05828940","Losartan and Memory",[92],"2022-03-31","2019-10-01",[2881],"PTSD",[2841],{"intervention":2884,"totalTrials":595,"cells":2885},"BCG Danish",{"EARLY_PHASE1":2886,"PHASE1":2888,"PHASE2":2908,"PHASE3":2910,"PHASE4":2912,"NA":2914},{"trials":2887,"activeCount":99},[],{"trials":2889,"activeCount":99},[2890,2898],{"nctId":2891,"briefTitle":2892,"status":109,"phases":2893,"primaryCompletion":2894,"completion":2894,"start":2895,"enrollment":31,"conditions":2896,"interventions":2897},"NCT04777721","Aerosol BCG Challenge Study in Historically BCG-vaccinated Volunteers",[88],"2023-06-20","2022-05-17",[18],[2884],{"nctId":2899,"briefTitle":2900,"status":2901,"phases":2902,"primaryCompletion":2903,"completion":2903,"start":2904,"enrollment":2905,"conditions":2906,"interventions":2907},"NCT03912207","Investigating Immune Responses to Aerosol BCG Challenge in Healthy UK Adults","UNKNOWN",[88],"2024-06","2019-04-19",94,[18],[2884],{"trials":2909,"activeCount":99},[],{"trials":2911,"activeCount":99},[],{"trials":2913,"activeCount":99},[],{"trials":2915,"activeCount":168,"soonestReadout":2920},[2916,2925],{"nctId":2917,"briefTitle":2918,"status":155,"phases":2919,"primaryCompletion":2920,"completion":2920,"start":2921,"enrollment":1778,"conditions":2922,"interventions":2923},"NCT06670755","ID93\u002FGLA-SE Vaccination + BCG Challenge",[92],"2027-07","2024-12-18",[18],[2924,2884],"ID93\u002FGLA-SE",{"nctId":2926,"briefTitle":2927,"status":155,"phases":2928,"primaryCompletion":2929,"completion":2929,"start":2930,"enrollment":1848,"conditions":2931,"interventions":2932},"NCT06246851","BCG Revaccination Study in Diabetic and Non-Diabetic Adults",[92],"2028-08-31","2024-04-03",[18],[2884],{"intervention":2934,"totalTrials":2935,"cells":2936},"Citalopram",6,{"EARLY_PHASE1":2937,"PHASE1":2939,"PHASE2":2952,"PHASE3":2954,"PHASE4":2956,"NA":2958},{"trials":2938,"activeCount":99},[],{"trials":2940,"activeCount":99},[2941],{"nctId":2942,"briefTitle":2943,"status":109,"phases":2944,"primaryCompletion":2945,"completion":2945,"start":2946,"enrollment":2947,"conditions":2948,"interventions":2950},"NCT03516604","PF-04995274 and Emotional Processing in Un-medicated Depression",[88],"2022-07-29","2018-05-16",90,[2949],"Depression, Unipolar",[2951,2934],"PF-04995274",{"trials":2953,"activeCount":99},[],{"trials":2955,"activeCount":99},[],{"trials":2957,"activeCount":99},[],{"trials":2959,"activeCount":151,"soonestReadout":439},[2960,2970,2983,2993,3001],{"nctId":2961,"briefTitle":2962,"status":109,"phases":2963,"primaryCompletion":2964,"completion":2964,"start":2965,"enrollment":2527,"conditions":2966,"interventions":2969},"NCT05627154","Combined Antidepressant and Behavioural Intervention",[92],"2023-11-17","2021-05-28",[2967,21,2968],"Low Mood","Anxiety",[2934],{"nctId":2971,"briefTitle":2972,"status":2901,"phases":2973,"primaryCompletion":2974,"completion":2974,"start":2975,"enrollment":1530,"conditions":2976,"interventions":2982},"NCT04161209","Citalopram and Stress Reactivity",[92],"2020-09","2019-10-11",[21,2977,2978,2979,2980,2981],"Depressive Disorder","Mental Disorder","Antidepressive Agents","Cognition","Stress",[2934],{"nctId":2984,"briefTitle":2985,"status":109,"phases":2986,"primaryCompletion":2987,"completion":2987,"start":2988,"enrollment":2989,"conditions":2990,"interventions":2992},"NCT01946607","Antidepressants, Emotions and Personality",[92],"2010-11","2009-07",42,[2991],"Antidepressive Agents, Second-Generation",[2934],{"nctId":2994,"briefTitle":2995,"status":122,"phases":2996,"primaryCompletion":439,"completion":439,"start":2997,"enrollment":2337,"conditions":2998,"interventions":3000},"NCT06412315","7T Amygdala and Citalopram Study",[92],"2025-02-13",[372,2980,2999,2977,21],"Mood Disorders",[2934],{"nctId":3002,"briefTitle":3003,"status":2901,"phases":3004,"primaryCompletion":2974,"completion":2974,"start":2975,"enrollment":2586,"conditions":3005,"interventions":3007},"NCT04169230","Citalopram and Self Emotional Processing",[92],[3006,21,2977,2978,2979,2980],"Molecular Mechanisms of Pharmacological Action",[2934],{"intervention":3009,"totalTrials":168,"cells":3010},"Medical air",{"EARLY_PHASE1":3011,"PHASE1":3013,"PHASE2":3015,"PHASE3":3017,"PHASE4":3019,"NA":3021},{"trials":3012,"activeCount":99},[],{"trials":3014,"activeCount":99},[],{"trials":3016,"activeCount":99},[],{"trials":3018,"activeCount":99},[],{"trials":3020,"activeCount":99},[],{"trials":3022,"activeCount":151,"soonestReadout":75},[3023,3032],{"nctId":3024,"briefTitle":3025,"status":109,"phases":3026,"primaryCompletion":3027,"completion":3027,"start":541,"enrollment":2337,"conditions":3028,"interventions":3030},"NCT01611064","A Study Investigating Ways to Make Local Anaesthetic Hand Surgery Less Painful - Reducing Tourniquet Associated Pain",[92],"2012-06",[3029],"Hand Injuries\u002FDisease Requiring Surgery to the Hand",[3031,3009],"Oxygen",{"nctId":73,"briefTitle":74,"status":122,"phases":3033,"primaryCompletion":75,"completion":85,"start":1509,"enrollment":3034,"conditions":3035,"interventions":3036},[92],88,[21],[76,3037],"Medical Air",{"intervention":3039,"totalTrials":151,"cells":3040},"Pfizer-BioNTech COVID-19 vaccine",{"EARLY_PHASE1":3041,"PHASE1":3043,"PHASE2":3045,"PHASE3":3047,"PHASE4":3049,"NA":3051},{"trials":3042,"activeCount":99},[],{"trials":3044,"activeCount":99},[],{"trials":3046,"activeCount":99},[],{"trials":3048,"activeCount":99},[],{"trials":3050,"activeCount":99},[],{"trials":3052,"activeCount":151,"soonestReadout":3057},[3053],{"nctId":3054,"briefTitle":3055,"status":122,"phases":3056,"primaryCompletion":3057,"completion":3057,"start":3058,"enrollment":3059,"conditions":3060,"interventions":3062},"NCT05571735","Immunogenicity of COVID-19 Vaccines in Tuberculosis Patients",[],"2026-06-30","2023-04-15",133,[3061,18],"Covid-19 Pandemics",[3039,3063,3064],"AstraZeneca vaccine","Janssen Ad26.COV2.S COVID-19 vaccine",{"intervention":3063,"totalTrials":151,"cells":3066},{"EARLY_PHASE1":3067,"PHASE1":3069,"PHASE2":3071,"PHASE3":3073,"PHASE4":3075,"NA":3077},{"trials":3068,"activeCount":99},[],{"trials":3070,"activeCount":99},[],{"trials":3072,"activeCount":99},[],{"trials":3074,"activeCount":99},[],{"trials":3076,"activeCount":99},[],{"trials":3078,"activeCount":151,"soonestReadout":3057},[3079],{"nctId":3054,"briefTitle":3055,"status":122,"phases":3080,"primaryCompletion":3057,"completion":3057,"start":3058,"enrollment":3059,"conditions":3081,"interventions":3082},[],[3061,18],[3039,3063,3064],{"intervention":3064,"totalTrials":151,"cells":3084},{"EARLY_PHASE1":3085,"PHASE1":3087,"PHASE2":3089,"PHASE3":3091,"PHASE4":3093,"NA":3095},{"trials":3086,"activeCount":99},[],{"trials":3088,"activeCount":99},[],{"trials":3090,"activeCount":99},[],{"trials":3092,"activeCount":99},[],{"trials":3094,"activeCount":99},[],{"trials":3096,"activeCount":151,"soonestReadout":3057},[3097],{"nctId":3054,"briefTitle":3055,"status":122,"phases":3098,"primaryCompletion":3057,"completion":3057,"start":3058,"enrollment":3059,"conditions":3099,"interventions":3100},[],[3061,18],[3039,3063,3064],{"intervention":3102,"totalTrials":151,"cells":3103},"Pimavanserin 10mg",{"EARLY_PHASE1":3104,"PHASE1":3106,"PHASE2":3108,"PHASE3":3110,"PHASE4":3112,"NA":3114},{"trials":3105,"activeCount":99},[],{"trials":3107,"activeCount":99},[],{"trials":3109,"activeCount":99},[],{"trials":3111,"activeCount":99},[],{"trials":3113,"activeCount":99},[],{"trials":3115,"activeCount":151,"soonestReadout":775},[3116],{"nctId":3117,"briefTitle":3118,"status":122,"phases":3119,"primaryCompletion":775,"completion":2102,"start":3120,"enrollment":799,"conditions":3121,"interventions":3122},"NCT07022366","Investigating the Neuropsychological Effects of 5-HT2a Antagonism",[92],"2025-02-10",[24],[3102],{"intervention":2924,"totalTrials":151,"cells":3124},{"EARLY_PHASE1":3125,"PHASE1":3127,"PHASE2":3129,"PHASE3":3131,"PHASE4":3133,"NA":3135},{"trials":3126,"activeCount":99},[],{"trials":3128,"activeCount":99},[],{"trials":3130,"activeCount":99},[],{"trials":3132,"activeCount":99},[],{"trials":3134,"activeCount":99},[],{"trials":3136,"activeCount":151,"soonestReadout":2920},[3137],{"nctId":2917,"briefTitle":2918,"status":155,"phases":3138,"primaryCompletion":2920,"completion":2920,"start":2921,"enrollment":1778,"conditions":3139,"interventions":3140},[92],[18],[2924,2884],{"intervention":3142,"totalTrials":151,"cells":3143},"An inoculum of malaria parasitised red blood cells with whole dose blood-stage inoculum",{"EARLY_PHASE1":3144,"PHASE1":3146,"PHASE2":3148,"PHASE3":3150,"PHASE4":3152,"NA":3154},{"trials":3145,"activeCount":99},[],{"trials":3147,"activeCount":99},[],{"trials":3149,"activeCount":99},[],{"trials":3151,"activeCount":99},[],{"trials":3153,"activeCount":99},[],{"trials":3155,"activeCount":151,"soonestReadout":3160},[3156],{"nctId":3157,"briefTitle":3158,"status":122,"phases":3159,"primaryCompletion":3160,"completion":3160,"start":3161,"enrollment":1778,"conditions":3162,"interventions":3163},"NCT05071079","A Controlled Human Vivax Malaria Infection Study Through Inoculation of Infected Erythrocytes",[92],"2026-11","2022-05-23",[1850],[3142,3164,3165,3166],"An inoculum of malaria parasitised red blood cells with 1:5 dilution blood-stage inoculum","An inoculum of malaria parasitised red blood cells with 1:10 dilution blood-stage inoculum","An inoculum of malaria parasitised red blood cells with 1:20 dilution blood-stage inoculum",{"intervention":3164,"totalTrials":151,"cells":3168},{"EARLY_PHASE1":3169,"PHASE1":3171,"PHASE2":3173,"PHASE3":3175,"PHASE4":3177,"NA":3179},{"trials":3170,"activeCount":99},[],{"trials":3172,"activeCount":99},[],{"trials":3174,"activeCount":99},[],{"trials":3176,"activeCount":99},[],{"trials":3178,"activeCount":99},[],{"trials":3180,"activeCount":151,"soonestReadout":3160},[3181],{"nctId":3157,"briefTitle":3158,"status":122,"phases":3182,"primaryCompletion":3160,"completion":3160,"start":3161,"enrollment":1778,"conditions":3183,"interventions":3184},[92],[1850],[3142,3164,3165,3166],{"intervention":3165,"totalTrials":151,"cells":3186},{"EARLY_PHASE1":3187,"PHASE1":3189,"PHASE2":3191,"PHASE3":3193,"PHASE4":3195,"NA":3197},{"trials":3188,"activeCount":99},[],{"trials":3190,"activeCount":99},[],{"trials":3192,"activeCount":99},[],{"trials":3194,"activeCount":99},[],{"trials":3196,"activeCount":99},[],{"trials":3198,"activeCount":151,"soonestReadout":3160},[3199],{"nctId":3157,"briefTitle":3158,"status":122,"phases":3200,"primaryCompletion":3160,"completion":3160,"start":3161,"enrollment":1778,"conditions":3201,"interventions":3202},[92],[1850],[3142,3164,3165,3166],{"intervention":3166,"totalTrials":151,"cells":3204},{"EARLY_PHASE1":3205,"PHASE1":3207,"PHASE2":3209,"PHASE3":3211,"PHASE4":3213,"NA":3215},{"trials":3206,"activeCount":99},[],{"trials":3208,"activeCount":99},[],{"trials":3210,"activeCount":99},[],{"trials":3212,"activeCount":99},[],{"trials":3214,"activeCount":99},[],{"trials":3216,"activeCount":151,"soonestReadout":3160},[3217],{"nctId":3157,"briefTitle":3158,"status":122,"phases":3218,"primaryCompletion":3160,"completion":3160,"start":3161,"enrollment":1778,"conditions":3219,"interventions":3220},[92],[1850],[3142,3164,3165,3166],{"intervention":76,"totalTrials":151,"cells":3222},{"EARLY_PHASE1":3223,"PHASE1":3225,"PHASE2":3227,"PHASE3":3229,"PHASE4":3231,"NA":3233},{"trials":3224,"activeCount":99},[],{"trials":3226,"activeCount":99},[],{"trials":3228,"activeCount":99},[],{"trials":3230,"activeCount":99},[],{"trials":3232,"activeCount":99},[],{"trials":3234,"activeCount":151,"soonestReadout":75},[3235],{"nctId":73,"briefTitle":74,"status":122,"phases":3236,"primaryCompletion":75,"completion":85,"start":1509,"enrollment":3034,"conditions":3237,"interventions":3238},[92],[21],[76,3037],{"intervention":3240,"totalTrials":95,"cells":3241},"Adalimumab",{"EARLY_PHASE1":3242,"PHASE1":3244,"PHASE2":3246,"PHASE3":3260,"PHASE4":3273,"NA":3288},{"trials":3243,"activeCount":99},[],{"trials":3245,"activeCount":99},[],{"trials":3247,"activeCount":99},[3248],{"nctId":3249,"briefTitle":3250,"status":109,"phases":3251,"primaryCompletion":3252,"completion":3253,"start":3254,"enrollment":3255,"conditions":3256,"interventions":3258},"NCT03180957","Repurposing Anti-TNF for Treating Dupuytren's Disease",[89],"2020-11","2020-12","2016-03-02",140,[3257],"Dupuytren's Disease",[3240,3259],"Saline",{"trials":3261,"activeCount":99},[3262],{"nctId":3263,"briefTitle":3264,"status":109,"phases":3265,"primaryCompletion":3266,"completion":3267,"start":3268,"enrollment":3269,"conditions":3270,"interventions":3272},"NCT05299242","The Anti-Freaze-F Study- \"Anti-TNF for Treatment of Frozen Shoulder - a Feasibility Study\"",[89,90],"2023-05-09","2023-06-12","2022-07-21",9,[3271],"Frozen Shoulder",[3240],{"trials":3274,"activeCount":99},[3275],{"nctId":3276,"briefTitle":3277,"status":109,"phases":3278,"primaryCompletion":3279,"completion":3279,"start":3280,"enrollment":3281,"conditions":3282,"interventions":3284},"NCT03739853","Severe Psoriatic Arthritis - Early intervEntion to Control Disease: the SPEED Trial",[91],"2024-10-31","2019-05-14",192,[3283],"Psoriatic Arthritis",[3285,3286,3287,3240],"Methotrexate","Sulfasalazine","Leflunomide",{"trials":3289,"activeCount":99},[],{"intervention":3286,"totalTrials":168,"cells":3291},{"EARLY_PHASE1":3292,"PHASE1":3294,"PHASE2":3296,"PHASE3":3298,"PHASE4":3300,"NA":3316},{"trials":3293,"activeCount":99},[],{"trials":3295,"activeCount":99},[],{"trials":3297,"activeCount":99},[],{"trials":3299,"activeCount":99},[],{"trials":3301,"activeCount":99},[3302,3312],{"nctId":3303,"briefTitle":3304,"status":109,"phases":3305,"primaryCompletion":3306,"completion":3306,"start":3307,"enrollment":151,"conditions":3308,"interventions":3309},"NCT03797872","Psoriatic Oligoarthritis Intervention With Symptomatic thErapy",[91],"2020-07-16","2019-04-17",[3283],[3285,3286,3287,3310,3311],"Methylprednisolone","Triamcinolone",{"nctId":3276,"briefTitle":3277,"status":109,"phases":3313,"primaryCompletion":3279,"completion":3279,"start":3280,"enrollment":3281,"conditions":3314,"interventions":3315},[91],[3283],[3285,3286,3287,3240],{"trials":3317,"activeCount":99},[],{"intervention":3287,"totalTrials":168,"cells":3319},{"EARLY_PHASE1":3320,"PHASE1":3322,"PHASE2":3324,"PHASE3":3326,"PHASE4":3328,"NA":3338},{"trials":3321,"activeCount":99},[],{"trials":3323,"activeCount":99},[],{"trials":3325,"activeCount":99},[],{"trials":3327,"activeCount":99},[],{"trials":3329,"activeCount":99},[3330,3334],{"nctId":3303,"briefTitle":3304,"status":109,"phases":3331,"primaryCompletion":3306,"completion":3306,"start":3307,"enrollment":151,"conditions":3332,"interventions":3333},[91],[3283],[3285,3286,3287,3310,3311],{"nctId":3276,"briefTitle":3277,"status":109,"phases":3335,"primaryCompletion":3279,"completion":3279,"start":3280,"enrollment":3281,"conditions":3336,"interventions":3337},[91],[3283],[3285,3286,3287,3240],{"trials":3339,"activeCount":99},[],{"intervention":534,"totalTrials":168,"cells":3341},{"EARLY_PHASE1":3342,"PHASE1":3344,"PHASE2":3346,"PHASE3":3348,"PHASE4":3354,"NA":3360},{"trials":3343,"activeCount":99},[],{"trials":3345,"activeCount":99},[],{"trials":3347,"activeCount":99},[],{"trials":3349,"activeCount":99},[3350],{"nctId":524,"briefTitle":525,"status":109,"phases":3351,"primaryCompletion":527,"completion":527,"start":528,"enrollment":529,"conditions":3352,"interventions":3353},[90],[531],[533,202,534],{"trials":3355,"activeCount":99},[3356],{"nctId":549,"briefTitle":550,"status":109,"phases":3357,"primaryCompletion":552,"completion":552,"start":553,"enrollment":554,"conditions":3358,"interventions":3359},[91],[531],[202,534],{"trials":3361,"activeCount":99},[],{"intervention":3363,"totalTrials":168,"cells":3364},"Atorvastatin",{"EARLY_PHASE1":3365,"PHASE1":3367,"PHASE2":3369,"PHASE3":3371,"PHASE4":3383,"NA":3396},{"trials":3366,"activeCount":99},[],{"trials":3368,"activeCount":99},[],{"trials":3370,"activeCount":99},[],{"trials":3372,"activeCount":99},[3373],{"nctId":3374,"briefTitle":3375,"status":109,"phases":3376,"primaryCompletion":3377,"completion":3377,"start":3378,"enrollment":3379,"conditions":3380,"interventions":3382},"NCT01278459","Can Atorvastatin Improve Vascular Function in Women With a History of Preeclampsia?",[90],"2012-04","2011-10",11,[3381],"Pre-Eclampsia",[3363],{"trials":3384,"activeCount":99},[3385],{"nctId":3386,"briefTitle":3387,"status":109,"phases":3388,"primaryCompletion":1456,"completion":1456,"start":3389,"enrollment":799,"conditions":3390,"interventions":3395},"NCT01780740","Statin Therapy In Atrial Refractoriness and Reperfusion Injury",[91],"2012-01",[3391,3392,3393,3394],"Disorder; Heart, Functional, Postoperative, Cardiac Surgery","Cardiac Insufficiency Following Cardiac Surgery","Atrial Fibrillation","Ischaemia-reperfusion Injury",[3363],{"trials":3397,"activeCount":99},[],{"intervention":3399,"totalTrials":168,"cells":3400},"10-valent pneumococcal conjugate vaccine",{"EARLY_PHASE1":3401,"PHASE1":3403,"PHASE2":3405,"PHASE3":3407,"PHASE4":3419,"NA":3432},{"trials":3402,"activeCount":99},[],{"trials":3404,"activeCount":99},[],{"trials":3406,"activeCount":99},[],{"trials":3408,"activeCount":99},[3409],{"nctId":3410,"briefTitle":3411,"status":109,"phases":3412,"primaryCompletion":3413,"start":3377,"enrollment":3414,"conditions":3415,"interventions":3417},"NCT01443416","An Alternative Booster Vaccine Against Meningitis and Ear Infections",[90],"2013-08",178,[3416],"Invasive Streptococcus Pneumoniae Disease",[3418,3399],"13-valent pneumococcal conjugate vaccine",{"trials":3420,"activeCount":99},[3421],{"nctId":3422,"briefTitle":3423,"status":109,"phases":3424,"primaryCompletion":3425,"completion":3426,"start":3427,"enrollment":3428,"conditions":3429,"interventions":3431},"NCT02385513","PCV10 Immunogenicity Study Nepal 2015",[91],"2017-01-20","2017-02-23","2015-08-21",304,[3430],"Streptococcus Pneumoniae",[3399],{"trials":3433,"activeCount":99},[],{"intervention":3418,"totalTrials":168,"cells":3435},{"EARLY_PHASE1":3436,"PHASE1":3438,"PHASE2":3440,"PHASE3":3442,"PHASE4":3448,"NA":3459},{"trials":3437,"activeCount":99},[],{"trials":3439,"activeCount":99},[],{"trials":3441,"activeCount":99},[],{"trials":3443,"activeCount":99},[3444],{"nctId":3410,"briefTitle":3411,"status":109,"phases":3445,"primaryCompletion":3413,"start":3377,"enrollment":3414,"conditions":3446,"interventions":3447},[90],[3416],[3418,3399],{"trials":3449,"activeCount":99},[3450],{"nctId":3451,"briefTitle":3452,"status":109,"phases":3453,"primaryCompletion":3454,"completion":3455,"start":3413,"enrollment":2337,"conditions":3456,"interventions":3458},"NCT01939522","Protection Against Pneumococcal Infection in Children With T1DM",[91],"2016-04","2017-01",[3457],"Type 1 Diabetes Mellitus",[3418],{"trials":3460,"activeCount":99},[],{"intervention":3462,"totalTrials":168,"cells":3463},"Prednisolone",{"EARLY_PHASE1":3464,"PHASE1":3466,"PHASE2":3468,"PHASE3":3483,"PHASE4":3485,"NA":3498},{"trials":3465,"activeCount":99},[],{"trials":3467,"activeCount":99},[],{"trials":3469,"activeCount":99},[3470],{"nctId":3471,"briefTitle":3472,"status":2901,"phases":3473,"primaryCompletion":3474,"completion":3475,"start":3476,"enrollment":3477,"conditions":3478,"interventions":3481},"NCT04098718","Acute Exacerbations Treated With BenRAlizumab (The ABRA Study)",[89],"2024-02-19","2024-11-19","2021-03-29",158,[3479,3480],"Asthma","COPD",[3482,3462],"Benralizumab",{"trials":3484,"activeCount":99},[],{"trials":3486,"activeCount":99},[3487],{"nctId":3488,"briefTitle":3489,"status":109,"phases":3490,"primaryCompletion":3491,"completion":3492,"start":3493,"enrollment":3494,"conditions":3495,"interventions":3497},"NCT04458636","Stratified TreAtment to Reduce Risk in COPD",[91],"2020-02-28","2020-04-30","2017-11-02",203,[3496],"COPD Exacerbation",[3462],{"trials":3499,"activeCount":99},[],{"intervention":3310,"totalTrials":151,"cells":3501},{"EARLY_PHASE1":3502,"PHASE1":3504,"PHASE2":3506,"PHASE3":3508,"PHASE4":3510,"NA":3516},{"trials":3503,"activeCount":99},[],{"trials":3505,"activeCount":99},[],{"trials":3507,"activeCount":99},[],{"trials":3509,"activeCount":99},[],{"trials":3511,"activeCount":99},[3512],{"nctId":3303,"briefTitle":3304,"status":109,"phases":3513,"primaryCompletion":3306,"completion":3306,"start":3307,"enrollment":151,"conditions":3514,"interventions":3515},[91],[3283],[3285,3286,3287,3310,3311],{"trials":3517,"activeCount":99},[],{"intervention":3311,"totalTrials":151,"cells":3519},{"EARLY_PHASE1":3520,"PHASE1":3522,"PHASE2":3524,"PHASE3":3526,"PHASE4":3528,"NA":3534},{"trials":3521,"activeCount":99},[],{"trials":3523,"activeCount":99},[],{"trials":3525,"activeCount":99},[],{"trials":3527,"activeCount":99},[],{"trials":3529,"activeCount":99},[3530],{"nctId":3303,"briefTitle":3304,"status":109,"phases":3531,"primaryCompletion":3306,"completion":3306,"start":3307,"enrollment":151,"conditions":3532,"interventions":3533},[91],[3283],[3285,3286,3287,3310,3311],{"trials":3535,"activeCount":99},[],{"intervention":3537,"totalTrials":151,"cells":3538},"quinine",{"EARLY_PHASE1":3539,"PHASE1":3541,"PHASE2":3543,"PHASE3":3545,"PHASE4":3547,"NA":3560},{"trials":3540,"activeCount":99},[],{"trials":3542,"activeCount":99},[],{"trials":3544,"activeCount":99},[],{"trials":3546,"activeCount":99},[],{"trials":3548,"activeCount":99},[3549],{"nctId":3550,"briefTitle":3551,"status":109,"phases":3552,"primaryCompletion":3553,"completion":3553,"start":3554,"enrollment":3555,"conditions":3556,"interventions":3558},"NCT02092766","Parenteral Artesunate Compared to Quinine as a Cause of Late Anaemia in African Children With Malaria",[91],"2015-04","2014-06",217,[3557],"Anaemia",[3559,3537],"artesunate",{"trials":3561,"activeCount":99},[],{"intervention":3563,"totalTrials":151,"cells":3564},"Modafinil",{"EARLY_PHASE1":3565,"PHASE1":3567,"PHASE2":3569,"PHASE3":3571,"PHASE4":3573,"NA":3585},{"trials":3566,"activeCount":99},[],{"trials":3568,"activeCount":99},[],{"trials":3570,"activeCount":99},[],{"trials":3572,"activeCount":99},[],{"trials":3574,"activeCount":99},[3575],{"nctId":3576,"briefTitle":3577,"status":109,"phases":3578,"primaryCompletion":3579,"completion":3579,"start":3580,"enrollment":3581,"conditions":3582,"interventions":3584},"NCT00829322","Modafinil for the Treatment of Fatigue in Lung Cancer V9.0",[91],"2012-05","2009-02",208,[3583],"Carcinoma, Non-Small-Cell Lung",[3563],{"trials":3586,"activeCount":99},[],{"intervention":3588,"totalTrials":151,"cells":3589},"Combined Oral Contraceptive Pill",{"EARLY_PHASE1":3590,"PHASE1":3592,"PHASE2":3594,"PHASE3":3596,"PHASE4":3598,"NA":3609},{"trials":3591,"activeCount":99},[],{"trials":3593,"activeCount":99},[],{"trials":3595,"activeCount":99},[],{"trials":3597,"activeCount":99},[],{"trials":3599,"activeCount":99},[3600],{"nctId":3601,"briefTitle":3602,"status":795,"phases":3603,"primaryCompletion":3604,"completion":3604,"start":3605,"enrollment":1273,"conditions":3606,"interventions":3608},"NCT01757249","Pituitary Down-regulation Before IVF for Women With Endometriosis",[91],"2013-11","2013-01",[3607],"Fertility",[3588],{"trials":3610,"activeCount":99},[],{"intervention":3612,"totalTrials":151,"cells":3613},"clopidogrel and metoprolol",{"EARLY_PHASE1":3614,"PHASE1":3616,"PHASE2":3618,"PHASE3":3620,"PHASE4":3622,"NA":3634},{"trials":3615,"activeCount":99},[],{"trials":3617,"activeCount":99},[],{"trials":3619,"activeCount":99},[],{"trials":3621,"activeCount":99},[],{"trials":3623,"activeCount":99},[3624],{"nctId":3625,"briefTitle":3626,"status":109,"phases":3627,"completion":3628,"start":3629,"enrollment":3630,"conditions":3631,"interventions":3633},"NCT00222573","Efficacy and Safety of Adding Clopidogrel to Aspirin or Use of Metoprolol in Myocardial Infarction",[91],"2005-02","1999-07",46000,[3632],"Acute Myocardial Infarction",[3612],{"trials":3635,"activeCount":99},[],{"intervention":3637,"totalTrials":151,"cells":3638},"Hepatitis B vaccine",{"EARLY_PHASE1":3639,"PHASE1":3641,"PHASE2":3643,"PHASE3":3645,"PHASE4":3647,"NA":3660},{"trials":3640,"activeCount":99},[],{"trials":3642,"activeCount":99},[],{"trials":3644,"activeCount":99},[],{"trials":3646,"activeCount":99},[],{"trials":3648,"activeCount":99},[3649],{"nctId":3650,"briefTitle":3651,"status":109,"phases":3652,"primaryCompletion":3653,"completion":3654,"start":3655,"enrollment":3656,"conditions":3657,"interventions":3659},"NCT01821547","New Methods to Measure the Immune Response to Hepatitis B Vaccine",[91],"2014-04","2016-05","2013-03",21,[3658],"Hepatitis B",[3637],{"trials":3661,"activeCount":99},[],{"intervention":566,"totalTrials":151,"cells":3663},{"EARLY_PHASE1":3664,"PHASE1":3666,"PHASE2":3668,"PHASE3":3670,"PHASE4":3672,"NA":3678},{"trials":3665,"activeCount":99},[],{"trials":3667,"activeCount":99},[],{"trials":3669,"activeCount":99},[],{"trials":3671,"activeCount":99},[],{"trials":3673,"activeCount":99},[3674],{"nctId":558,"briefTitle":559,"status":109,"phases":3675,"primaryCompletion":561,"completion":561,"start":562,"enrollment":563,"conditions":3676,"interventions":3677},[91],[531],[202,566,567],{"trials":3679,"activeCount":99},[],{"intervention":567,"totalTrials":151,"cells":3681},{"EARLY_PHASE1":3682,"PHASE1":3684,"PHASE2":3686,"PHASE3":3688,"PHASE4":3690,"NA":3696},{"trials":3683,"activeCount":99},[],{"trials":3685,"activeCount":99},[],{"trials":3687,"activeCount":99},[],{"trials":3689,"activeCount":99},[],{"trials":3691,"activeCount":99},[3692],{"nctId":558,"briefTitle":559,"status":109,"phases":3693,"primaryCompletion":561,"completion":561,"start":562,"enrollment":563,"conditions":3694,"interventions":3695},[91],[531],[202,566,567],{"trials":3697,"activeCount":99},[],{"intervention":3699,"totalTrials":151,"cells":3700},"Cetrorelix Acetate",{"EARLY_PHASE1":3701,"PHASE1":3703,"PHASE2":3705,"PHASE3":3707,"PHASE4":3709,"NA":3721},{"trials":3702,"activeCount":99},[],{"trials":3704,"activeCount":99},[],{"trials":3706,"activeCount":99},[],{"trials":3708,"activeCount":99},[],{"trials":3710,"activeCount":99},[3711],{"nctId":3712,"briefTitle":3713,"status":2901,"phases":3714,"primaryCompletion":3715,"completion":3715,"start":3716,"enrollment":3717,"conditions":3718,"interventions":3720},"NCT03763786","Frozen Embryo Transfer With GnRH-antagonist Trial",[91],"2021-01","2018-12-13",300,[3719],"Infertility",[3699],{"trials":3722,"activeCount":99},[],{"intervention":3724,"totalTrials":151,"cells":3725},"BCG, NeisVac-C®, Pediacel®, Infanrix™, Prevenar-13®, Menitorix®, Priorix®, Rotarix®",{"EARLY_PHASE1":3726,"PHASE1":3728,"PHASE2":3730,"PHASE3":3732,"PHASE4":3734,"NA":3750},{"trials":3727,"activeCount":99},[],{"trials":3729,"activeCount":99},[],{"trials":3731,"activeCount":99},[],{"trials":3733,"activeCount":99},[],{"trials":3735,"activeCount":99},[3736],{"nctId":3737,"briefTitle":3738,"status":109,"phases":3739,"primaryCompletion":3740,"completion":3741,"start":3742,"enrollment":3743,"conditions":3744,"interventions":3748},"NCT02002156","A Study of the Interaction Between BCG And MenC Immunisation: BAM",[91],"2016-08","2018-06-27","2014-06-20",28,[3745,3746,3747],"BCG Infection","Reaction - Vaccine","Immune Response",[3724,3724,3749],"NeisVac-C®, Pediacel®, Infanrix™, Prevenar-13®, Menitorix®, Priorix®, Rotarix®",{"trials":3751,"activeCount":99},[],{"intervention":3749,"totalTrials":151,"cells":3753},{"EARLY_PHASE1":3754,"PHASE1":3756,"PHASE2":3758,"PHASE3":3760,"PHASE4":3762,"NA":3768},{"trials":3755,"activeCount":99},[],{"trials":3757,"activeCount":99},[],{"trials":3759,"activeCount":99},[],{"trials":3761,"activeCount":99},[],{"trials":3763,"activeCount":99},[3764],{"nctId":3737,"briefTitle":3738,"status":109,"phases":3765,"primaryCompletion":3740,"completion":3741,"start":3742,"enrollment":3743,"conditions":3766,"interventions":3767},[91],[3745,3746,3747],[3724,3724,3749],{"trials":3769,"activeCount":99},[],{"intervention":3771,"totalTrials":151,"cells":3772},"Mefloquine and Dihydroartemisinin-piperaquine",{"EARLY_PHASE1":3773,"PHASE1":3775,"PHASE2":3777,"PHASE3":3779,"PHASE4":3781,"NA":3792},{"trials":3774,"activeCount":99},[],{"trials":3776,"activeCount":99},[],{"trials":3778,"activeCount":99},[],{"trials":3780,"activeCount":99},[],{"trials":3782,"activeCount":99},[3783],{"nctId":3784,"briefTitle":3785,"status":109,"phases":3786,"primaryCompletion":3787,"completion":3787,"start":3788,"enrollment":578,"conditions":3789,"interventions":3790},"NCT02324738","Pharmacokinetic and Pharmacodynamic Study of Mefloquine and Dihydroartemisinin-Piperaquine in Healthy Subjects",[91],"2015-05","2015-01",[24],[3771,3791],"Mefloquine",{"trials":3793,"activeCount":99},[],{"intervention":3791,"totalTrials":151,"cells":3795},{"EARLY_PHASE1":3796,"PHASE1":3798,"PHASE2":3800,"PHASE3":3802,"PHASE4":3804,"NA":3810},{"trials":3797,"activeCount":99},[],{"trials":3799,"activeCount":99},[],{"trials":3801,"activeCount":99},[],{"trials":3803,"activeCount":99},[],{"trials":3805,"activeCount":99},[3806],{"nctId":3784,"briefTitle":3785,"status":109,"phases":3807,"primaryCompletion":3787,"completion":3787,"start":3788,"enrollment":578,"conditions":3808,"interventions":3809},[91],[24],[3771,3791],{"trials":3811,"activeCount":99},[],{"intervention":3813,"totalTrials":151,"cells":3814},"Glyco-conjugate Neisseria meningitidis serogroup C (MenC) vaccine",{"EARLY_PHASE1":3815,"PHASE1":3817,"PHASE2":3819,"PHASE3":3821,"PHASE4":3823,"NA":3836},{"trials":3816,"activeCount":99},[],{"trials":3818,"activeCount":99},[],{"trials":3820,"activeCount":99},[],{"trials":3822,"activeCount":99},[],{"trials":3824,"activeCount":99},[3825],{"nctId":3826,"briefTitle":3827,"status":109,"phases":3828,"primaryCompletion":3829,"start":3830,"enrollment":3831,"conditions":3832,"interventions":3834},"NCT01129518","Can we Reduce the Number of Vaccine Injections for Children?",[91],"2013-07","2010-06",404,[3833],"Invasive Meningococcal Disease",[3813,3835],"Routine schedule immunisations except monovalent MenC vaccine",{"trials":3837,"activeCount":99},[],{"intervention":3835,"totalTrials":151,"cells":3839},{"EARLY_PHASE1":3840,"PHASE1":3842,"PHASE2":3844,"PHASE3":3846,"PHASE4":3848,"NA":3854},{"trials":3841,"activeCount":99},[],{"trials":3843,"activeCount":99},[],{"trials":3845,"activeCount":99},[],{"trials":3847,"activeCount":99},[],{"trials":3849,"activeCount":99},[3850],{"nctId":3826,"briefTitle":3827,"status":109,"phases":3851,"primaryCompletion":3829,"start":3830,"enrollment":3831,"conditions":3852,"interventions":3853},[91],[3833],[3813,3835],{"trials":3855,"activeCount":99},[],{"intervention":3857,"totalTrials":151,"cells":3858},"4CMenB",{"EARLY_PHASE1":3859,"PHASE1":3861,"PHASE2":3863,"PHASE3":3865,"PHASE4":3867,"NA":3880},{"trials":3860,"activeCount":99},[],{"trials":3862,"activeCount":99},[],{"trials":3864,"activeCount":99},[],{"trials":3866,"activeCount":99},[],{"trials":3868,"activeCount":99},[3869],{"nctId":3870,"briefTitle":3871,"status":109,"phases":3872,"primaryCompletion":3873,"completion":3874,"start":3875,"enrollment":3876,"conditions":3877,"interventions":3879},"NCT02080559","Investigating the Immune Response to 4CMenB in Infants",[91],"2016-06","2018-04-27","2014-07-21",187,[3878],"Meningitis",[3857],{"trials":3881,"activeCount":99},[],{"intervention":3883,"totalTrials":151,"cells":3884},"Artesunate 2",{"EARLY_PHASE1":3885,"PHASE1":3887,"PHASE2":3889,"PHASE3":3891,"PHASE4":3893,"NA":3905},{"trials":3886,"activeCount":99},[],{"trials":3888,"activeCount":99},[],{"trials":3890,"activeCount":99},[],{"trials":3892,"activeCount":99},[],{"trials":3894,"activeCount":99},[3895],{"nctId":3896,"briefTitle":3897,"status":109,"phases":3898,"primaryCompletion":3653,"completion":680,"start":3899,"enrollment":3900,"conditions":3901,"interventions":3903},"NCT01350856","Tracking Resistance to Artemisinin (TRAC)",[91],"2011-05",1700,[3902],"Falciparum Malaria",[3883,3904],"Artesunate 4",{"trials":3906,"activeCount":99},[],{"intervention":3904,"totalTrials":151,"cells":3908},{"EARLY_PHASE1":3909,"PHASE1":3911,"PHASE2":3913,"PHASE3":3915,"PHASE4":3917,"NA":3923},{"trials":3910,"activeCount":99},[],{"trials":3912,"activeCount":99},[],{"trials":3914,"activeCount":99},[],{"trials":3916,"activeCount":99},[],{"trials":3918,"activeCount":99},[3919],{"nctId":3896,"briefTitle":3897,"status":109,"phases":3920,"primaryCompletion":3653,"completion":680,"start":3899,"enrollment":3900,"conditions":3921,"interventions":3922},[91],[3902],[3883,3904],{"trials":3924,"activeCount":99},[],{"intervention":3926,"totalTrials":151,"cells":3927},"Intravitreal injection of pegaptanib sodium",{"EARLY_PHASE1":3928,"PHASE1":3930,"PHASE2":3932,"PHASE3":3934,"PHASE4":3936,"NA":3946},{"trials":3929,"activeCount":99},[],{"trials":3931,"activeCount":99},[],{"trials":3933,"activeCount":99},[],{"trials":3935,"activeCount":99},[],{"trials":3937,"activeCount":99},[3938],{"nctId":3939,"briefTitle":3940,"status":109,"phases":3941,"primaryCompletion":3655,"completion":3655,"start":3942,"enrollment":1699,"conditions":3943,"interventions":3945},"NCT01175070","Intravitreal Macugen for Ischaemic Diabetic Macular Oedema",[91],"2011-01",[3944],"Diabetic Macular Oedema",[3926],{"trials":3947,"activeCount":99},[],{"intervention":3949,"totalTrials":151,"cells":3950},"Standard childhood UK ALL protocol",{"EARLY_PHASE1":3951,"PHASE1":3953,"PHASE2":3955,"PHASE3":3957,"PHASE4":3959,"NA":3971},{"trials":3952,"activeCount":99},[],{"trials":3954,"activeCount":99},[],{"trials":3956,"activeCount":99},[],{"trials":3958,"activeCount":99},[],{"trials":3960,"activeCount":99},[3961],{"nctId":3962,"briefTitle":3963,"status":2901,"phases":3964,"primaryCompletion":3413,"completion":3413,"start":3965,"enrollment":3966,"conditions":3967,"interventions":3969},"NCT00222612","Medical Research Council (MRC) Working Party on Leukaemia in Children UK National Acute Lymphoblastic Leukaemia (ALL) Trial: UKALL 2003",[91],"2003-10",2100,[3968],"Acute Lymphoblastic Leukemia",[3949,3970],"Intensified treatment including Capizzi maintenance",{"trials":3972,"activeCount":99},[],{"intervention":3970,"totalTrials":151,"cells":3974},{"EARLY_PHASE1":3975,"PHASE1":3977,"PHASE2":3979,"PHASE3":3981,"PHASE4":3983,"NA":3989},{"trials":3976,"activeCount":99},[],{"trials":3978,"activeCount":99},[],{"trials":3980,"activeCount":99},[],{"trials":3982,"activeCount":99},[],{"trials":3984,"activeCount":99},[3985],{"nctId":3962,"briefTitle":3963,"status":2901,"phases":3986,"primaryCompletion":3413,"completion":3413,"start":3965,"enrollment":3966,"conditions":3987,"interventions":3988},[91],[3968],[3949,3970],{"trials":3990,"activeCount":99},[],{"intervention":3992,"totalTrials":151,"cells":3993},"Vitamin A",{"EARLY_PHASE1":3994,"PHASE1":3996,"PHASE2":3998,"PHASE3":4000,"PHASE4":4002,"NA":4014},{"trials":3995,"activeCount":99},[],{"trials":3997,"activeCount":99},[],{"trials":3999,"activeCount":99},[],{"trials":4001,"activeCount":99},[],{"trials":4003,"activeCount":99},[4004],{"nctId":4005,"briefTitle":4006,"status":109,"phases":4007,"completion":3628,"start":4008,"enrollment":4009,"conditions":4010,"interventions":4012},"NCT00222547","Deworming and Enhanced Vitamin A Every 6 Month in Rural Indian Children Aged 1-6",[91],"1999-01",720000,[4011],"Village Children",[3992,4013],"Albendazole",{"trials":4015,"activeCount":99},[],{"intervention":4013,"totalTrials":151,"cells":4017},{"EARLY_PHASE1":4018,"PHASE1":4020,"PHASE2":4022,"PHASE3":4024,"PHASE4":4026,"NA":4032},{"trials":4019,"activeCount":99},[],{"trials":4021,"activeCount":99},[],{"trials":4023,"activeCount":99},[],{"trials":4025,"activeCount":99},[],{"trials":4027,"activeCount":99},[4028],{"nctId":4005,"briefTitle":4006,"status":109,"phases":4029,"completion":3628,"start":4008,"enrollment":4009,"conditions":4030,"interventions":4031},[91],[4011],[3992,4013],{"trials":4033,"activeCount":99},[],{"intervention":4035,"totalTrials":151,"cells":4036},"Acarbose",{"EARLY_PHASE1":4037,"PHASE1":4039,"PHASE2":4041,"PHASE3":4043,"PHASE4":4045,"NA":4061},{"trials":4038,"activeCount":99},[],{"trials":4040,"activeCount":99},[],{"trials":4042,"activeCount":99},[],{"trials":4044,"activeCount":99},[],{"trials":4046,"activeCount":99},[4047],{"nctId":4048,"briefTitle":4049,"status":109,"phases":4050,"primaryCompletion":4051,"completion":4052,"start":4053,"enrollment":4054,"conditions":4055,"interventions":4060},"NCT00829660","Acarbose Cardiovascular Evaluation Trial",[91],"2017-04-11","2017-04-18","2009-02-17",6526,[4056,4057,4058,4059],"Coronary Heart Disease","Acute Coronary Syndrome","Impaired Glucose Tolerance","Type 2 Diabetes Mellitus (T2DM)",[4035],{"trials":4062,"activeCount":99},[],{"intervention":4064,"totalTrials":151,"cells":4065},"Montelukast",{"EARLY_PHASE1":4066,"PHASE1":4068,"PHASE2":4070,"PHASE3":4072,"PHASE4":4074,"NA":4085},{"trials":4067,"activeCount":99},[],{"trials":4069,"activeCount":99},[],{"trials":4071,"activeCount":99},[],{"trials":4073,"activeCount":99},[],{"trials":4075,"activeCount":99},[4076],{"nctId":4077,"briefTitle":4078,"status":2901,"phases":4079,"primaryCompletion":527,"completion":1458,"start":3899,"enrollment":4080,"conditions":4081,"interventions":4084},"NCT01279668","Montelukast for Persistent Cough in Young People and Adults",[91],276,[4082,4083],"Persistent Cough","Whooping Cough",[4064],{"trials":4086,"activeCount":99},[],{"intervention":4088,"totalTrials":151,"cells":4089},"sodium iodide",{"EARLY_PHASE1":4090,"PHASE1":4092,"PHASE2":4094,"PHASE3":4096,"PHASE4":4098,"NA":4110},{"trials":4091,"activeCount":99},[],{"trials":4093,"activeCount":99},[],{"trials":4095,"activeCount":99},[],{"trials":4097,"activeCount":99},[],{"trials":4099,"activeCount":99},[4100],{"nctId":4101,"briefTitle":4102,"status":109,"phases":4103,"primaryCompletion":3553,"completion":3787,"start":4104,"enrollment":4105,"conditions":4106,"interventions":4108},"NCT00638092","A Randomised Controlled Trial of Iodide Supplementation in Preterm Infants Follow-up at 2 Years",[91],"2010-03",1275,[4107],"Transient Hypothyroxinemia",[4088,4109],"Sodium Chloride",{"trials":4111,"activeCount":99},[],{"intervention":4113,"totalTrials":151,"cells":4114},"Hep-V Vax",{"EARLY_PHASE1":4115,"PHASE1":4117,"PHASE2":4119,"PHASE3":4121,"PHASE4":4123,"NA":4136},{"trials":4116,"activeCount":99},[],{"trials":4118,"activeCount":99},[],{"trials":4120,"activeCount":99},[],{"trials":4122,"activeCount":99},[],{"trials":4124,"activeCount":99},[4125],{"nctId":4126,"briefTitle":4127,"status":109,"phases":4128,"completion":4129,"start":4130,"enrollment":4131,"conditions":4132,"interventions":4135},"NCT00222664","Qidong Hepatitis B Intervention Study",[91],"2004-12","1983-09",80000,[3658,4133,4134],"Liver Neoplasms","Liver Diseases",[4113],{"trials":4137,"activeCount":99},[],{"intervention":4139,"totalTrials":151,"cells":4140},"PCV13",{"EARLY_PHASE1":4141,"PHASE1":4143,"PHASE2":4145,"PHASE3":4147,"PHASE4":4149,"NA":4161},{"trials":4142,"activeCount":99},[],{"trials":4144,"activeCount":99},[],{"trials":4146,"activeCount":99},[],{"trials":4148,"activeCount":99},[],{"trials":4150,"activeCount":99},[4151],{"nctId":4152,"briefTitle":4153,"status":109,"phases":4154,"primaryCompletion":4155,"completion":4156,"start":4157,"enrollment":4158,"conditions":4159,"interventions":4160},"NCT01095471","13 Valent Pneumococcal Conjugate Vaccine - Follow-on Study",[91],"2010-12","2011-03","2010-04",100,[398],[4139],{"trials":4162,"activeCount":99},[],{"intervention":4164,"totalTrials":151,"cells":4165},"active oseltamivir",{"EARLY_PHASE1":4166,"PHASE1":4168,"PHASE2":4170,"PHASE3":4172,"PHASE4":4174,"NA":4186},{"trials":4167,"activeCount":99},[],{"trials":4169,"activeCount":99},[],{"trials":4171,"activeCount":99},[],{"trials":4173,"activeCount":99},[],{"trials":4175,"activeCount":99},[4176],{"nctId":4177,"briefTitle":4178,"status":109,"phases":4179,"primaryCompletion":4180,"completion":4180,"start":4181,"enrollment":4182,"conditions":4183,"interventions":4184},"NCT00980109","Long Term Influenza Prophylaxis With Inhaled Zanamivir or Oral Oseltamivir",[91],"2010-09","2009-09",390,[30],[4164,4185],"zanamivir for inhalation",{"trials":4187,"activeCount":99},[],{"intervention":4185,"totalTrials":151,"cells":4189},{"EARLY_PHASE1":4190,"PHASE1":4192,"PHASE2":4194,"PHASE3":4196,"PHASE4":4198,"NA":4204},{"trials":4191,"activeCount":99},[],{"trials":4193,"activeCount":99},[],{"trials":4195,"activeCount":99},[],{"trials":4197,"activeCount":99},[],{"trials":4199,"activeCount":99},[4200],{"nctId":4177,"briefTitle":4178,"status":109,"phases":4201,"primaryCompletion":4180,"completion":4180,"start":4181,"enrollment":4182,"conditions":4202,"interventions":4203},[91],[30],[4164,4185],{"trials":4205,"activeCount":99},[],{"intervention":4207,"totalTrials":151,"cells":4208},"Yellow fever vaccine, Institut Pasteur",{"EARLY_PHASE1":4209,"PHASE1":4211,"PHASE2":4213,"PHASE3":4215,"PHASE4":4217,"NA":4230},{"trials":4210,"activeCount":99},[],{"trials":4212,"activeCount":99},[],{"trials":4214,"activeCount":99},[],{"trials":4216,"activeCount":99},[],{"trials":4218,"activeCount":99},[4219],{"nctId":4220,"briefTitle":4221,"status":109,"phases":4222,"primaryCompletion":4223,"completion":4224,"start":4225,"enrollment":4226,"conditions":4227,"interventions":4229},"NCT04059471","Non- Inferiority Fractional-doses Trial for Yellow Fever Vaccine",[91],"2020-03-30","2023-06-24","2019-11-11",900,[4228],"Yellow Fever",[4207],{"trials":4231,"activeCount":99},[],{"intervention":4233,"totalTrials":151,"cells":4234},"Aripiprazole",{"EARLY_PHASE1":4235,"PHASE1":4237,"PHASE2":4239,"PHASE3":4241,"PHASE4":4243,"NA":4252},{"trials":4236,"activeCount":99},[],{"trials":4238,"activeCount":99},[],{"trials":4240,"activeCount":99},[],{"trials":4242,"activeCount":99},[],{"trials":4244,"activeCount":99},[4245],{"nctId":4246,"briefTitle":4247,"status":109,"phases":4248,"primaryCompletion":680,"completion":680,"start":4157,"enrollment":28,"conditions":4249,"interventions":4251},"NCT01085383","Aripiprazole and Prolactin Study",[91],[4250],"Hyperprolactinemia",[4233],{"trials":4253,"activeCount":99},[],{"intervention":4255,"totalTrials":151,"cells":4256},"Fenofibrate 145 mg",{"EARLY_PHASE1":4257,"PHASE1":4259,"PHASE2":4261,"PHASE3":4263,"PHASE4":4265,"NA":4277},{"trials":4258,"activeCount":99},[],{"trials":4260,"activeCount":99},[],{"trials":4262,"activeCount":99},[],{"trials":4264,"activeCount":99},[],{"trials":4266,"activeCount":99},[4267],{"nctId":4268,"briefTitle":4269,"status":109,"phases":4270,"primaryCompletion":2964,"completion":4271,"start":4272,"enrollment":4273,"conditions":4274,"interventions":4276},"NCT03439345","Lowering Events in Non-proliferative Retinopathy in Scotland",[91],"2024-02-16","2018-07-23",1151,[4275],"Diabetic Retinopathy",[4255],{"trials":4278,"activeCount":99},[],{"intervention":4280,"totalTrials":151,"cells":4281},"Fenfluramine",{"EARLY_PHASE1":4282,"PHASE1":4284,"PHASE2":4286,"PHASE3":4288,"PHASE4":4290,"NA":4301},{"trials":4283,"activeCount":99},[],{"trials":4285,"activeCount":99},[],{"trials":4287,"activeCount":99},[],{"trials":4289,"activeCount":99},[],{"trials":4291,"activeCount":99},[4292],{"nctId":4293,"briefTitle":4294,"status":109,"phases":4295,"primaryCompletion":4296,"completion":4296,"start":4297,"enrollment":1561,"conditions":4298,"interventions":4300},"NCT05026398","Fenfluramine and Cognition",[91],"2022-06-22","2021-04-12",[4299],"Cognitive Function",[4280],{"trials":4302,"activeCount":99},[],{"intervention":4304,"totalTrials":151,"cells":4305},"MenACWY-CRM conjugate vaccine",{"EARLY_PHASE1":4306,"PHASE1":4308,"PHASE2":4310,"PHASE3":4312,"PHASE4":4314,"NA":4328},{"trials":4307,"activeCount":99},[],{"trials":4309,"activeCount":99},[],{"trials":4311,"activeCount":99},[],{"trials":4313,"activeCount":99},[],{"trials":4315,"activeCount":99},[4316],{"nctId":4317,"briefTitle":4318,"status":109,"phases":4319,"primaryCompletion":4320,"completion":4320,"start":681,"enrollment":1674,"conditions":4321,"interventions":4324},"NCT01593514","Understanding the Immune Response to Two Different Meningitis Vaccines",[91],"2013-04",[3878,4322,4323],"Meningococcal Disease","Septicaemia",[4304,4325,4325,4326,4327],"MenACWY-PS polysaccharide vaccine,","1\u002F5th dose MenACWY-PS polysaccharide vaccine,","Polysaccharide (subcutaneously)-conjugate",{"trials":4329,"activeCount":99},[],{"intervention":4325,"totalTrials":151,"cells":4331},{"EARLY_PHASE1":4332,"PHASE1":4334,"PHASE2":4336,"PHASE3":4338,"PHASE4":4340,"NA":4346},{"trials":4333,"activeCount":99},[],{"trials":4335,"activeCount":99},[],{"trials":4337,"activeCount":99},[],{"trials":4339,"activeCount":99},[],{"trials":4341,"activeCount":99},[4342],{"nctId":4317,"briefTitle":4318,"status":109,"phases":4343,"primaryCompletion":4320,"completion":4320,"start":681,"enrollment":1674,"conditions":4344,"interventions":4345},[91],[3878,4322,4323],[4304,4325,4325,4326,4327],{"trials":4347,"activeCount":99},[],{"intervention":4326,"totalTrials":151,"cells":4349},{"EARLY_PHASE1":4350,"PHASE1":4352,"PHASE2":4354,"PHASE3":4356,"PHASE4":4358,"NA":4364},{"trials":4351,"activeCount":99},[],{"trials":4353,"activeCount":99},[],{"trials":4355,"activeCount":99},[],{"trials":4357,"activeCount":99},[],{"trials":4359,"activeCount":99},[4360],{"nctId":4317,"briefTitle":4318,"status":109,"phases":4361,"primaryCompletion":4320,"completion":4320,"start":681,"enrollment":1674,"conditions":4362,"interventions":4363},[91],[3878,4322,4323],[4304,4325,4325,4326,4327],{"trials":4365,"activeCount":99},[],{"intervention":4327,"totalTrials":151,"cells":4367},{"EARLY_PHASE1":4368,"PHASE1":4370,"PHASE2":4372,"PHASE3":4374,"PHASE4":4376,"NA":4382},{"trials":4369,"activeCount":99},[],{"trials":4371,"activeCount":99},[],{"trials":4373,"activeCount":99},[],{"trials":4375,"activeCount":99},[],{"trials":4377,"activeCount":99},[4378],{"nctId":4317,"briefTitle":4318,"status":109,"phases":4379,"primaryCompletion":4320,"completion":4320,"start":681,"enrollment":1674,"conditions":4380,"interventions":4381},[91],[3878,4322,4323],[4304,4325,4325,4326,4327],{"trials":4383,"activeCount":99},[],{"intervention":4385,"totalTrials":151,"cells":4386},"Boostrix®-IPV combination vaccine",{"EARLY_PHASE1":4387,"PHASE1":4389,"PHASE2":4391,"PHASE3":4393,"PHASE4":4395,"NA":4407},{"trials":4388,"activeCount":99},[],{"trials":4390,"activeCount":99},[],{"trials":4392,"activeCount":99},[],{"trials":4394,"activeCount":99},[],{"trials":4396,"activeCount":99},[4397],{"nctId":4398,"briefTitle":4399,"status":109,"phases":4400,"primaryCompletion":4401,"completion":4401,"start":4402,"enrollment":4403,"conditions":4404,"interventions":4406},"NCT03697798","A Study Exploring Whooping Cough Protection in Children and Adults",[91],"2020-01-14","2018-04-18",122,[4405],"Pertussis",[4385],{"trials":4408,"activeCount":99},[],{"intervention":4410,"totalTrials":151,"cells":4411},"Escitalopram",{"EARLY_PHASE1":4412,"PHASE1":4414,"PHASE2":4416,"PHASE3":4418,"PHASE4":4420,"NA":4431},{"trials":4413,"activeCount":99},[],{"trials":4415,"activeCount":99},[],{"trials":4417,"activeCount":99},[],{"trials":4419,"activeCount":99},[],{"trials":4421,"activeCount":99},[4422],{"nctId":4423,"briefTitle":4424,"status":109,"phases":4425,"primaryCompletion":4156,"completion":4156,"start":4426,"enrollment":4427,"conditions":4428,"interventions":4430},"NCT01101685","Neural Responses and Dysphoria: Modulation by a Pharmacological Probe",[91],"2010-02",160,[4429],"Dysphoria",[4410],{"trials":4432,"activeCount":99},[],{"intervention":4434,"totalTrials":151,"cells":4435},"Nafarelin acetate, Oestradiol Valerate, Progesterone",{"EARLY_PHASE1":4436,"PHASE1":4438,"PHASE2":4440,"PHASE3":4442,"PHASE4":4444,"NA":4455},{"trials":4437,"activeCount":99},[],{"trials":4439,"activeCount":99},[],{"trials":4441,"activeCount":99},[],{"trials":4443,"activeCount":99},[],{"trials":4445,"activeCount":99},[4446],{"nctId":4447,"briefTitle":4448,"status":109,"phases":4449,"primaryCompletion":4450,"completion":4450,"start":4451,"enrollment":4452,"conditions":4453,"interventions":4454},"NCT00843570","Natural Versus HRT Cycles in Frozen Embryo Replacement Treatment",[91],"2013-05","2009-11",159,[3719],[4434],{"trials":4456,"activeCount":99},[],{"intervention":4458,"totalTrials":151,"cells":4459},"Simvastatin 20 mg",{"EARLY_PHASE1":4460,"PHASE1":4462,"PHASE2":4464,"PHASE3":4466,"PHASE4":4468,"NA":4481},{"trials":4461,"activeCount":99},[],{"trials":4463,"activeCount":99},[],{"trials":4465,"activeCount":99},[],{"trials":4467,"activeCount":99},[],{"trials":4469,"activeCount":99},[4470],{"nctId":4471,"briefTitle":4472,"status":109,"phases":4473,"primaryCompletion":4474,"completion":4474,"start":4475,"enrollment":4476,"conditions":4477,"interventions":4479},"NCT00125593","Study of Heart and Renal Protection",[91],"2010-08","2003-06",9438,[4478],"Kidney Disease, Chronic",[4458,4480],"Ezetimibe 10mg",{"trials":4482,"activeCount":99},[],{"intervention":4480,"totalTrials":151,"cells":4484},{"EARLY_PHASE1":4485,"PHASE1":4487,"PHASE2":4489,"PHASE3":4491,"PHASE4":4493,"NA":4499},{"trials":4486,"activeCount":99},[],{"trials":4488,"activeCount":99},[],{"trials":4490,"activeCount":99},[],{"trials":4492,"activeCount":99},[],{"trials":4494,"activeCount":99},[4495],{"nctId":4471,"briefTitle":4472,"status":109,"phases":4496,"primaryCompletion":4474,"completion":4474,"start":4475,"enrollment":4476,"conditions":4497,"interventions":4498},[91],[4478],[4458,4480],{"trials":4500,"activeCount":99},[],{"intervention":4502,"totalTrials":151,"cells":4503},"Rosuvastatin",{"EARLY_PHASE1":4504,"PHASE1":4506,"PHASE2":4508,"PHASE3":4510,"PHASE4":4512,"NA":4523},{"trials":4505,"activeCount":99},[],{"trials":4507,"activeCount":99},[],{"trials":4509,"activeCount":99},[],{"trials":4511,"activeCount":99},[],{"trials":4513,"activeCount":99},[4514],{"nctId":4515,"briefTitle":4516,"status":109,"phases":4517,"primaryCompletion":1457,"completion":1457,"start":4518,"enrollment":4519,"conditions":4520,"interventions":4522},"NCT01573143","Statin Therapy In Cardiac Surgery",[91],"2011-09",1922,[3393,4521],"Myocardium; Injury",[4502],{"trials":4524,"activeCount":99},[],{"intervention":4526,"totalTrials":595,"cells":4527},"ChAdOx1 nCoV-19",{"EARLY_PHASE1":4528,"PHASE1":4530,"PHASE2":4542,"PHASE3":4570,"PHASE4":4587,"NA":4589},{"trials":4529,"activeCount":99},[],{"trials":4531,"activeCount":99},[4532],{"nctId":4533,"briefTitle":4534,"status":109,"phases":4535,"primaryCompletion":4536,"completion":4536,"start":4537,"enrollment":2989,"conditions":4538,"interventions":4540},"NCT04816019","A Study of Intranasal ChAdOx1 nCOV-19",[88],"2022-09-30","2021-04-01",[4539],"Coronavirus",[4541],"ChAdOx1 nCov-19",{"trials":4543,"activeCount":99},[4544,4554],{"nctId":4545,"briefTitle":4546,"status":2901,"phases":4547,"primaryCompletion":3253,"completion":4548,"start":4549,"enrollment":4550,"conditions":4551,"interventions":4552},"NCT04444674","COVID-19 Vaccine (ChAdOx1 nCoV-19) Trial in South African Adults With and Without HIV-infection",[88,89],"2021-12","2020-06-24",2130,[4539],[4526,4553],"Normal saline 0.9%",{"nctId":4555,"briefTitle":4556,"status":109,"phases":4557,"primaryCompletion":4558,"completion":4558,"start":4559,"enrollment":4560,"conditions":4561,"interventions":4562},"NCT04324606","A Study of a Candidate COVID-19 Vaccine (COV001)",[88,89],"2025-02-05","2020-04-23",1077,[4539],[4526,4563,4564,4565,4566,4567,4568,4569,4569],"MenACWY","ChAdOx1 nCoV-19 full boost","ChAdOx1 nCoV-19 half boost","MenACWY boost","Paracetamol","ChAdOx1 nCoV-19 0.5mL boost","ChAdOx1 nCoV-19 0.5mL",{"trials":4571,"activeCount":99},[4572],{"nctId":4573,"briefTitle":4574,"status":109,"phases":4575,"primaryCompletion":4558,"completion":4558,"start":4576,"enrollment":4577,"conditions":4578,"interventions":4579},"NCT04400838","Investigating a Vaccine Against COVID-19",[89,90],"2020-05-28",10811,[4539],[4526,4580,4581,4582,4526,4583,4584,4585,4586],"MenACWY vaccine","ChAdOx1 nCoV-19 (Abs 260) + 2.2x10^10vp (qPCR) boost","Two dose MenACWY vaccine","ChAdOx1 nCoV-19 0.5mL prime plus boost","Two dose MenACWY vaccine min. 4 weeks apart","Two dose ChAdOx1 nCoV-19\u002FCovishield 0.5mL","Two dose ChAdOx1 nCoV-19\u002FCovishield 0.25mL & 0.5mL",{"trials":4588,"activeCount":99},[],{"trials":4590,"activeCount":99},[],{"intervention":4592,"totalTrials":95,"cells":4593},"Ceftriaxone",{"EARLY_PHASE1":4594,"PHASE1":4596,"PHASE2":4598,"PHASE3":4612,"PHASE4":4641,"NA":4643},{"trials":4595,"activeCount":99},[],{"trials":4597,"activeCount":99},[],{"trials":4599,"activeCount":99},[4600],{"nctId":4601,"briefTitle":4602,"status":2901,"phases":4603,"primaryCompletion":4604,"completion":4605,"start":4606,"enrollment":4607,"conditions":4608,"interventions":4610},"NCT02746276","Optimising Antibiotic Treatment for Sick Malnourished Children",[89],"2016-09-30","2017-09-30","2016-04-01",81,[4609],"Malnutrition",[4592,4611],"Metronidazole",{"trials":4613,"activeCount":99},[4614,4629],{"nctId":4615,"briefTitle":4616,"status":2901,"phases":4617,"primaryCompletion":4618,"completion":4619,"start":4620,"enrollment":4621,"conditions":4622,"interventions":4626},"NCT03174236","First Line Antimicrobials in Children With Complicated Severe Acute Malnutrition",[90],"2020-01-31","2020-12-31","2017-09-04",2000,[4623,4624,4625],"Malnutrition Severe","Antibiotic Resistance","Antibiotic Toxicity",[4592,4627,4611,4628],"Benzyl penicillin","Gentamicin",{"nctId":4630,"briefTitle":4631,"status":109,"phases":4632,"primaryCompletion":4633,"completion":4633,"start":4634,"enrollment":4635,"conditions":4636,"interventions":4637},"NCT04041791","A Study to Compare Different Antibiotics and Different Modes of Fluid Treatment for Children With Severe Pneumonia",[90],"2024-04-05","2019-08-19",4392,[129],[4627,4638,4592,4639,4640],"Gentamicin Sulfate","Amoxicillin Clavulanate","Ampicillin",{"trials":4642,"activeCount":99},[],{"trials":4644,"activeCount":99},[],{"intervention":4646,"totalTrials":168,"cells":4647},"Artesunate-mefloquine+piperaquine",{"EARLY_PHASE1":4648,"PHASE1":4650,"PHASE2":4652,"PHASE3":4654,"PHASE4":4681,"NA":4683},{"trials":4649,"activeCount":99},[],{"trials":4651,"activeCount":99},[],{"trials":4653,"activeCount":99},[],{"trials":4655,"activeCount":99},[4656,4670],{"nctId":4657,"briefTitle":4658,"status":109,"phases":4659,"primaryCompletion":4660,"completion":4661,"start":4662,"enrollment":4663,"conditions":4664,"interventions":4666},"NCT03939104","A Trial to Compare the Efficacy, Safety and Tolerability of Combinations of 3 Anti-malarial Drugs Against Combinations of 2 Anti-malarial Drugs (Asia)",[90],"2023-01-06","2023-01-28","2021-06-30",103,[4665],"Plasmodium Falciparum Malaria (Uncomplicated)",[4667,4668,4646,4669],"Artemether-lumefantrine+amodiaquine","Artemether-lumefantrine+placebo","Artesunate-mefloquine+placebo",{"nctId":4671,"briefTitle":4672,"status":109,"phases":4673,"primaryCompletion":4674,"completion":4674,"start":4675,"enrollment":4676,"conditions":4677,"interventions":4678},"NCT03923725","A Trial to Compare the Efficacy, Safety and Tolerability of Combinations of 3 Anti-malarial Drugs Against Combina-tions of 2 Anti-malarial Drugs.",[90],"2024-03-15","2020-09-01",2583,[4665],[4679,4680,4646,4669],"Artemether-lumefantrine+ Amodiaquine","Artemether-lumefantrine + placebo",{"trials":4682,"activeCount":99},[],{"trials":4684,"activeCount":99},[],{"intervention":4669,"totalTrials":168,"cells":4686},{"EARLY_PHASE1":4687,"PHASE1":4689,"PHASE2":4691,"PHASE3":4693,"PHASE4":4703,"NA":4705},{"trials":4688,"activeCount":99},[],{"trials":4690,"activeCount":99},[],{"trials":4692,"activeCount":99},[],{"trials":4694,"activeCount":99},[4695,4699],{"nctId":4657,"briefTitle":4658,"status":109,"phases":4696,"primaryCompletion":4660,"completion":4661,"start":4662,"enrollment":4663,"conditions":4697,"interventions":4698},[90],[4665],[4667,4668,4646,4669],{"nctId":4671,"briefTitle":4672,"status":109,"phases":4700,"primaryCompletion":4674,"completion":4674,"start":4675,"enrollment":4676,"conditions":4701,"interventions":4702},[90],[4665],[4679,4680,4646,4669],{"trials":4704,"activeCount":99},[],{"trials":4706,"activeCount":99},[],{"intervention":4627,"totalTrials":168,"cells":4708},{"EARLY_PHASE1":4709,"PHASE1":4711,"PHASE2":4713,"PHASE3":4715,"PHASE4":4725,"NA":4727},{"trials":4710,"activeCount":99},[],{"trials":4712,"activeCount":99},[],{"trials":4714,"activeCount":99},[],{"trials":4716,"activeCount":99},[4717,4721],{"nctId":4615,"briefTitle":4616,"status":2901,"phases":4718,"primaryCompletion":4618,"completion":4619,"start":4620,"enrollment":4621,"conditions":4719,"interventions":4720},[90],[4623,4624,4625],[4592,4627,4611,4628],{"nctId":4630,"briefTitle":4631,"status":109,"phases":4722,"primaryCompletion":4633,"completion":4633,"start":4634,"enrollment":4635,"conditions":4723,"interventions":4724},[90],[129],[4627,4638,4592,4639,4640],{"trials":4726,"activeCount":99},[],{"trials":4728,"activeCount":99},[],{"intervention":4611,"totalTrials":168,"cells":4730},{"EARLY_PHASE1":4731,"PHASE1":4733,"PHASE2":4735,"PHASE3":4741,"PHASE4":4747,"NA":4749},{"trials":4732,"activeCount":99},[],{"trials":4734,"activeCount":99},[],{"trials":4736,"activeCount":99},[4737],{"nctId":4601,"briefTitle":4602,"status":2901,"phases":4738,"primaryCompletion":4604,"completion":4605,"start":4606,"enrollment":4607,"conditions":4739,"interventions":4740},[89],[4609],[4592,4611],{"trials":4742,"activeCount":99},[4743],{"nctId":4615,"briefTitle":4616,"status":2901,"phases":4744,"primaryCompletion":4618,"completion":4619,"start":4620,"enrollment":4621,"conditions":4745,"interventions":4746},[90],[4623,4624,4625],[4592,4627,4611,4628],{"trials":4748,"activeCount":99},[],{"trials":4750,"activeCount":99},[],{"intervention":4628,"totalTrials":168,"cells":4752},{"EARLY_PHASE1":4753,"PHASE1":4755,"PHASE2":4757,"PHASE3":4759,"PHASE4":4778,"NA":4780},{"trials":4754,"activeCount":99},[],{"trials":4756,"activeCount":99},[],{"trials":4758,"activeCount":99},[],{"trials":4760,"activeCount":99},[4761,4765],{"nctId":4615,"briefTitle":4616,"status":2901,"phases":4762,"primaryCompletion":4618,"completion":4619,"start":4620,"enrollment":4621,"conditions":4763,"interventions":4764},[90],[4623,4624,4625],[4592,4627,4611,4628],{"nctId":4766,"briefTitle":4767,"status":109,"phases":4768,"primaryCompletion":4769,"completion":4558,"start":4770,"enrollment":4771,"conditions":4772,"interventions":4775},"NCT04110340","Ciprofloxacin Versus an Aminoglycoside Followed by Ciprofloxacin for Bubonic Plague",[90],"2024-04-30","2020-02-15",222,[4773,4774],"Plague, Bubonic","Plague, Pneumonic",[4776,4777,4628],"Ciprofloxacin","Streptomycin",{"trials":4779,"activeCount":99},[],{"trials":4781,"activeCount":99},[],{"intervention":4783,"totalTrials":168,"cells":4784},"ACT",{"EARLY_PHASE1":4785,"PHASE1":4787,"PHASE2":4789,"PHASE3":4791,"PHASE4":4812,"NA":4814},{"trials":4786,"activeCount":99},[],{"trials":4788,"activeCount":99},[],{"trials":4790,"activeCount":99},[],{"trials":4792,"activeCount":99},[4793,4803],{"nctId":4794,"briefTitle":4795,"status":109,"phases":4796,"primaryCompletion":4797,"completion":4797,"start":4798,"enrollment":4799,"conditions":4800,"interventions":4801},"NCT02453308","A Study by the Tracking Resistance to Artemisinin Collaboration (TRAC)",[89,90],"2018-03","2015-08",1110,[2828],[4783,4802],"TACT",{"nctId":4804,"briefTitle":4805,"status":109,"phases":4806,"primaryCompletion":4807,"completion":4807,"start":4808,"enrollment":4809,"conditions":4810,"interventions":4811},"NCT03355664","Study to Compare the Triple ACT AL+AQ With the ACT AL in Cambodia and Vietnam",[90],"2020-03-04","2018-03-19",310,[2828],[4783,4802],{"trials":4813,"activeCount":99},[],{"trials":4815,"activeCount":99},[],{"intervention":4802,"totalTrials":168,"cells":4817},{"EARLY_PHASE1":4818,"PHASE1":4820,"PHASE2":4822,"PHASE3":4824,"PHASE4":4834,"NA":4836},{"trials":4819,"activeCount":99},[],{"trials":4821,"activeCount":99},[],{"trials":4823,"activeCount":99},[],{"trials":4825,"activeCount":99},[4826,4830],{"nctId":4794,"briefTitle":4795,"status":109,"phases":4827,"primaryCompletion":4797,"completion":4797,"start":4798,"enrollment":4799,"conditions":4828,"interventions":4829},[89,90],[2828],[4783,4802],{"nctId":4804,"briefTitle":4805,"status":109,"phases":4831,"primaryCompletion":4807,"completion":4807,"start":4808,"enrollment":4809,"conditions":4832,"interventions":4833},[90],[2828],[4783,4802],{"trials":4835,"activeCount":99},[],{"trials":4837,"activeCount":99},[],{"intervention":4839,"totalTrials":168,"cells":4840},"Basiliximab",{"EARLY_PHASE1":4841,"PHASE1":4843,"PHASE2":4845,"PHASE3":4847,"PHASE4":4869,"NA":4871},{"trials":4842,"activeCount":99},[],{"trials":4844,"activeCount":99},[],{"trials":4846,"activeCount":99},[],{"trials":4848,"activeCount":99},[4849,4858],{"nctId":4850,"briefTitle":4851,"status":2901,"phases":4852,"primaryCompletion":3579,"completion":3654,"start":3942,"enrollment":1530,"conditions":4853,"interventions":4856},"NCT01239563","Thymoglobulin Induction in Kidney Transplant Recipients",[90],[4854,4855],"Kidney Transplantation","Ischemia-Reperfusion Injury",[4857,4839],"antithymocyte globulin",{"nctId":4859,"briefTitle":4860,"status":109,"phases":4861,"primaryCompletion":552,"completion":4862,"start":4180,"enrollment":4863,"conditions":4864,"interventions":4865},"NCT01120028","Campath, Calcineurin Inhibitor Reduction and Chronic Allograft Nephropathy",[89,90],"2020-03",852,[4854],[4866,4839,4867,4868],"Alemtuzumab","Sirolimus","Tacrolimus",{"trials":4870,"activeCount":99},[],{"trials":4872,"activeCount":99},[],{"intervention":4874,"totalTrials":151,"cells":4875},"Prevenar 13",{"EARLY_PHASE1":4876,"PHASE1":4878,"PHASE2":4880,"PHASE3":4882,"PHASE4":4891,"NA":4893},{"trials":4877,"activeCount":99},[],{"trials":4879,"activeCount":99},[],{"trials":4881,"activeCount":99},[],{"trials":4883,"activeCount":99},[4884],{"nctId":4885,"briefTitle":4886,"status":109,"phases":4887,"primaryCompletion":1435,"start":3389,"enrollment":595,"conditions":4888,"interventions":4889},"NCT01432158","Pneumococcal Adult Kinetics Study - Understanding the B Cell Response to Pneumococcal Vaccines",[90],[398],[4874,4890],"Pneumovax II",{"trials":4892,"activeCount":99},[],{"trials":4894,"activeCount":99},[],{"intervention":4890,"totalTrials":151,"cells":4896},{"EARLY_PHASE1":4897,"PHASE1":4899,"PHASE2":4901,"PHASE3":4903,"PHASE4":4909,"NA":4911},{"trials":4898,"activeCount":99},[],{"trials":4900,"activeCount":99},[],{"trials":4902,"activeCount":99},[],{"trials":4904,"activeCount":99},[4905],{"nctId":4885,"briefTitle":4886,"status":109,"phases":4906,"primaryCompletion":1435,"start":3389,"enrollment":595,"conditions":4907,"interventions":4908},[90],[398],[4874,4890],{"trials":4910,"activeCount":99},[],{"trials":4912,"activeCount":99},[],{"intervention":4914,"totalTrials":151,"cells":4915},"Immunoglobulins, Intravenous",{"EARLY_PHASE1":4916,"PHASE1":4918,"PHASE2":4920,"PHASE3":4922,"PHASE4":4933,"NA":4935},{"trials":4917,"activeCount":99},[],{"trials":4919,"activeCount":99},[],{"trials":4921,"activeCount":99},[],{"trials":4923,"activeCount":99},[4924],{"nctId":4925,"briefTitle":4926,"status":109,"phases":4927,"primaryCompletion":4928,"completion":4928,"start":4929,"enrollment":1511,"conditions":4930,"interventions":4932},"NCT02308982","Investigating the Role of Early Intravenous Immunoglobulin Treatment for Children With Encephalitis",[90],"2022-09","2016-01",[4931],"Encephalitis",[4914],{"trials":4934,"activeCount":99},[],{"trials":4936,"activeCount":99},[],{"intervention":4667,"totalTrials":151,"cells":4938},{"EARLY_PHASE1":4939,"PHASE1":4941,"PHASE2":4943,"PHASE3":4945,"PHASE4":4951,"NA":4953},{"trials":4940,"activeCount":99},[],{"trials":4942,"activeCount":99},[],{"trials":4944,"activeCount":99},[],{"trials":4946,"activeCount":99},[4947],{"nctId":4657,"briefTitle":4658,"status":109,"phases":4948,"primaryCompletion":4660,"completion":4661,"start":4662,"enrollment":4663,"conditions":4949,"interventions":4950},[90],[4665],[4667,4668,4646,4669],{"trials":4952,"activeCount":99},[],{"trials":4954,"activeCount":99},[],{"intervention":4668,"totalTrials":151,"cells":4956},{"EARLY_PHASE1":4957,"PHASE1":4959,"PHASE2":4961,"PHASE3":4963,"PHASE4":4969,"NA":4971},{"trials":4958,"activeCount":99},[],{"trials":4960,"activeCount":99},[],{"trials":4962,"activeCount":99},[],{"trials":4964,"activeCount":99},[4965],{"nctId":4657,"briefTitle":4658,"status":109,"phases":4966,"primaryCompletion":4660,"completion":4661,"start":4662,"enrollment":4663,"conditions":4967,"interventions":4968},[90],[4665],[4667,4668,4646,4669],{"trials":4970,"activeCount":99},[],{"trials":4972,"activeCount":99},[],{"intervention":118,"totalTrials":151,"cells":4974},{"EARLY_PHASE1":4975,"PHASE1":4977,"PHASE2":4979,"PHASE3":4981,"PHASE4":4987,"NA":4989},{"trials":4976,"activeCount":99},[],{"trials":4978,"activeCount":99},[],{"trials":4980,"activeCount":99},[],{"trials":4982,"activeCount":99},[4983],{"nctId":107,"briefTitle":108,"status":109,"phases":4984,"primaryCompletion":111,"completion":111,"start":112,"enrollment":113,"conditions":4985,"interventions":4986},[90],[115,116],[118,118,47],{"trials":4988,"activeCount":99},[],{"trials":4990,"activeCount":99},[],{"intervention":4992,"totalTrials":151,"cells":4993},"Artesunate-mefloquine",{"EARLY_PHASE1":4994,"PHASE1":4996,"PHASE2":4998,"PHASE3":5000,"PHASE4":5013,"NA":5015},{"trials":4995,"activeCount":99},[],{"trials":4997,"activeCount":99},[],{"trials":4999,"activeCount":99},[],{"trials":5001,"activeCount":99},[5002],{"nctId":5003,"briefTitle":5004,"status":109,"phases":5005,"primaryCompletion":5006,"completion":5006,"start":5007,"enrollment":5008,"conditions":5009,"interventions":5010},"NCT01054248","Randomised Trial of 3 Artemisinin Combination Therapy for Malaria in Pregnancy",[90],"2016-09","2010-02-16",511,[15],[5011,4992,5012],"dihydroartemisinin-piperaquine","arthemeter-lumefantrin",{"trials":5014,"activeCount":99},[],{"trials":5016,"activeCount":99},[],{"intervention":5012,"totalTrials":151,"cells":5018},{"EARLY_PHASE1":5019,"PHASE1":5021,"PHASE2":5023,"PHASE3":5025,"PHASE4":5031,"NA":5033},{"trials":5020,"activeCount":99},[],{"trials":5022,"activeCount":99},[],{"trials":5024,"activeCount":99},[],{"trials":5026,"activeCount":99},[5027],{"nctId":5003,"briefTitle":5004,"status":109,"phases":5028,"primaryCompletion":5006,"completion":5006,"start":5007,"enrollment":5008,"conditions":5029,"interventions":5030},[90],[15],[5011,4992,5012],{"trials":5032,"activeCount":99},[],{"trials":5034,"activeCount":99},[],{"intervention":4580,"totalTrials":151,"cells":5036},{"EARLY_PHASE1":5037,"PHASE1":5039,"PHASE2":5041,"PHASE3":5043,"PHASE4":5049,"NA":5051},{"trials":5038,"activeCount":99},[],{"trials":5040,"activeCount":99},[],{"trials":5042,"activeCount":99},[],{"trials":5044,"activeCount":99},[5045],{"nctId":4573,"briefTitle":4574,"status":109,"phases":5046,"primaryCompletion":4558,"completion":4558,"start":4576,"enrollment":4577,"conditions":5047,"interventions":5048},[89,90],[4539],[4526,4580,4581,4582,4526,4583,4584,4585,4586],{"trials":5050,"activeCount":99},[],{"trials":5052,"activeCount":99},[],{"intervention":4581,"totalTrials":151,"cells":5054},{"EARLY_PHASE1":5055,"PHASE1":5057,"PHASE2":5059,"PHASE3":5061,"PHASE4":5067,"NA":5069},{"trials":5056,"activeCount":99},[],{"trials":5058,"activeCount":99},[],{"trials":5060,"activeCount":99},[],{"trials":5062,"activeCount":99},[5063],{"nctId":4573,"briefTitle":4574,"status":109,"phases":5064,"primaryCompletion":4558,"completion":4558,"start":4576,"enrollment":4577,"conditions":5065,"interventions":5066},[89,90],[4539],[4526,4580,4581,4582,4526,4583,4584,4585,4586],{"trials":5068,"activeCount":99},[],{"trials":5070,"activeCount":99},[],{"intervention":4582,"totalTrials":151,"cells":5072},{"EARLY_PHASE1":5073,"PHASE1":5075,"PHASE2":5077,"PHASE3":5079,"PHASE4":5085,"NA":5087},{"trials":5074,"activeCount":99},[],{"trials":5076,"activeCount":99},[],{"trials":5078,"activeCount":99},[],{"trials":5080,"activeCount":99},[5081],{"nctId":4573,"briefTitle":4574,"status":109,"phases":5082,"primaryCompletion":4558,"completion":4558,"start":4576,"enrollment":4577,"conditions":5083,"interventions":5084},[89,90],[4539],[4526,4580,4581,4582,4526,4583,4584,4585,4586],{"trials":5086,"activeCount":99},[],{"trials":5088,"activeCount":99},[],{"intervention":4583,"totalTrials":151,"cells":5090},{"EARLY_PHASE1":5091,"PHASE1":5093,"PHASE2":5095,"PHASE3":5097,"PHASE4":5103,"NA":5105},{"trials":5092,"activeCount":99},[],{"trials":5094,"activeCount":99},[],{"trials":5096,"activeCount":99},[],{"trials":5098,"activeCount":99},[5099],{"nctId":4573,"briefTitle":4574,"status":109,"phases":5100,"primaryCompletion":4558,"completion":4558,"start":4576,"enrollment":4577,"conditions":5101,"interventions":5102},[89,90],[4539],[4526,4580,4581,4582,4526,4583,4584,4585,4586],{"trials":5104,"activeCount":99},[],{"trials":5106,"activeCount":99},[],{"intervention":4584,"totalTrials":151,"cells":5108},{"EARLY_PHASE1":5109,"PHASE1":5111,"PHASE2":5113,"PHASE3":5115,"PHASE4":5121,"NA":5123},{"trials":5110,"activeCount":99},[],{"trials":5112,"activeCount":99},[],{"trials":5114,"activeCount":99},[],{"trials":5116,"activeCount":99},[5117],{"nctId":4573,"briefTitle":4574,"status":109,"phases":5118,"primaryCompletion":4558,"completion":4558,"start":4576,"enrollment":4577,"conditions":5119,"interventions":5120},[89,90],[4539],[4526,4580,4581,4582,4526,4583,4584,4585,4586],{"trials":5122,"activeCount":99},[],{"trials":5124,"activeCount":99},[],{"intervention":4585,"totalTrials":151,"cells":5126},{"EARLY_PHASE1":5127,"PHASE1":5129,"PHASE2":5131,"PHASE3":5133,"PHASE4":5139,"NA":5141},{"trials":5128,"activeCount":99},[],{"trials":5130,"activeCount":99},[],{"trials":5132,"activeCount":99},[],{"trials":5134,"activeCount":99},[5135],{"nctId":4573,"briefTitle":4574,"status":109,"phases":5136,"primaryCompletion":4558,"completion":4558,"start":4576,"enrollment":4577,"conditions":5137,"interventions":5138},[89,90],[4539],[4526,4580,4581,4582,4526,4583,4584,4585,4586],{"trials":5140,"activeCount":99},[],{"trials":5142,"activeCount":99},[],{"intervention":4586,"totalTrials":151,"cells":5144},{"EARLY_PHASE1":5145,"PHASE1":5147,"PHASE2":5149,"PHASE3":5151,"PHASE4":5157,"NA":5159},{"trials":5146,"activeCount":99},[],{"trials":5148,"activeCount":99},[],{"trials":5150,"activeCount":99},[],{"trials":5152,"activeCount":99},[5153],{"nctId":4573,"briefTitle":4574,"status":109,"phases":5154,"primaryCompletion":4558,"completion":4558,"start":4576,"enrollment":4577,"conditions":5155,"interventions":5156},[89,90],[4539],[4526,4580,4581,4582,4526,4583,4584,4585,4586],{"trials":5158,"activeCount":99},[],{"trials":5160,"activeCount":99},[],{"intervention":1317,"totalTrials":151,"cells":5162},{"EARLY_PHASE1":5163,"PHASE1":5165,"PHASE2":5167,"PHASE3":5169,"PHASE4":5175,"NA":5177},{"trials":5164,"activeCount":99},[],{"trials":5166,"activeCount":99},[],{"trials":5168,"activeCount":99},[],{"trials":5170,"activeCount":99},[5171],{"nctId":1308,"briefTitle":1309,"status":109,"phases":5172,"primaryCompletion":1311,"completion":1311,"start":1312,"enrollment":1313,"conditions":5173,"interventions":5174},[90],[1315],[1317,1318,1272],{"trials":5176,"activeCount":99},[],{"trials":5178,"activeCount":99},[],{"intervention":1318,"totalTrials":151,"cells":5180},{"EARLY_PHASE1":5181,"PHASE1":5183,"PHASE2":5185,"PHASE3":5187,"PHASE4":5193,"NA":5195},{"trials":5182,"activeCount":99},[],{"trials":5184,"activeCount":99},[],{"trials":5186,"activeCount":99},[],{"trials":5188,"activeCount":99},[5189],{"nctId":1308,"briefTitle":1309,"status":109,"phases":5190,"primaryCompletion":1311,"completion":1311,"start":1312,"enrollment":1313,"conditions":5191,"interventions":5192},[90],[1315],[1317,1318,1272],{"trials":5194,"activeCount":99},[],{"trials":5196,"activeCount":99},[],{"intervention":5198,"totalTrials":151,"cells":5199},"Reducing Antibiotics treatment duration",{"EARLY_PHASE1":5200,"PHASE1":5202,"PHASE2":5204,"PHASE3":5206,"PHASE4":5221,"NA":5223},{"trials":5201,"activeCount":99},[],{"trials":5203,"activeCount":99},[],{"trials":5205,"activeCount":99},[],{"trials":5207,"activeCount":99},[5208],{"nctId":5209,"briefTitle":5210,"status":109,"phases":5211,"primaryCompletion":5212,"completion":5213,"start":5214,"enrollment":5215,"conditions":5216,"interventions":5219},"NCT03382548","Defining Antibiotic Treatment Duration for Ventilator - Associated Lung Infection",[90],"2023-01-23","2023-03-22","2018-02-21",460,[5217,5218],"Ventilator Associated Pneumonia","Pneumonia, Bacterial",[5198,5220],"Standard Antibiotics treatment duration",{"trials":5222,"activeCount":99},[],{"trials":5224,"activeCount":99},[],{"intervention":5220,"totalTrials":151,"cells":5226},{"EARLY_PHASE1":5227,"PHASE1":5229,"PHASE2":5231,"PHASE3":5233,"PHASE4":5239,"NA":5241},{"trials":5228,"activeCount":99},[],{"trials":5230,"activeCount":99},[],{"trials":5232,"activeCount":99},[],{"trials":5234,"activeCount":99},[5235],{"nctId":5209,"briefTitle":5210,"status":109,"phases":5236,"primaryCompletion":5212,"completion":5213,"start":5214,"enrollment":5215,"conditions":5237,"interventions":5238},[90],[5217,5218],[5198,5220],{"trials":5240,"activeCount":99},[],{"trials":5242,"activeCount":99},[],{"intervention":5244,"totalTrials":151,"cells":5245},"3-day artemether-lumefantrine",{"EARLY_PHASE1":5246,"PHASE1":5248,"PHASE2":5250,"PHASE3":5252,"PHASE4":5263,"NA":5265},{"trials":5247,"activeCount":99},[],{"trials":5249,"activeCount":99},[],{"trials":5251,"activeCount":99},[],{"trials":5253,"activeCount":99},[5254],{"nctId":5255,"briefTitle":5256,"status":109,"phases":5257,"primaryCompletion":5258,"start":3829,"enrollment":5259,"conditions":5260,"interventions":5261},"NCT01916954","Comparison of Two Regimens of Artemether-lumefantrine for the Treatment of Malaria in Pregnancy",[90],"2014-03",96,[15],[5244,5262],"5-day artemether-lumefantrine",{"trials":5264,"activeCount":99},[],{"trials":5266,"activeCount":99},[],{"intervention":5262,"totalTrials":151,"cells":5268},{"EARLY_PHASE1":5269,"PHASE1":5271,"PHASE2":5273,"PHASE3":5275,"PHASE4":5281,"NA":5283},{"trials":5270,"activeCount":99},[],{"trials":5272,"activeCount":99},[],{"trials":5274,"activeCount":99},[],{"trials":5276,"activeCount":99},[5277],{"nctId":5255,"briefTitle":5256,"status":109,"phases":5278,"primaryCompletion":5258,"start":3829,"enrollment":5259,"conditions":5279,"interventions":5280},[90],[15],[5244,5262],{"trials":5282,"activeCount":99},[],{"trials":5284,"activeCount":99},[],{"intervention":5286,"totalTrials":151,"cells":5287},"Dihydroartemisinin\u002Fpiperaquine + primaquine",{"EARLY_PHASE1":5288,"PHASE1":5290,"PHASE2":5292,"PHASE3":5294,"PHASE4":5304,"NA":5306},{"trials":5289,"activeCount":99},[],{"trials":5291,"activeCount":99},[],{"trials":5293,"activeCount":99},[],{"trials":5295,"activeCount":99},[5296],{"nctId":5297,"briefTitle":5298,"status":109,"phases":5299,"primaryCompletion":3377,"completion":3377,"start":3942,"enrollment":5300,"conditions":5301,"interventions":5302},"NCT01288820","Study of ACTs Plus Primaquine for Uncomplicated Plasmodium Vivax Malaria",[90],331,[531],[5286,5303],"Artesunate-amodiaquine + primaquine",{"trials":5305,"activeCount":99},[],{"trials":5307,"activeCount":99},[],{"intervention":5303,"totalTrials":151,"cells":5309},{"EARLY_PHASE1":5310,"PHASE1":5312,"PHASE2":5314,"PHASE3":5316,"PHASE4":5322,"NA":5324},{"trials":5311,"activeCount":99},[],{"trials":5313,"activeCount":99},[],{"trials":5315,"activeCount":99},[],{"trials":5317,"activeCount":99},[5318],{"nctId":5297,"briefTitle":5298,"status":109,"phases":5319,"primaryCompletion":3377,"completion":3377,"start":3942,"enrollment":5300,"conditions":5320,"interventions":5321},[90],[531],[5286,5303],{"trials":5323,"activeCount":99},[],{"trials":5325,"activeCount":99},[],{"intervention":4679,"totalTrials":151,"cells":5327},{"EARLY_PHASE1":5328,"PHASE1":5330,"PHASE2":5332,"PHASE3":5334,"PHASE4":5340,"NA":5342},{"trials":5329,"activeCount":99},[],{"trials":5331,"activeCount":99},[],{"trials":5333,"activeCount":99},[],{"trials":5335,"activeCount":99},[5336],{"nctId":4671,"briefTitle":4672,"status":109,"phases":5337,"primaryCompletion":4674,"completion":4674,"start":4675,"enrollment":4676,"conditions":5338,"interventions":5339},[90],[4665],[4679,4680,4646,4669],{"trials":5341,"activeCount":99},[],{"trials":5343,"activeCount":99},[],{"intervention":4680,"totalTrials":151,"cells":5345},{"EARLY_PHASE1":5346,"PHASE1":5348,"PHASE2":5350,"PHASE3":5352,"PHASE4":5358,"NA":5360},{"trials":5347,"activeCount":99},[],{"trials":5349,"activeCount":99},[],{"trials":5351,"activeCount":99},[],{"trials":5353,"activeCount":99},[5354],{"nctId":4671,"briefTitle":4672,"status":109,"phases":5355,"primaryCompletion":4674,"completion":4674,"start":4675,"enrollment":4676,"conditions":5356,"interventions":5357},[90],[4665],[4679,4680,4646,4669],{"trials":5359,"activeCount":99},[],{"trials":5361,"activeCount":99},[],{"intervention":5363,"totalTrials":151,"cells":5364},"Arterolane maleate-piperaquine phosphate",{"EARLY_PHASE1":5365,"PHASE1":5367,"PHASE2":5369,"PHASE3":5371,"PHASE4":5384,"NA":5386},{"trials":5366,"activeCount":99},[],{"trials":5368,"activeCount":99},[],{"trials":5370,"activeCount":99},[],{"trials":5372,"activeCount":99},[5373],{"nctId":5374,"briefTitle":5375,"status":183,"phases":5376,"primaryCompletion":5377,"completion":5377,"start":5378,"enrollment":99,"conditions":5379,"interventions":5382},"NCT02461186","Arterolane-PQP Versus DHA-PQP in Uncomplicated Falciparum Malaria in Eastern Myanmar",[89,90],"2017-06","2015-06",[5380,5381],"Uncomplicated Falciparum Malaria","Artemisinin-resistant",[5363,5383],"Dihydroartemisinin-piperaquine phosphate",{"trials":5385,"activeCount":99},[],{"trials":5387,"activeCount":99},[],{"intervention":5383,"totalTrials":151,"cells":5389},{"EARLY_PHASE1":5390,"PHASE1":5392,"PHASE2":5394,"PHASE3":5396,"PHASE4":5402,"NA":5404},{"trials":5391,"activeCount":99},[],{"trials":5393,"activeCount":99},[],{"trials":5395,"activeCount":99},[],{"trials":5397,"activeCount":99},[5398],{"nctId":5374,"briefTitle":5375,"status":183,"phases":5399,"primaryCompletion":5377,"completion":5377,"start":5378,"enrollment":99,"conditions":5400,"interventions":5401},[89,90],[5380,5381],[5363,5383],{"trials":5403,"activeCount":99},[],{"trials":5405,"activeCount":99},[],{"intervention":5407,"totalTrials":151,"cells":5408},"Meningococcal (Groups A, C, Y and W-135) Conjugate",{"EARLY_PHASE1":5409,"PHASE1":5411,"PHASE2":5413,"PHASE3":5415,"PHASE4":5428,"NA":5430},{"trials":5410,"activeCount":99},[],{"trials":5412,"activeCount":99},[],{"trials":5414,"activeCount":99},[],{"trials":5416,"activeCount":99},[5417],{"nctId":5418,"briefTitle":5419,"status":109,"phases":5420,"primaryCompletion":5421,"completion":5421,"start":5422,"enrollment":5423,"conditions":5424,"interventions":5426},"NCT00901940","Understanding the Immune Response to Meningitis Vaccines",[90],"2010-10","2009-06",150,[3878,5425],"Septicemia",[5407,5427],"Meningococcal polysaccharide A, C, Y and W135 and Menveo",{"trials":5429,"activeCount":99},[],{"trials":5431,"activeCount":99},[],{"intervention":5427,"totalTrials":151,"cells":5433},{"EARLY_PHASE1":5434,"PHASE1":5436,"PHASE2":5438,"PHASE3":5440,"PHASE4":5446,"NA":5448},{"trials":5435,"activeCount":99},[],{"trials":5437,"activeCount":99},[],{"trials":5439,"activeCount":99},[],{"trials":5441,"activeCount":99},[5442],{"nctId":5418,"briefTitle":5419,"status":109,"phases":5443,"primaryCompletion":5421,"completion":5421,"start":5422,"enrollment":5423,"conditions":5444,"interventions":5445},[90],[3878,5425],[5407,5427],{"trials":5447,"activeCount":99},[],{"trials":5449,"activeCount":99},[],{"intervention":4857,"totalTrials":151,"cells":5451},{"EARLY_PHASE1":5452,"PHASE1":5454,"PHASE2":5456,"PHASE3":5458,"PHASE4":5464,"NA":5466},{"trials":5453,"activeCount":99},[],{"trials":5455,"activeCount":99},[],{"trials":5457,"activeCount":99},[],{"trials":5459,"activeCount":99},[5460],{"nctId":4850,"briefTitle":4851,"status":2901,"phases":5461,"primaryCompletion":3579,"completion":3654,"start":3942,"enrollment":1530,"conditions":5462,"interventions":5463},[90],[4854,4855],[4857,4839],{"trials":5465,"activeCount":99},[],{"trials":5467,"activeCount":99},[],{"intervention":4638,"totalTrials":151,"cells":5469},{"EARLY_PHASE1":5470,"PHASE1":5472,"PHASE2":5474,"PHASE3":5476,"PHASE4":5482,"NA":5484},{"trials":5471,"activeCount":99},[],{"trials":5473,"activeCount":99},[],{"trials":5475,"activeCount":99},[],{"trials":5477,"activeCount":99},[5478],{"nctId":4630,"briefTitle":4631,"status":109,"phases":5479,"primaryCompletion":4633,"completion":4633,"start":4634,"enrollment":4635,"conditions":5480,"interventions":5481},[90],[129],[4627,4638,4592,4639,4640],{"trials":5483,"activeCount":99},[],{"trials":5485,"activeCount":99},[],{"intervention":4639,"totalTrials":151,"cells":5487},{"EARLY_PHASE1":5488,"PHASE1":5490,"PHASE2":5492,"PHASE3":5494,"PHASE4":5500,"NA":5502},{"trials":5489,"activeCount":99},[],{"trials":5491,"activeCount":99},[],{"trials":5493,"activeCount":99},[],{"trials":5495,"activeCount":99},[5496],{"nctId":4630,"briefTitle":4631,"status":109,"phases":5497,"primaryCompletion":4633,"completion":4633,"start":4634,"enrollment":4635,"conditions":5498,"interventions":5499},[90],[129],[4627,4638,4592,4639,4640],{"trials":5501,"activeCount":99},[],{"trials":5503,"activeCount":99},[],{"intervention":4640,"totalTrials":151,"cells":5505},{"EARLY_PHASE1":5506,"PHASE1":5508,"PHASE2":5510,"PHASE3":5512,"PHASE4":5518,"NA":5520},{"trials":5507,"activeCount":99},[],{"trials":5509,"activeCount":99},[],{"trials":5511,"activeCount":99},[],{"trials":5513,"activeCount":99},[5514],{"nctId":4630,"briefTitle":4631,"status":109,"phases":5515,"primaryCompletion":4633,"completion":4633,"start":4634,"enrollment":4635,"conditions":5516,"interventions":5517},[90],[129],[4627,4638,4592,4639,4640],{"trials":5519,"activeCount":99},[],{"trials":5521,"activeCount":99},[],{"intervention":5523,"totalTrials":151,"cells":5524},"ChAdOx1 nCoV-19 single dose + paracetamol",{"EARLY_PHASE1":5525,"PHASE1":5527,"PHASE2":5529,"PHASE3":5531,"PHASE4":5545,"NA":5547},{"trials":5526,"activeCount":99},[],{"trials":5528,"activeCount":99},[],{"trials":5530,"activeCount":99},[],{"trials":5532,"activeCount":99},[5533],{"nctId":5534,"briefTitle":5535,"status":2901,"phases":5536,"primaryCompletion":5537,"completion":5537,"start":5538,"enrollment":5539,"conditions":5540,"interventions":5541},"NCT04536051","A Study of a Candidate COVID-19 Vaccine (COV003)",[90],"2021-09","2020-06-02",10300,[4539],[5523,5542,5543,5544],"MenACWY single dose + paracetamol","ChAdOx1 nCoV-19 two dose + paracetamol","MenACWY prime & saline placebo boost + paracetamol",{"trials":5546,"activeCount":99},[],{"trials":5548,"activeCount":99},[],{"intervention":5542,"totalTrials":151,"cells":5550},{"EARLY_PHASE1":5551,"PHASE1":5553,"PHASE2":5555,"PHASE3":5557,"PHASE4":5563,"NA":5565},{"trials":5552,"activeCount":99},[],{"trials":5554,"activeCount":99},[],{"trials":5556,"activeCount":99},[],{"trials":5558,"activeCount":99},[5559],{"nctId":5534,"briefTitle":5535,"status":2901,"phases":5560,"primaryCompletion":5537,"completion":5537,"start":5538,"enrollment":5539,"conditions":5561,"interventions":5562},[90],[4539],[5523,5542,5543,5544],{"trials":5564,"activeCount":99},[],{"trials":5566,"activeCount":99},[],{"intervention":5543,"totalTrials":151,"cells":5568},{"EARLY_PHASE1":5569,"PHASE1":5571,"PHASE2":5573,"PHASE3":5575,"PHASE4":5581,"NA":5583},{"trials":5570,"activeCount":99},[],{"trials":5572,"activeCount":99},[],{"trials":5574,"activeCount":99},[],{"trials":5576,"activeCount":99},[5577],{"nctId":5534,"briefTitle":5535,"status":2901,"phases":5578,"primaryCompletion":5537,"completion":5537,"start":5538,"enrollment":5539,"conditions":5579,"interventions":5580},[90],[4539],[5523,5542,5543,5544],{"trials":5582,"activeCount":99},[],{"trials":5584,"activeCount":99},[],{"intervention":5544,"totalTrials":151,"cells":5586},{"EARLY_PHASE1":5587,"PHASE1":5589,"PHASE2":5591,"PHASE3":5593,"PHASE4":5599,"NA":5601},{"trials":5588,"activeCount":99},[],{"trials":5590,"activeCount":99},[],{"trials":5592,"activeCount":99},[],{"trials":5594,"activeCount":99},[5595],{"nctId":5534,"briefTitle":5535,"status":2901,"phases":5596,"primaryCompletion":5537,"completion":5537,"start":5538,"enrollment":5539,"conditions":5597,"interventions":5598},[90],[4539],[5523,5542,5543,5544],{"trials":5600,"activeCount":99},[],{"trials":5602,"activeCount":99},[],{"intervention":5604,"totalTrials":151,"cells":5605},"Cotrimoxazole dispersible",{"EARLY_PHASE1":5606,"PHASE1":5608,"PHASE2":5610,"PHASE3":5612,"PHASE4":5623,"NA":5625},{"trials":5607,"activeCount":99},[],{"trials":5609,"activeCount":99},[],{"trials":5611,"activeCount":99},[],{"trials":5613,"activeCount":99},[5614],{"nctId":5615,"briefTitle":5616,"status":109,"phases":5617,"primaryCompletion":3653,"completion":3653,"start":4451,"enrollment":5618,"conditions":5619,"interventions":5622},"NCT00934492","Cotrimoxazole Prophylaxis in Severely Malnourished Children",[90],1781,[5620,5621],"Nutrition Disorders","Life-threatening Infection",[5604],{"trials":5624,"activeCount":99},[],{"trials":5626,"activeCount":99},[],{"intervention":5628,"totalTrials":151,"cells":5629},"Artemether-lumefantrine 3 days",{"EARLY_PHASE1":5630,"PHASE1":5632,"PHASE2":5634,"PHASE3":5636,"PHASE4":5649,"NA":5651},{"trials":5631,"activeCount":99},[],{"trials":5633,"activeCount":99},[],{"trials":5635,"activeCount":99},[],{"trials":5637,"activeCount":99},[5638],{"nctId":5639,"briefTitle":5640,"status":109,"phases":5641,"primaryCompletion":5642,"completion":5643,"start":5644,"enrollment":5423,"conditions":5645,"interventions":5647},"NCT02020330","Optimising Operational Use of Artemether-lumefantrine Comparing 3 Day Versus 5 Day",[90],"2015-02-04","2015-03-25","2013-11-25",[5646],"Plasmodium Falciparum Infection",[5628,5648],"Artemether-lumefantrine 5 days",{"trials":5650,"activeCount":99},[],{"trials":5652,"activeCount":99},[],{"intervention":5648,"totalTrials":151,"cells":5654},{"EARLY_PHASE1":5655,"PHASE1":5657,"PHASE2":5659,"PHASE3":5661,"PHASE4":5667,"NA":5669},{"trials":5656,"activeCount":99},[],{"trials":5658,"activeCount":99},[],{"trials":5660,"activeCount":99},[],{"trials":5662,"activeCount":99},[5663],{"nctId":5639,"briefTitle":5640,"status":109,"phases":5664,"primaryCompletion":5642,"completion":5643,"start":5644,"enrollment":5423,"conditions":5665,"interventions":5666},[90],[5646],[5628,5648],{"trials":5668,"activeCount":99},[],{"trials":5670,"activeCount":99},[],{"intervention":5672,"totalTrials":151,"cells":5673},"Pancreatic Enzyme",{"EARLY_PHASE1":5674,"PHASE1":5676,"PHASE2":5678,"PHASE3":5680,"PHASE4":5695,"NA":5697},{"trials":5675,"activeCount":99},[],{"trials":5677,"activeCount":99},[],{"trials":5679,"activeCount":99},[],{"trials":5681,"activeCount":99},[5682],{"nctId":5683,"briefTitle":5684,"status":2901,"phases":5685,"primaryCompletion":5686,"completion":5687,"start":5688,"enrollment":5689,"conditions":5690,"interventions":5693},"NCT04542473","Pancreatic Enzymes and Bile Acids in Acutely Ill Severely Malnourished Children",[89,90],"2023-10-31","2024-06-30","2021-07-01",400,[5691,5692],"SEPSIS","MALNUTRITION, CHILD",[5672,5694],"Ursodeoxycholic acid",{"trials":5696,"activeCount":99},[],{"trials":5698,"activeCount":99},[],{"intervention":5694,"totalTrials":151,"cells":5700},{"EARLY_PHASE1":5701,"PHASE1":5703,"PHASE2":5705,"PHASE3":5707,"PHASE4":5713,"NA":5715},{"trials":5702,"activeCount":99},[],{"trials":5704,"activeCount":99},[],{"trials":5706,"activeCount":99},[],{"trials":5708,"activeCount":99},[5709],{"nctId":5683,"briefTitle":5684,"status":2901,"phases":5710,"primaryCompletion":5686,"completion":5687,"start":5688,"enrollment":5689,"conditions":5711,"interventions":5712},[89,90],[5691,5692],[5672,5694],{"trials":5714,"activeCount":99},[],{"trials":5716,"activeCount":99},[],{"intervention":4776,"totalTrials":151,"cells":5718},{"EARLY_PHASE1":5719,"PHASE1":5721,"PHASE2":5723,"PHASE3":5725,"PHASE4":5731,"NA":5733},{"trials":5720,"activeCount":99},[],{"trials":5722,"activeCount":99},[],{"trials":5724,"activeCount":99},[],{"trials":5726,"activeCount":99},[5727],{"nctId":4766,"briefTitle":4767,"status":109,"phases":5728,"primaryCompletion":4769,"completion":4558,"start":4770,"enrollment":4771,"conditions":5729,"interventions":5730},[90],[4773,4774],[4776,4777,4628],{"trials":5732,"activeCount":99},[],{"trials":5734,"activeCount":99},[],{"intervention":4777,"totalTrials":151,"cells":5736},{"EARLY_PHASE1":5737,"PHASE1":5739,"PHASE2":5741,"PHASE3":5743,"PHASE4":5749,"NA":5751},{"trials":5738,"activeCount":99},[],{"trials":5740,"activeCount":99},[],{"trials":5742,"activeCount":99},[],{"trials":5744,"activeCount":99},[5745],{"nctId":4766,"briefTitle":4767,"status":109,"phases":5746,"primaryCompletion":4769,"completion":4558,"start":4770,"enrollment":4771,"conditions":5747,"interventions":5748},[90],[4773,4774],[4776,4777,4628],{"trials":5750,"activeCount":99},[],{"trials":5752,"activeCount":99},[],{"intervention":5754,"totalTrials":151,"cells":5755},"Dihydroartemisinin + Piperaquine",{"EARLY_PHASE1":5756,"PHASE1":5758,"PHASE2":5760,"PHASE3":5762,"PHASE4":5773,"NA":5775},{"trials":5757,"activeCount":99},[],{"trials":5759,"activeCount":99},[],{"trials":5761,"activeCount":99},[],{"trials":5763,"activeCount":99},[5764],{"nctId":5765,"briefTitle":5766,"status":109,"phases":5767,"primaryCompletion":4426,"completion":4426,"start":5768,"enrollment":5769,"conditions":5770,"interventions":5771},"NCT00682578","A Comparative Study of Artekin With Standard Malarial Treatment Regimes in Afghanistan",[90],"2007-07",1086,[5380,531],[5754,5772],"artesunate-sulphadoxin\u002Fpyrimethamine, chloroquine",{"trials":5774,"activeCount":99},[],{"trials":5776,"activeCount":99},[],{"intervention":5772,"totalTrials":151,"cells":5778},{"EARLY_PHASE1":5779,"PHASE1":5781,"PHASE2":5783,"PHASE3":5785,"PHASE4":5791,"NA":5793},{"trials":5780,"activeCount":99},[],{"trials":5782,"activeCount":99},[],{"trials":5784,"activeCount":99},[],{"trials":5786,"activeCount":99},[5787],{"nctId":5765,"briefTitle":5766,"status":109,"phases":5788,"primaryCompletion":4426,"completion":4426,"start":5768,"enrollment":5769,"conditions":5789,"interventions":5790},[90],[5380,531],[5754,5772],{"trials":5792,"activeCount":99},[],{"trials":5794,"activeCount":99},[],{"intervention":5796,"totalTrials":151,"cells":5797},"tamoxifen citrate",{"EARLY_PHASE1":5798,"PHASE1":5800,"PHASE2":5802,"PHASE3":5804,"PHASE4":5814,"NA":5816},{"trials":5799,"activeCount":99},[],{"trials":5801,"activeCount":99},[],{"trials":5803,"activeCount":99},[],{"trials":5805,"activeCount":99},[5806],{"nctId":5807,"briefTitle":5808,"status":2901,"phases":5809,"start":5810,"enrollment":506,"conditions":5811,"interventions":5813},"NCT00003016","Prolonged Tamoxifen Compared With Shorter Tamoxifen in Treating Patients Who Have Breast Cancer",[90],"1995-10",[5812],"Breast Cancer",[5796],{"trials":5815,"activeCount":99},[],{"trials":5817,"activeCount":99},[],{"intervention":5819,"totalTrials":151,"cells":5820},"ER niacin\u002Flaropiprant",{"EARLY_PHASE1":5821,"PHASE1":5823,"PHASE2":5825,"PHASE3":5827,"PHASE4":5841,"NA":5843},{"trials":5822,"activeCount":99},[],{"trials":5824,"activeCount":99},[],{"trials":5826,"activeCount":99},[],{"trials":5828,"activeCount":99},[5829],{"nctId":5830,"briefTitle":5831,"status":109,"phases":5832,"primaryCompletion":527,"completion":527,"start":5833,"enrollment":5834,"conditions":5835,"interventions":5838},"NCT00461630","Treatment of HDL to Reduce the Incidence of Vascular Events HPS2-THRIVE",[90],"2007-01",25673,[5836,5837,161,4056],"Cardiovascular Disease","Peripheral Arterial Disease",[5819,5839,5840],"simvastatin","ezetimibe\u002Fsimvastatin",{"trials":5842,"activeCount":99},[],{"trials":5844,"activeCount":99},[],{"intervention":5839,"totalTrials":151,"cells":5846},{"EARLY_PHASE1":5847,"PHASE1":5849,"PHASE2":5851,"PHASE3":5853,"PHASE4":5859,"NA":5861},{"trials":5848,"activeCount":99},[],{"trials":5850,"activeCount":99},[],{"trials":5852,"activeCount":99},[],{"trials":5854,"activeCount":99},[5855],{"nctId":5830,"briefTitle":5831,"status":109,"phases":5856,"primaryCompletion":527,"completion":527,"start":5833,"enrollment":5834,"conditions":5857,"interventions":5858},[90],[5836,5837,161,4056],[5819,5839,5840],{"trials":5860,"activeCount":99},[],{"trials":5862,"activeCount":99},[],{"intervention":5840,"totalTrials":151,"cells":5864},{"EARLY_PHASE1":5865,"PHASE1":5867,"PHASE2":5869,"PHASE3":5871,"PHASE4":5877,"NA":5879},{"trials":5866,"activeCount":99},[],{"trials":5868,"activeCount":99},[],{"trials":5870,"activeCount":99},[],{"trials":5872,"activeCount":99},[5873],{"nctId":5830,"briefTitle":5831,"status":109,"phases":5874,"primaryCompletion":527,"completion":527,"start":5833,"enrollment":5834,"conditions":5875,"interventions":5876},[90],[5836,5837,161,4056],[5819,5839,5840],{"trials":5878,"activeCount":99},[],{"trials":5880,"activeCount":99},[],{"intervention":4866,"totalTrials":151,"cells":5882},{"EARLY_PHASE1":5883,"PHASE1":5885,"PHASE2":5887,"PHASE3":5889,"PHASE4":5895,"NA":5897},{"trials":5884,"activeCount":99},[],{"trials":5886,"activeCount":99},[],{"trials":5888,"activeCount":99},[],{"trials":5890,"activeCount":99},[5891],{"nctId":4859,"briefTitle":4860,"status":109,"phases":5892,"primaryCompletion":552,"completion":4862,"start":4180,"enrollment":4863,"conditions":5893,"interventions":5894},[89,90],[4854],[4866,4839,4867,4868],{"trials":5896,"activeCount":99},[],{"trials":5898,"activeCount":99},[],{"intervention":4867,"totalTrials":151,"cells":5900},{"EARLY_PHASE1":5901,"PHASE1":5903,"PHASE2":5905,"PHASE3":5907,"PHASE4":5913,"NA":5915},{"trials":5902,"activeCount":99},[],{"trials":5904,"activeCount":99},[],{"trials":5906,"activeCount":99},[],{"trials":5908,"activeCount":99},[5909],{"nctId":4859,"briefTitle":4860,"status":109,"phases":5910,"primaryCompletion":552,"completion":4862,"start":4180,"enrollment":4863,"conditions":5911,"interventions":5912},[89,90],[4854],[4866,4839,4867,4868],{"trials":5914,"activeCount":99},[],{"trials":5916,"activeCount":99},[],{"intervention":4868,"totalTrials":151,"cells":5918},{"EARLY_PHASE1":5919,"PHASE1":5921,"PHASE2":5923,"PHASE3":5925,"PHASE4":5931,"NA":5933},{"trials":5920,"activeCount":99},[],{"trials":5922,"activeCount":99},[],{"trials":5924,"activeCount":99},[],{"trials":5926,"activeCount":99},[5927],{"nctId":4859,"briefTitle":4860,"status":109,"phases":5928,"primaryCompletion":552,"completion":4862,"start":4180,"enrollment":4863,"conditions":5929,"interventions":5930},[89,90],[4854],[4866,4839,4867,4868],{"trials":5932,"activeCount":99},[],{"trials":5934,"activeCount":99},[],{"intervention":5936,"totalTrials":151,"cells":5937},"Simvastatin 20 mg daily",{"EARLY_PHASE1":5938,"PHASE1":5940,"PHASE2":5942,"PHASE3":5944,"PHASE4":5956,"NA":5958},{"trials":5939,"activeCount":99},[],{"trials":5941,"activeCount":99},[],{"trials":5943,"activeCount":99},[],{"trials":5945,"activeCount":99},[5946],{"nctId":5947,"briefTitle":5948,"status":109,"phases":5949,"primaryCompletion":5950,"completion":5950,"start":5951,"enrollment":5952,"conditions":5953,"interventions":5954},"NCT00124072","Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine",[90],"2008-05","1998-07",12064,[5836],[5936,5955],"Simvastatin 80 mg daily",{"trials":5957,"activeCount":99},[],{"trials":5959,"activeCount":99},[],{"intervention":5955,"totalTrials":151,"cells":5961},{"EARLY_PHASE1":5962,"PHASE1":5964,"PHASE2":5966,"PHASE3":5968,"PHASE4":5974,"NA":5976},{"trials":5963,"activeCount":99},[],{"trials":5965,"activeCount":99},[],{"trials":5967,"activeCount":99},[],{"trials":5969,"activeCount":99},[5970],{"nctId":5947,"briefTitle":5948,"status":109,"phases":5971,"primaryCompletion":5950,"completion":5950,"start":5951,"enrollment":5952,"conditions":5972,"interventions":5973},[90],[5836],[5936,5955],{"trials":5975,"activeCount":99},[],{"trials":5977,"activeCount":99},[],{"intervention":5979,"totalTrials":151,"cells":5980},"Artemisone\u002FMefloquine",{"EARLY_PHASE1":5981,"PHASE1":5983,"PHASE2":5985,"PHASE3":5987,"PHASE4":5995,"NA":5997},{"trials":5982,"activeCount":99},[],{"trials":5984,"activeCount":99},[],{"trials":5986,"activeCount":99},[],{"trials":5988,"activeCount":99},[5989],{"nctId":5990,"briefTitle":5991,"status":183,"phases":5992,"primaryCompletion":5421,"completion":5421,"start":5421,"enrollment":99,"conditions":5993,"interventions":5994},"NCT00936767","Artemisone for the Treatment of Uncomplicated Falciparum Malaria in Western Cambodia",[89,90],[5380],[5979,533],{"trials":5996,"activeCount":99},[],{"trials":5998,"activeCount":99},[],{"intervention":6000,"totalTrials":28,"cells":6001},"MVA85A",{"EARLY_PHASE1":6002,"PHASE1":6004,"PHASE2":6101,"PHASE3":6132,"PHASE4":6134,"NA":6136},{"trials":6003,"activeCount":99},[],{"trials":6005,"activeCount":99},[6006,6014,6022,6031,6039,6049,6056,6064,6070,6078,6087,6094],{"nctId":6007,"briefTitle":6008,"status":109,"phases":6009,"primaryCompletion":680,"completion":680,"start":3829,"enrollment":1699,"conditions":6010,"interventions":6012},"NCT01879163","Phase I Trial Evaluating Safety and Immunogenicity of MVA85A-IMX313 Compared to MVA85A in BCG Vaccinated Adults",[88],[6011],"Tuberculosis (TB)",[6013,6000],"MVA85A-IMX313",{"nctId":6015,"briefTitle":6016,"status":109,"phases":6017,"primaryCompletion":4929,"completion":4929,"start":6018,"enrollment":6019,"conditions":6020,"interventions":6021},"NCT01954563","Study Evaluating Aerosol and Intradermal Administration of a Candidate Tuberculosis (TB) Vaccine, MVA85A, as a Way to Increase Immune Response and Avoid Anti-vector Immunity",[88],"2013-10",37,[18],[6000],{"nctId":6023,"briefTitle":6024,"status":109,"phases":6025,"completion":6026,"start":6027,"enrollment":6028,"conditions":6029,"interventions":6030},"NCT00423566","A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M. Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers.",[88],"2003-07","2002-09",14,[18],[6000],{"nctId":6032,"briefTitle":6033,"status":109,"phases":6034,"completion":6035,"start":6036,"enrollment":578,"conditions":6037,"interventions":6038},"NCT00427830","A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M. Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers Who Have Previously Received BCG",[88],"2005-01","2003-05",[18],[6000],{"nctId":6040,"briefTitle":6041,"status":109,"phases":6042,"primaryCompletion":6043,"completion":6043,"start":6044,"enrollment":1674,"conditions":6045,"interventions":6047},"NCT00395720","The Safety and Immunogenicity of a TB Vaccine; MVA85A, in Healthy Volunteers Who Are Infected With HIV",[88],"2010-07","2006-11",[18,6046],"HIV Infections",[6000,6048],"MVA 85A",{"nctId":6050,"briefTitle":6051,"status":109,"phases":6052,"primaryCompletion":3454,"completion":3454,"start":3829,"enrollment":2989,"conditions":6053,"interventions":6054},"NCT01829490","Safety Study of ChAdOx1 85A Vaccination With and Without MVA85A Boost in Healthy Adults",[88],[18],[6055,6000],"ChAdOx1 85A",{"nctId":6057,"briefTitle":6058,"status":109,"phases":6059,"primaryCompletion":1456,"completion":1456,"start":6060,"enrollment":1530,"conditions":6061,"interventions":6062},"NCT01683773","Safety Study of Tuberculosis Vaccines AERAS-402 and MVA85A",[88],"2012-09",[18],[6063,6000],"AERAS-402",{"nctId":6065,"briefTitle":6066,"status":109,"phases":6067,"completion":158,"start":4475,"enrollment":31,"conditions":6068,"interventions":6069},"NCT00427453","A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M. Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers Who Have Received BCG Immunisation 1 Month Previously",[88],[18],[6000],{"nctId":6071,"briefTitle":6072,"status":109,"phases":6073,"completion":6074,"start":6075,"enrollment":31,"conditions":6076,"interventions":6077},"NCT00423839","A Phase I Study of the Safety and Immunogenicity of MVA85A in Healthy Gambian Volunteers",[88],"2005-07","2003-03",[18],[6000],{"nctId":6079,"briefTitle":6080,"status":109,"phases":6081,"primaryCompletion":6082,"completion":6082,"start":6083,"enrollment":19,"conditions":6084,"interventions":6085},"NCT00653770","A Phase I Study to Assess the Safety and Immunogenicity of Tuberculosis (TB) Vaccine Candidates FP85A and MVA85A",[88],"2010-01","2007-09",[18],[6086,6000],"FP85A",{"nctId":6088,"briefTitle":6089,"status":109,"phases":6090,"primaryCompletion":3942,"completion":3942,"start":6091,"enrollment":2572,"conditions":6092,"interventions":6093},"NCT00731471","A Phase I Study of a New Tuberculosis (TB) Vaccine, MVA85A, in Healthy Volunteers With HIV",[88],"2008-08",[18],[6000],{"nctId":6095,"briefTitle":6096,"status":109,"phases":6097,"primaryCompletion":6082,"completion":6082,"start":6098,"enrollment":31,"conditions":6099,"interventions":6100},"NCT00548444","T-Cell Turnover Following Vaccination With MVA85A",[88],"2007-10",[18],[6000],{"trials":6102,"activeCount":99},[6103,6116,6122],{"nctId":6104,"briefTitle":6105,"status":109,"phases":6106,"primaryCompletion":6107,"completion":6107,"start":6108,"enrollment":6109,"conditions":6110,"interventions":6113},"NCT03681860","EMaBS TB Vaccine Study",[88,89],"2021-05-24","2019-07-01",72,[6111,6112],"Safety","Immunogenicity",[6114,6000,6115],"ChAdOx185A","BCG",{"nctId":6117,"briefTitle":6118,"status":109,"phases":6119,"primaryCompletion":3788,"completion":3788,"start":3554,"enrollment":1848,"conditions":6120,"interventions":6121},"NCT02178748","Trial to Investigate the Effect of Schistosoma Mansoni Infection on the Response to Vaccination With MVA85A in BCG-vaccinated African Adolescents",[89],[18],[6000],{"nctId":6123,"briefTitle":6124,"status":109,"phases":6125,"primaryCompletion":6126,"completion":6126,"start":6127,"enrollment":6128,"conditions":6129,"interventions":6130},"NCT00679159","A Study of MVA85A in Healthy Children and Infants",[89],"2009-12","2008-02",168,[18],[6000,6131],"Prevenar",{"trials":6133,"activeCount":99},[],{"trials":6135,"activeCount":99},[],{"trials":6137,"activeCount":99},[],{"intervention":6139,"totalTrials":2935,"cells":6140},"MVA ME-TRAP",{"EARLY_PHASE1":6141,"PHASE1":6143,"PHASE2":6155,"PHASE3":6202,"PHASE4":6204,"NA":6206},{"trials":6142,"activeCount":99},[],{"trials":6144,"activeCount":99},[6145],{"nctId":6146,"briefTitle":6147,"status":109,"phases":6148,"primaryCompletion":6149,"completion":6149,"start":6150,"enrollment":6151,"conditions":6152,"interventions":6153},"NCT03084289","A Study to Assess the Safety and Immunogenicity of a Candidate Malaria Vaccine Using Novel Routes of Administration",[88],"2020-07-06","2017-03-28",26,[15],[6154,6139],"ChAd63-METRAP",{"trials":6156,"activeCount":99},[6157,6167,6176,6184,6195],{"nctId":6158,"briefTitle":6159,"status":109,"phases":6160,"completion":6161,"start":6162,"enrollment":1699,"conditions":6163,"interventions":6164},"NCT00408668","Efficacy of Combined PEV3A Virosomal Vaccine and FP9-MVA ME-TRAP Prime Boost Regimen",[88,89],"2006-02","2005-08",[15,2828],[6165,6166,6139],"PEV3A","FP9 ME-TRAP",{"nctId":6168,"briefTitle":6169,"status":109,"phases":6170,"primaryCompletion":1456,"completion":1456,"start":6171,"enrollment":1778,"conditions":6172,"interventions":6173},"NCT01883609","A Safety and Efficacy Study of ChAd63\u002FMVA METRAP + RTS,S",[88,89],"2013-09",[33],[6174,6175,6139],"RTS,S\u002FAS01B","ChAd63 ME-TRAP",{"nctId":6177,"briefTitle":6178,"status":109,"phases":6179,"primaryCompletion":6180,"completion":6180,"start":3740,"enrollment":1422,"conditions":6181,"interventions":6182},"NCT02905019","A Safety and Efficacy Study of R21 +\u002F- ChAd63\u002FMVA ME-TRAP",[88,89],"2017-12-21",[15],[6183,6175,6139],"R21 with Matrix-M1",{"nctId":6185,"briefTitle":6186,"status":109,"phases":6187,"primaryCompletion":4426,"completion":6188,"start":6189,"enrollment":6190,"conditions":6191,"interventions":6192},"NCT00890760","A Study to Assess the Effectiveness of a New Malaria Vaccine Candidate by Infecting Vaccinated Volunteers With Malaria Parasites",[88,89],"2011-02","2009-03",55,[15],[6193,6139,6194],"AdCh63 ME-TRAP","Mixture of AdCh63 ME-TRAP and MVA ME-TRAP intramuscularly",{"nctId":6196,"briefTitle":6197,"status":109,"phases":6198,"primaryCompletion":6199,"completion":6199,"start":3788,"enrollment":1778,"conditions":6200,"interventions":6201},"NCT02252640","A Safety and Efficacy Study of Concomitant Administration of ChAd63\u002FMVA ME-TRAP + RTS,S",[88,89],"2015-10",[33],[6174,6174,6175,6139],{"trials":6203,"activeCount":99},[],{"trials":6205,"activeCount":99},[],{"trials":6207,"activeCount":99},[],{"intervention":6209,"totalTrials":95,"cells":6210},"MVA.HIVconsv",{"EARLY_PHASE1":6211,"PHASE1":6213,"PHASE2":6239,"PHASE3":6251,"PHASE4":6253,"NA":6255},{"trials":6212,"activeCount":99},[],{"trials":6214,"activeCount":99},[6215,6225],{"nctId":6216,"briefTitle":6217,"status":109,"phases":6218,"primaryCompletion":3653,"completion":3653,"start":5421,"enrollment":1394,"conditions":6219,"interventions":6221},"NCT01151319","Safety and Immunogenicity Study of Three Candidate HIV-1 Vaccines, Administered in Combination to Healthy HIV-1 Uninfected Adults",[88],[6220],"HIV-1 Infections",[6222,6223,6224,6209],"ChAdV63.HIVconsv low dose.","ChAdV63.HIVconsv high dose.","pSG2.HIVconsv",{"nctId":6226,"briefTitle":6227,"status":109,"phases":6228,"primaryCompletion":3740,"completion":6229,"start":6230,"enrollment":6231,"conditions":6232,"interventions":6235},"NCT02362217","A Study to Assess the Safety of HIV and Hep C Vaccine Candidates When Given Separately or in Combination",[88],"2017-10-31","2014-10",33,[6233,6234],"Hepatitis C Infection","HIV Infection",[6236,6237,6238,6209],"AdCh3NSmut1","MVA-NSmut","ChAdV63.HIVconsv",{"trials":6240,"activeCount":99},[6241],{"nctId":6242,"briefTitle":6243,"status":109,"phases":6244,"primaryCompletion":4798,"completion":4798,"start":5258,"enrollment":6109,"conditions":6245,"interventions":6247},"NCT02099994","Safety & Immunogenicity of HIV Vaccines in Healthy Kenyan Adults",[88,89],[6246],"AIDS",[6248,6209,6249,6250],"Ad35-GRIN","pSG2.HIVconsv DNA","Electroporated pSG2.HIVconsv",{"trials":6252,"activeCount":99},[],{"trials":6254,"activeCount":99},[],{"trials":6256,"activeCount":99},[],{"intervention":6175,"totalTrials":95,"cells":6258},{"EARLY_PHASE1":6259,"PHASE1":6261,"PHASE2":6263,"PHASE3":6277,"PHASE4":6279,"NA":6281},{"trials":6260,"activeCount":99},[],{"trials":6262,"activeCount":99},[],{"trials":6264,"activeCount":99},[6265,6269,6273],{"nctId":6168,"briefTitle":6169,"status":109,"phases":6266,"primaryCompletion":1456,"completion":1456,"start":6171,"enrollment":1778,"conditions":6267,"interventions":6268},[88,89],[33],[6174,6175,6139],{"nctId":6177,"briefTitle":6178,"status":109,"phases":6270,"primaryCompletion":6180,"completion":6180,"start":3740,"enrollment":1422,"conditions":6271,"interventions":6272},[88,89],[15],[6183,6175,6139],{"nctId":6196,"briefTitle":6197,"status":109,"phases":6274,"primaryCompletion":6199,"completion":6199,"start":3788,"enrollment":1778,"conditions":6275,"interventions":6276},[88,89],[33],[6174,6174,6175,6139],{"trials":6278,"activeCount":99},[],{"trials":6280,"activeCount":99},[],{"trials":6282,"activeCount":99},[],{"intervention":6284,"totalTrials":95,"cells":6285},"Capecitabine",{"EARLY_PHASE1":6286,"PHASE1":6288,"PHASE2":6313,"PHASE3":6327,"PHASE4":6329,"NA":6331},{"trials":6287,"activeCount":99},[],{"trials":6289,"activeCount":99},[6290,6303],{"nctId":6291,"briefTitle":6292,"status":109,"phases":6293,"primaryCompletion":6294,"completion":6294,"start":6295,"enrollment":1848,"conditions":6296,"interventions":6300},"NCT03641547","M6620 Plus Standard Treatment in Oesophageal and Other Cancer",[88],"2022-04-04","2018-12-04",[6297,6298,6299],"Oesophageal Adenocarcinoma","Squamous Cell Carcinoma","Solid Tumor",[6301,6302,6284],"M6620","Cisplatin",{"nctId":6304,"briefTitle":6305,"status":109,"phases":6306,"primaryCompletion":6307,"completion":6307,"start":6308,"enrollment":31,"conditions":6309,"interventions":6311},"NCT03916510","Chemoradiation With Enadenotucirev as a Radiosensitiser in Locally Advanced Rectal Cancer",[88],"2023-02-24","2019-07-29",[6310],"Locally Advanced Rectal Cancer",[6312,6284],"Enadenotucirev",{"trials":6314,"activeCount":99},[6315],{"nctId":6316,"briefTitle":6317,"status":109,"phases":6318,"primaryCompletion":6319,"completion":6319,"start":6320,"enrollment":4452,"conditions":6321,"interventions":6323},"NCT02024009","Systemic Therapy and Chemoradiation in Advanced Localised Pancreatic Cancer - 2",[88,89],"2021-06-23","2016-03",[6322],"Pancreatic Neoplasms (Locally Advanced Non-metastatic)",[6324,6325,6284,6326],"nab-paclitaxel","Nelfinavir","Gemcitabine",{"trials":6328,"activeCount":99},[],{"trials":6330,"activeCount":99},[],{"trials":6332,"activeCount":99},[],{"intervention":6334,"totalTrials":168,"cells":6335},"Ebselen",{"EARLY_PHASE1":6336,"PHASE1":6338,"PHASE2":6349,"PHASE3":6361,"PHASE4":6363,"NA":6365},{"trials":6337,"activeCount":99},[],{"trials":6339,"activeCount":99},[6340],{"nctId":6341,"briefTitle":6342,"status":2901,"phases":6343,"primaryCompletion":6344,"completion":6344,"start":6345,"enrollment":2337,"conditions":6346,"interventions":6348},"NCT05117710","IMPase in Treatment-resistant Depression",[88],"2024-05-31","2021-04-22",[6347],"Depressive Disorder, Treatment-Resistant",[6334],{"trials":6350,"activeCount":99},[6351],{"nctId":6352,"briefTitle":6353,"status":109,"phases":6354,"primaryCompletion":6355,"completion":6355,"start":6356,"enrollment":16,"conditions":6357,"interventions":6360},"NCT03013400","Ebselen as an add-on Treatment in Hypo\u002FMania",[89],"2019-07-09","2017-10-01",[6358,6359],"Bipolar Disorder","Bipolar Disorder, Manic",[6334],{"trials":6362,"activeCount":99},[],{"trials":6364,"activeCount":99},[],{"trials":6366,"activeCount":99},[],{"intervention":6174,"totalTrials":168,"cells":6368},{"EARLY_PHASE1":6369,"PHASE1":6371,"PHASE2":6373,"PHASE3":6383,"PHASE4":6385,"NA":6387},{"trials":6370,"activeCount":99},[],{"trials":6372,"activeCount":99},[],{"trials":6374,"activeCount":99},[6375,6379],{"nctId":6168,"briefTitle":6169,"status":109,"phases":6376,"primaryCompletion":1456,"completion":1456,"start":6171,"enrollment":1778,"conditions":6377,"interventions":6378},[88,89],[33],[6174,6175,6139],{"nctId":6196,"briefTitle":6197,"status":109,"phases":6380,"primaryCompletion":6199,"completion":6199,"start":3788,"enrollment":1778,"conditions":6381,"interventions":6382},[88,89],[33],[6174,6174,6175,6139],{"trials":6384,"activeCount":99},[],{"trials":6386,"activeCount":99},[],{"trials":6388,"activeCount":99},[],{"intervention":1439,"totalTrials":168,"cells":6390},{"EARLY_PHASE1":6391,"PHASE1":6393,"PHASE2":6395,"PHASE3":6405,"PHASE4":6407,"NA":6409},{"trials":6392,"activeCount":99},[],{"trials":6394,"activeCount":99},[],{"trials":6396,"activeCount":99},[6397,6401],{"nctId":1431,"briefTitle":1432,"status":109,"phases":6398,"primaryCompletion":1434,"completion":1434,"start":1435,"enrollment":1436,"conditions":6399,"interventions":6400},[89],[15],[1439,1410],{"nctId":1453,"briefTitle":1454,"status":109,"phases":6402,"primaryCompletion":1456,"completion":1457,"start":1458,"enrollment":1459,"conditions":6403,"interventions":6404},[88,89],[15],[1439,1410],{"trials":6406,"activeCount":99},[],{"trials":6408,"activeCount":99},[],{"trials":6410,"activeCount":99},[],{"intervention":6193,"totalTrials":168,"cells":6412},{"EARLY_PHASE1":6413,"PHASE1":6415,"PHASE2":6426,"PHASE3":6432,"PHASE4":6434,"NA":6436},{"trials":6414,"activeCount":99},[],{"trials":6416,"activeCount":99},[6417],{"nctId":6418,"briefTitle":6419,"status":109,"phases":6420,"primaryCompletion":6421,"completion":4518,"start":5768,"enrollment":6422,"conditions":6423,"interventions":6424},"NCT00890019","A Study of AdCh63 ME-TRAP Alone and With MVA ME-TRAP",[88],"2011-08",54,[15],[6193,6425],"AdCh63 ME-TRAP; MVA ME-TRAP",{"trials":6427,"activeCount":99},[6428],{"nctId":6185,"briefTitle":6186,"status":109,"phases":6429,"primaryCompletion":4426,"completion":6188,"start":6189,"enrollment":6190,"conditions":6430,"interventions":6431},[88,89],[15],[6193,6139,6194],{"trials":6433,"activeCount":99},[],{"trials":6435,"activeCount":99},[],{"trials":6437,"activeCount":99},[],{"intervention":6439,"totalTrials":168,"cells":6440},"MVA-NP+M1",{"EARLY_PHASE1":6441,"PHASE1":6443,"PHASE2":6451,"PHASE3":6460,"PHASE4":6462,"NA":6464},{"trials":6442,"activeCount":99},[],{"trials":6444,"activeCount":99},[6445],{"nctId":6446,"briefTitle":6447,"status":109,"phases":6448,"primaryCompletion":1458,"completion":1458,"start":6091,"enrollment":2314,"conditions":6449,"interventions":6450},"NCT00942071","A Study to Assess the Safety and Immunogenicity of a New Influenza Vaccine Candidate MVA-NP+M1 in Healthy Adults",[88],[30],[6439,6439,6439],{"trials":6452,"activeCount":99},[6453],{"nctId":6454,"briefTitle":6455,"status":109,"phases":6456,"primaryCompletion":4104,"completion":4104,"start":5422,"enrollment":6457,"conditions":6458,"interventions":6459},"NCT00993083","A Study to Assess the Safety and Efficacy of a New Influenza Candidate Vaccine MVA-NP+M1 In Healthy Adults",[89],27,[30],[6439],{"trials":6461,"activeCount":99},[],{"trials":6463,"activeCount":99},[],{"trials":6465,"activeCount":99},[],{"intervention":1290,"totalTrials":168,"cells":6467},{"EARLY_PHASE1":6468,"PHASE1":6470,"PHASE2":6476,"PHASE3":6482,"PHASE4":6484,"NA":6486},{"trials":6469,"activeCount":99},[],{"trials":6471,"activeCount":99},[6472],{"nctId":1280,"briefTitle":1281,"status":795,"phases":6473,"primaryCompletion":1283,"completion":1283,"start":1284,"enrollment":1285,"conditions":6474,"interventions":6475},[88],[1287,24,1288],[1272,1290,1272,1291],{"trials":6477,"activeCount":99},[6478],{"nctId":1295,"briefTitle":1296,"status":795,"phases":6479,"primaryCompletion":1298,"completion":1298,"start":1299,"enrollment":1300,"conditions":6480,"interventions":6481},[88,89],[1287,1288,24],[1272,1290,1272,1291,190,1303,1304,1303],{"trials":6483,"activeCount":99},[],{"trials":6485,"activeCount":99},[],{"trials":6487,"activeCount":99},[],{"intervention":1291,"totalTrials":168,"cells":6489},{"EARLY_PHASE1":6490,"PHASE1":6492,"PHASE2":6498,"PHASE3":6504,"PHASE4":6506,"NA":6508},{"trials":6491,"activeCount":99},[],{"trials":6493,"activeCount":99},[6494],{"nctId":1280,"briefTitle":1281,"status":795,"phases":6495,"primaryCompletion":1283,"completion":1283,"start":1284,"enrollment":1285,"conditions":6496,"interventions":6497},[88],[1287,24,1288],[1272,1290,1272,1291],{"trials":6499,"activeCount":99},[6500],{"nctId":1295,"briefTitle":1296,"status":795,"phases":6501,"primaryCompletion":1298,"completion":1298,"start":1299,"enrollment":1300,"conditions":6502,"interventions":6503},[88,89],[1287,1288,24],[1272,1290,1272,1291,190,1303,1304,1303],{"trials":6505,"activeCount":99},[],{"trials":6507,"activeCount":99},[],{"trials":6509,"activeCount":99},[],{"intervention":6511,"totalTrials":151,"cells":6512},"R21 in Matrix- M adjuvant vaccine",{"EARLY_PHASE1":6513,"PHASE1":6515,"PHASE2":6517,"PHASE3":6528,"PHASE4":6530,"NA":6532},{"trials":6514,"activeCount":99},[],{"trials":6516,"activeCount":99},[],{"trials":6518,"activeCount":99},[6519],{"nctId":6520,"briefTitle":6521,"status":109,"phases":6522,"primaryCompletion":6523,"completion":6523,"start":6524,"enrollment":6525,"conditions":6526,"interventions":6527},"NCT03580824","A Study to Determine if a New Malaria Vaccine is Safe and Induces Immunity Among Kenyan Adults, Young Children and Infants",[88,89],"2022-06-14","2019-04-30",91,[27],[6511],{"trials":6529,"activeCount":99},[],{"trials":6531,"activeCount":99},[],{"trials":6533,"activeCount":99},[],{"intervention":6165,"totalTrials":151,"cells":6535},{"EARLY_PHASE1":6536,"PHASE1":6538,"PHASE2":6540,"PHASE3":6546,"PHASE4":6548,"NA":6550},{"trials":6537,"activeCount":99},[],{"trials":6539,"activeCount":99},[],{"trials":6541,"activeCount":99},[6542],{"nctId":6158,"briefTitle":6159,"status":109,"phases":6543,"completion":6161,"start":6162,"enrollment":1699,"conditions":6544,"interventions":6545},[88,89],[15,2828],[6165,6166,6139],{"trials":6547,"activeCount":99},[],{"trials":6549,"activeCount":99},[],{"trials":6551,"activeCount":99},[],{"intervention":6166,"totalTrials":151,"cells":6553},{"EARLY_PHASE1":6554,"PHASE1":6556,"PHASE2":6558,"PHASE3":6564,"PHASE4":6566,"NA":6568},{"trials":6555,"activeCount":99},[],{"trials":6557,"activeCount":99},[],{"trials":6559,"activeCount":99},[6560],{"nctId":6158,"briefTitle":6159,"status":109,"phases":6561,"completion":6161,"start":6162,"enrollment":1699,"conditions":6562,"interventions":6563},[88,89],[15,2828],[6165,6166,6139],{"trials":6565,"activeCount":99},[],{"trials":6567,"activeCount":99},[],{"trials":6569,"activeCount":99},[],{"intervention":6571,"totalTrials":151,"cells":6572},"Argesun 60mg",{"EARLY_PHASE1":6573,"PHASE1":6575,"PHASE2":6577,"PHASE3":6590,"PHASE4":6592,"NA":6594},{"trials":6574,"activeCount":99},[],{"trials":6576,"activeCount":99},[],{"trials":6578,"activeCount":99},[6579],{"nctId":6580,"briefTitle":6581,"status":109,"phases":6582,"primaryCompletion":2945,"completion":6583,"start":6584,"enrollment":6585,"conditions":6586,"interventions":6588},"NCT05140278","Study to Compare Feasibility of 1-step Injectable Artesunate vs. Conventional 2-step Injectable Artesunate",[89],"2023-08-11","2022-07-18",200,[6587],"Severe Malaria",[6571,6589],"Artesun 60mg",{"trials":6591,"activeCount":99},[],{"trials":6593,"activeCount":99},[],{"trials":6595,"activeCount":99},[],{"intervention":6589,"totalTrials":151,"cells":6597},{"EARLY_PHASE1":6598,"PHASE1":6600,"PHASE2":6602,"PHASE3":6608,"PHASE4":6610,"NA":6612},{"trials":6599,"activeCount":99},[],{"trials":6601,"activeCount":99},[],{"trials":6603,"activeCount":99},[6604],{"nctId":6580,"briefTitle":6581,"status":109,"phases":6605,"primaryCompletion":2945,"completion":6583,"start":6584,"enrollment":6585,"conditions":6606,"interventions":6607},[89],[6587],[6571,6589],{"trials":6609,"activeCount":99},[],{"trials":6611,"activeCount":99},[],{"trials":6613,"activeCount":99},[],{"intervention":6615,"totalTrials":151,"cells":6616},"ChAd63-MVA CS",{"EARLY_PHASE1":6617,"PHASE1":6619,"PHASE2":6621,"PHASE3":6630,"PHASE4":6632,"NA":6634},{"trials":6618,"activeCount":99},[],{"trials":6620,"activeCount":99},[],{"trials":6622,"activeCount":99},[6623],{"nctId":6624,"briefTitle":6625,"status":109,"phases":6626,"primaryCompletion":1458,"completion":1458,"start":3377,"enrollment":1699,"conditions":6627,"interventions":6628},"NCT01623557","A Challenge Study to Assess the Protective Efficacy of Two Malaria Vaccine Candidates",[88,89],[33],[6615,6629],"ChAd63-MVA ME-TRAP",{"trials":6631,"activeCount":99},[],{"trials":6633,"activeCount":99},[],{"trials":6635,"activeCount":99},[],{"intervention":6629,"totalTrials":151,"cells":6637},{"EARLY_PHASE1":6638,"PHASE1":6640,"PHASE2":6642,"PHASE3":6648,"PHASE4":6650,"NA":6652},{"trials":6639,"activeCount":99},[],{"trials":6641,"activeCount":99},[],{"trials":6643,"activeCount":99},[6644],{"nctId":6624,"briefTitle":6625,"status":109,"phases":6645,"primaryCompletion":1458,"completion":1458,"start":3377,"enrollment":1699,"conditions":6646,"interventions":6647},[88,89],[33],[6615,6629],{"trials":6649,"activeCount":99},[],{"trials":6651,"activeCount":99},[],{"trials":6653,"activeCount":99},[],{"intervention":6655,"totalTrials":151,"cells":6656},"Ofatumumab",{"EARLY_PHASE1":6657,"PHASE1":6659,"PHASE2":6661,"PHASE3":6674,"PHASE4":6676,"NA":6678},{"trials":6658,"activeCount":99},[],{"trials":6660,"activeCount":99},[],{"trials":6662,"activeCount":99},[6663],{"nctId":6664,"briefTitle":6665,"status":109,"phases":6666,"primaryCompletion":6667,"completion":6668,"start":6669,"enrollment":6670,"conditions":6671,"interventions":6673},"NCT01171378","Study of Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone (CHOP) With Ofatumumab in Patients With Richter's Syndrome",[89],"2015-02","2016-04-19","2011-04",43,[6672],"Richter's Syndrome",[6655],{"trials":6675,"activeCount":99},[],{"trials":6677,"activeCount":99},[],{"trials":6679,"activeCount":99},[],{"intervention":6681,"totalTrials":151,"cells":6682},"AdCh63-MSP1 (lower dose) vaccine and MVA-MSP1 vaccine",{"EARLY_PHASE1":6683,"PHASE1":6685,"PHASE2":6687,"PHASE3":6696,"PHASE4":6698,"NA":6700},{"trials":6684,"activeCount":99},[],{"trials":6686,"activeCount":99},[],{"trials":6688,"activeCount":99},[6689],{"nctId":6690,"briefTitle":6691,"status":109,"phases":6692,"primaryCompletion":4180,"completion":4180,"start":4451,"enrollment":578,"conditions":6693,"interventions":6694},"NCT01003314","A Study of the Safety and Effectiveness of Two New Malaria Vaccines",[88,89],[15],[6681,6695],"AdCh63-MSP1 vaccine (higher dose) and MVA-MSP1 vaccine followed by challenge",{"trials":6697,"activeCount":99},[],{"trials":6699,"activeCount":99},[],{"trials":6701,"activeCount":99},[],{"intervention":6695,"totalTrials":151,"cells":6703},{"EARLY_PHASE1":6704,"PHASE1":6706,"PHASE2":6708,"PHASE3":6714,"PHASE4":6716,"NA":6718},{"trials":6705,"activeCount":99},[],{"trials":6707,"activeCount":99},[],{"trials":6709,"activeCount":99},[6710],{"nctId":6690,"briefTitle":6691,"status":109,"phases":6711,"primaryCompletion":4180,"completion":4180,"start":4451,"enrollment":578,"conditions":6712,"interventions":6713},[88,89],[15],[6681,6695],{"trials":6715,"activeCount":99},[],{"trials":6717,"activeCount":99},[],{"trials":6719,"activeCount":99},[],{"intervention":4553,"totalTrials":151,"cells":6721},{"EARLY_PHASE1":6722,"PHASE1":6724,"PHASE2":6726,"PHASE3":6732,"PHASE4":6734,"NA":6736},{"trials":6723,"activeCount":99},[],{"trials":6725,"activeCount":99},[],{"trials":6727,"activeCount":99},[6728],{"nctId":4545,"briefTitle":4546,"status":2901,"phases":6729,"primaryCompletion":3253,"completion":4548,"start":4549,"enrollment":4550,"conditions":6730,"interventions":6731},[88,89],[4539],[4526,4553],{"trials":6733,"activeCount":99},[],{"trials":6735,"activeCount":99},[],{"trials":6737,"activeCount":99},[],{"intervention":4563,"totalTrials":151,"cells":6739},{"EARLY_PHASE1":6740,"PHASE1":6742,"PHASE2":6744,"PHASE3":6750,"PHASE4":6752,"NA":6754},{"trials":6741,"activeCount":99},[],{"trials":6743,"activeCount":99},[],{"trials":6745,"activeCount":99},[6746],{"nctId":4555,"briefTitle":4556,"status":109,"phases":6747,"primaryCompletion":4558,"completion":4558,"start":4559,"enrollment":4560,"conditions":6748,"interventions":6749},[88,89],[4539],[4526,4563,4564,4565,4566,4567,4568,4569,4569],{"trials":6751,"activeCount":99},[],{"trials":6753,"activeCount":99},[],{"trials":6755,"activeCount":99},[],{"intervention":4564,"totalTrials":151,"cells":6757},{"EARLY_PHASE1":6758,"PHASE1":6760,"PHASE2":6762,"PHASE3":6768,"PHASE4":6770,"NA":6772},{"trials":6759,"activeCount":99},[],{"trials":6761,"activeCount":99},[],{"trials":6763,"activeCount":99},[6764],{"nctId":4555,"briefTitle":4556,"status":109,"phases":6765,"primaryCompletion":4558,"completion":4558,"start":4559,"enrollment":4560,"conditions":6766,"interventions":6767},[88,89],[4539],[4526,4563,4564,4565,4566,4567,4568,4569,4569],{"trials":6769,"activeCount":99},[],{"trials":6771,"activeCount":99},[],{"trials":6773,"activeCount":99},[],{"intervention":4565,"totalTrials":151,"cells":6775},{"EARLY_PHASE1":6776,"PHASE1":6778,"PHASE2":6780,"PHASE3":6786,"PHASE4":6788,"NA":6790},{"trials":6777,"activeCount":99},[],{"trials":6779,"activeCount":99},[],{"trials":6781,"activeCount":99},[6782],{"nctId":4555,"briefTitle":4556,"status":109,"phases":6783,"primaryCompletion":4558,"completion":4558,"start":4559,"enrollment":4560,"conditions":6784,"interventions":6785},[88,89],[4539],[4526,4563,4564,4565,4566,4567,4568,4569,4569],{"trials":6787,"activeCount":99},[],{"trials":6789,"activeCount":99},[],{"trials":6791,"activeCount":99},[],{"intervention":4566,"totalTrials":151,"cells":6793},{"EARLY_PHASE1":6794,"PHASE1":6796,"PHASE2":6798,"PHASE3":6804,"PHASE4":6806,"NA":6808},{"trials":6795,"activeCount":99},[],{"trials":6797,"activeCount":99},[],{"trials":6799,"activeCount":99},[6800],{"nctId":4555,"briefTitle":4556,"status":109,"phases":6801,"primaryCompletion":4558,"completion":4558,"start":4559,"enrollment":4560,"conditions":6802,"interventions":6803},[88,89],[4539],[4526,4563,4564,4565,4566,4567,4568,4569,4569],{"trials":6805,"activeCount":99},[],{"trials":6807,"activeCount":99},[],{"trials":6809,"activeCount":99},[],{"intervention":4568,"totalTrials":151,"cells":6811},{"EARLY_PHASE1":6812,"PHASE1":6814,"PHASE2":6816,"PHASE3":6822,"PHASE4":6824,"NA":6826},{"trials":6813,"activeCount":99},[],{"trials":6815,"activeCount":99},[],{"trials":6817,"activeCount":99},[6818],{"nctId":4555,"briefTitle":4556,"status":109,"phases":6819,"primaryCompletion":4558,"completion":4558,"start":4559,"enrollment":4560,"conditions":6820,"interventions":6821},[88,89],[4539],[4526,4563,4564,4565,4566,4567,4568,4569,4569],{"trials":6823,"activeCount":99},[],{"trials":6825,"activeCount":99},[],{"trials":6827,"activeCount":99},[],{"intervention":4569,"totalTrials":151,"cells":6829},{"EARLY_PHASE1":6830,"PHASE1":6832,"PHASE2":6834,"PHASE3":6840,"PHASE4":6842,"NA":6844},{"trials":6831,"activeCount":99},[],{"trials":6833,"activeCount":99},[],{"trials":6835,"activeCount":99},[6836],{"nctId":4555,"briefTitle":4556,"status":109,"phases":6837,"primaryCompletion":4558,"completion":4558,"start":4559,"enrollment":4560,"conditions":6838,"interventions":6839},[88,89],[4539],[4526,4563,4564,4565,4566,4567,4568,4569,4569],{"trials":6841,"activeCount":99},[],{"trials":6843,"activeCount":99},[],{"trials":6845,"activeCount":99},[],{"intervention":6847,"totalTrials":151,"cells":6848},"MF59 - ATIV",{"EARLY_PHASE1":6849,"PHASE1":6851,"PHASE2":6853,"PHASE3":6861,"PHASE4":6863,"NA":6865},{"trials":6850,"activeCount":99},[],{"trials":6852,"activeCount":99},[],{"trials":6854,"activeCount":99},[6855],{"nctId":6856,"briefTitle":6857,"status":109,"phases":6858,"primaryCompletion":3454,"completion":3454,"start":4798,"enrollment":1436,"conditions":6859,"interventions":6860},"NCT02529904","ADITEC FLU 2 STUDY: Understanding the Genetics Basis for Immune Responses to Flu Vaccines in Children and Adults",[89],[30],[6847],{"trials":6862,"activeCount":99},[],{"trials":6864,"activeCount":99},[],{"trials":6866,"activeCount":99},[],{"intervention":6868,"totalTrials":151,"cells":6869},"Levetiracetam",{"EARLY_PHASE1":6870,"PHASE1":6872,"PHASE2":6874,"PHASE3":6886,"PHASE4":6888,"NA":6890},{"trials":6871,"activeCount":99},[],{"trials":6873,"activeCount":99},[],{"trials":6875,"activeCount":99},[6876],{"nctId":6877,"briefTitle":6878,"status":109,"phases":6879,"primaryCompletion":6880,"completion":6880,"start":6881,"enrollment":1285,"conditions":6882,"interventions":6885},"NCT03489044","An Investigation of Levetiracetam in Alzheimer's Disease",[89],"2022-03-21","2018-10-28",[6883,6884],"Alzheimer Disease","Epilepsy",[6868],{"trials":6887,"activeCount":99},[],{"trials":6889,"activeCount":99},[],{"trials":6891,"activeCount":99},[],{"intervention":6324,"totalTrials":151,"cells":6893},{"EARLY_PHASE1":6894,"PHASE1":6896,"PHASE2":6898,"PHASE3":6904,"PHASE4":6906,"NA":6908},{"trials":6895,"activeCount":99},[],{"trials":6897,"activeCount":99},[],{"trials":6899,"activeCount":99},[6900],{"nctId":6316,"briefTitle":6317,"status":109,"phases":6901,"primaryCompletion":6319,"completion":6319,"start":6320,"enrollment":4452,"conditions":6902,"interventions":6903},[88,89],[6322],[6324,6325,6284,6326],{"trials":6905,"activeCount":99},[],{"trials":6907,"activeCount":99},[],{"trials":6909,"activeCount":99},[],{"intervention":6325,"totalTrials":151,"cells":6911},{"EARLY_PHASE1":6912,"PHASE1":6914,"PHASE2":6916,"PHASE3":6922,"PHASE4":6924,"NA":6926},{"trials":6913,"activeCount":99},[],{"trials":6915,"activeCount":99},[],{"trials":6917,"activeCount":99},[6918],{"nctId":6316,"briefTitle":6317,"status":109,"phases":6919,"primaryCompletion":6319,"completion":6319,"start":6320,"enrollment":4452,"conditions":6920,"interventions":6921},[88,89],[6322],[6324,6325,6284,6326],{"trials":6923,"activeCount":99},[],{"trials":6925,"activeCount":99},[],{"trials":6927,"activeCount":99},[],{"intervention":6326,"totalTrials":151,"cells":6929},{"EARLY_PHASE1":6930,"PHASE1":6932,"PHASE2":6934,"PHASE3":6940,"PHASE4":6942,"NA":6944},{"trials":6931,"activeCount":99},[],{"trials":6933,"activeCount":99},[],{"trials":6935,"activeCount":99},[6936],{"nctId":6316,"briefTitle":6317,"status":109,"phases":6937,"primaryCompletion":6319,"completion":6319,"start":6320,"enrollment":4452,"conditions":6938,"interventions":6939},[88,89],[6322],[6324,6325,6284,6326],{"trials":6941,"activeCount":99},[],{"trials":6943,"activeCount":99},[],{"trials":6945,"activeCount":99},[],{"intervention":6947,"totalTrials":151,"cells":6948},"Pyronaridine-artesunate",{"EARLY_PHASE1":6949,"PHASE1":6951,"PHASE2":6953,"PHASE3":6964,"PHASE4":6966,"NA":6968},{"trials":6950,"activeCount":99},[],{"trials":6952,"activeCount":99},[],{"trials":6954,"activeCount":99},[6955],{"nctId":6956,"briefTitle":6957,"status":109,"phases":6958,"primaryCompletion":6959,"completion":6960,"start":6961,"enrollment":11,"conditions":6962,"interventions":6963},"NCT02389439","Efficacy and Safety of Pyronaridine-artesunate for the Treatment in Uncomplicated Falciparum Malaria",[89],"2015-12-01","2016-06-01","2015-03-01",[2828],[6947],{"trials":6965,"activeCount":99},[],{"trials":6967,"activeCount":99},[],{"trials":6969,"activeCount":99},[],{"intervention":6971,"totalTrials":151,"cells":6972},"Dapagliflozin 10 MG Oral",{"EARLY_PHASE1":6973,"PHASE1":6975,"PHASE2":6977,"PHASE3":6988,"PHASE4":6990,"NA":6992},{"trials":6974,"activeCount":99},[],{"trials":6976,"activeCount":99},[],{"trials":6978,"activeCount":99},[6979],{"nctId":6980,"briefTitle":6981,"status":795,"phases":6982,"primaryCompletion":6983,"completion":6983,"start":6984,"enrollment":3269,"conditions":6985,"interventions":6987},"NCT03537131","Dapagliflozin During Exercise for the PrevenTion of Hypoglycaemia",[89],"2021-07-14","2018-06-02",[6986],"Diabetes Mellitus, Type 1",[6971],{"trials":6989,"activeCount":99},[],{"trials":6991,"activeCount":99},[],{"trials":6993,"activeCount":99},[],{"intervention":6995,"totalTrials":151,"cells":6996},"Vi-TCV",{"EARLY_PHASE1":6997,"PHASE1":6999,"PHASE2":7001,"PHASE3":7016,"PHASE4":7018,"NA":7020},{"trials":6998,"activeCount":99},[],{"trials":7000,"activeCount":99},[],{"trials":7002,"activeCount":99},[7003],{"nctId":7004,"briefTitle":7005,"status":109,"phases":7006,"primaryCompletion":7007,"completion":7008,"start":576,"enrollment":7009,"conditions":7010,"interventions":7013},"NCT02324751","Vaccines Against Salmonella Typhi",[89],"2017-12-02","2022-06-27",112,[7011,7012],"Typhoid Fever","Enteric Fever",[6995,7014,7015],"Vi-PS Vaccine","Control",{"trials":7017,"activeCount":99},[],{"trials":7019,"activeCount":99},[],{"trials":7021,"activeCount":99},[],{"intervention":7014,"totalTrials":151,"cells":7023},{"EARLY_PHASE1":7024,"PHASE1":7026,"PHASE2":7028,"PHASE3":7034,"PHASE4":7036,"NA":7038},{"trials":7025,"activeCount":99},[],{"trials":7027,"activeCount":99},[],{"trials":7029,"activeCount":99},[7030],{"nctId":7004,"briefTitle":7005,"status":109,"phases":7031,"primaryCompletion":7007,"completion":7008,"start":576,"enrollment":7009,"conditions":7032,"interventions":7033},[89],[7011,7012],[6995,7014,7015],{"trials":7035,"activeCount":99},[],{"trials":7037,"activeCount":99},[],{"trials":7039,"activeCount":99},[],{"intervention":7015,"totalTrials":151,"cells":7041},{"EARLY_PHASE1":7042,"PHASE1":7044,"PHASE2":7046,"PHASE3":7052,"PHASE4":7054,"NA":7056},{"trials":7043,"activeCount":99},[],{"trials":7045,"activeCount":99},[],{"trials":7047,"activeCount":99},[7048],{"nctId":7004,"briefTitle":7005,"status":109,"phases":7049,"primaryCompletion":7007,"completion":7008,"start":576,"enrollment":7009,"conditions":7050,"interventions":7051},[89],[7011,7012],[6995,7014,7015],{"trials":7053,"activeCount":99},[],{"trials":7055,"activeCount":99},[],{"trials":7057,"activeCount":99},[],{"intervention":7059,"totalTrials":151,"cells":7060},"R21\u002FMatrix-M vaccination",{"EARLY_PHASE1":7061,"PHASE1":7063,"PHASE2":7065,"PHASE3":7079,"PHASE4":7081,"NA":7083},{"trials":7062,"activeCount":99},[],{"trials":7064,"activeCount":99},[],{"trials":7066,"activeCount":99},[7067],{"nctId":7068,"briefTitle":7069,"status":109,"phases":7070,"primaryCompletion":7071,"completion":7072,"start":7073,"enrollment":7074,"conditions":7075,"interventions":7076},"NCT05252845","Safety and Immunogenicity of the Malaria Vaccine, R21\u002FMatrixM, in Healthy Thai Adults",[89],"2023-06-08","2023-09-18","2023-01-04",127,[27],[7059,7077,7078],"DHA-PIP","PQ",{"trials":7080,"activeCount":99},[],{"trials":7082,"activeCount":99},[],{"trials":7084,"activeCount":99},[],{"intervention":7077,"totalTrials":151,"cells":7086},{"EARLY_PHASE1":7087,"PHASE1":7089,"PHASE2":7091,"PHASE3":7097,"PHASE4":7099,"NA":7101},{"trials":7088,"activeCount":99},[],{"trials":7090,"activeCount":99},[],{"trials":7092,"activeCount":99},[7093],{"nctId":7068,"briefTitle":7069,"status":109,"phases":7094,"primaryCompletion":7071,"completion":7072,"start":7073,"enrollment":7074,"conditions":7095,"interventions":7096},[89],[27],[7059,7077,7078],{"trials":7098,"activeCount":99},[],{"trials":7100,"activeCount":99},[],{"trials":7102,"activeCount":99},[],{"intervention":7078,"totalTrials":151,"cells":7104},{"EARLY_PHASE1":7105,"PHASE1":7107,"PHASE2":7109,"PHASE3":7115,"PHASE4":7117,"NA":7119},{"trials":7106,"activeCount":99},[],{"trials":7108,"activeCount":99},[],{"trials":7110,"activeCount":99},[7111],{"nctId":7068,"briefTitle":7069,"status":109,"phases":7112,"primaryCompletion":7071,"completion":7072,"start":7073,"enrollment":7074,"conditions":7113,"interventions":7114},[89],[27],[7059,7077,7078],{"trials":7116,"activeCount":99},[],{"trials":7118,"activeCount":99},[],{"trials":7120,"activeCount":99},[],{"intervention":6183,"totalTrials":151,"cells":7122},{"EARLY_PHASE1":7123,"PHASE1":7125,"PHASE2":7127,"PHASE3":7133,"PHASE4":7135,"NA":7137},{"trials":7124,"activeCount":99},[],{"trials":7126,"activeCount":99},[],{"trials":7128,"activeCount":99},[7129],{"nctId":6177,"briefTitle":6178,"status":109,"phases":7130,"primaryCompletion":6180,"completion":6180,"start":3740,"enrollment":1422,"conditions":7131,"interventions":7132},[88,89],[15],[6183,6175,6139],{"trials":7134,"activeCount":99},[],{"trials":7136,"activeCount":99},[],{"trials":7138,"activeCount":99},[],{"intervention":7140,"totalTrials":151,"cells":7141},"6-Mercaptopurine",{"EARLY_PHASE1":7142,"PHASE1":7144,"PHASE2":7146,"PHASE3":7156,"PHASE4":7158,"NA":7160},{"trials":7143,"activeCount":99},[],{"trials":7145,"activeCount":99},[],{"trials":7147,"activeCount":99},[7148],{"nctId":7149,"briefTitle":7150,"status":109,"phases":7151,"primaryCompletion":680,"completion":3787,"start":3899,"enrollment":7152,"conditions":7153,"interventions":7155},"NCT01432145","A Clinical Trial in Patients With Breast Cancer Susceptibility Gene (BRCA) Defective Tumours",[89],74,[5812,7154],"Ovarian Cancer",[7140,3285],{"trials":7157,"activeCount":99},[],{"trials":7159,"activeCount":99},[],{"trials":7161,"activeCount":99},[],{"intervention":7163,"totalTrials":151,"cells":7164},"ChAdOx1-MVA 5T4 vaccine",{"EARLY_PHASE1":7165,"PHASE1":7167,"PHASE2":7169,"PHASE3":7181,"PHASE4":7183,"NA":7185},{"trials":7166,"activeCount":99},[],{"trials":7168,"activeCount":99},[],{"trials":7170,"activeCount":99},[7171],{"nctId":7172,"briefTitle":7173,"status":795,"phases":7174,"primaryCompletion":4549,"completion":4549,"start":7175,"enrollment":25,"conditions":7176,"interventions":7179},"NCT03815942","VAccination in Early and ADvanced Prostate caNCEr",[88,89],"2018-12-10",[7177,7178],"Intermediate Risk Prostate Cancer","Castration-resistant Prostate Cancer",[7163,7180],"Nivolumab Infusion [Opdivo]",{"trials":7182,"activeCount":99},[],{"trials":7184,"activeCount":99},[],{"trials":7186,"activeCount":99},[],{"intervention":7180,"totalTrials":151,"cells":7188},{"EARLY_PHASE1":7189,"PHASE1":7191,"PHASE2":7193,"PHASE3":7199,"PHASE4":7201,"NA":7203},{"trials":7190,"activeCount":99},[],{"trials":7192,"activeCount":99},[],{"trials":7194,"activeCount":99},[7195],{"nctId":7172,"briefTitle":7173,"status":795,"phases":7196,"primaryCompletion":4549,"completion":4549,"start":7175,"enrollment":25,"conditions":7197,"interventions":7198},[88,89],[7177,7178],[7163,7180],{"trials":7200,"activeCount":99},[],{"trials":7202,"activeCount":99},[],{"trials":7204,"activeCount":99},[],{"intervention":7206,"totalTrials":151,"cells":7207},"Docetaxel and AZD6244",{"EARLY_PHASE1":7208,"PHASE1":7210,"PHASE2":7212,"PHASE3":7224,"PHASE4":7226,"NA":7228},{"trials":7209,"activeCount":99},[],{"trials":7211,"activeCount":99},[],{"trials":7213,"activeCount":99},[7214],{"nctId":7215,"briefTitle":7216,"status":109,"phases":7217,"primaryCompletion":527,"completion":7218,"start":5421,"enrollment":7219,"conditions":7220,"interventions":7222},"NCT01256359","Docetaxel With or Without AZD6244 in Melanoma",[89],"2020-02",83,[7221],"Melanoma",[7206,7223],"Docetaxel and placebo",{"trials":7225,"activeCount":99},[],{"trials":7227,"activeCount":99},[],{"trials":7229,"activeCount":99},[],{"intervention":7223,"totalTrials":151,"cells":7231},{"EARLY_PHASE1":7232,"PHASE1":7234,"PHASE2":7236,"PHASE3":7242,"PHASE4":7244,"NA":7246},{"trials":7233,"activeCount":99},[],{"trials":7235,"activeCount":99},[],{"trials":7237,"activeCount":99},[7238],{"nctId":7215,"briefTitle":7216,"status":109,"phases":7239,"primaryCompletion":527,"completion":7218,"start":5421,"enrollment":7219,"conditions":7240,"interventions":7241},[89],[7221],[7206,7223],{"trials":7243,"activeCount":99},[],{"trials":7245,"activeCount":99},[],{"trials":7247,"activeCount":99},[],{"intervention":7249,"totalTrials":151,"cells":7250},"Pembrolizumab",{"EARLY_PHASE1":7251,"PHASE1":7253,"PHASE2":7255,"PHASE3":7267,"PHASE4":7269,"NA":7271},{"trials":7252,"activeCount":99},[],{"trials":7254,"activeCount":99},[],{"trials":7256,"activeCount":99},[7257],{"nctId":7258,"briefTitle":7259,"status":795,"phases":7260,"primaryCompletion":7261,"completion":7262,"start":7263,"enrollment":2935,"conditions":7264,"interventions":7266},"NCT03167151","Pembrolizumab in Intermediate Risk Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)",[88,89],"2019-03-26","2019-06-26","2018-03-02",[7265],"Non-muscle Invasive Bladder Cancer (NMIBC)",[7249],{"trials":7268,"activeCount":99},[],{"trials":7270,"activeCount":99},[],{"trials":7272,"activeCount":99},[],{"intervention":7274,"totalTrials":151,"cells":7275},"RH5.1\u002F ASO1",{"EARLY_PHASE1":7276,"PHASE1":7278,"PHASE2":7280,"PHASE3":7290,"PHASE4":7292,"NA":7294},{"trials":7277,"activeCount":99},[],{"trials":7279,"activeCount":99},[],{"trials":7281,"activeCount":99},[7282],{"nctId":7283,"briefTitle":7284,"status":109,"phases":7285,"primaryCompletion":7286,"completion":7286,"start":7287,"enrollment":3034,"conditions":7288,"interventions":7289},"NCT02927145","A Challenge Study to Assess the Safety, Immunogenicity and Efficacy of a Malaria Vaccine Candidate",[88,89],"2019-06-27","2016-10-17",[15],[7274],{"trials":7291,"activeCount":99},[],{"trials":7293,"activeCount":99},[],{"trials":7295,"activeCount":99},[],{"intervention":7297,"totalTrials":151,"cells":7298},"ChAdOx1 LS2",{"EARLY_PHASE1":7299,"PHASE1":7301,"PHASE2":7303,"PHASE3":7314,"PHASE4":7316,"NA":7318},{"trials":7300,"activeCount":99},[],{"trials":7302,"activeCount":99},[],{"trials":7304,"activeCount":99},[7305],{"nctId":7306,"briefTitle":7307,"status":109,"phases":7308,"primaryCompletion":7309,"completion":7309,"start":7310,"enrollment":1511,"conditions":7311,"interventions":7312},"NCT03203421","A Safety and Efficacy Study of ChAdOx1 LS2 and MVA LS2",[88,89],"2017-12-20","2017-07-03",[15],[7297,7313],"MVA LS2",{"trials":7315,"activeCount":99},[],{"trials":7317,"activeCount":99},[],{"trials":7319,"activeCount":99},[],{"intervention":7313,"totalTrials":151,"cells":7321},{"EARLY_PHASE1":7322,"PHASE1":7324,"PHASE2":7326,"PHASE3":7332,"PHASE4":7334,"NA":7336},{"trials":7323,"activeCount":99},[],{"trials":7325,"activeCount":99},[],{"trials":7327,"activeCount":99},[7328],{"nctId":7306,"briefTitle":7307,"status":109,"phases":7329,"primaryCompletion":7309,"completion":7309,"start":7310,"enrollment":1511,"conditions":7330,"interventions":7331},[88,89],[15],[7297,7313],{"trials":7333,"activeCount":99},[],{"trials":7335,"activeCount":99},[],{"trials":7337,"activeCount":99},[],{"intervention":7339,"totalTrials":151,"cells":7340},"Light activated WST11",{"EARLY_PHASE1":7341,"PHASE1":7343,"PHASE2":7345,"PHASE3":7355,"PHASE4":7357,"NA":7359},{"trials":7342,"activeCount":99},[],{"trials":7344,"activeCount":99},[],{"trials":7346,"activeCount":99},[7347],{"nctId":7348,"briefTitle":7349,"status":795,"phases":7350,"primaryCompletion":7351,"completion":5378,"start":4450,"enrollment":1273,"conditions":7352,"interventions":7354},"NCT01573156","Vascular Targeted Photodynamic Therapy T1a Renal Tumours",[88,89],"2014-05",[7353],"Renal Cancer",[7339],{"trials":7356,"activeCount":99},[],{"trials":7358,"activeCount":99},[],{"trials":7360,"activeCount":99},[],{"intervention":7362,"totalTrials":151,"cells":7363},"Budesonide dry powder inhaler",{"EARLY_PHASE1":7364,"PHASE1":7366,"PHASE2":7368,"PHASE3":7379,"PHASE4":7381,"NA":7383},{"trials":7365,"activeCount":99},[],{"trials":7367,"activeCount":99},[],{"trials":7369,"activeCount":99},[7370],{"nctId":7371,"briefTitle":7372,"status":795,"phases":7373,"primaryCompletion":7374,"completion":7374,"start":3306,"enrollment":7375,"conditions":7376,"interventions":7378},"NCT04416399","STerOids in COVID-19 Study",[89],"2021-01-12",146,[7377],"Coronavirus Infection",[7362],{"trials":7380,"activeCount":99},[],{"trials":7382,"activeCount":99},[],{"trials":7384,"activeCount":99},[],{"intervention":7386,"totalTrials":151,"cells":7387},"Intrarectal artesunate",{"EARLY_PHASE1":7388,"PHASE1":7390,"PHASE2":7392,"PHASE3":7403,"PHASE4":7405,"NA":7407},{"trials":7389,"activeCount":99},[],{"trials":7391,"activeCount":99},[],{"trials":7393,"activeCount":99},[7394],{"nctId":7395,"briefTitle":7396,"status":109,"phases":7397,"primaryCompletion":6199,"completion":6199,"start":539,"enrollment":7398,"conditions":7399,"interventions":7400},"NCT02492178","Bio-availability of Rectal Artesunate in Children With Severe Falciparum Malaria",[89],82,[15],[7386,7401,7402],"Intravenous artesunate","Intravenous quinine",{"trials":7404,"activeCount":99},[],{"trials":7406,"activeCount":99},[],{"trials":7408,"activeCount":99},[],{"intervention":7401,"totalTrials":151,"cells":7410},{"EARLY_PHASE1":7411,"PHASE1":7413,"PHASE2":7415,"PHASE3":7421,"PHASE4":7423,"NA":7425},{"trials":7412,"activeCount":99},[],{"trials":7414,"activeCount":99},[],{"trials":7416,"activeCount":99},[7417],{"nctId":7395,"briefTitle":7396,"status":109,"phases":7418,"primaryCompletion":6199,"completion":6199,"start":539,"enrollment":7398,"conditions":7419,"interventions":7420},[89],[15],[7386,7401,7402],{"trials":7422,"activeCount":99},[],{"trials":7424,"activeCount":99},[],{"trials":7426,"activeCount":99},[],{"intervention":7402,"totalTrials":151,"cells":7428},{"EARLY_PHASE1":7429,"PHASE1":7431,"PHASE2":7433,"PHASE3":7439,"PHASE4":7441,"NA":7443},{"trials":7430,"activeCount":99},[],{"trials":7432,"activeCount":99},[],{"trials":7434,"activeCount":99},[7435],{"nctId":7395,"briefTitle":7396,"status":109,"phases":7436,"primaryCompletion":6199,"completion":6199,"start":539,"enrollment":7398,"conditions":7437,"interventions":7438},[89],[15],[7386,7401,7402],{"trials":7440,"activeCount":99},[],{"trials":7442,"activeCount":99},[],{"trials":7444,"activeCount":99},[],{"intervention":6114,"totalTrials":151,"cells":7446},{"EARLY_PHASE1":7447,"PHASE1":7449,"PHASE2":7451,"PHASE3":7457,"PHASE4":7459,"NA":7461},{"trials":7448,"activeCount":99},[],{"trials":7450,"activeCount":99},[],{"trials":7452,"activeCount":99},[7453],{"nctId":6104,"briefTitle":6105,"status":109,"phases":7454,"primaryCompletion":6107,"completion":6107,"start":6108,"enrollment":6109,"conditions":7455,"interventions":7456},[88,89],[6111,6112],[6114,6000,6115],{"trials":7458,"activeCount":99},[],{"trials":7460,"activeCount":99},[],{"trials":7462,"activeCount":99},[],{"intervention":6194,"totalTrials":151,"cells":7464},{"EARLY_PHASE1":7465,"PHASE1":7467,"PHASE2":7469,"PHASE3":7475,"PHASE4":7477,"NA":7479},{"trials":7466,"activeCount":99},[],{"trials":7468,"activeCount":99},[],{"trials":7470,"activeCount":99},[7471],{"nctId":6185,"briefTitle":6186,"status":109,"phases":7472,"primaryCompletion":4426,"completion":6188,"start":6189,"enrollment":6190,"conditions":7473,"interventions":7474},[88,89],[15],[6193,6139,6194],{"trials":7476,"activeCount":99},[],{"trials":7478,"activeCount":99},[],{"trials":7480,"activeCount":99},[],{"intervention":7482,"totalTrials":151,"cells":7483},"Vaccine placebo",{"EARLY_PHASE1":7484,"PHASE1":7486,"PHASE2":7488,"PHASE3":7502,"PHASE4":7504,"NA":7506},{"trials":7485,"activeCount":99},[],{"trials":7487,"activeCount":99},[],{"trials":7489,"activeCount":99},[7490],{"nctId":7491,"briefTitle":7492,"status":109,"phases":7493,"primaryCompletion":540,"completion":7494,"start":7495,"enrollment":7496,"conditions":7497,"interventions":7499},"NCT01405521","Understanding Typhoid Disease After Vaccination",[89],"2022-05-06","2011-10-07",99,[7011,7012,7498],"Typhoid",[7482,7500,7501],"Ty21a","M10ZH09 vaccine",{"trials":7503,"activeCount":99},[],{"trials":7505,"activeCount":99},[],{"trials":7507,"activeCount":99},[],{"intervention":7500,"totalTrials":151,"cells":7509},{"EARLY_PHASE1":7510,"PHASE1":7512,"PHASE2":7514,"PHASE3":7520,"PHASE4":7522,"NA":7524},{"trials":7511,"activeCount":99},[],{"trials":7513,"activeCount":99},[],{"trials":7515,"activeCount":99},[7516],{"nctId":7491,"briefTitle":7492,"status":109,"phases":7517,"primaryCompletion":540,"completion":7494,"start":7495,"enrollment":7496,"conditions":7518,"interventions":7519},[89],[7011,7012,7498],[7482,7500,7501],{"trials":7521,"activeCount":99},[],{"trials":7523,"activeCount":99},[],{"trials":7525,"activeCount":99},[],{"intervention":7501,"totalTrials":151,"cells":7527},{"EARLY_PHASE1":7528,"PHASE1":7530,"PHASE2":7532,"PHASE3":7538,"PHASE4":7540,"NA":7542},{"trials":7529,"activeCount":99},[],{"trials":7531,"activeCount":99},[],{"trials":7533,"activeCount":99},[7534],{"nctId":7491,"briefTitle":7492,"status":109,"phases":7535,"primaryCompletion":540,"completion":7494,"start":7495,"enrollment":7496,"conditions":7536,"interventions":7537},[89],[7011,7012,7498],[7482,7500,7501],{"trials":7539,"activeCount":99},[],{"trials":7541,"activeCount":99},[],{"trials":7543,"activeCount":99},[],{"intervention":1471,"totalTrials":151,"cells":7545},{"EARLY_PHASE1":7546,"PHASE1":7548,"PHASE2":7550,"PHASE3":7556,"PHASE4":7558,"NA":7560},{"trials":7547,"activeCount":99},[],{"trials":7549,"activeCount":99},[],{"trials":7551,"activeCount":99},[7552],{"nctId":1463,"briefTitle":1464,"status":109,"phases":7553,"primaryCompletion":1466,"completion":1466,"start":1467,"enrollment":1468,"conditions":7554,"interventions":7555},[88,89],[27],[1471,1427,1472],{"trials":7557,"activeCount":99},[],{"trials":7559,"activeCount":99},[],{"trials":7561,"activeCount":99},[],{"intervention":1472,"totalTrials":151,"cells":7563},{"EARLY_PHASE1":7564,"PHASE1":7566,"PHASE2":7568,"PHASE3":7574,"PHASE4":7576,"NA":7578},{"trials":7565,"activeCount":99},[],{"trials":7567,"activeCount":99},[],{"trials":7569,"activeCount":99},[7570],{"nctId":1463,"briefTitle":1464,"status":109,"phases":7571,"primaryCompletion":1466,"completion":1466,"start":1467,"enrollment":1468,"conditions":7572,"interventions":7573},[88,89],[27],[1471,1427,1472],{"trials":7575,"activeCount":99},[],{"trials":7577,"activeCount":99},[],{"trials":7579,"activeCount":99},[],{"intervention":7581,"totalTrials":151,"cells":7582},"AAV-mediated REP1 gene replacement",{"EARLY_PHASE1":7583,"PHASE1":7585,"PHASE2":7587,"PHASE3":7598,"PHASE4":7600,"NA":7602},{"trials":7584,"activeCount":99},[],{"trials":7586,"activeCount":99},[],{"trials":7588,"activeCount":99},[7589],{"nctId":7590,"briefTitle":7591,"status":109,"phases":7592,"primaryCompletion":7593,"completion":7593,"start":7594,"enrollment":1699,"conditions":7595,"interventions":7597},"NCT02407678","REP1 Gene Replacement Therapy for Choroideremia",[89],"2021-07-23","2016-08-16",[7596],"Choroideremia",[7581],{"trials":7599,"activeCount":99},[],{"trials":7601,"activeCount":99},[],{"trials":7603,"activeCount":99},[],{"intervention":7605,"totalTrials":151,"cells":7606},"Amiloride",{"EARLY_PHASE1":7607,"PHASE1":7609,"PHASE2":7611,"PHASE3":7623,"PHASE4":7625,"NA":7627},{"trials":7608,"activeCount":99},[],{"trials":7610,"activeCount":99},[],{"trials":7612,"activeCount":99},[7613],{"nctId":7614,"briefTitle":7615,"status":109,"phases":7616,"primaryCompletion":7617,"completion":7617,"start":1434,"enrollment":7618,"conditions":7619,"interventions":7622},"NCT01802489","Amiloride Clinical Trial In Optic Neuritis",[89],"2015-11",46,[7620,7621],"Optic Neuritis","Multiple Sclerosis",[7605],{"trials":7624,"activeCount":99},[],{"trials":7626,"activeCount":99},[],{"trials":7628,"activeCount":99},[],{"intervention":802,"totalTrials":151,"cells":7630},{"EARLY_PHASE1":7631,"PHASE1":7633,"PHASE2":7635,"PHASE3":7641,"PHASE4":7643,"NA":7645},{"trials":7632,"activeCount":99},[],{"trials":7634,"activeCount":99},[],{"trials":7636,"activeCount":99},[7637],{"nctId":793,"briefTitle":794,"status":795,"phases":7638,"primaryCompletion":797,"completion":797,"start":798,"enrollment":799,"conditions":7639,"interventions":7640},[89],[27],[57,802,803],{"trials":7642,"activeCount":99},[],{"trials":7644,"activeCount":99},[],{"trials":7646,"activeCount":99},[],{"intervention":803,"totalTrials":151,"cells":7648},{"EARLY_PHASE1":7649,"PHASE1":7651,"PHASE2":7653,"PHASE3":7659,"PHASE4":7661,"NA":7663},{"trials":7650,"activeCount":99},[],{"trials":7652,"activeCount":99},[],{"trials":7654,"activeCount":99},[7655],{"nctId":793,"briefTitle":794,"status":795,"phases":7656,"primaryCompletion":797,"completion":797,"start":798,"enrollment":799,"conditions":7657,"interventions":7658},[89],[27],[57,802,803],{"trials":7660,"activeCount":99},[],{"trials":7662,"activeCount":99},[],{"trials":7664,"activeCount":99},[],{"intervention":7666,"totalTrials":151,"cells":7667},"ChAd63 CS\u002FME-TRAP",{"EARLY_PHASE1":7668,"PHASE1":7670,"PHASE2":7672,"PHASE3":7683,"PHASE4":7685,"NA":7687},{"trials":7669,"activeCount":99},[],{"trials":7671,"activeCount":99},[],{"trials":7673,"activeCount":99},[7674],{"nctId":7675,"briefTitle":7676,"status":109,"phases":7677,"primaryCompletion":6018,"completion":6018,"start":3605,"enrollment":1778,"conditions":7678,"interventions":7679},"NCT01739036","A Phase I\u002FIIa Sporozoite Challenge Study to Assess the Efficacy of Candidate Combination Malaria Vaccine Approaches Using the ChAd63 and MVA Vectors Encoding the Antigens ME-TRAP, CS and AMA1",[88,89],[33],[7666,7680,7681,7682],"MVA CS\u002FME-TRAP","ChAd63 CS\u002FME-TRAP\u002FAMA1","MVA CS\u002FME-TRAP\u002FAMA1",{"trials":7684,"activeCount":99},[],{"trials":7686,"activeCount":99},[],{"trials":7688,"activeCount":99},[],{"intervention":7680,"totalTrials":151,"cells":7690},{"EARLY_PHASE1":7691,"PHASE1":7693,"PHASE2":7695,"PHASE3":7701,"PHASE4":7703,"NA":7705},{"trials":7692,"activeCount":99},[],{"trials":7694,"activeCount":99},[],{"trials":7696,"activeCount":99},[7697],{"nctId":7675,"briefTitle":7676,"status":109,"phases":7698,"primaryCompletion":6018,"completion":6018,"start":3605,"enrollment":1778,"conditions":7699,"interventions":7700},[88,89],[33],[7666,7680,7681,7682],{"trials":7702,"activeCount":99},[],{"trials":7704,"activeCount":99},[],{"trials":7706,"activeCount":99},[],{"intervention":7681,"totalTrials":151,"cells":7708},{"EARLY_PHASE1":7709,"PHASE1":7711,"PHASE2":7713,"PHASE3":7719,"PHASE4":7721,"NA":7723},{"trials":7710,"activeCount":99},[],{"trials":7712,"activeCount":99},[],{"trials":7714,"activeCount":99},[7715],{"nctId":7675,"briefTitle":7676,"status":109,"phases":7716,"primaryCompletion":6018,"completion":6018,"start":3605,"enrollment":1778,"conditions":7717,"interventions":7718},[88,89],[33],[7666,7680,7681,7682],{"trials":7720,"activeCount":99},[],{"trials":7722,"activeCount":99},[],{"trials":7724,"activeCount":99},[],{"intervention":7682,"totalTrials":151,"cells":7726},{"EARLY_PHASE1":7727,"PHASE1":7729,"PHASE2":7731,"PHASE3":7737,"PHASE4":7739,"NA":7741},{"trials":7728,"activeCount":99},[],{"trials":7730,"activeCount":99},[],{"trials":7732,"activeCount":99},[7733],{"nctId":7675,"briefTitle":7676,"status":109,"phases":7734,"primaryCompletion":6018,"completion":6018,"start":3605,"enrollment":1778,"conditions":7735,"interventions":7736},[88,89],[33],[7666,7680,7681,7682],{"trials":7738,"activeCount":99},[],{"trials":7740,"activeCount":99},[],{"trials":7742,"activeCount":99},[],{"intervention":7744,"totalTrials":151,"cells":7745},"AdCh63 MSP1, MVA MSP1, challenge",{"EARLY_PHASE1":7746,"PHASE1":7748,"PHASE2":7750,"PHASE3":7763,"PHASE4":7765,"NA":7767},{"trials":7747,"activeCount":99},[],{"trials":7749,"activeCount":99},[],{"trials":7751,"activeCount":99},[7752],{"nctId":7753,"briefTitle":7754,"status":109,"phases":7755,"primaryCompletion":4156,"completion":4156,"start":3830,"enrollment":7756,"conditions":7757,"interventions":7758},"NCT01142765","Study to Assess Efficacy of New Malaria Vaccine Candidates AdCh63 AMA1, MVA AMA1, AdCh63 MSP1, MVA MSP1, AdCh63 ME-TRAP & MVA ME-TRAP",[88,89],52,[15],[7744,7759,7760,7761,7762],"AdCh63 AMA1, MVA AMA1, challenge","AdCh63 AMA1, AdCh63 MSP1, MVA AMA1, MVA MSP1, challenge","AdCh63 MSP1, AdCh63 ME-TRAP, MVA MSP1, MVA ME-TRAP, challenge","Sporozoite challenge",{"trials":7764,"activeCount":99},[],{"trials":7766,"activeCount":99},[],{"trials":7768,"activeCount":99},[],{"intervention":7759,"totalTrials":151,"cells":7770},{"EARLY_PHASE1":7771,"PHASE1":7773,"PHASE2":7775,"PHASE3":7781,"PHASE4":7783,"NA":7785},{"trials":7772,"activeCount":99},[],{"trials":7774,"activeCount":99},[],{"trials":7776,"activeCount":99},[7777],{"nctId":7753,"briefTitle":7754,"status":109,"phases":7778,"primaryCompletion":4156,"completion":4156,"start":3830,"enrollment":7756,"conditions":7779,"interventions":7780},[88,89],[15],[7744,7759,7760,7761,7762],{"trials":7782,"activeCount":99},[],{"trials":7784,"activeCount":99},[],{"trials":7786,"activeCount":99},[],{"intervention":7760,"totalTrials":151,"cells":7788},{"EARLY_PHASE1":7789,"PHASE1":7791,"PHASE2":7793,"PHASE3":7799,"PHASE4":7801,"NA":7803},{"trials":7790,"activeCount":99},[],{"trials":7792,"activeCount":99},[],{"trials":7794,"activeCount":99},[7795],{"nctId":7753,"briefTitle":7754,"status":109,"phases":7796,"primaryCompletion":4156,"completion":4156,"start":3830,"enrollment":7756,"conditions":7797,"interventions":7798},[88,89],[15],[7744,7759,7760,7761,7762],{"trials":7800,"activeCount":99},[],{"trials":7802,"activeCount":99},[],{"trials":7804,"activeCount":99},[],{"intervention":7761,"totalTrials":151,"cells":7806},{"EARLY_PHASE1":7807,"PHASE1":7809,"PHASE2":7811,"PHASE3":7817,"PHASE4":7819,"NA":7821},{"trials":7808,"activeCount":99},[],{"trials":7810,"activeCount":99},[],{"trials":7812,"activeCount":99},[7813],{"nctId":7753,"briefTitle":7754,"status":109,"phases":7814,"primaryCompletion":4156,"completion":4156,"start":3830,"enrollment":7756,"conditions":7815,"interventions":7816},[88,89],[15],[7744,7759,7760,7761,7762],{"trials":7818,"activeCount":99},[],{"trials":7820,"activeCount":99},[],{"trials":7822,"activeCount":99},[],{"intervention":7762,"totalTrials":151,"cells":7824},{"EARLY_PHASE1":7825,"PHASE1":7827,"PHASE2":7829,"PHASE3":7835,"PHASE4":7837,"NA":7839},{"trials":7826,"activeCount":99},[],{"trials":7828,"activeCount":99},[],{"trials":7830,"activeCount":99},[7831],{"nctId":7753,"briefTitle":7754,"status":109,"phases":7832,"primaryCompletion":4156,"completion":4156,"start":3830,"enrollment":7756,"conditions":7833,"interventions":7834},[88,89],[15],[7744,7759,7760,7761,7762],{"trials":7836,"activeCount":99},[],{"trials":7838,"activeCount":99},[],{"trials":7840,"activeCount":99},[],{"intervention":7842,"totalTrials":151,"cells":7843},"RTS,S\u002FAS01B Fractional dose",{"EARLY_PHASE1":7844,"PHASE1":7846,"PHASE2":7848,"PHASE3":7865,"PHASE4":7867,"NA":7869},{"trials":7845,"activeCount":99},[],{"trials":7847,"activeCount":99},[],{"trials":7849,"activeCount":99},[7850],{"nctId":7851,"briefTitle":7852,"status":109,"phases":7853,"primaryCompletion":7854,"completion":7854,"start":7855,"enrollment":7856,"conditions":7857,"interventions":7858},"NCT02992119","Malaria Vaccine Safety and Immunogenicity Study in Healthy Adults",[89],"2018-02-20","2017-06-04",193,[1835],[7842,7859,7860,7861,7862,7863,7864],"Double RTS,S\u002FAS01E Fractional dose","RTS,S\u002FAS01E Standard dose","RTS,S\u002FAS01E + DHA-PIP+PQ Standard dose","RTS,S\u002FAS01E Fractional dose","RTS,S\u002FAS01E + DHA-PIP+PQ Fractional dose","RTS,S\u002FAS01E + DHA-PIP+PQ Fractional two-dose",{"trials":7866,"activeCount":99},[],{"trials":7868,"activeCount":99},[],{"trials":7870,"activeCount":99},[],{"intervention":7859,"totalTrials":151,"cells":7872},{"EARLY_PHASE1":7873,"PHASE1":7875,"PHASE2":7877,"PHASE3":7883,"PHASE4":7885,"NA":7887},{"trials":7874,"activeCount":99},[],{"trials":7876,"activeCount":99},[],{"trials":7878,"activeCount":99},[7879],{"nctId":7851,"briefTitle":7852,"status":109,"phases":7880,"primaryCompletion":7854,"completion":7854,"start":7855,"enrollment":7856,"conditions":7881,"interventions":7882},[89],[1835],[7842,7859,7860,7861,7862,7863,7864],{"trials":7884,"activeCount":99},[],{"trials":7886,"activeCount":99},[],{"trials":7888,"activeCount":99},[],{"intervention":7860,"totalTrials":151,"cells":7890},{"EARLY_PHASE1":7891,"PHASE1":7893,"PHASE2":7895,"PHASE3":7901,"PHASE4":7903,"NA":7905},{"trials":7892,"activeCount":99},[],{"trials":7894,"activeCount":99},[],{"trials":7896,"activeCount":99},[7897],{"nctId":7851,"briefTitle":7852,"status":109,"phases":7898,"primaryCompletion":7854,"completion":7854,"start":7855,"enrollment":7856,"conditions":7899,"interventions":7900},[89],[1835],[7842,7859,7860,7861,7862,7863,7864],{"trials":7902,"activeCount":99},[],{"trials":7904,"activeCount":99},[],{"trials":7906,"activeCount":99},[],{"intervention":7861,"totalTrials":151,"cells":7908},{"EARLY_PHASE1":7909,"PHASE1":7911,"PHASE2":7913,"PHASE3":7919,"PHASE4":7921,"NA":7923},{"trials":7910,"activeCount":99},[],{"trials":7912,"activeCount":99},[],{"trials":7914,"activeCount":99},[7915],{"nctId":7851,"briefTitle":7852,"status":109,"phases":7916,"primaryCompletion":7854,"completion":7854,"start":7855,"enrollment":7856,"conditions":7917,"interventions":7918},[89],[1835],[7842,7859,7860,7861,7862,7863,7864],{"trials":7920,"activeCount":99},[],{"trials":7922,"activeCount":99},[],{"trials":7924,"activeCount":99},[],{"intervention":7862,"totalTrials":151,"cells":7926},{"EARLY_PHASE1":7927,"PHASE1":7929,"PHASE2":7931,"PHASE3":7937,"PHASE4":7939,"NA":7941},{"trials":7928,"activeCount":99},[],{"trials":7930,"activeCount":99},[],{"trials":7932,"activeCount":99},[7933],{"nctId":7851,"briefTitle":7852,"status":109,"phases":7934,"primaryCompletion":7854,"completion":7854,"start":7855,"enrollment":7856,"conditions":7935,"interventions":7936},[89],[1835],[7842,7859,7860,7861,7862,7863,7864],{"trials":7938,"activeCount":99},[],{"trials":7940,"activeCount":99},[],{"trials":7942,"activeCount":99},[],{"intervention":7863,"totalTrials":151,"cells":7944},{"EARLY_PHASE1":7945,"PHASE1":7947,"PHASE2":7949,"PHASE3":7955,"PHASE4":7957,"NA":7959},{"trials":7946,"activeCount":99},[],{"trials":7948,"activeCount":99},[],{"trials":7950,"activeCount":99},[7951],{"nctId":7851,"briefTitle":7852,"status":109,"phases":7952,"primaryCompletion":7854,"completion":7854,"start":7855,"enrollment":7856,"conditions":7953,"interventions":7954},[89],[1835],[7842,7859,7860,7861,7862,7863,7864],{"trials":7956,"activeCount":99},[],{"trials":7958,"activeCount":99},[],{"trials":7960,"activeCount":99},[],{"intervention":7864,"totalTrials":151,"cells":7962},{"EARLY_PHASE1":7963,"PHASE1":7965,"PHASE2":7967,"PHASE3":7973,"PHASE4":7975,"NA":7977},{"trials":7964,"activeCount":99},[],{"trials":7966,"activeCount":99},[],{"trials":7968,"activeCount":99},[7969],{"nctId":7851,"briefTitle":7852,"status":109,"phases":7970,"primaryCompletion":7854,"completion":7854,"start":7855,"enrollment":7856,"conditions":7971,"interventions":7972},[89],[1835],[7842,7859,7860,7861,7862,7863,7864],{"trials":7974,"activeCount":99},[],{"trials":7976,"activeCount":99},[],{"trials":7978,"activeCount":99},[],{"intervention":7980,"totalTrials":151,"cells":7981},"6R-BH4",{"EARLY_PHASE1":7982,"PHASE1":7984,"PHASE2":7986,"PHASE3":7996,"PHASE4":7998,"NA":8000},{"trials":7983,"activeCount":99},[],{"trials":7985,"activeCount":99},[],{"trials":7987,"activeCount":99},[7988],{"nctId":7989,"briefTitle":7990,"status":2901,"phases":7991,"primaryCompletion":3580,"completion":3580,"start":6044,"enrollment":7992,"conditions":7993,"interventions":7995},"NCT00423280","Effect of 6R-BH4 Treatment in Coronary Artery Disease (OXBIO Study)",[89],66,[7994],"Coronary Artery Disease",[7980],{"trials":7997,"activeCount":99},[],{"trials":7999,"activeCount":99},[],{"trials":8001,"activeCount":99},[],{"intervention":8003,"totalTrials":151,"cells":8004},"Olaparib",{"EARLY_PHASE1":8005,"PHASE1":8007,"PHASE2":8009,"PHASE3":8023,"PHASE4":8025,"NA":8027},{"trials":8006,"activeCount":99},[],{"trials":8008,"activeCount":99},[],{"trials":8010,"activeCount":99},[8011],{"nctId":8012,"briefTitle":8013,"status":109,"phases":8014,"primaryCompletion":8015,"completion":8016,"start":8017,"enrollment":8018,"conditions":8019,"interventions":8020},"NCT03117933","Olaparib +\u002F- Cediranib or Chemotherapy in Patients With Platinum-resistant Ovarian Cancer",[89],"2021-03-12","2023-12-31","2017-03-09",139,[7154],[8003,8021,8022],"Cediranib","Paclitaxel",{"trials":8024,"activeCount":99},[],{"trials":8026,"activeCount":99},[],{"trials":8028,"activeCount":99},[],{"intervention":8021,"totalTrials":151,"cells":8030},{"EARLY_PHASE1":8031,"PHASE1":8033,"PHASE2":8035,"PHASE3":8041,"PHASE4":8043,"NA":8045},{"trials":8032,"activeCount":99},[],{"trials":8034,"activeCount":99},[],{"trials":8036,"activeCount":99},[8037],{"nctId":8012,"briefTitle":8013,"status":109,"phases":8038,"primaryCompletion":8015,"completion":8016,"start":8017,"enrollment":8018,"conditions":8039,"interventions":8040},[89],[7154],[8003,8021,8022],{"trials":8042,"activeCount":99},[],{"trials":8044,"activeCount":99},[],{"trials":8046,"activeCount":99},[],{"intervention":8022,"totalTrials":151,"cells":8048},{"EARLY_PHASE1":8049,"PHASE1":8051,"PHASE2":8053,"PHASE3":8059,"PHASE4":8061,"NA":8063},{"trials":8050,"activeCount":99},[],{"trials":8052,"activeCount":99},[],{"trials":8054,"activeCount":99},[8055],{"nctId":8012,"briefTitle":8013,"status":109,"phases":8056,"primaryCompletion":8015,"completion":8016,"start":8017,"enrollment":8018,"conditions":8057,"interventions":8058},[89],[7154],[8003,8021,8022],{"trials":8060,"activeCount":99},[],{"trials":8062,"activeCount":99},[],{"trials":8064,"activeCount":99},[],{"intervention":8066,"totalTrials":151,"cells":8067},"Buspirone 20mg",{"EARLY_PHASE1":8068,"PHASE1":8070,"PHASE2":8072,"PHASE3":8083,"PHASE4":8085,"NA":8087},{"trials":8069,"activeCount":99},[],{"trials":8071,"activeCount":99},[],{"trials":8073,"activeCount":99},[8074],{"nctId":8075,"briefTitle":8076,"status":109,"phases":8077,"primaryCompletion":8078,"completion":8078,"start":8079,"enrollment":1422,"conditions":8080,"interventions":8082},"NCT05357547","Serotonin-receptor Agonism in Reward Processing",[89],"2023-04-18","2022-05-13",[8081],"Anhedonia",[8066],{"trials":8084,"activeCount":99},[],{"trials":8086,"activeCount":99},[],{"trials":8088,"activeCount":99},[],{"intervention":8090,"totalTrials":151,"cells":8091},"Citalopram 20mg",{"EARLY_PHASE1":8092,"PHASE1":8094,"PHASE2":8096,"PHASE3":8106,"PHASE4":8108,"NA":8110},{"trials":8093,"activeCount":99},[],{"trials":8095,"activeCount":99},[],{"trials":8097,"activeCount":99},[8098],{"nctId":8099,"briefTitle":8100,"status":2901,"phases":8101,"primaryCompletion":8102,"completion":8102,"start":8103,"enrollment":1530,"conditions":8104,"interventions":8105},"NCT06017037","REward Processing And Citalopram Study",[88,89],"2024-05-01","2023-05-19",[8081],[8090],{"trials":8107,"activeCount":99},[],{"trials":8109,"activeCount":99},[],{"trials":8111,"activeCount":99},[],{"intervention":8113,"totalTrials":151,"cells":8114},"Mifamurtide",{"EARLY_PHASE1":8115,"PHASE1":8117,"PHASE2":8119,"PHASE3":8130,"PHASE4":8132,"NA":8134},{"trials":8116,"activeCount":99},[],{"trials":8118,"activeCount":99},[],{"trials":8120,"activeCount":99},[8121],{"nctId":8122,"briefTitle":8123,"status":795,"phases":8124,"primaryCompletion":8125,"completion":8125,"start":6230,"enrollment":1285,"conditions":8126,"interventions":8128},"NCT02441309","A Eurosarc Study of Mifamurtide in Advanced Osteosarcoma (MEMOS)",[89],"2016-11-04",[8127],"Osteosarcoma",[8113,8129],"Ifosfamide",{"trials":8131,"activeCount":99},[],{"trials":8133,"activeCount":99},[],{"trials":8135,"activeCount":99},[],{"intervention":8129,"totalTrials":151,"cells":8137},{"EARLY_PHASE1":8138,"PHASE1":8140,"PHASE2":8142,"PHASE3":8148,"PHASE4":8150,"NA":8152},{"trials":8139,"activeCount":99},[],{"trials":8141,"activeCount":99},[],{"trials":8143,"activeCount":99},[8144],{"nctId":8122,"briefTitle":8123,"status":795,"phases":8145,"primaryCompletion":8125,"completion":8125,"start":6230,"enrollment":1285,"conditions":8146,"interventions":8147},[89],[8127],[8113,8129],{"trials":8149,"activeCount":99},[],{"trials":8151,"activeCount":99},[],{"trials":8153,"activeCount":99},[],{"intervention":8155,"totalTrials":151,"cells":8156},"PvDBPII\u002FMatrix-M1",{"EARLY_PHASE1":8157,"PHASE1":8159,"PHASE2":8161,"PHASE3":8172,"PHASE4":8174,"NA":8176},{"trials":8158,"activeCount":99},[],{"trials":8160,"activeCount":99},[],{"trials":8162,"activeCount":99},[8163],{"nctId":8164,"briefTitle":8165,"status":109,"phases":8166,"primaryCompletion":8167,"completion":8167,"start":8168,"enrollment":2572,"conditions":8169,"interventions":8171},"NCT04201431","Safety, Immunogenicity and Efficacy of the Blood-stage Plasmodium Vivax Malaria Vaccine Candidate PvDBPII in Matrix M1",[88,89],"2022-07-14","2020-01-24",[8170],"Malaria, Vivax",[8155],{"trials":8173,"activeCount":99},[],{"trials":8175,"activeCount":99},[],{"trials":8177,"activeCount":99},[],{"intervention":8179,"totalTrials":151,"cells":8180},"Dihydroartemisinin-piperaquine (DP) + Primaquine (PQ) placebo",{"EARLY_PHASE1":8181,"PHASE1":8183,"PHASE2":8185,"PHASE3":8196,"PHASE4":8198,"NA":8200},{"trials":8182,"activeCount":99},[],{"trials":8184,"activeCount":99},[],{"trials":8186,"activeCount":99},[8187],{"nctId":8188,"briefTitle":8189,"status":109,"phases":8190,"primaryCompletion":8191,"completion":8191,"start":8192,"enrollment":2104,"conditions":8193,"interventions":8195},"NCT02802813","P.Vivax Treatment Trial",[88,89],"2018-06-15","2016-06-14",[8194],"Plasmodium Vivax",[581,8179],{"trials":8197,"activeCount":99},[],{"trials":8199,"activeCount":99},[],{"trials":8201,"activeCount":99},[],{"intervention":1303,"totalTrials":151,"cells":8203},{"EARLY_PHASE1":8204,"PHASE1":8206,"PHASE2":8208,"PHASE3":8214,"PHASE4":8216,"NA":8218},{"trials":8205,"activeCount":99},[],{"trials":8207,"activeCount":99},[],{"trials":8209,"activeCount":99},[8210],{"nctId":1295,"briefTitle":1296,"status":795,"phases":8211,"primaryCompletion":1298,"completion":1298,"start":1299,"enrollment":1300,"conditions":8212,"interventions":8213},[88,89],[1287,1288,24],[1272,1290,1272,1291,190,1303,1304,1303],{"trials":8215,"activeCount":99},[],{"trials":8217,"activeCount":99},[],{"trials":8219,"activeCount":99},[],{"intervention":1304,"totalTrials":151,"cells":8221},{"EARLY_PHASE1":8222,"PHASE1":8224,"PHASE2":8226,"PHASE3":8232,"PHASE4":8234,"NA":8236},{"trials":8223,"activeCount":99},[],{"trials":8225,"activeCount":99},[],{"trials":8227,"activeCount":99},[8228],{"nctId":1295,"briefTitle":1296,"status":795,"phases":8229,"primaryCompletion":1298,"completion":1298,"start":1299,"enrollment":1300,"conditions":8230,"interventions":8231},[88,89],[1287,1288,24],[1272,1290,1272,1291,190,1303,1304,1303],{"trials":8233,"activeCount":99},[],{"trials":8235,"activeCount":99},[],{"trials":8237,"activeCount":99},[],{"intervention":8239,"totalTrials":151,"cells":8240},"5-Aminolevulinic Acid hydrochloride",{"EARLY_PHASE1":8241,"PHASE1":8243,"PHASE2":8245,"PHASE3":8260,"PHASE4":8262,"NA":8264},{"trials":8242,"activeCount":99},[],{"trials":8244,"activeCount":99},[],{"trials":8246,"activeCount":99},[8247],{"nctId":8248,"briefTitle":8249,"status":109,"phases":8250,"primaryCompletion":8251,"completion":8251,"start":8252,"enrollment":1778,"conditions":8253,"interventions":8258},"NCT07027670","Treatment With 5-AminoLEvuliNic Acid Before Cardiac Surgery",[89],"2022-06-30","2021-02-01",[8254,8255,8256,8257],"Cardiac Surgical Procedures","Coronary Artery Bypass","Aortic Valve Disease","Mitral Valve Disease",[8239,8259],"Sodium ferrous citrate",{"trials":8261,"activeCount":99},[],{"trials":8263,"activeCount":99},[],{"trials":8265,"activeCount":99},[],{"intervention":8259,"totalTrials":151,"cells":8267},{"EARLY_PHASE1":8268,"PHASE1":8270,"PHASE2":8272,"PHASE3":8278,"PHASE4":8280,"NA":8282},{"trials":8269,"activeCount":99},[],{"trials":8271,"activeCount":99},[],{"trials":8273,"activeCount":99},[8274],{"nctId":8248,"briefTitle":8249,"status":109,"phases":8275,"primaryCompletion":8251,"completion":8251,"start":8252,"enrollment":1778,"conditions":8276,"interventions":8277},[89],[8254,8255,8256,8257],[8239,8259],{"trials":8279,"activeCount":99},[],{"trials":8281,"activeCount":99},[],{"trials":8283,"activeCount":99},[],{"intervention":8285,"totalTrials":151,"cells":8286},"AZD4017 and prednisolone",{"EARLY_PHASE1":8287,"PHASE1":8289,"PHASE2":8291,"PHASE3":8302,"PHASE4":8304,"NA":8306},{"trials":8288,"activeCount":99},[],{"trials":8290,"activeCount":99},[],{"trials":8292,"activeCount":99},[8293],{"nctId":8294,"briefTitle":8295,"status":109,"phases":8296,"primaryCompletion":8297,"completion":8297,"start":8298,"enrollment":1394,"conditions":8299,"interventions":8301},"NCT03111810","Targeting Iatrogenic Cushing's Syndrome With 11β-hydroxysteroid Dehydrogenase Type 1 Inhibition",[89],"2020-08-01","2017-05-25",[8300],"Iatrogenic Cushing's Disease",[8285],{"trials":8303,"activeCount":99},[],{"trials":8305,"activeCount":99},[],{"trials":8307,"activeCount":99},[],{"intervention":8309,"totalTrials":151,"cells":8310},"Glibenclamide",{"EARLY_PHASE1":8311,"PHASE1":8313,"PHASE2":8315,"PHASE3":8324,"PHASE4":8326,"NA":8328},{"trials":8312,"activeCount":99},[],{"trials":8314,"activeCount":99},[],{"trials":8316,"activeCount":99},[8317],{"nctId":8318,"briefTitle":8319,"status":109,"phases":8320,"primaryCompletion":8017,"completion":8017,"start":8321,"enrollment":578,"conditions":8322,"interventions":8323},"NCT02830048","Low dosE GlibENclamide in Diabetes Part A",[89],"2016-07",[508],[8309],{"trials":8325,"activeCount":99},[],{"trials":8327,"activeCount":99},[],{"trials":8329,"activeCount":99},[],{"intervention":2589,"totalTrials":151,"cells":8331},{"EARLY_PHASE1":8332,"PHASE1":8334,"PHASE2":8336,"PHASE3":8342,"PHASE4":8344,"NA":8346},{"trials":8333,"activeCount":99},[],{"trials":8335,"activeCount":99},[],{"trials":8337,"activeCount":99},[8338],{"nctId":2580,"briefTitle":2581,"status":2582,"phases":8339,"primaryCompletion":393,"completion":2584,"start":2585,"enrollment":2586,"conditions":8340,"interventions":8341},[88,89],[27],[2589,2590,2559,2591,190],{"trials":8343,"activeCount":99},[],{"trials":8345,"activeCount":99},[],{"trials":8347,"activeCount":99},[],{"intervention":2590,"totalTrials":151,"cells":8349},{"EARLY_PHASE1":8350,"PHASE1":8352,"PHASE2":8354,"PHASE3":8360,"PHASE4":8362,"NA":8364},{"trials":8351,"activeCount":99},[],{"trials":8353,"activeCount":99},[],{"trials":8355,"activeCount":99},[8356],{"nctId":2580,"briefTitle":2581,"status":2582,"phases":8357,"primaryCompletion":393,"completion":2584,"start":2585,"enrollment":2586,"conditions":8358,"interventions":8359},[88,89],[27],[2589,2590,2559,2591,190],{"trials":8361,"activeCount":99},[],{"trials":8363,"activeCount":99},[],{"trials":8365,"activeCount":99},[],{"intervention":2591,"totalTrials":151,"cells":8367},{"EARLY_PHASE1":8368,"PHASE1":8370,"PHASE2":8372,"PHASE3":8378,"PHASE4":8380,"NA":8382},{"trials":8369,"activeCount":99},[],{"trials":8371,"activeCount":99},[],{"trials":8373,"activeCount":99},[8374],{"nctId":2580,"briefTitle":2581,"status":2582,"phases":8375,"primaryCompletion":393,"completion":2584,"start":2585,"enrollment":2586,"conditions":8376,"interventions":8377},[88,89],[27],[2589,2590,2559,2591,190],{"trials":8379,"activeCount":99},[],{"trials":8381,"activeCount":99},[],{"trials":8383,"activeCount":99},[],{"intervention":8385,"totalTrials":151,"cells":8386},"AMA1-C1\u002FAlhydrogel® + CPG 7909",{"EARLY_PHASE1":8387,"PHASE1":8389,"PHASE2":8391,"PHASE3":8399,"PHASE4":8401,"NA":8403},{"trials":8388,"activeCount":99},[],{"trials":8390,"activeCount":99},[],{"trials":8392,"activeCount":99},[8393],{"nctId":8394,"briefTitle":8395,"status":109,"phases":8396,"primaryCompletion":4180,"completion":4180,"start":6082,"enrollment":1285,"conditions":8397,"interventions":8398},"NCT00984763","A Study to Assess Safety, Immunogenicity and Parasite Growth Inhibition of an Asexual Blood Stage Vaccine for P. Falciparum Malaria",[88,89],[15],[8385],{"trials":8400,"activeCount":99},[],{"trials":8402,"activeCount":99},[],{"trials":8404,"activeCount":99},[],{"intervention":8406,"totalTrials":151,"cells":8407},"rAAV2.REP1",{"EARLY_PHASE1":8408,"PHASE1":8410,"PHASE2":8412,"PHASE3":8421,"PHASE4":8423,"NA":8425},{"trials":8409,"activeCount":99},[],{"trials":8411,"activeCount":99},[],{"trials":8413,"activeCount":99},[8414],{"nctId":8415,"briefTitle":8416,"status":109,"phases":8417,"primaryCompletion":8418,"completion":8418,"start":3378,"enrollment":6028,"conditions":8419,"interventions":8420},"NCT01461213","Gene Therapy for Blindness Caused by Choroideremia",[88,89],"2017-10",[7596],[8406],{"trials":8422,"activeCount":99},[],{"trials":8424,"activeCount":99},[],{"trials":8426,"activeCount":99},[],{"intervention":8428,"totalTrials":151,"cells":8429},"ChAd63 PvDBP and MVA PvDBP",{"EARLY_PHASE1":8430,"PHASE1":8432,"PHASE2":8434,"PHASE3":8444,"PHASE4":8446,"NA":8448},{"trials":8431,"activeCount":99},[],{"trials":8433,"activeCount":99},[],{"trials":8435,"activeCount":99},[8436],{"nctId":8437,"briefTitle":8438,"status":109,"phases":8439,"primaryCompletion":8440,"completion":8440,"start":8441,"enrollment":578,"conditions":8442,"interventions":8443},"NCT04009096","VAC071: A Study to Assess Efficacy of the ChAd63\u002FMVA PvDBP Vaccines",[89],"2022-07-07","2019-07-18",[8170],[8428],{"trials":8445,"activeCount":99},[],{"trials":8447,"activeCount":99},[],{"trials":8449,"activeCount":99},[],{"intervention":8451,"totalTrials":151,"cells":8452},"Tofacitinib 5 MG [Xeljanz]",{"EARLY_PHASE1":8453,"PHASE1":8455,"PHASE2":8457,"PHASE3":8467,"PHASE4":8469,"NA":8471},{"trials":8454,"activeCount":99},[],{"trials":8456,"activeCount":99},[],{"trials":8458,"activeCount":99},[8459],{"nctId":8460,"briefTitle":8461,"status":795,"phases":8462,"primaryCompletion":3161,"completion":3161,"start":8463,"enrollment":168,"conditions":8464,"interventions":8466},"NCT04141904","Tofacitinib in Depression (TIDE)",[88,89],"2020-02-10",[21,8465],"Inflammation",[8451],{"trials":8468,"activeCount":99},[],{"trials":8470,"activeCount":99},[],{"trials":8472,"activeCount":99},[],{"intervention":8474,"totalTrials":151,"cells":8475},"FMP2.1\u002FAS01B",{"EARLY_PHASE1":8476,"PHASE1":8478,"PHASE2":8480,"PHASE3":8488,"PHASE4":8490,"NA":8492},{"trials":8477,"activeCount":99},[],{"trials":8479,"activeCount":99},[],{"trials":8481,"activeCount":99},[8482],{"nctId":8483,"briefTitle":8484,"status":109,"phases":8485,"primaryCompletion":680,"completion":680,"start":5258,"enrollment":1699,"conditions":8486,"interventions":8487},"NCT02044198","A Phase I\u002FIIa Study of the Safety, Immunogenicity and Efficacy of FMP2.1\u002FAS01B, an Asexual Blood-Stage Vaccine for Plasmodium Falciparum Malaria",[88,89],[33],[8474],{"trials":8489,"activeCount":99},[],{"trials":8491,"activeCount":99},[],{"trials":8493,"activeCount":99},[],{"intervention":1491,"totalTrials":151,"cells":8495},{"EARLY_PHASE1":8496,"PHASE1":8498,"PHASE2":8500,"PHASE3":8506,"PHASE4":8508,"NA":8510},{"trials":8497,"activeCount":99},[],{"trials":8499,"activeCount":99},[],{"trials":8501,"activeCount":99},[8502],{"nctId":1485,"briefTitle":1486,"status":109,"phases":8503,"primaryCompletion":1435,"completion":1435,"start":1488,"enrollment":1436,"conditions":8504,"interventions":8505},[89],[15],[1491,1410],{"trials":8507,"activeCount":99},[],{"trials":8509,"activeCount":99},[],{"trials":8511,"activeCount":99},[],{"intervention":8513,"totalTrials":151,"cells":8514},"TIV",{"EARLY_PHASE1":8515,"PHASE1":8517,"PHASE2":8519,"PHASE3":8528,"PHASE4":8530,"NA":8532},{"trials":8516,"activeCount":99},[],{"trials":8518,"activeCount":99},[],{"trials":8520,"activeCount":99},[8521],{"nctId":8522,"briefTitle":8523,"status":109,"phases":8524,"primaryCompletion":1434,"completion":3788,"start":6060,"enrollment":2947,"conditions":8525,"interventions":8526},"NCT01682369","ADITEC FLU STUDY: Understanding the Genetic Basis for Immune Responses",[89],[30],[8513,8527],"ATIV",{"trials":8529,"activeCount":99},[],{"trials":8531,"activeCount":99},[],{"trials":8533,"activeCount":99},[],{"intervention":8527,"totalTrials":151,"cells":8535},{"EARLY_PHASE1":8536,"PHASE1":8538,"PHASE2":8540,"PHASE3":8546,"PHASE4":8548,"NA":8550},{"trials":8537,"activeCount":99},[],{"trials":8539,"activeCount":99},[],{"trials":8541,"activeCount":99},[8542],{"nctId":8522,"briefTitle":8523,"status":109,"phases":8543,"primaryCompletion":1434,"completion":3788,"start":6060,"enrollment":2947,"conditions":8544,"interventions":8545},[89],[30],[8513,8527],{"trials":8547,"activeCount":99},[],{"trials":8549,"activeCount":99},[],{"trials":8551,"activeCount":99},[],{"intervention":8553,"totalTrials":151,"cells":8554},"DTaP\u002FIPV\u002FHib vaccine",{"EARLY_PHASE1":8555,"PHASE1":8557,"PHASE2":8559,"PHASE3":8576,"PHASE4":8578,"NA":8580},{"trials":8556,"activeCount":99},[],{"trials":8558,"activeCount":99},[],{"trials":8560,"activeCount":99},[8561],{"nctId":8562,"briefTitle":8563,"status":109,"phases":8564,"primaryCompletion":8565,"completion":8566,"start":4798,"enrollment":8567,"conditions":8568,"interventions":8570},"NCT02482636","Baby Vaccine Study (Sched3)",[89],"2017-11-01","2021-06",189,[8569],"Infectious Diseases",[8553,8571,8572,8573,8574,8575],"13 valent Pneumococcal Conjugate Vaccine","Rotavirus vaccine","4-component Meningococcal B vaccine","Meningococcal C\u002FHib vaccine","Measles\u002FMumps\u002FRubella Vaccine",{"trials":8577,"activeCount":99},[],{"trials":8579,"activeCount":99},[],{"trials":8581,"activeCount":99},[],{"intervention":8571,"totalTrials":151,"cells":8583},{"EARLY_PHASE1":8584,"PHASE1":8586,"PHASE2":8588,"PHASE3":8594,"PHASE4":8596,"NA":8598},{"trials":8585,"activeCount":99},[],{"trials":8587,"activeCount":99},[],{"trials":8589,"activeCount":99},[8590],{"nctId":8562,"briefTitle":8563,"status":109,"phases":8591,"primaryCompletion":8565,"completion":8566,"start":4798,"enrollment":8567,"conditions":8592,"interventions":8593},[89],[8569],[8553,8571,8572,8573,8574,8575],{"trials":8595,"activeCount":99},[],{"trials":8597,"activeCount":99},[],{"trials":8599,"activeCount":99},[],{"intervention":8572,"totalTrials":151,"cells":8601},{"EARLY_PHASE1":8602,"PHASE1":8604,"PHASE2":8606,"PHASE3":8612,"PHASE4":8614,"NA":8616},{"trials":8603,"activeCount":99},[],{"trials":8605,"activeCount":99},[],{"trials":8607,"activeCount":99},[8608],{"nctId":8562,"briefTitle":8563,"status":109,"phases":8609,"primaryCompletion":8565,"completion":8566,"start":4798,"enrollment":8567,"conditions":8610,"interventions":8611},[89],[8569],[8553,8571,8572,8573,8574,8575],{"trials":8613,"activeCount":99},[],{"trials":8615,"activeCount":99},[],{"trials":8617,"activeCount":99},[],{"intervention":8573,"totalTrials":151,"cells":8619},{"EARLY_PHASE1":8620,"PHASE1":8622,"PHASE2":8624,"PHASE3":8630,"PHASE4":8632,"NA":8634},{"trials":8621,"activeCount":99},[],{"trials":8623,"activeCount":99},[],{"trials":8625,"activeCount":99},[8626],{"nctId":8562,"briefTitle":8563,"status":109,"phases":8627,"primaryCompletion":8565,"completion":8566,"start":4798,"enrollment":8567,"conditions":8628,"interventions":8629},[89],[8569],[8553,8571,8572,8573,8574,8575],{"trials":8631,"activeCount":99},[],{"trials":8633,"activeCount":99},[],{"trials":8635,"activeCount":99},[],{"intervention":8574,"totalTrials":151,"cells":8637},{"EARLY_PHASE1":8638,"PHASE1":8640,"PHASE2":8642,"PHASE3":8648,"PHASE4":8650,"NA":8652},{"trials":8639,"activeCount":99},[],{"trials":8641,"activeCount":99},[],{"trials":8643,"activeCount":99},[8644],{"nctId":8562,"briefTitle":8563,"status":109,"phases":8645,"primaryCompletion":8565,"completion":8566,"start":4798,"enrollment":8567,"conditions":8646,"interventions":8647},[89],[8569],[8553,8571,8572,8573,8574,8575],{"trials":8649,"activeCount":99},[],{"trials":8651,"activeCount":99},[],{"trials":8653,"activeCount":99},[],{"intervention":8575,"totalTrials":151,"cells":8655},{"EARLY_PHASE1":8656,"PHASE1":8658,"PHASE2":8660,"PHASE3":8666,"PHASE4":8668,"NA":8670},{"trials":8657,"activeCount":99},[],{"trials":8659,"activeCount":99},[],{"trials":8661,"activeCount":99},[8662],{"nctId":8562,"briefTitle":8563,"status":109,"phases":8663,"primaryCompletion":8565,"completion":8566,"start":4798,"enrollment":8567,"conditions":8664,"interventions":8665},[89],[8569],[8553,8571,8572,8573,8574,8575],{"trials":8667,"activeCount":99},[],{"trials":8669,"activeCount":99},[],{"trials":8671,"activeCount":99},[],{"intervention":8673,"totalTrials":151,"cells":8674},"Sildenafil",{"EARLY_PHASE1":8675,"PHASE1":8677,"PHASE2":8679,"PHASE3":8691,"PHASE4":8693,"NA":8695},{"trials":8676,"activeCount":99},[],{"trials":8678,"activeCount":99},[],{"trials":8680,"activeCount":99},[8681],{"nctId":8682,"briefTitle":8683,"status":109,"phases":8684,"primaryCompletion":8685,"completion":4660,"start":1420,"enrollment":8686,"conditions":8687,"interventions":8689},"NCT03855332","Oxford Haemodynamic Adaptation to Reduce Pulsatility Trial",[89],"2022-12-06",75,[8688],"Small Vessel Cerebrovascular Disease",[8673,8690],"Cilostazol",{"trials":8692,"activeCount":99},[],{"trials":8694,"activeCount":99},[],{"trials":8696,"activeCount":99},[],{"intervention":8690,"totalTrials":151,"cells":8698},{"EARLY_PHASE1":8699,"PHASE1":8701,"PHASE2":8703,"PHASE3":8709,"PHASE4":8711,"NA":8713},{"trials":8700,"activeCount":99},[],{"trials":8702,"activeCount":99},[],{"trials":8704,"activeCount":99},[8705],{"nctId":8682,"briefTitle":8683,"status":109,"phases":8706,"primaryCompletion":8685,"completion":4660,"start":1420,"enrollment":8686,"conditions":8707,"interventions":8708},[89],[8688],[8673,8690],{"trials":8710,"activeCount":99},[],{"trials":8712,"activeCount":99},[],{"trials":8714,"activeCount":99},[],{"intervention":8716,"totalTrials":151,"cells":8717},"Baxter Novel Influenza A H1N1 Whole Virus Vaccine",{"EARLY_PHASE1":8718,"PHASE1":8720,"PHASE2":8722,"PHASE3":8731,"PHASE4":8733,"NA":8735},{"trials":8719,"activeCount":99},[],{"trials":8721,"activeCount":99},[],{"trials":8723,"activeCount":99},[8724],{"nctId":8725,"briefTitle":8726,"status":109,"phases":8727,"primaryCompletion":6126,"completion":6126,"start":4181,"enrollment":563,"conditions":8728,"interventions":8729},"NCT00980850","Swine Flu (Novel Influenza A H1N1) Vaccine Study",[89],[30],[8716,8730],"GlaxoSmithKline Novel Influenza A H1N1 Split Virion Vaccine",{"trials":8732,"activeCount":99},[],{"trials":8734,"activeCount":99},[],{"trials":8736,"activeCount":99},[],{"intervention":8730,"totalTrials":151,"cells":8738},{"EARLY_PHASE1":8739,"PHASE1":8741,"PHASE2":8743,"PHASE3":8749,"PHASE4":8751,"NA":8753},{"trials":8740,"activeCount":99},[],{"trials":8742,"activeCount":99},[],{"trials":8744,"activeCount":99},[8745],{"nctId":8725,"briefTitle":8726,"status":109,"phases":8746,"primaryCompletion":6126,"completion":6126,"start":4181,"enrollment":563,"conditions":8747,"interventions":8748},[89],[30],[8716,8730],{"trials":8750,"activeCount":99},[],{"trials":8752,"activeCount":99},[],{"trials":8754,"activeCount":99},[],{"intervention":3482,"totalTrials":151,"cells":8756},{"EARLY_PHASE1":8757,"PHASE1":8759,"PHASE2":8761,"PHASE3":8767,"PHASE4":8769,"NA":8771},{"trials":8758,"activeCount":99},[],{"trials":8760,"activeCount":99},[],{"trials":8762,"activeCount":99},[8763],{"nctId":3471,"briefTitle":3472,"status":2901,"phases":8764,"primaryCompletion":3474,"completion":3475,"start":3476,"enrollment":3477,"conditions":8765,"interventions":8766},[89],[3479,3480],[3482,3462],{"trials":8768,"activeCount":99},[],{"trials":8770,"activeCount":99},[],{"trials":8772,"activeCount":99},[],{"intervention":8774,"totalTrials":151,"cells":8775},"Licenced Measles-Rubella vaccine",{"EARLY_PHASE1":8776,"PHASE1":8778,"PHASE2":8780,"PHASE3":8791,"PHASE4":8793,"NA":8795},{"trials":8777,"activeCount":99},[],{"trials":8779,"activeCount":99},[],{"trials":8781,"activeCount":99},[8782],{"nctId":8783,"briefTitle":8784,"status":2901,"phases":8785,"primaryCompletion":8786,"completion":8786,"start":8787,"enrollment":1468,"conditions":8788,"interventions":8790},"NCT06667206","Earlier Prime-BOOST Schedule to Improve MEasles Protection in High Burden Settings",[89],"2026-05-10","2023-11-15",[8789],"Measles",[8774],{"trials":8792,"activeCount":99},[],{"trials":8794,"activeCount":99},[],{"trials":8796,"activeCount":99},[],{"intervention":8798,"totalTrials":151,"cells":8799},"Oral ivermectin",{"EARLY_PHASE1":8800,"PHASE1":8802,"PHASE2":8804,"PHASE3":8816,"PHASE4":8818,"NA":8820},{"trials":8801,"activeCount":99},[],{"trials":8803,"activeCount":99},[],{"trials":8805,"activeCount":99},[8806],{"nctId":8807,"briefTitle":8808,"status":109,"phases":8809,"primaryCompletion":8810,"completion":8810,"start":8811,"enrollment":1447,"conditions":8812,"interventions":8814},"NCT04332068","Ivermectin Safety in Small Children",[89],"2025-04-04","2023-11-18",[8813],"Scabies",[8798,8815],"Permethrin Cream",{"trials":8817,"activeCount":99},[],{"trials":8819,"activeCount":99},[],{"trials":8821,"activeCount":99},[],{"intervention":8815,"totalTrials":151,"cells":8823},{"EARLY_PHASE1":8824,"PHASE1":8826,"PHASE2":8828,"PHASE3":8834,"PHASE4":8836,"NA":8838},{"trials":8825,"activeCount":99},[],{"trials":8827,"activeCount":99},[],{"trials":8829,"activeCount":99},[8830],{"nctId":8807,"briefTitle":8808,"status":109,"phases":8831,"primaryCompletion":8810,"completion":8810,"start":8811,"enrollment":1447,"conditions":8832,"interventions":8833},[89],[8813],[8798,8815],{"trials":8835,"activeCount":99},[],{"trials":8837,"activeCount":99},[],{"trials":8839,"activeCount":99},[],{"intervention":8841,"totalTrials":151,"cells":8842},"R21 Matrix-M vaccination",{"EARLY_PHASE1":8843,"PHASE1":8845,"PHASE2":8847,"PHASE3":8860,"PHASE4":8862,"NA":8864},{"trials":8844,"activeCount":99},[],{"trials":8846,"activeCount":99},[],{"trials":8848,"activeCount":99},[8849],{"nctId":8850,"briefTitle":8851,"status":109,"phases":8852,"primaryCompletion":8853,"completion":8853,"start":8854,"enrollment":8855,"conditions":8856,"interventions":8857},"NCT03970993","VAC 072-An Efficacy Study of R21\u002FMM in Different Dose Schedules",[88,89],"2021-08-24","2019-06-17",78,[15],[8841,8858,8859],"R21 Matrix-M vaccination and CHMI","R21 Matrix-M vaccination booster",{"trials":8861,"activeCount":99},[],{"trials":8863,"activeCount":99},[],{"trials":8865,"activeCount":99},[],{"intervention":8858,"totalTrials":151,"cells":8867},{"EARLY_PHASE1":8868,"PHASE1":8870,"PHASE2":8872,"PHASE3":8878,"PHASE4":8880,"NA":8882},{"trials":8869,"activeCount":99},[],{"trials":8871,"activeCount":99},[],{"trials":8873,"activeCount":99},[8874],{"nctId":8850,"briefTitle":8851,"status":109,"phases":8875,"primaryCompletion":8853,"completion":8853,"start":8854,"enrollment":8855,"conditions":8876,"interventions":8877},[88,89],[15],[8841,8858,8859],{"trials":8879,"activeCount":99},[],{"trials":8881,"activeCount":99},[],{"trials":8883,"activeCount":99},[],{"intervention":8859,"totalTrials":151,"cells":8885},{"EARLY_PHASE1":8886,"PHASE1":8888,"PHASE2":8890,"PHASE3":8896,"PHASE4":8898,"NA":8900},{"trials":8887,"activeCount":99},[],{"trials":8889,"activeCount":99},[],{"trials":8891,"activeCount":99},[8892],{"nctId":8850,"briefTitle":8851,"status":109,"phases":8893,"primaryCompletion":8853,"completion":8853,"start":8854,"enrollment":8855,"conditions":8894,"interventions":8895},[88,89],[15],[8841,8858,8859],{"trials":8897,"activeCount":99},[],{"trials":8899,"activeCount":99},[],{"trials":8901,"activeCount":99},[],{"intervention":6248,"totalTrials":151,"cells":8903},{"EARLY_PHASE1":8904,"PHASE1":8906,"PHASE2":8908,"PHASE3":8914,"PHASE4":8916,"NA":8918},{"trials":8905,"activeCount":99},[],{"trials":8907,"activeCount":99},[],{"trials":8909,"activeCount":99},[8910],{"nctId":6242,"briefTitle":6243,"status":109,"phases":8911,"primaryCompletion":4798,"completion":4798,"start":5258,"enrollment":6109,"conditions":8912,"interventions":8913},[88,89],[6246],[6248,6209,6249,6250],{"trials":8915,"activeCount":99},[],{"trials":8917,"activeCount":99},[],{"trials":8919,"activeCount":99},[],{"intervention":6249,"totalTrials":151,"cells":8921},{"EARLY_PHASE1":8922,"PHASE1":8924,"PHASE2":8926,"PHASE3":8932,"PHASE4":8934,"NA":8936},{"trials":8923,"activeCount":99},[],{"trials":8925,"activeCount":99},[],{"trials":8927,"activeCount":99},[8928],{"nctId":6242,"briefTitle":6243,"status":109,"phases":8929,"primaryCompletion":4798,"completion":4798,"start":5258,"enrollment":6109,"conditions":8930,"interventions":8931},[88,89],[6246],[6248,6209,6249,6250],{"trials":8933,"activeCount":99},[],{"trials":8935,"activeCount":99},[],{"trials":8937,"activeCount":99},[],{"intervention":6250,"totalTrials":151,"cells":8939},{"EARLY_PHASE1":8940,"PHASE1":8942,"PHASE2":8944,"PHASE3":8950,"PHASE4":8952,"NA":8954},{"trials":8941,"activeCount":99},[],{"trials":8943,"activeCount":99},[],{"trials":8945,"activeCount":99},[8946],{"nctId":6242,"briefTitle":6243,"status":109,"phases":8947,"primaryCompletion":4798,"completion":4798,"start":5258,"enrollment":6109,"conditions":8948,"interventions":8949},[88,89],[6246],[6248,6209,6249,6250],{"trials":8951,"activeCount":99},[],{"trials":8953,"activeCount":99},[],{"trials":8955,"activeCount":99},[],{"intervention":8957,"totalTrials":151,"cells":8958},"ChAdOx1.HTI and MVA.HTI",{"EARLY_PHASE1":8959,"PHASE1":8961,"PHASE2":8963,"PHASE3":8973,"PHASE4":8975,"NA":8977},{"trials":8960,"activeCount":99},[],{"trials":8962,"activeCount":99},[],{"trials":8964,"activeCount":99},[8965],{"nctId":8966,"briefTitle":8967,"status":109,"phases":8968,"primaryCompletion":8969,"completion":8969,"start":8970,"enrollment":34,"conditions":8971,"interventions":8972},"NCT04563377","Safety and Immunogenicity of Candidate HIV Vaccines Given Sequentially",[88,89],"2022-08-16","2021-11-01",[24],[8957],{"trials":8974,"activeCount":99},[],{"trials":8976,"activeCount":99},[],{"trials":8978,"activeCount":99},[],{"intervention":8980,"totalTrials":151,"cells":8981},"Methylene Blue",{"EARLY_PHASE1":8982,"PHASE1":8984,"PHASE2":8986,"PHASE3":8999,"PHASE4":9001,"NA":9003},{"trials":8983,"activeCount":99},[],{"trials":8985,"activeCount":99},[],{"trials":8987,"activeCount":99},[8988],{"nctId":8989,"briefTitle":8990,"status":109,"phases":8991,"primaryCompletion":8992,"completion":8992,"start":8993,"enrollment":2337,"conditions":8994,"interventions":8998},"NCT03177070","Fluorescent Imaging & Methylene Blue: Ureter Study",[89],"2017-05-02","2016-05-09",[8995,8996,8997],"Ureteric Injury","Surgery","Surgery--Complications",[8980],{"trials":9000,"activeCount":99},[],{"trials":9002,"activeCount":99},[],{"trials":9004,"activeCount":99},[],{"intervention":9006,"totalTrials":151,"cells":9007},"Tenofovir Disoproxil Fumarate",{"EARLY_PHASE1":9008,"PHASE1":9010,"PHASE2":9012,"PHASE3":9024,"PHASE4":9026,"NA":9028},{"trials":9009,"activeCount":99},[],{"trials":9011,"activeCount":99},[],{"trials":9013,"activeCount":99},[9014],{"nctId":9015,"briefTitle":9016,"status":109,"phases":9017,"primaryCompletion":9018,"completion":9018,"start":9019,"enrollment":6457,"conditions":9020,"interventions":9023},"NCT04114890","Tenofovir in Pregnancy to Prevent Mother to Child Transmission of Hepatitis B.",[89],"2023-09-29","2021-01-08",[3658,9021,9022],"Tenofovir","Pregnancy",[9006],{"trials":9025,"activeCount":99},[],{"trials":9027,"activeCount":99},[],{"trials":9029,"activeCount":99},[],{"intervention":9031,"totalTrials":151,"cells":9032},"CHILD-IVITAB",{"EARLY_PHASE1":9033,"PHASE1":9035,"PHASE2":9037,"PHASE3":9047,"PHASE4":9049,"NA":9051},{"trials":9034,"activeCount":99},[],{"trials":9036,"activeCount":99},[],{"trials":9038,"activeCount":99},[9039],{"nctId":9040,"briefTitle":9041,"status":109,"phases":9042,"primaryCompletion":9043,"completion":9043,"start":9044,"enrollment":1730,"conditions":9045,"interventions":9046},"NCT06404333","Evaluating Pediatric Ivermectin in Children Under 15 kg (EPIC-15)",[89],"2025-11-30","2025-02-25",[8813],[9031,9031],{"trials":9048,"activeCount":99},[],{"trials":9050,"activeCount":99},[],{"trials":9052,"activeCount":99},[],{"intervention":9054,"totalTrials":151,"cells":9055},"Linsitinib",{"EARLY_PHASE1":9056,"PHASE1":9058,"PHASE2":9060,"PHASE3":9071,"PHASE4":9073,"NA":9075},{"trials":9057,"activeCount":99},[],{"trials":9059,"activeCount":99},[],{"trials":9061,"activeCount":99},[9062],{"nctId":9063,"briefTitle":9064,"status":109,"phases":9065,"primaryCompletion":9066,"completion":9066,"start":5258,"enrollment":578,"conditions":9067,"interventions":9070},"NCT02546544","Eurosarc Trial of Linsitinib in Advanced Ewing Sarcoma",[89],"2016-07-15",[9068,9069],"Relapsed Ewing Sarcoma","Refractory Ewing Sarcoma",[9054],{"trials":9072,"activeCount":99},[],{"trials":9074,"activeCount":99},[],{"trials":9076,"activeCount":99},[],{"intervention":9078,"totalTrials":151,"cells":9079},"ChAd63 ME-TRAP and MVA ME-TRAP vaccination",{"EARLY_PHASE1":9080,"PHASE1":9082,"PHASE2":9084,"PHASE3":9093,"PHASE4":9095,"NA":9097},{"trials":9081,"activeCount":99},[],{"trials":9083,"activeCount":99},[],{"trials":9085,"activeCount":99},[9086],{"nctId":9087,"briefTitle":9088,"status":109,"phases":9089,"primaryCompletion":9090,"completion":9090,"start":863,"enrollment":6670,"conditions":9091,"interventions":9092},"NCT03707353","An Efficacy Study of IV Boosting With ChAd63\u002FMVA ME-TRAP",[88,89],"2019-06-10",[15],[9078],{"trials":9094,"activeCount":99},[],{"trials":9096,"activeCount":99},[],{"trials":9098,"activeCount":99},[],{"intervention":6131,"totalTrials":151,"cells":9100},{"EARLY_PHASE1":9101,"PHASE1":9103,"PHASE2":9105,"PHASE3":9111,"PHASE4":9113,"NA":9115},{"trials":9102,"activeCount":99},[],{"trials":9104,"activeCount":99},[],{"trials":9106,"activeCount":99},[9107],{"nctId":6123,"briefTitle":6124,"status":109,"phases":9108,"primaryCompletion":6126,"completion":6126,"start":6127,"enrollment":6128,"conditions":9109,"interventions":9110},[89],[18],[6000,6131],{"trials":9112,"activeCount":99},[],{"trials":9114,"activeCount":99},[],{"trials":9116,"activeCount":99},[],{"intervention":9118,"totalTrials":151,"cells":9119},"Irbesartan 150-300mg capsules daily for 6 months",{"EARLY_PHASE1":9120,"PHASE1":9122,"PHASE2":9124,"PHASE3":9137,"PHASE4":9139,"NA":9141},{"trials":9121,"activeCount":99},[],{"trials":9123,"activeCount":99},[],{"trials":9125,"activeCount":99},[9126],{"nctId":9127,"briefTitle":9128,"status":2901,"phases":9129,"primaryCompletion":6199,"completion":9130,"start":6018,"enrollment":1561,"conditions":9131,"interventions":9133},"NCT01949233","The Oxford Marfan Trial",[89],"2017-12",[9132],"Marfan Syndrome",[9118,9134,9135,9136],"Doxycycline 100-200mg capsules daily for 6 months","Doxycycline placebo capsules daily for 6 months","Irbesartan placebo capsules daily for 6 months",{"trials":9138,"activeCount":99},[],{"trials":9140,"activeCount":99},[],{"trials":9142,"activeCount":99},[],{"intervention":9134,"totalTrials":151,"cells":9144},{"EARLY_PHASE1":9145,"PHASE1":9147,"PHASE2":9149,"PHASE3":9155,"PHASE4":9157,"NA":9159},{"trials":9146,"activeCount":99},[],{"trials":9148,"activeCount":99},[],{"trials":9150,"activeCount":99},[9151],{"nctId":9127,"briefTitle":9128,"status":2901,"phases":9152,"primaryCompletion":6199,"completion":9130,"start":6018,"enrollment":1561,"conditions":9153,"interventions":9154},[89],[9132],[9118,9134,9135,9136],{"trials":9156,"activeCount":99},[],{"trials":9158,"activeCount":99},[],{"trials":9160,"activeCount":99},[],{"intervention":9135,"totalTrials":151,"cells":9162},{"EARLY_PHASE1":9163,"PHASE1":9165,"PHASE2":9167,"PHASE3":9173,"PHASE4":9175,"NA":9177},{"trials":9164,"activeCount":99},[],{"trials":9166,"activeCount":99},[],{"trials":9168,"activeCount":99},[9169],{"nctId":9127,"briefTitle":9128,"status":2901,"phases":9170,"primaryCompletion":6199,"completion":9130,"start":6018,"enrollment":1561,"conditions":9171,"interventions":9172},[89],[9132],[9118,9134,9135,9136],{"trials":9174,"activeCount":99},[],{"trials":9176,"activeCount":99},[],{"trials":9178,"activeCount":99},[],{"intervention":9136,"totalTrials":151,"cells":9180},{"EARLY_PHASE1":9181,"PHASE1":9183,"PHASE2":9185,"PHASE3":9191,"PHASE4":9193,"NA":9195},{"trials":9182,"activeCount":99},[],{"trials":9184,"activeCount":99},[],{"trials":9186,"activeCount":99},[9187],{"nctId":9127,"briefTitle":9128,"status":2901,"phases":9188,"primaryCompletion":6199,"completion":9130,"start":6018,"enrollment":1561,"conditions":9189,"interventions":9190},[89],[9132],[9118,9134,9135,9136],{"trials":9192,"activeCount":99},[],{"trials":9194,"activeCount":99},[],{"trials":9196,"activeCount":99},[],{"intervention":6048,"totalTrials":513,"cells":9198},{"EARLY_PHASE1":9199,"PHASE1":9201,"PHASE2":9249,"PHASE3":9251,"PHASE4":9253,"NA":9255},{"trials":9200,"activeCount":99},[],{"trials":9202,"activeCount":99},[9203,9209,9213,9221,9230,9236,9243],{"nctId":9204,"briefTitle":9205,"status":109,"phases":9206,"primaryCompletion":3942,"completion":3942,"start":6082,"enrollment":2572,"conditions":9207,"interventions":9208},"NCT01181856","Safety of Tuberculosis Vaccine, MVA85A, Administered by the Intramuscular Route and the Intradermal Route",[88],[18],[6048],{"nctId":6040,"briefTitle":6041,"status":109,"phases":9210,"primaryCompletion":6043,"completion":6043,"start":6044,"enrollment":1674,"conditions":9211,"interventions":9212},[88],[18,6046],[6000,6048],{"nctId":9214,"briefTitle":9215,"status":109,"phases":9216,"primaryCompletion":9217,"completion":9217,"start":9218,"enrollment":1848,"conditions":9219,"interventions":9220},"NCT00460590","Safety and Immunogenicity of MVA85A, in Healthy Volunteers in Cape Town",[88],"2008-06","2005-10",[18],[6048],{"nctId":9222,"briefTitle":9223,"status":109,"phases":9224,"primaryCompletion":6126,"completion":6126,"start":9225,"enrollment":9226,"conditions":9227,"interventions":9229},"NCT00480454","Safety, Immunogenicity, and Impact of MVA85A, on the Immunogenicity of the EPI Vaccines",[88],"2006-10",214,[9228],"TB",[6048],{"nctId":9231,"briefTitle":9232,"status":109,"phases":9233,"primaryCompletion":6083,"completion":6083,"start":9218,"enrollment":2572,"conditions":9234,"interventions":9235},"NCT00465465","A Study of 2 Doses of a New TB Vaccine, MVA85A, in Healthy Volunteers Previously Vaccinated With BCG",[88],[18],[6048],{"nctId":9237,"briefTitle":9238,"status":109,"phases":9239,"completion":9240,"start":6162,"enrollment":31,"conditions":9241,"interventions":9242},"NCT00456183","Safety and Immunogenicity of MVA85A in Volunteers Latently Infected With TB.",[88],"2007-04",[18],[6048],{"nctId":9244,"briefTitle":9245,"status":109,"phases":9246,"primaryCompletion":3942,"completion":3942,"start":5768,"enrollment":1778,"conditions":9247,"interventions":9248},"NCT00480558","A Study of MVA85A, in Asymptomatic Volunteers Infected With TB, HIV or Both",[88],[6046,9228],[6048],{"trials":9250,"activeCount":99},[],{"trials":9252,"activeCount":99},[],{"trials":9254,"activeCount":99},[],{"trials":9256,"activeCount":99},[],{"intervention":6236,"totalTrials":168,"cells":9258},{"EARLY_PHASE1":9259,"PHASE1":9261,"PHASE2":9275,"PHASE3":9277,"PHASE4":9279,"NA":9281},{"trials":9260,"activeCount":99},[],{"trials":9262,"activeCount":99},[9263,9271],{"nctId":9264,"briefTitle":9265,"status":109,"phases":9266,"primaryCompletion":9267,"completion":6229,"start":9268,"enrollment":1674,"conditions":9269,"interventions":9270},"NCT02568332","A Study to Assess the Safety of Hep C Vaccine Candidates in HIV Seropositive Individuals",[88],"2017-01-26","2015-07-21",[6233],[6236,6237],{"nctId":6226,"briefTitle":6227,"status":109,"phases":9272,"primaryCompletion":3740,"completion":6229,"start":6230,"enrollment":6231,"conditions":9273,"interventions":9274},[88],[6233,6234],[6236,6237,6238,6209],{"trials":9276,"activeCount":99},[],{"trials":9278,"activeCount":99},[],{"trials":9280,"activeCount":99},[],{"trials":9282,"activeCount":99},[],{"intervention":6237,"totalTrials":168,"cells":9284},{"EARLY_PHASE1":9285,"PHASE1":9287,"PHASE2":9297,"PHASE3":9299,"PHASE4":9301,"NA":9303},{"trials":9286,"activeCount":99},[],{"trials":9288,"activeCount":99},[9289,9293],{"nctId":9264,"briefTitle":9265,"status":109,"phases":9290,"primaryCompletion":9267,"completion":6229,"start":9268,"enrollment":1674,"conditions":9291,"interventions":9292},[88],[6233],[6236,6237],{"nctId":6226,"briefTitle":6227,"status":109,"phases":9294,"primaryCompletion":3740,"completion":6229,"start":6230,"enrollment":6231,"conditions":9295,"interventions":9296},[88],[6233,6234],[6236,6237,6238,6209],{"trials":9298,"activeCount":99},[],{"trials":9300,"activeCount":99},[],{"trials":9302,"activeCount":99},[],{"trials":9304,"activeCount":99},[],{"intervention":9306,"totalTrials":168,"cells":9307},"ChAdOx1 biEBOV",{"EARLY_PHASE1":9308,"PHASE1":9310,"PHASE2":9328,"PHASE3":9330,"PHASE4":9332,"NA":9334},{"trials":9309,"activeCount":99},[],{"trials":9311,"activeCount":99},[9312,9321],{"nctId":9313,"briefTitle":9314,"status":2901,"phases":9315,"primaryCompletion":9316,"completion":9316,"start":9317,"enrollment":2803,"conditions":9318,"interventions":9320},"NCT05301504","A Study in Tanzania of a New Vaccine Against Two Types of Ebola",[88],"2023-12","2022-03-30",[9319],"Ebola",[9306],{"nctId":9322,"briefTitle":9323,"status":109,"phases":9324,"primaryCompletion":56,"completion":56,"start":9325,"enrollment":6151,"conditions":9326,"interventions":9327},"NCT05079750","A Study of a New Vaccine Against Two Types of Ebola",[88],"2021-11-11",[9319],[9306],{"trials":9329,"activeCount":99},[],{"trials":9331,"activeCount":99},[],{"trials":9333,"activeCount":99},[],{"trials":9335,"activeCount":99},[],{"intervention":9337,"totalTrials":168,"cells":9338},"ChAd3-EBO Z",{"EARLY_PHASE1":9339,"PHASE1":9341,"PHASE2":9360,"PHASE3":9362,"PHASE4":9364,"NA":9366},{"trials":9340,"activeCount":99},[],{"trials":9342,"activeCount":99},[9343,9351],{"nctId":9344,"briefTitle":9345,"status":109,"phases":9346,"primaryCompletion":4929,"completion":4929,"start":539,"enrollment":1530,"conditions":9347,"interventions":9349},"NCT02485912","Evaluation of a New Ebola Vaccine Using a Short-interval Prime-boost Vaccination",[88],[9348],"Ebola Virus Disease",[9337,9350],"MVA-EBO Z",{"nctId":9352,"briefTitle":9353,"status":795,"phases":9354,"primaryCompletion":9355,"completion":9355,"start":9356,"enrollment":9357,"conditions":9358,"interventions":9359},"NCT02451891","A Phase I Study to Assess Ebola Vaccines cAd3-EBO Z and MVA-EBO Z",[88],"2017-08-22","2015-05-06",38,[9348],[9350,9337],{"trials":9361,"activeCount":99},[],{"trials":9363,"activeCount":99},[],{"trials":9365,"activeCount":99},[],{"trials":9367,"activeCount":99},[],{"intervention":9350,"totalTrials":168,"cells":9369},{"EARLY_PHASE1":9370,"PHASE1":9372,"PHASE2":9382,"PHASE3":9384,"PHASE4":9386,"NA":9388},{"trials":9371,"activeCount":99},[],{"trials":9373,"activeCount":99},[9374,9378],{"nctId":9344,"briefTitle":9345,"status":109,"phases":9375,"primaryCompletion":4929,"completion":4929,"start":539,"enrollment":1530,"conditions":9376,"interventions":9377},[88],[9348],[9337,9350],{"nctId":9352,"briefTitle":9353,"status":795,"phases":9379,"primaryCompletion":9355,"completion":9355,"start":9356,"enrollment":9357,"conditions":9380,"interventions":9381},[88],[9348],[9350,9337],{"trials":9383,"activeCount":99},[],{"trials":9385,"activeCount":99},[],{"trials":9387,"activeCount":99},[],{"trials":9389,"activeCount":99},[],{"intervention":9391,"totalTrials":168,"cells":9392},"AdCh63 ME-TRAP, MVA ME-TRAP",{"EARLY_PHASE1":9393,"PHASE1":9395,"PHASE2":9412,"PHASE3":9414,"PHASE4":9416,"NA":9418},{"trials":9394,"activeCount":99},[],{"trials":9396,"activeCount":99},[9397,9405],{"nctId":9398,"briefTitle":9399,"status":109,"phases":9400,"primaryCompletion":9401,"completion":9401,"start":3830,"enrollment":7756,"conditions":9402,"interventions":9403},"NCT01373879","AdCh63 ME-TRAP and MVA ME-TRAP Malaria Vaccines Evaluation in Healthy Adults and Children in a Malaria Endemic Area",[88],"2011-12",[15],[9391,9391,9391,9391,9404,9391,9391,9404],"HDCRV",{"nctId":9406,"briefTitle":9407,"status":109,"phases":9408,"primaryCompletion":3655,"completion":3655,"start":3378,"enrollment":6109,"conditions":9409,"interventions":9410},"NCT01450293","AdCh63 ME-TRAP and MVA ME-TRAP Malaria Vaccines Evaluation in Healthy Children in a Malaria Endemic Area",[88],[15],[9391,9411],"AdCH63 ME-TRAP, MVA ME-TRAP",{"trials":9413,"activeCount":99},[],{"trials":9415,"activeCount":99},[],{"trials":9417,"activeCount":99},[],{"trials":9419,"activeCount":99},[],{"intervention":9421,"totalTrials":168,"cells":9422},"Aerosol inhaled MVA85A",{"EARLY_PHASE1":9423,"PHASE1":9425,"PHASE2":9444,"PHASE3":9446,"PHASE4":9448,"NA":9450},{"trials":9424,"activeCount":99},[],{"trials":9426,"activeCount":99},[9427,9434],{"nctId":9428,"briefTitle":9429,"status":109,"phases":9430,"primaryCompletion":527,"completion":4320,"start":4518,"enrollment":2572,"conditions":9431,"interventions":9432},"NCT01497769","Safety of Tuberculosis Vaccine, MVA85A, Administered by the Aerosol Route and the Intradermal Route",[88],[18],[9421,9433],"Intradermal MVA85A",{"nctId":9435,"briefTitle":9436,"status":795,"phases":9437,"primaryCompletion":9438,"completion":9438,"start":576,"enrollment":168,"conditions":9439,"interventions":9440},"NCT02532036","MVA85A Aerosol vs Intramuscular Vaccination in Adults With Latent Mycobacterium Tuberculosis (M. tb) Infection",[88],"2018-10-04",[18],[9421,9441,9442,9443],"Intramuscular MVA85A","Intramuscular Saline placebo","Aerosol inhaled Saline placebo",{"trials":9445,"activeCount":99},[],{"trials":9447,"activeCount":99},[],{"trials":9449,"activeCount":99},[],{"trials":9451,"activeCount":99},[],{"intervention":9453,"totalTrials":168,"cells":9454},"A",{"EARLY_PHASE1":9455,"PHASE1":9457,"PHASE2":9472,"PHASE3":9474,"PHASE4":9476,"NA":9478},{"trials":9456,"activeCount":99},[],{"trials":9458,"activeCount":99},[9459,9466],{"nctId":9460,"briefTitle":9461,"status":109,"phases":9462,"primaryCompletion":6060,"completion":6060,"start":3027,"enrollment":578,"conditions":9463,"interventions":9464},"NCT01525511","Pharmacokinetic Study of Primaquine and Dihydroartemisinin-Piperaquine in Healthy Subjects",[88],[24],[9453,9465],"B",{"nctId":9467,"briefTitle":9468,"status":109,"phases":9469,"primaryCompletion":3378,"completion":1488,"start":5421,"enrollment":578,"conditions":9470,"interventions":9471},"NCT01218932","Pharmacokinetic Study of Primaquine and Chloroquine in Healthy Subjects",[88],[531],[9453,9465],{"trials":9473,"activeCount":99},[],{"trials":9475,"activeCount":99},[],{"trials":9477,"activeCount":99},[],{"trials":9479,"activeCount":99},[],{"intervention":9465,"totalTrials":168,"cells":9481},{"EARLY_PHASE1":9482,"PHASE1":9484,"PHASE2":9494,"PHASE3":9496,"PHASE4":9498,"NA":9500},{"trials":9483,"activeCount":99},[],{"trials":9485,"activeCount":99},[9486,9490],{"nctId":9460,"briefTitle":9461,"status":109,"phases":9487,"primaryCompletion":6060,"completion":6060,"start":3027,"enrollment":578,"conditions":9488,"interventions":9489},[88],[24],[9453,9465],{"nctId":9467,"briefTitle":9468,"status":109,"phases":9491,"primaryCompletion":3378,"completion":1488,"start":5421,"enrollment":578,"conditions":9492,"interventions":9493},[88],[531],[9453,9465],{"trials":9495,"activeCount":99},[],{"trials":9497,"activeCount":99},[],{"trials":9499,"activeCount":99},[],{"trials":9501,"activeCount":99},[],{"intervention":2951,"totalTrials":168,"cells":9503},{"EARLY_PHASE1":9504,"PHASE1":9506,"PHASE2":9521,"PHASE3":9523,"PHASE4":9525,"NA":9527},{"trials":9505,"activeCount":99},[],{"trials":9507,"activeCount":99},[9508,9517],{"nctId":9509,"briefTitle":9510,"status":109,"phases":9511,"primaryCompletion":9512,"completion":9512,"start":9513,"enrollment":6422,"conditions":9514,"interventions":9516},"NCT03515733","PF-04995274 and Emotional Processing in Treatment Resistant Depression",[88],"2022-07-26","2018-05-31",[2949,9515],"Treatment Resistant Depression",[2951],{"nctId":2942,"briefTitle":2943,"status":109,"phases":9518,"primaryCompletion":2945,"completion":2945,"start":2946,"enrollment":2947,"conditions":9519,"interventions":9520},[88],[2949],[2951,2934],{"trials":9522,"activeCount":99},[],{"trials":9524,"activeCount":99},[],{"trials":9526,"activeCount":99},[],{"trials":9528,"activeCount":99},[],{"intervention":9530,"totalTrials":151,"cells":9531},"Primaquine and Pyronaridine-artesunate",{"EARLY_PHASE1":9532,"PHASE1":9534,"PHASE2":9543,"PHASE3":9545,"PHASE4":9547,"NA":9549},{"trials":9533,"activeCount":99},[],{"trials":9535,"activeCount":99},[9536],{"nctId":9537,"briefTitle":9538,"status":109,"phases":9539,"primaryCompletion":527,"completion":527,"start":3579,"enrollment":1300,"conditions":9540,"interventions":9541},"NCT01552330","Pharmacokinetic Study of Primaquine and Pyronaridine-Artesunate in Healthy Subjects",[88],[24],[9530,9542],"Primaquine and Pyronaridine-Artesunate",{"trials":9544,"activeCount":99},[],{"trials":9546,"activeCount":99},[],{"trials":9548,"activeCount":99},[],{"trials":9550,"activeCount":99},[],{"intervention":9552,"totalTrials":151,"cells":9553},"ChAd63 Pfs25-IMX313",{"EARLY_PHASE1":9554,"PHASE1":9556,"PHASE2":9566,"PHASE3":9568,"PHASE4":9570,"NA":9572},{"trials":9555,"activeCount":99},[],{"trials":9557,"activeCount":99},[9558],{"nctId":9559,"briefTitle":9560,"status":109,"phases":9561,"primaryCompletion":8298,"completion":8298,"start":9562,"enrollment":6151,"conditions":9563,"interventions":9564},"NCT02532049","A Clinical Trial to Assess the Safety and Immunogenicity of New Malaria Vaccine Candidates ChAd63 Pfs25-IMX313 and MVA Pfs25-IMX313",[88],"2015-10-12",[15],[9552,9565],"MVA Pfs25-IMX313",{"trials":9567,"activeCount":99},[],{"trials":9569,"activeCount":99},[],{"trials":9571,"activeCount":99},[],{"trials":9573,"activeCount":99},[],{"intervention":9565,"totalTrials":151,"cells":9575},{"EARLY_PHASE1":9576,"PHASE1":9578,"PHASE2":9584,"PHASE3":9586,"PHASE4":9588,"NA":9590},{"trials":9577,"activeCount":99},[],{"trials":9579,"activeCount":99},[9580],{"nctId":9559,"briefTitle":9560,"status":109,"phases":9581,"primaryCompletion":8298,"completion":8298,"start":9562,"enrollment":6151,"conditions":9582,"interventions":9583},[88],[15],[9552,9565],{"trials":9585,"activeCount":99},[],{"trials":9587,"activeCount":99},[],{"trials":9589,"activeCount":99},[],{"trials":9591,"activeCount":99},[],{"intervention":6222,"totalTrials":151,"cells":9593},{"EARLY_PHASE1":9594,"PHASE1":9596,"PHASE2":9602,"PHASE3":9604,"PHASE4":9606,"NA":9608},{"trials":9595,"activeCount":99},[],{"trials":9597,"activeCount":99},[9598],{"nctId":6216,"briefTitle":6217,"status":109,"phases":9599,"primaryCompletion":3653,"completion":3653,"start":5421,"enrollment":1394,"conditions":9600,"interventions":9601},[88],[6220],[6222,6223,6224,6209],{"trials":9603,"activeCount":99},[],{"trials":9605,"activeCount":99},[],{"trials":9607,"activeCount":99},[],{"trials":9609,"activeCount":99},[],{"intervention":6223,"totalTrials":151,"cells":9611},{"EARLY_PHASE1":9612,"PHASE1":9614,"PHASE2":9620,"PHASE3":9622,"PHASE4":9624,"NA":9626},{"trials":9613,"activeCount":99},[],{"trials":9615,"activeCount":99},[9616],{"nctId":6216,"briefTitle":6217,"status":109,"phases":9617,"primaryCompletion":3653,"completion":3653,"start":5421,"enrollment":1394,"conditions":9618,"interventions":9619},[88],[6220],[6222,6223,6224,6209],{"trials":9621,"activeCount":99},[],{"trials":9623,"activeCount":99},[],{"trials":9625,"activeCount":99},[],{"trials":9627,"activeCount":99},[],{"intervention":6224,"totalTrials":151,"cells":9629},{"EARLY_PHASE1":9630,"PHASE1":9632,"PHASE2":9638,"PHASE3":9640,"PHASE4":9642,"NA":9644},{"trials":9631,"activeCount":99},[],{"trials":9633,"activeCount":99},[9634],{"nctId":6216,"briefTitle":6217,"status":109,"phases":9635,"primaryCompletion":3653,"completion":3653,"start":5421,"enrollment":1394,"conditions":9636,"interventions":9637},[88],[6220],[6222,6223,6224,6209],{"trials":9639,"activeCount":99},[],{"trials":9641,"activeCount":99},[],{"trials":9643,"activeCount":99},[],{"trials":9645,"activeCount":99},[],{"intervention":9647,"totalTrials":151,"cells":9648},"Atovaquone Oral Suspension",{"EARLY_PHASE1":9649,"PHASE1":9651,"PHASE2":9663,"PHASE3":9665,"PHASE4":9667,"NA":9669},{"trials":9650,"activeCount":99},[],{"trials":9652,"activeCount":99},[9653],{"nctId":9654,"briefTitle":9655,"status":109,"phases":9656,"primaryCompletion":9657,"completion":9657,"start":9658,"enrollment":3656,"conditions":9659,"interventions":9661},"NCT04648033","Atovaquone With Radical ChemorADIotherapy in Locally Advanced NSCLC",[88],"2023-10-02","2020-12-07",[9660],"Locally Advanced Non-Small Cell Lung Cancer",[9647,9662],"Standard of care chemotherapy",{"trials":9664,"activeCount":99},[],{"trials":9666,"activeCount":99},[],{"trials":9668,"activeCount":99},[],{"trials":9670,"activeCount":99},[],{"intervention":9662,"totalTrials":151,"cells":9672},{"EARLY_PHASE1":9673,"PHASE1":9675,"PHASE2":9681,"PHASE3":9683,"PHASE4":9685,"NA":9687},{"trials":9674,"activeCount":99},[],{"trials":9676,"activeCount":99},[9677],{"nctId":9654,"briefTitle":9655,"status":109,"phases":9678,"primaryCompletion":9657,"completion":9657,"start":9658,"enrollment":3656,"conditions":9679,"interventions":9680},[88],[9660],[9647,9662],{"trials":9682,"activeCount":99},[],{"trials":9684,"activeCount":99},[],{"trials":9686,"activeCount":99},[],{"trials":9688,"activeCount":99},[],{"intervention":9690,"totalTrials":151,"cells":9691},"ChAd63 ME-TRAP \u002F MVA ME-TRAP",{"EARLY_PHASE1":9692,"PHASE1":9694,"PHASE2":9703,"PHASE3":9705,"PHASE4":9707,"NA":9709},{"trials":9693,"activeCount":99},[],{"trials":9695,"activeCount":99},[9696],{"nctId":9697,"briefTitle":9698,"status":109,"phases":9699,"primaryCompletion":7617,"completion":7617,"start":552,"enrollment":9700,"conditions":9701,"interventions":9702},"NCT02083887","A Phase I Study to Assess the Safety and Immunogenicity of ChAd63 ME-TRAP - MVA ME-TRAP Heterologous Prime-boost Vaccination Co-administered With EPI Vaccines in Gambian Infants",[88],65,[15],[9690],{"trials":9704,"activeCount":99},[],{"trials":9706,"activeCount":99},[],{"trials":9708,"activeCount":99},[],{"trials":9710,"activeCount":99},[],{"intervention":6013,"totalTrials":151,"cells":9712},{"EARLY_PHASE1":9713,"PHASE1":9715,"PHASE2":9721,"PHASE3":9723,"PHASE4":9725,"NA":9727},{"trials":9714,"activeCount":99},[],{"trials":9716,"activeCount":99},[9717],{"nctId":6007,"briefTitle":6008,"status":109,"phases":9718,"primaryCompletion":680,"completion":680,"start":3829,"enrollment":1699,"conditions":9719,"interventions":9720},[88],[6011],[6013,6000],{"trials":9722,"activeCount":99},[],{"trials":9724,"activeCount":99},[],{"trials":9726,"activeCount":99},[],{"trials":9728,"activeCount":99},[],{"intervention":9730,"totalTrials":151,"cells":9731},"MVA NP+M1",{"EARLY_PHASE1":9732,"PHASE1":9734,"PHASE2":9744,"PHASE3":9746,"PHASE4":9748,"NA":9750},{"trials":9733,"activeCount":99},[],{"trials":9735,"activeCount":99},[9736],{"nctId":9737,"briefTitle":9738,"status":109,"phases":9739,"primaryCompletion":7617,"completion":7617,"start":4320,"enrollment":6109,"conditions":9740,"interventions":9742},"NCT01818362","A Phase I Study of Candidate Influenza Vaccines MVA-NP+M1 and ChAdOx1 NP+M1",[88],[9741],"Seasonal Influenza",[9730,9743],"ChAdOx1 NP+M1",{"trials":9745,"activeCount":99},[],{"trials":9747,"activeCount":99},[],{"trials":9749,"activeCount":99},[],{"trials":9751,"activeCount":99},[],{"intervention":9743,"totalTrials":151,"cells":9753},{"EARLY_PHASE1":9754,"PHASE1":9756,"PHASE2":9762,"PHASE3":9764,"PHASE4":9766,"NA":9768},{"trials":9755,"activeCount":99},[],{"trials":9757,"activeCount":99},[9758],{"nctId":9737,"briefTitle":9738,"status":109,"phases":9759,"primaryCompletion":7617,"completion":7617,"start":4320,"enrollment":6109,"conditions":9760,"interventions":9761},[88],[9741],[9730,9743],{"trials":9763,"activeCount":99},[],{"trials":9765,"activeCount":99},[],{"trials":9767,"activeCount":99},[],{"trials":9769,"activeCount":99},[],{"intervention":9771,"totalTrials":151,"cells":9772},"Isoniazid",{"EARLY_PHASE1":9773,"PHASE1":9775,"PHASE2":9789,"PHASE3":9791,"PHASE4":9793,"NA":9795},{"trials":9774,"activeCount":99},[],{"trials":9776,"activeCount":99},[9777],{"nctId":9778,"briefTitle":9779,"status":109,"phases":9780,"primaryCompletion":9781,"completion":9781,"start":9782,"enrollment":9783,"conditions":9784,"interventions":9785},"NCT02457208","PK Study of Anti-TB Drugs",[88],"2018-01-14","2015-07-07",61,[18],[9771,9786,9787,9788],"Rifampicin","Pyrazinamide","Ethambutol",{"trials":9790,"activeCount":99},[],{"trials":9792,"activeCount":99},[],{"trials":9794,"activeCount":99},[],{"trials":9796,"activeCount":99},[],{"intervention":9786,"totalTrials":151,"cells":9798},{"EARLY_PHASE1":9799,"PHASE1":9801,"PHASE2":9807,"PHASE3":9809,"PHASE4":9811,"NA":9813},{"trials":9800,"activeCount":99},[],{"trials":9802,"activeCount":99},[9803],{"nctId":9778,"briefTitle":9779,"status":109,"phases":9804,"primaryCompletion":9781,"completion":9781,"start":9782,"enrollment":9783,"conditions":9805,"interventions":9806},[88],[18],[9771,9786,9787,9788],{"trials":9808,"activeCount":99},[],{"trials":9810,"activeCount":99},[],{"trials":9812,"activeCount":99},[],{"trials":9814,"activeCount":99},[],{"intervention":9787,"totalTrials":151,"cells":9816},{"EARLY_PHASE1":9817,"PHASE1":9819,"PHASE2":9825,"PHASE3":9827,"PHASE4":9829,"NA":9831},{"trials":9818,"activeCount":99},[],{"trials":9820,"activeCount":99},[9821],{"nctId":9778,"briefTitle":9779,"status":109,"phases":9822,"primaryCompletion":9781,"completion":9781,"start":9782,"enrollment":9783,"conditions":9823,"interventions":9824},[88],[18],[9771,9786,9787,9788],{"trials":9826,"activeCount":99},[],{"trials":9828,"activeCount":99},[],{"trials":9830,"activeCount":99},[],{"trials":9832,"activeCount":99},[],{"intervention":9788,"totalTrials":151,"cells":9834},{"EARLY_PHASE1":9835,"PHASE1":9837,"PHASE2":9843,"PHASE3":9845,"PHASE4":9847,"NA":9849},{"trials":9836,"activeCount":99},[],{"trials":9838,"activeCount":99},[9839],{"nctId":9778,"briefTitle":9779,"status":109,"phases":9840,"primaryCompletion":9781,"completion":9781,"start":9782,"enrollment":9783,"conditions":9841,"interventions":9842},[88],[18],[9771,9786,9787,9788],{"trials":9844,"activeCount":99},[],{"trials":9846,"activeCount":99},[],{"trials":9848,"activeCount":99},[],{"trials":9850,"activeCount":99},[],{"intervention":9852,"totalTrials":151,"cells":9853},"A. Ceftriaxone",{"EARLY_PHASE1":9854,"PHASE1":9856,"PHASE2":9866,"PHASE3":9868,"PHASE4":9870,"NA":9872},{"trials":9855,"activeCount":99},[],{"trials":9857,"activeCount":99},[9858],{"nctId":9859,"briefTitle":9860,"status":2582,"phases":9861,"primaryCompletion":394,"completion":394,"start":394,"enrollment":6019,"conditions":9862,"interventions":9863},"NCT03895567","Study to Compare Blood Levels of Ceftriaxone Given by Suppository or Injection.",[88],[24],[9852,9864,9865],"B. Ceftriaxone rectal dosage form test formulation 1","C. Ceftriaxone rectal dosage form test formulation 2",{"trials":9867,"activeCount":99},[],{"trials":9869,"activeCount":99},[],{"trials":9871,"activeCount":99},[],{"trials":9873,"activeCount":99},[],{"intervention":9864,"totalTrials":151,"cells":9875},{"EARLY_PHASE1":9876,"PHASE1":9878,"PHASE2":9884,"PHASE3":9886,"PHASE4":9888,"NA":9890},{"trials":9877,"activeCount":99},[],{"trials":9879,"activeCount":99},[9880],{"nctId":9859,"briefTitle":9860,"status":2582,"phases":9881,"primaryCompletion":394,"completion":394,"start":394,"enrollment":6019,"conditions":9882,"interventions":9883},[88],[24],[9852,9864,9865],{"trials":9885,"activeCount":99},[],{"trials":9887,"activeCount":99},[],{"trials":9889,"activeCount":99},[],{"trials":9891,"activeCount":99},[],{"intervention":9865,"totalTrials":151,"cells":9893},{"EARLY_PHASE1":9894,"PHASE1":9896,"PHASE2":9902,"PHASE3":9904,"PHASE4":9906,"NA":9908},{"trials":9895,"activeCount":99},[],{"trials":9897,"activeCount":99},[9898],{"nctId":9859,"briefTitle":9860,"status":2582,"phases":9899,"primaryCompletion":394,"completion":394,"start":394,"enrollment":6019,"conditions":9900,"interventions":9901},[88],[24],[9852,9864,9865],{"trials":9903,"activeCount":99},[],{"trials":9905,"activeCount":99},[],{"trials":9907,"activeCount":99},[],{"trials":9909,"activeCount":99},[],{"intervention":9911,"totalTrials":151,"cells":9912},"ChAdOx1 MERS",{"EARLY_PHASE1":9913,"PHASE1":9915,"PHASE2":9926,"PHASE3":9928,"PHASE4":9930,"NA":9932},{"trials":9914,"activeCount":99},[],{"trials":9916,"activeCount":99},[9917],{"nctId":9918,"briefTitle":9919,"status":795,"phases":9920,"primaryCompletion":9921,"completion":9921,"start":9922,"enrollment":22,"conditions":9923,"interventions":9925},"NCT03399578","Safety and Immunogenicity of a Candidate MERS-CoV Vaccine (MERS001)",[88],"2021-09-17","2018-03-14",[9924],"MERS (Middle East Respiratory Syndrome)",[9911],{"trials":9927,"activeCount":99},[],{"trials":9929,"activeCount":99},[],{"trials":9931,"activeCount":99},[],{"trials":9933,"activeCount":99},[],{"intervention":9935,"totalTrials":151,"cells":9936},"R21\u002FMatrix-M™",{"EARLY_PHASE1":9937,"PHASE1":9939,"PHASE2":9949,"PHASE3":9951,"PHASE4":9953,"NA":9955},{"trials":9938,"activeCount":99},[],{"trials":9940,"activeCount":99},[9941],{"nctId":9942,"briefTitle":9943,"status":109,"phases":9944,"primaryCompletion":9945,"completion":9945,"start":9946,"enrollment":4403,"conditions":9947,"interventions":9948},"NCT05385510","Assessment of Safety and Immunogenicity of R21\u002FMatrix-M™ in African Children Living With HIV",[88],"2025-09-03","2023-01-10",[15],[9935],{"trials":9950,"activeCount":99},[],{"trials":9952,"activeCount":99},[],{"trials":9954,"activeCount":99},[],{"trials":9956,"activeCount":99},[],{"intervention":9958,"totalTrials":151,"cells":9959},"Vaccination Schedule One",{"EARLY_PHASE1":9960,"PHASE1":9962,"PHASE2":9977,"PHASE3":9979,"PHASE4":9981,"NA":9983},{"trials":9961,"activeCount":99},[],{"trials":9963,"activeCount":99},[9964],{"nctId":9965,"briefTitle":9966,"status":109,"phases":9967,"primaryCompletion":3829,"completion":3829,"start":694,"enrollment":9968,"conditions":9969,"interventions":9970},"NCT01364883","Safety and Immunogenicity of Novel Vaccination Schedules With Malaria Vaccines AdCh63 ME-TRAP and MVA ME-TRAP",[88],39,[15],[9958,9971,9972,9973,9974,9975,9976],"Vaccination Schedule Two","Vaccination Schedule Three","Vaccination Schedule Four","Vaccination Schedule Five","Vaccination Schedule Six","Vaccination Schedule Seven",{"trials":9978,"activeCount":99},[],{"trials":9980,"activeCount":99},[],{"trials":9982,"activeCount":99},[],{"trials":9984,"activeCount":99},[],{"intervention":9971,"totalTrials":151,"cells":9986},{"EARLY_PHASE1":9987,"PHASE1":9989,"PHASE2":9995,"PHASE3":9997,"PHASE4":9999,"NA":10001},{"trials":9988,"activeCount":99},[],{"trials":9990,"activeCount":99},[9991],{"nctId":9965,"briefTitle":9966,"status":109,"phases":9992,"primaryCompletion":3829,"completion":3829,"start":694,"enrollment":9968,"conditions":9993,"interventions":9994},[88],[15],[9958,9971,9972,9973,9974,9975,9976],{"trials":9996,"activeCount":99},[],{"trials":9998,"activeCount":99},[],{"trials":10000,"activeCount":99},[],{"trials":10002,"activeCount":99},[],{"intervention":9972,"totalTrials":151,"cells":10004},{"EARLY_PHASE1":10005,"PHASE1":10007,"PHASE2":10013,"PHASE3":10015,"PHASE4":10017,"NA":10019},{"trials":10006,"activeCount":99},[],{"trials":10008,"activeCount":99},[10009],{"nctId":9965,"briefTitle":9966,"status":109,"phases":10010,"primaryCompletion":3829,"completion":3829,"start":694,"enrollment":9968,"conditions":10011,"interventions":10012},[88],[15],[9958,9971,9972,9973,9974,9975,9976],{"trials":10014,"activeCount":99},[],{"trials":10016,"activeCount":99},[],{"trials":10018,"activeCount":99},[],{"trials":10020,"activeCount":99},[],{"intervention":9973,"totalTrials":151,"cells":10022},{"EARLY_PHASE1":10023,"PHASE1":10025,"PHASE2":10031,"PHASE3":10033,"PHASE4":10035,"NA":10037},{"trials":10024,"activeCount":99},[],{"trials":10026,"activeCount":99},[10027],{"nctId":9965,"briefTitle":9966,"status":109,"phases":10028,"primaryCompletion":3829,"completion":3829,"start":694,"enrollment":9968,"conditions":10029,"interventions":10030},[88],[15],[9958,9971,9972,9973,9974,9975,9976],{"trials":10032,"activeCount":99},[],{"trials":10034,"activeCount":99},[],{"trials":10036,"activeCount":99},[],{"trials":10038,"activeCount":99},[],{"intervention":9974,"totalTrials":151,"cells":10040},{"EARLY_PHASE1":10041,"PHASE1":10043,"PHASE2":10049,"PHASE3":10051,"PHASE4":10053,"NA":10055},{"trials":10042,"activeCount":99},[],{"trials":10044,"activeCount":99},[10045],{"nctId":9965,"briefTitle":9966,"status":109,"phases":10046,"primaryCompletion":3829,"completion":3829,"start":694,"enrollment":9968,"conditions":10047,"interventions":10048},[88],[15],[9958,9971,9972,9973,9974,9975,9976],{"trials":10050,"activeCount":99},[],{"trials":10052,"activeCount":99},[],{"trials":10054,"activeCount":99},[],{"trials":10056,"activeCount":99},[],{"intervention":9975,"totalTrials":151,"cells":10058},{"EARLY_PHASE1":10059,"PHASE1":10061,"PHASE2":10067,"PHASE3":10069,"PHASE4":10071,"NA":10073},{"trials":10060,"activeCount":99},[],{"trials":10062,"activeCount":99},[10063],{"nctId":9965,"briefTitle":9966,"status":109,"phases":10064,"primaryCompletion":3829,"completion":3829,"start":694,"enrollment":9968,"conditions":10065,"interventions":10066},[88],[15],[9958,9971,9972,9973,9974,9975,9976],{"trials":10068,"activeCount":99},[],{"trials":10070,"activeCount":99},[],{"trials":10072,"activeCount":99},[],{"trials":10074,"activeCount":99},[],{"intervention":9976,"totalTrials":151,"cells":10076},{"EARLY_PHASE1":10077,"PHASE1":10079,"PHASE2":10085,"PHASE3":10087,"PHASE4":10089,"NA":10091},{"trials":10078,"activeCount":99},[],{"trials":10080,"activeCount":99},[10081],{"nctId":9965,"briefTitle":9966,"status":109,"phases":10082,"primaryCompletion":3829,"completion":3829,"start":694,"enrollment":9968,"conditions":10083,"interventions":10084},[88],[15],[9958,9971,9972,9973,9974,9975,9976],{"trials":10086,"activeCount":99},[],{"trials":10088,"activeCount":99},[],{"trials":10090,"activeCount":99},[],{"trials":10092,"activeCount":99},[],{"intervention":1767,"totalTrials":151,"cells":10094},{"EARLY_PHASE1":10095,"PHASE1":10097,"PHASE2":10103,"PHASE3":10105,"PHASE4":10107,"NA":10109},{"trials":10096,"activeCount":99},[],{"trials":10098,"activeCount":99},[10099],{"nctId":1759,"briefTitle":1760,"status":109,"phases":10100,"primaryCompletion":1762,"completion":1762,"start":1763,"enrollment":1730,"conditions":10101,"interventions":10102},[88],[1765],[1752,1752,1767,1768],{"trials":10104,"activeCount":99},[],{"trials":10106,"activeCount":99},[],{"trials":10108,"activeCount":99},[],{"trials":10110,"activeCount":99},[],{"intervention":9404,"totalTrials":151,"cells":10112},{"EARLY_PHASE1":10113,"PHASE1":10115,"PHASE2":10121,"PHASE3":10123,"PHASE4":10125,"NA":10127},{"trials":10114,"activeCount":99},[],{"trials":10116,"activeCount":99},[10117],{"nctId":9398,"briefTitle":9399,"status":109,"phases":10118,"primaryCompletion":9401,"completion":9401,"start":3830,"enrollment":7756,"conditions":10119,"interventions":10120},[88],[15],[9391,9391,9391,9391,9404,9391,9391,9404],{"trials":10122,"activeCount":99},[],{"trials":10124,"activeCount":99},[],{"trials":10126,"activeCount":99},[],{"trials":10128,"activeCount":99},[],{"intervention":10130,"totalTrials":151,"cells":10131},"ThermoDox®",{"EARLY_PHASE1":10132,"PHASE1":10134,"PHASE2":10145,"PHASE3":10147,"PHASE4":10149,"NA":10151},{"trials":10133,"activeCount":99},[],{"trials":10135,"activeCount":99},[10136],{"nctId":10137,"briefTitle":10138,"status":109,"phases":10139,"primaryCompletion":10140,"completion":10141,"start":577,"enrollment":34,"conditions":10142,"interventions":10144},"NCT02181075","Targeted Chemotherapy Using Focused Ultrasound for Liver Tumours",[88],"2017-03","2017-04",[10143],"Liver Tumour",[10130],{"trials":10146,"activeCount":99},[],{"trials":10148,"activeCount":99},[],{"trials":10150,"activeCount":99},[],{"trials":10152,"activeCount":99},[],{"intervention":10154,"totalTrials":151,"cells":10155},"ChAd3-EBO-Z",{"EARLY_PHASE1":10156,"PHASE1":10158,"PHASE2":10168,"PHASE3":10170,"PHASE4":10172,"NA":10174},{"trials":10157,"activeCount":99},[],{"trials":10159,"activeCount":99},[10160],{"nctId":10161,"briefTitle":10162,"status":109,"phases":10163,"primaryCompletion":9355,"completion":9355,"start":10164,"enrollment":1394,"conditions":10165,"interventions":10166},"NCT02495246","A Study to Assess Ebola Vaccines ChAd3-EBO-Z and Ad26.ZEBOV",[88],"2015-09-21",[9348],[10154,10167],"Ad26.ZEBOV",{"trials":10169,"activeCount":99},[],{"trials":10171,"activeCount":99},[],{"trials":10173,"activeCount":99},[],{"trials":10175,"activeCount":99},[],{"intervention":10167,"totalTrials":151,"cells":10177},{"EARLY_PHASE1":10178,"PHASE1":10180,"PHASE2":10186,"PHASE3":10188,"PHASE4":10190,"NA":10192},{"trials":10179,"activeCount":99},[],{"trials":10181,"activeCount":99},[10182],{"nctId":10161,"briefTitle":10162,"status":109,"phases":10183,"primaryCompletion":9355,"completion":9355,"start":10164,"enrollment":1394,"conditions":10184,"interventions":10185},[88],[9348],[10154,10167],{"trials":10187,"activeCount":99},[],{"trials":10189,"activeCount":99},[],{"trials":10191,"activeCount":99},[],{"trials":10193,"activeCount":99},[],{"intervention":10195,"totalTrials":151,"cells":10196},"JNJ-40346527",{"EARLY_PHASE1":10197,"PHASE1":10199,"PHASE2":10210,"PHASE3":10212,"PHASE4":10214,"NA":10216},{"trials":10198,"activeCount":99},[],{"trials":10200,"activeCount":99},[10201],{"nctId":10202,"briefTitle":10203,"status":795,"phases":10204,"primaryCompletion":10205,"completion":10205,"start":10206,"enrollment":168,"conditions":10207,"interventions":10209},"NCT04121208","MIcroglial Colony Stimulating Factor-1 Receptor (CSF1R) in Alzheimer's Disease",[88],"2022-02-18","2021-04-07",[6883,10208],"Mild Cognitive Impairment",[10195],{"trials":10211,"activeCount":99},[],{"trials":10213,"activeCount":99},[],{"trials":10215,"activeCount":99},[],{"trials":10217,"activeCount":99},[],{"intervention":9433,"totalTrials":151,"cells":10219},{"EARLY_PHASE1":10220,"PHASE1":10222,"PHASE2":10228,"PHASE3":10230,"PHASE4":10232,"NA":10234},{"trials":10221,"activeCount":99},[],{"trials":10223,"activeCount":99},[10224],{"nctId":9428,"briefTitle":9429,"status":109,"phases":10225,"primaryCompletion":527,"completion":4320,"start":4518,"enrollment":2572,"conditions":10226,"interventions":10227},[88],[18],[9421,9433],{"trials":10229,"activeCount":99},[],{"trials":10231,"activeCount":99},[],{"trials":10233,"activeCount":99},[],{"trials":10235,"activeCount":99},[],{"intervention":10237,"totalTrials":151,"cells":10238},"ChAdOx1-NP+M1",{"EARLY_PHASE1":10239,"PHASE1":10241,"PHASE2":10249,"PHASE3":10251,"PHASE4":10253,"NA":10255},{"trials":10240,"activeCount":99},[],{"trials":10242,"activeCount":99},[10243],{"nctId":10244,"briefTitle":10245,"status":109,"phases":10246,"primaryCompletion":3655,"completion":3655,"start":3027,"enrollment":28,"conditions":10247,"interventions":10248},"NCT01623518","A Phase I Study to Determine the Safety and Immunogenicity of the Candidate Influenza Vaccine ChAdOx1-NP+M1",[88],[30],[10237],{"trials":10250,"activeCount":99},[],{"trials":10252,"activeCount":99},[],{"trials":10254,"activeCount":99},[],{"trials":10256,"activeCount":99},[],{"intervention":10258,"totalTrials":151,"cells":10259},"MVA.HIVconsv low dose",{"EARLY_PHASE1":10260,"PHASE1":10262,"PHASE2":10273,"PHASE3":10275,"PHASE4":10277,"NA":10279},{"trials":10261,"activeCount":99},[],{"trials":10263,"activeCount":99},[10264],{"nctId":10265,"briefTitle":10266,"status":795,"phases":10267,"primaryCompletion":3604,"completion":3604,"start":6126,"enrollment":10268,"conditions":10269,"interventions":10271},"NCT01024842","Safety and Immunogenicity of MVA.HIVconsv in HIV-1 Seropositive Adults on HAART",[88],19,[10270],"HIV-1",[10258,10272],"MVA.HIVconsv high dose",{"trials":10274,"activeCount":99},[],{"trials":10276,"activeCount":99},[],{"trials":10278,"activeCount":99},[],{"trials":10280,"activeCount":99},[],{"intervention":10272,"totalTrials":151,"cells":10282},{"EARLY_PHASE1":10283,"PHASE1":10285,"PHASE2":10291,"PHASE3":10293,"PHASE4":10295,"NA":10297},{"trials":10284,"activeCount":99},[],{"trials":10286,"activeCount":99},[10287],{"nctId":10265,"briefTitle":10266,"status":795,"phases":10288,"primaryCompletion":3604,"completion":3604,"start":6126,"enrollment":10268,"conditions":10289,"interventions":10290},[88],[10270],[10258,10272],{"trials":10292,"activeCount":99},[],{"trials":10294,"activeCount":99},[],{"trials":10296,"activeCount":99},[],{"trials":10298,"activeCount":99},[],{"intervention":10300,"totalTrials":151,"cells":10301},"MenPF-1.",{"EARLY_PHASE1":10302,"PHASE1":10304,"PHASE2":10313,"PHASE3":10315,"PHASE4":10317,"NA":10319},{"trials":10303,"activeCount":99},[],{"trials":10305,"activeCount":99},[10306],{"nctId":10307,"briefTitle":10308,"status":109,"phases":10309,"primaryCompletion":3829,"completion":7494,"start":1435,"enrollment":7756,"conditions":10310,"interventions":10312},"NCT01640652","MenPF-1 - A New Vaccine Against Meningococcal Disease",[88],[10311],"Serogroup B Meningococcal Disease",[10300],{"trials":10314,"activeCount":99},[],{"trials":10316,"activeCount":99},[],{"trials":10318,"activeCount":99},[],{"trials":10320,"activeCount":99},[],{"intervention":10322,"totalTrials":151,"cells":10323},"ChAdOx1 Chik",{"EARLY_PHASE1":10324,"PHASE1":10326,"PHASE2":10337,"PHASE3":10339,"PHASE4":10341,"NA":10343},{"trials":10325,"activeCount":99},[],{"trials":10327,"activeCount":99},[10328],{"nctId":10329,"briefTitle":10330,"status":109,"phases":10331,"primaryCompletion":10332,"completion":10332,"start":10333,"enrollment":2572,"conditions":10334,"interventions":10336},"NCT03590392","Safety and Immunogenicity of a Candidate CHIKV Vaccine (CHIK001)",[88],"2019-09-30","2018-07-31",[10335],"Chikungunya Fever",[10322],{"trials":10338,"activeCount":99},[],{"trials":10340,"activeCount":99},[],{"trials":10342,"activeCount":99},[],{"trials":10344,"activeCount":99},[],{"intervention":10346,"totalTrials":151,"cells":10347},"Vaccine",{"EARLY_PHASE1":10348,"PHASE1":10350,"PHASE2":10361,"PHASE3":10363,"PHASE4":10365,"NA":10367},{"trials":10349,"activeCount":99},[],{"trials":10351,"activeCount":99},[10352],{"nctId":10353,"briefTitle":10354,"status":2901,"phases":10355,"primaryCompletion":10356,"completion":10356,"start":10357,"enrollment":3034,"conditions":10358,"interventions":10360},"NCT04553016","A Study to Test Three Experimental HIV Vaccines in Healthy Adults.",[88],"2022-11","2021-08-16",[10359],"HIV-1-infection",[10346],{"trials":10362,"activeCount":99},[],{"trials":10364,"activeCount":99},[],{"trials":10366,"activeCount":99},[],{"trials":10368,"activeCount":99},[],{"intervention":6301,"totalTrials":151,"cells":10370},{"EARLY_PHASE1":10371,"PHASE1":10373,"PHASE2":10379,"PHASE3":10381,"PHASE4":10383,"NA":10385},{"trials":10372,"activeCount":99},[],{"trials":10374,"activeCount":99},[10375],{"nctId":6291,"briefTitle":6292,"status":109,"phases":10376,"primaryCompletion":6294,"completion":6294,"start":6295,"enrollment":1848,"conditions":10377,"interventions":10378},[88],[6297,6298,6299],[6301,6302,6284],{"trials":10380,"activeCount":99},[],{"trials":10382,"activeCount":99},[],{"trials":10384,"activeCount":99},[],{"trials":10386,"activeCount":99},[],{"intervention":6302,"totalTrials":151,"cells":10388},{"EARLY_PHASE1":10389,"PHASE1":10391,"PHASE2":10397,"PHASE3":10399,"PHASE4":10401,"NA":10403},{"trials":10390,"activeCount":99},[],{"trials":10392,"activeCount":99},[10393],{"nctId":6291,"briefTitle":6292,"status":109,"phases":10394,"primaryCompletion":6294,"completion":6294,"start":6295,"enrollment":1848,"conditions":10395,"interventions":10396},[88],[6297,6298,6299],[6301,6302,6284],{"trials":10398,"activeCount":99},[],{"trials":10400,"activeCount":99},[],{"trials":10402,"activeCount":99},[],{"trials":10404,"activeCount":99},[],{"intervention":10406,"totalTrials":151,"cells":10407},"Pfs25-IMX313",{"EARLY_PHASE1":10408,"PHASE1":10410,"PHASE2":10420,"PHASE3":10422,"PHASE4":10424,"NA":10426},{"trials":10409,"activeCount":99},[],{"trials":10411,"activeCount":99},[10412],{"nctId":10413,"briefTitle":10414,"status":795,"phases":10415,"primaryCompletion":3474,"completion":3474,"start":10416,"enrollment":10417,"conditions":10418,"interventions":10419},"NCT04271306","Safety, Immunogenicity and ex Vivo Efficacy of Pfs25-IMX313\u002FMatrix-M in Healthy Volunteers in Bagamoyo, Tanzania.",[88],"2021-05-25",34,[27],[10406,10406,10406],{"trials":10421,"activeCount":99},[],{"trials":10423,"activeCount":99},[],{"trials":10425,"activeCount":99},[],{"trials":10427,"activeCount":99},[],{"intervention":10429,"totalTrials":151,"cells":10430},"Iron sucrose.",{"EARLY_PHASE1":10431,"PHASE1":10433,"PHASE2":10443,"PHASE3":10445,"PHASE4":10447,"NA":10449},{"trials":10432,"activeCount":99},[],{"trials":10434,"activeCount":99},[10435],{"nctId":10436,"briefTitle":10437,"status":109,"phases":10438,"primaryCompletion":3788,"completion":3553,"start":2987,"enrollment":31,"conditions":10439,"interventions":10441},"NCT01265108","Effects of Iron on Exercise Capacity During Hypoxia",[88],[10440],"Healthy Volunteers",[10429,10442],"Normal saline",{"trials":10444,"activeCount":99},[],{"trials":10446,"activeCount":99},[],{"trials":10448,"activeCount":99},[],{"trials":10450,"activeCount":99},[],{"intervention":10452,"totalTrials":151,"cells":10453},"Matrix-M with RH5.2 VLP and\u002For R21",{"EARLY_PHASE1":10454,"PHASE1":10456,"PHASE2":10468,"PHASE3":10470,"PHASE4":10472,"NA":10474},{"trials":10455,"activeCount":99},[],{"trials":10457,"activeCount":99},[10458],{"nctId":10459,"briefTitle":10460,"status":109,"phases":10461,"primaryCompletion":10462,"completion":10462,"start":10463,"enrollment":10464,"conditions":10465,"interventions":10467},"NCT05357560","A Study to Assess the Experimental Malaria Vaccines RH5.2-VLP and R21",[88],"2025-12-11","2023-07-10",107,[10466],"Malaria, Plasmodium Falciparum",[10452],{"trials":10469,"activeCount":99},[],{"trials":10471,"activeCount":99},[],{"trials":10473,"activeCount":99},[],{"trials":10475,"activeCount":99},[],{"intervention":1555,"totalTrials":151,"cells":10477},{"EARLY_PHASE1":10478,"PHASE1":10480,"PHASE2":10486,"PHASE3":10488,"PHASE4":10490,"NA":10492},{"trials":10479,"activeCount":99},[],{"trials":10481,"activeCount":99},[10482],{"nctId":1548,"briefTitle":1549,"status":109,"phases":10483,"primaryCompletion":1551,"completion":1551,"start":1552,"enrollment":19,"conditions":10484,"interventions":10485},[88],[15],[1541,1555],{"trials":10487,"activeCount":99},[],{"trials":10489,"activeCount":99},[],{"trials":10491,"activeCount":99},[],{"trials":10493,"activeCount":99},[],{"intervention":10495,"totalTrials":151,"cells":10496},"VSV-ZEBOV",{"EARLY_PHASE1":10497,"PHASE1":10499,"PHASE2":10507,"PHASE3":10509,"PHASE4":10511,"NA":10513},{"trials":10498,"activeCount":99},[],{"trials":10500,"activeCount":99},[10501],{"nctId":10502,"briefTitle":10503,"status":2901,"phases":10504,"primaryCompletion":2504,"completion":5006,"start":680,"enrollment":1530,"conditions":10505,"interventions":10506},"NCT02296983","A Study to Find Out if the New Ebola Vaccine is Safe and Stimulates Immunity That Might Protect Adults in Kilifi, Kenya.",[88],[9348],[10495],{"trials":10508,"activeCount":99},[],{"trials":10510,"activeCount":99},[],{"trials":10512,"activeCount":99},[],{"trials":10514,"activeCount":99},[],{"intervention":10516,"totalTrials":151,"cells":10517},"ChAd63 RH5 low dose",{"EARLY_PHASE1":10518,"PHASE1":10520,"PHASE2":10531,"PHASE3":10533,"PHASE4":10535,"NA":10537},{"trials":10519,"activeCount":99},[],{"trials":10521,"activeCount":99},[10522],{"nctId":10523,"briefTitle":10524,"status":109,"phases":10525,"primaryCompletion":6199,"completion":6199,"start":1456,"enrollment":6151,"conditions":10526,"interventions":10527},"NCT02181088","A Phase Ia Clinical Trial to Assess the Safety and Immunogenicity of New Plasmodium Falciparum Malaria Vaccine Candidates ChAd63 RH5 Alone and With MVA RH5",[88],[15,1315],[10516,10528,10529,10530],"ChAd63 RH5 full dose","MVA RH5 low dose","MVA RH5 full dose",{"trials":10532,"activeCount":99},[],{"trials":10534,"activeCount":99},[],{"trials":10536,"activeCount":99},[],{"trials":10538,"activeCount":99},[],{"intervention":10528,"totalTrials":151,"cells":10540},{"EARLY_PHASE1":10541,"PHASE1":10543,"PHASE2":10549,"PHASE3":10551,"PHASE4":10553,"NA":10555},{"trials":10542,"activeCount":99},[],{"trials":10544,"activeCount":99},[10545],{"nctId":10523,"briefTitle":10524,"status":109,"phases":10546,"primaryCompletion":6199,"completion":6199,"start":1456,"enrollment":6151,"conditions":10547,"interventions":10548},[88],[15,1315],[10516,10528,10529,10530],{"trials":10550,"activeCount":99},[],{"trials":10552,"activeCount":99},[],{"trials":10554,"activeCount":99},[],{"trials":10556,"activeCount":99},[],{"intervention":10529,"totalTrials":151,"cells":10558},{"EARLY_PHASE1":10559,"PHASE1":10561,"PHASE2":10567,"PHASE3":10569,"PHASE4":10571,"NA":10573},{"trials":10560,"activeCount":99},[],{"trials":10562,"activeCount":99},[10563],{"nctId":10523,"briefTitle":10524,"status":109,"phases":10564,"primaryCompletion":6199,"completion":6199,"start":1456,"enrollment":6151,"conditions":10565,"interventions":10566},[88],[15,1315],[10516,10528,10529,10530],{"trials":10568,"activeCount":99},[],{"trials":10570,"activeCount":99},[],{"trials":10572,"activeCount":99},[],{"trials":10574,"activeCount":99},[],{"intervention":10530,"totalTrials":151,"cells":10576},{"EARLY_PHASE1":10577,"PHASE1":10579,"PHASE2":10585,"PHASE3":10587,"PHASE4":10589,"NA":10591},{"trials":10578,"activeCount":99},[],{"trials":10580,"activeCount":99},[10581],{"nctId":10523,"briefTitle":10524,"status":109,"phases":10582,"primaryCompletion":6199,"completion":6199,"start":1456,"enrollment":6151,"conditions":10583,"interventions":10584},[88],[15,1315],[10516,10528,10529,10530],{"trials":10586,"activeCount":99},[],{"trials":10588,"activeCount":99},[],{"trials":10590,"activeCount":99},[],{"trials":10592,"activeCount":99},[],{"intervention":10594,"totalTrials":151,"cells":10595},"Control Regimen",{"EARLY_PHASE1":10596,"PHASE1":10598,"PHASE2":10609,"PHASE3":10611,"PHASE4":10613,"NA":10615},{"trials":10597,"activeCount":99},[],{"trials":10599,"activeCount":99},[10600],{"nctId":10601,"briefTitle":10602,"status":109,"phases":10603,"primaryCompletion":680,"completion":680,"start":1435,"enrollment":25,"conditions":10604,"interventions":10606},"NCT01669512","Adjuvanting Viral Vectored Malaria Vaccines With Matrix M",[88],[15,10605],"Matrix M",[10594,10607,10608],"Low Dose Matrix M Regimen","Standard Dose Matrix M Regimen",{"trials":10610,"activeCount":99},[],{"trials":10612,"activeCount":99},[],{"trials":10614,"activeCount":99},[],{"trials":10616,"activeCount":99},[],{"intervention":10607,"totalTrials":151,"cells":10618},{"EARLY_PHASE1":10619,"PHASE1":10621,"PHASE2":10627,"PHASE3":10629,"PHASE4":10631,"NA":10633},{"trials":10620,"activeCount":99},[],{"trials":10622,"activeCount":99},[10623],{"nctId":10601,"briefTitle":10602,"status":109,"phases":10624,"primaryCompletion":680,"completion":680,"start":1435,"enrollment":25,"conditions":10625,"interventions":10626},[88],[15,10605],[10594,10607,10608],{"trials":10628,"activeCount":99},[],{"trials":10630,"activeCount":99},[],{"trials":10632,"activeCount":99},[],{"trials":10634,"activeCount":99},[],{"intervention":10608,"totalTrials":151,"cells":10636},{"EARLY_PHASE1":10637,"PHASE1":10639,"PHASE2":10645,"PHASE3":10647,"PHASE4":10649,"NA":10651},{"trials":10638,"activeCount":99},[],{"trials":10640,"activeCount":99},[10641],{"nctId":10601,"briefTitle":10602,"status":109,"phases":10642,"primaryCompletion":680,"completion":680,"start":1435,"enrollment":25,"conditions":10643,"interventions":10644},[88],[15,10605],[10594,10607,10608],{"trials":10646,"activeCount":99},[],{"trials":10648,"activeCount":99},[],{"trials":10650,"activeCount":99},[],{"trials":10652,"activeCount":99},[],{"intervention":10654,"totalTrials":151,"cells":10655},"Regimen 1",{"EARLY_PHASE1":10656,"PHASE1":10658,"PHASE2":10670,"PHASE3":10672,"PHASE4":10674,"NA":10676},{"trials":10657,"activeCount":99},[],{"trials":10659,"activeCount":99},[10660],{"nctId":10661,"briefTitle":10662,"status":183,"phases":10663,"primaryCompletion":10664,"completion":10664,"start":10665,"enrollment":99,"conditions":10666,"interventions":10667},"NCT05938608","A Study to Assess the Availability of Oral Primaquine and Its Inert Metabolite, Carboxyprimaquine, in the Body",[88],"2025-03","2024-03",[24,1287],[10654,10668,10669],"Regimen 2","Regimen 3",{"trials":10671,"activeCount":99},[],{"trials":10673,"activeCount":99},[],{"trials":10675,"activeCount":99},[],{"trials":10677,"activeCount":99},[],{"intervention":10668,"totalTrials":151,"cells":10679},{"EARLY_PHASE1":10680,"PHASE1":10682,"PHASE2":10688,"PHASE3":10690,"PHASE4":10692,"NA":10694},{"trials":10681,"activeCount":99},[],{"trials":10683,"activeCount":99},[10684],{"nctId":10661,"briefTitle":10662,"status":183,"phases":10685,"primaryCompletion":10664,"completion":10664,"start":10665,"enrollment":99,"conditions":10686,"interventions":10687},[88],[24,1287],[10654,10668,10669],{"trials":10689,"activeCount":99},[],{"trials":10691,"activeCount":99},[],{"trials":10693,"activeCount":99},[],{"trials":10695,"activeCount":99},[],{"intervention":10669,"totalTrials":151,"cells":10697},{"EARLY_PHASE1":10698,"PHASE1":10700,"PHASE2":10706,"PHASE3":10708,"PHASE4":10710,"NA":10712},{"trials":10699,"activeCount":99},[],{"trials":10701,"activeCount":99},[10702],{"nctId":10661,"briefTitle":10662,"status":183,"phases":10703,"primaryCompletion":10664,"completion":10664,"start":10665,"enrollment":99,"conditions":10704,"interventions":10705},[88],[24,1287],[10654,10668,10669],{"trials":10707,"activeCount":99},[],{"trials":10709,"activeCount":99},[],{"trials":10711,"activeCount":99},[],{"trials":10713,"activeCount":99},[],{"intervention":10715,"totalTrials":151,"cells":10716},"CHIK low dose",{"EARLY_PHASE1":10717,"PHASE1":10719,"PHASE2":10736,"PHASE3":10738,"PHASE4":10740,"NA":10742},{"trials":10718,"activeCount":99},[],{"trials":10720,"activeCount":99},[10721],{"nctId":10722,"briefTitle":10723,"status":109,"phases":10724,"primaryCompletion":10205,"completion":10205,"start":10725,"enrollment":1436,"conditions":10726,"interventions":10729},"NCT04440774","Research Study to Assess New Chikungunya and Zika Vaccines in Healthy Adults in Mexico.",[88],"2020-10-23",[10727,10728],"Chikungunya","Zika",[10715,10730,10731,10732,10733,10734,10735],"CHIK mid dose","CHIK high dose","ZIKA low dose","ZIKA mid dose","ZIKA high dose","Saline placebo",{"trials":10737,"activeCount":99},[],{"trials":10739,"activeCount":99},[],{"trials":10741,"activeCount":99},[],{"trials":10743,"activeCount":99},[],{"intervention":10730,"totalTrials":151,"cells":10745},{"EARLY_PHASE1":10746,"PHASE1":10748,"PHASE2":10754,"PHASE3":10756,"PHASE4":10758,"NA":10760},{"trials":10747,"activeCount":99},[],{"trials":10749,"activeCount":99},[10750],{"nctId":10722,"briefTitle":10723,"status":109,"phases":10751,"primaryCompletion":10205,"completion":10205,"start":10725,"enrollment":1436,"conditions":10752,"interventions":10753},[88],[10727,10728],[10715,10730,10731,10732,10733,10734,10735],{"trials":10755,"activeCount":99},[],{"trials":10757,"activeCount":99},[],{"trials":10759,"activeCount":99},[],{"trials":10761,"activeCount":99},[],{"intervention":10731,"totalTrials":151,"cells":10763},{"EARLY_PHASE1":10764,"PHASE1":10766,"PHASE2":10772,"PHASE3":10774,"PHASE4":10776,"NA":10778},{"trials":10765,"activeCount":99},[],{"trials":10767,"activeCount":99},[10768],{"nctId":10722,"briefTitle":10723,"status":109,"phases":10769,"primaryCompletion":10205,"completion":10205,"start":10725,"enrollment":1436,"conditions":10770,"interventions":10771},[88],[10727,10728],[10715,10730,10731,10732,10733,10734,10735],{"trials":10773,"activeCount":99},[],{"trials":10775,"activeCount":99},[],{"trials":10777,"activeCount":99},[],{"trials":10779,"activeCount":99},[],{"intervention":10732,"totalTrials":151,"cells":10781},{"EARLY_PHASE1":10782,"PHASE1":10784,"PHASE2":10790,"PHASE3":10792,"PHASE4":10794,"NA":10796},{"trials":10783,"activeCount":99},[],{"trials":10785,"activeCount":99},[10786],{"nctId":10722,"briefTitle":10723,"status":109,"phases":10787,"primaryCompletion":10205,"completion":10205,"start":10725,"enrollment":1436,"conditions":10788,"interventions":10789},[88],[10727,10728],[10715,10730,10731,10732,10733,10734,10735],{"trials":10791,"activeCount":99},[],{"trials":10793,"activeCount":99},[],{"trials":10795,"activeCount":99},[],{"trials":10797,"activeCount":99},[],{"intervention":10733,"totalTrials":151,"cells":10799},{"EARLY_PHASE1":10800,"PHASE1":10802,"PHASE2":10808,"PHASE3":10810,"PHASE4":10812,"NA":10814},{"trials":10801,"activeCount":99},[],{"trials":10803,"activeCount":99},[10804],{"nctId":10722,"briefTitle":10723,"status":109,"phases":10805,"primaryCompletion":10205,"completion":10205,"start":10725,"enrollment":1436,"conditions":10806,"interventions":10807},[88],[10727,10728],[10715,10730,10731,10732,10733,10734,10735],{"trials":10809,"activeCount":99},[],{"trials":10811,"activeCount":99},[],{"trials":10813,"activeCount":99},[],{"trials":10815,"activeCount":99},[],{"intervention":10734,"totalTrials":151,"cells":10817},{"EARLY_PHASE1":10818,"PHASE1":10820,"PHASE2":10826,"PHASE3":10828,"PHASE4":10830,"NA":10832},{"trials":10819,"activeCount":99},[],{"trials":10821,"activeCount":99},[10822],{"nctId":10722,"briefTitle":10723,"status":109,"phases":10823,"primaryCompletion":10205,"completion":10205,"start":10725,"enrollment":1436,"conditions":10824,"interventions":10825},[88],[10727,10728],[10715,10730,10731,10732,10733,10734,10735],{"trials":10827,"activeCount":99},[],{"trials":10829,"activeCount":99},[],{"trials":10831,"activeCount":99},[],{"trials":10833,"activeCount":99},[],{"intervention":10735,"totalTrials":151,"cells":10835},{"EARLY_PHASE1":10836,"PHASE1":10838,"PHASE2":10844,"PHASE3":10846,"PHASE4":10848,"NA":10850},{"trials":10837,"activeCount":99},[],{"trials":10839,"activeCount":99},[10840],{"nctId":10722,"briefTitle":10723,"status":109,"phases":10841,"primaryCompletion":10205,"completion":10205,"start":10725,"enrollment":1436,"conditions":10842,"interventions":10843},[88],[10727,10728],[10715,10730,10731,10732,10733,10734,10735],{"trials":10845,"activeCount":99},[],{"trials":10847,"activeCount":99},[],{"trials":10849,"activeCount":99},[],{"trials":10851,"activeCount":99},[],{"intervention":6055,"totalTrials":151,"cells":10853},{"EARLY_PHASE1":10854,"PHASE1":10856,"PHASE2":10862,"PHASE3":10864,"PHASE4":10866,"NA":10868},{"trials":10855,"activeCount":99},[],{"trials":10857,"activeCount":99},[10858],{"nctId":6050,"briefTitle":6051,"status":109,"phases":10859,"primaryCompletion":3454,"completion":3454,"start":3829,"enrollment":2989,"conditions":10860,"interventions":10861},[88],[18],[6055,6000],{"trials":10863,"activeCount":99},[],{"trials":10865,"activeCount":99},[],{"trials":10867,"activeCount":99},[],{"trials":10869,"activeCount":99},[],{"intervention":1425,"totalTrials":151,"cells":10871},{"EARLY_PHASE1":10872,"PHASE1":10874,"PHASE2":10880,"PHASE3":10882,"PHASE4":10884,"NA":10886},{"trials":10873,"activeCount":99},[],{"trials":10875,"activeCount":99},[10876],{"nctId":1417,"briefTitle":1418,"status":109,"phases":10877,"primaryCompletion":1420,"completion":1420,"start":1421,"enrollment":1422,"conditions":10878,"interventions":10879},[88],[27],[1425,1426,1427],{"trials":10881,"activeCount":99},[],{"trials":10883,"activeCount":99},[],{"trials":10885,"activeCount":99},[],{"trials":10887,"activeCount":99},[],{"intervention":1426,"totalTrials":151,"cells":10889},{"EARLY_PHASE1":10890,"PHASE1":10892,"PHASE2":10898,"PHASE3":10900,"PHASE4":10902,"NA":10904},{"trials":10891,"activeCount":99},[],{"trials":10893,"activeCount":99},[10894],{"nctId":1417,"briefTitle":1418,"status":109,"phases":10895,"primaryCompletion":1420,"completion":1420,"start":1421,"enrollment":1422,"conditions":10896,"interventions":10897},[88],[27],[1425,1426,1427],{"trials":10899,"activeCount":99},[],{"trials":10901,"activeCount":99},[],{"trials":10903,"activeCount":99},[],{"trials":10905,"activeCount":99},[],{"intervention":6154,"totalTrials":151,"cells":10907},{"EARLY_PHASE1":10908,"PHASE1":10910,"PHASE2":10916,"PHASE3":10918,"PHASE4":10920,"NA":10922},{"trials":10909,"activeCount":99},[],{"trials":10911,"activeCount":99},[10912],{"nctId":6146,"briefTitle":6147,"status":109,"phases":10913,"primaryCompletion":6149,"completion":6149,"start":6150,"enrollment":6151,"conditions":10914,"interventions":10915},[88],[15],[6154,6139],{"trials":10917,"activeCount":99},[],{"trials":10919,"activeCount":99},[],{"trials":10921,"activeCount":99},[],{"trials":10923,"activeCount":99},[],{"intervention":10925,"totalTrials":151,"cells":10926},"BKM120",{"EARLY_PHASE1":10927,"PHASE1":10929,"PHASE2":10938,"PHASE3":10940,"PHASE4":10942,"NA":10944},{"trials":10928,"activeCount":99},[],{"trials":10930,"activeCount":99},[10931],{"nctId":10932,"briefTitle":10933,"status":109,"phases":10934,"primaryCompletion":10935,"completion":10935,"start":4320,"enrollment":3656,"conditions":10936,"interventions":10937},"NCT02128724","Palliative Thoracic Radiotherapy Plus BKM120",[88],"2017-10-17",[3583],[10925],{"trials":10939,"activeCount":99},[],{"trials":10941,"activeCount":99},[],{"trials":10943,"activeCount":99},[],{"trials":10945,"activeCount":99},[],{"intervention":10947,"totalTrials":151,"cells":10948},"AdCh63 ME-TRAP followed by MVA ME-TRAP",{"EARLY_PHASE1":10949,"PHASE1":10951,"PHASE2":10959,"PHASE3":10961,"PHASE4":10963,"NA":10965},{"trials":10950,"activeCount":99},[],{"trials":10952,"activeCount":99},[10953],{"nctId":10954,"briefTitle":10955,"status":109,"phases":10956,"primaryCompletion":3899,"completion":3899,"start":3830,"enrollment":1699,"conditions":10957,"interventions":10958},"NCT01379430","Safety and Immunogenicity of AdCh63 ME-TRAP and MVA ME-TRAP Vaccines in Malaria Endemic Areas",[88],[15],[10947,10947],{"trials":10960,"activeCount":99},[],{"trials":10962,"activeCount":99},[],{"trials":10964,"activeCount":99},[],{"trials":10966,"activeCount":99},[],{"intervention":10968,"totalTrials":151,"cells":10969},"Pfs25-IMX313\u002FMatrix-M1",{"EARLY_PHASE1":10970,"PHASE1":10972,"PHASE2":10982,"PHASE3":10984,"PHASE4":10986,"NA":10988},{"trials":10971,"activeCount":99},[],{"trials":10973,"activeCount":99},[10974],{"nctId":10975,"briefTitle":10976,"status":795,"phases":10977,"primaryCompletion":10978,"completion":10978,"start":10979,"enrollment":151,"conditions":10980,"interventions":10981},"NCT04130282","VAC077: Safety and Immunogenicity of the Pfs25-IMX313\u002FMatrix-M Vaccine",[88],"2020-09-22","2019-09-27",[27],[10968],{"trials":10983,"activeCount":99},[],{"trials":10985,"activeCount":99},[],{"trials":10987,"activeCount":99},[],{"trials":10989,"activeCount":99},[],{"intervention":10991,"totalTrials":151,"cells":10992},"BCG: 100 microlitres ~ 2-8 x 105 pfu",{"EARLY_PHASE1":10993,"PHASE1":10995,"PHASE2":11004,"PHASE3":11006,"PHASE4":11008,"NA":11010},{"trials":10994,"activeCount":99},[],{"trials":10996,"activeCount":99},[10997],{"nctId":10998,"briefTitle":10999,"status":109,"phases":11000,"primaryCompletion":3389,"completion":3389,"start":528,"enrollment":1778,"conditions":11001,"interventions":11002},"NCT01194180","A BCG Challenge Model Study to Assess Anti-mycobacterial Immunity Induced by BCG and a Candidate TB Vaccine, MVA85A",[88],[18],[10991,11003],"MVA85A: 1 x 108 pfu BCG: 100 microlitres ~ 2-8 x 105 pfu",{"trials":11005,"activeCount":99},[],{"trials":11007,"activeCount":99},[],{"trials":11009,"activeCount":99},[],{"trials":11011,"activeCount":99},[],{"intervention":11003,"totalTrials":151,"cells":11013},{"EARLY_PHASE1":11014,"PHASE1":11016,"PHASE2":11022,"PHASE3":11024,"PHASE4":11026,"NA":11028},{"trials":11015,"activeCount":99},[],{"trials":11017,"activeCount":99},[11018],{"nctId":10998,"briefTitle":10999,"status":109,"phases":11019,"primaryCompletion":3389,"completion":3389,"start":528,"enrollment":1778,"conditions":11020,"interventions":11021},[88],[18],[10991,11003],{"trials":11023,"activeCount":99},[],{"trials":11025,"activeCount":99},[],{"trials":11027,"activeCount":99},[],{"trials":11029,"activeCount":99},[],{"intervention":11031,"totalTrials":151,"cells":11032},"NUC-3373",{"EARLY_PHASE1":11033,"PHASE1":11035,"PHASE2":11046,"PHASE3":11048,"PHASE4":11050,"NA":11052},{"trials":11034,"activeCount":99},[],{"trials":11036,"activeCount":99},[11037],{"nctId":11038,"briefTitle":11039,"status":109,"phases":11040,"primaryCompletion":11041,"completion":11042,"start":4929,"enrollment":368,"conditions":11043,"interventions":11045},"NCT02723240","NUC-3373 in Advanced Solid Tumours",[88],"2020-02-24","2021-02-24",[11044],"Cancer",[11031],{"trials":11047,"activeCount":99},[],{"trials":11049,"activeCount":99},[],{"trials":11051,"activeCount":99},[],{"trials":11053,"activeCount":99},[],{"intervention":6063,"totalTrials":151,"cells":11055},{"EARLY_PHASE1":11056,"PHASE1":11058,"PHASE2":11064,"PHASE3":11066,"PHASE4":11068,"NA":11070},{"trials":11057,"activeCount":99},[],{"trials":11059,"activeCount":99},[11060],{"nctId":6057,"briefTitle":6058,"status":109,"phases":11061,"primaryCompletion":1456,"completion":1456,"start":6060,"enrollment":1530,"conditions":11062,"interventions":11063},[88],[18],[6063,6000],{"trials":11065,"activeCount":99},[],{"trials":11067,"activeCount":99},[],{"trials":11069,"activeCount":99},[],{"trials":11071,"activeCount":99},[],{"intervention":11073,"totalTrials":151,"cells":11074},"cAd3-EBO Z at 1 x 10^10 vp",{"EARLY_PHASE1":11075,"PHASE1":11077,"PHASE2":11092,"PHASE3":11094,"PHASE4":11096,"NA":11098},{"trials":11076,"activeCount":99},[],{"trials":11078,"activeCount":99},[11079],{"nctId":11080,"briefTitle":11081,"status":109,"phases":11082,"primaryCompletion":9355,"completion":9355,"start":11083,"enrollment":6525,"conditions":11084,"interventions":11086},"NCT02240875","A Study to Assess New Ebola Vaccines, cAd3-EBO Z and MVA-BN® Filo",[88],"2014-09-17",[9319,11085],"Ebola Zaire",[11073,11087,11088,11089,11090,11091],"cAd3-EBO Z at 2.5 x 10^10 vp","cAd3-EBO Z at 5 x 10^10 vp","4.4x10^8 TCID50s MVA-BN® Filo","2.2x10^8 TCID50s MVA-BN® Filo","4.4 x 10^7 TCID50s MVA-BN® Filo",{"trials":11093,"activeCount":99},[],{"trials":11095,"activeCount":99},[],{"trials":11097,"activeCount":99},[],{"trials":11099,"activeCount":99},[],{"intervention":11087,"totalTrials":151,"cells":11101},{"EARLY_PHASE1":11102,"PHASE1":11104,"PHASE2":11110,"PHASE3":11112,"PHASE4":11114,"NA":11116},{"trials":11103,"activeCount":99},[],{"trials":11105,"activeCount":99},[11106],{"nctId":11080,"briefTitle":11081,"status":109,"phases":11107,"primaryCompletion":9355,"completion":9355,"start":11083,"enrollment":6525,"conditions":11108,"interventions":11109},[88],[9319,11085],[11073,11087,11088,11089,11090,11091],{"trials":11111,"activeCount":99},[],{"trials":11113,"activeCount":99},[],{"trials":11115,"activeCount":99},[],{"trials":11117,"activeCount":99},[],{"intervention":11088,"totalTrials":151,"cells":11119},{"EARLY_PHASE1":11120,"PHASE1":11122,"PHASE2":11128,"PHASE3":11130,"PHASE4":11132,"NA":11134},{"trials":11121,"activeCount":99},[],{"trials":11123,"activeCount":99},[11124],{"nctId":11080,"briefTitle":11081,"status":109,"phases":11125,"primaryCompletion":9355,"completion":9355,"start":11083,"enrollment":6525,"conditions":11126,"interventions":11127},[88],[9319,11085],[11073,11087,11088,11089,11090,11091],{"trials":11129,"activeCount":99},[],{"trials":11131,"activeCount":99},[],{"trials":11133,"activeCount":99},[],{"trials":11135,"activeCount":99},[],{"intervention":11089,"totalTrials":151,"cells":11137},{"EARLY_PHASE1":11138,"PHASE1":11140,"PHASE2":11146,"PHASE3":11148,"PHASE4":11150,"NA":11152},{"trials":11139,"activeCount":99},[],{"trials":11141,"activeCount":99},[11142],{"nctId":11080,"briefTitle":11081,"status":109,"phases":11143,"primaryCompletion":9355,"completion":9355,"start":11083,"enrollment":6525,"conditions":11144,"interventions":11145},[88],[9319,11085],[11073,11087,11088,11089,11090,11091],{"trials":11147,"activeCount":99},[],{"trials":11149,"activeCount":99},[],{"trials":11151,"activeCount":99},[],{"trials":11153,"activeCount":99},[],{"intervention":11090,"totalTrials":151,"cells":11155},{"EARLY_PHASE1":11156,"PHASE1":11158,"PHASE2":11164,"PHASE3":11166,"PHASE4":11168,"NA":11170},{"trials":11157,"activeCount":99},[],{"trials":11159,"activeCount":99},[11160],{"nctId":11080,"briefTitle":11081,"status":109,"phases":11161,"primaryCompletion":9355,"completion":9355,"start":11083,"enrollment":6525,"conditions":11162,"interventions":11163},[88],[9319,11085],[11073,11087,11088,11089,11090,11091],{"trials":11165,"activeCount":99},[],{"trials":11167,"activeCount":99},[],{"trials":11169,"activeCount":99},[],{"trials":11171,"activeCount":99},[],{"intervention":11091,"totalTrials":151,"cells":11173},{"EARLY_PHASE1":11174,"PHASE1":11176,"PHASE2":11182,"PHASE3":11184,"PHASE4":11186,"NA":11188},{"trials":11175,"activeCount":99},[],{"trials":11177,"activeCount":99},[11178],{"nctId":11080,"briefTitle":11081,"status":109,"phases":11179,"primaryCompletion":9355,"completion":9355,"start":11083,"enrollment":6525,"conditions":11180,"interventions":11181},[88],[9319,11085],[11073,11087,11088,11089,11090,11091],{"trials":11183,"activeCount":99},[],{"trials":11185,"activeCount":99},[],{"trials":11187,"activeCount":99},[],{"trials":11189,"activeCount":99},[],{"intervention":6238,"totalTrials":151,"cells":11191},{"EARLY_PHASE1":11192,"PHASE1":11194,"PHASE2":11200,"PHASE3":11202,"PHASE4":11204,"NA":11206},{"trials":11193,"activeCount":99},[],{"trials":11195,"activeCount":99},[11196],{"nctId":6226,"briefTitle":6227,"status":109,"phases":11197,"primaryCompletion":3740,"completion":6229,"start":6230,"enrollment":6231,"conditions":11198,"interventions":11199},[88],[6233,6234],[6236,6237,6238,6209],{"trials":11201,"activeCount":99},[],{"trials":11203,"activeCount":99},[],{"trials":11205,"activeCount":99},[],{"trials":11207,"activeCount":99},[],{"intervention":11209,"totalTrials":151,"cells":11210},"ChAd63 PvDBP 5 x 10^9",{"EARLY_PHASE1":11211,"PHASE1":11213,"PHASE2":11224,"PHASE3":11226,"PHASE4":11228,"NA":11230},{"trials":11212,"activeCount":99},[],{"trials":11214,"activeCount":99},[11215],{"nctId":11216,"briefTitle":11217,"status":109,"phases":11218,"primaryCompletion":577,"completion":577,"start":4320,"enrollment":2572,"conditions":11219,"interventions":11220},"NCT01816113","Phase Ia Study of ChAd63\u002FMVA PvDBP",[88],[15,8194],[11209,11221,11222,11223],"ChAd63 PvDBP 5 x 10^10","MVA PvDBP 1 x 10^8","MVA PvDBP 2 x 10^8",{"trials":11225,"activeCount":99},[],{"trials":11227,"activeCount":99},[],{"trials":11229,"activeCount":99},[],{"trials":11231,"activeCount":99},[],{"intervention":11221,"totalTrials":151,"cells":11233},{"EARLY_PHASE1":11234,"PHASE1":11236,"PHASE2":11242,"PHASE3":11244,"PHASE4":11246,"NA":11248},{"trials":11235,"activeCount":99},[],{"trials":11237,"activeCount":99},[11238],{"nctId":11216,"briefTitle":11217,"status":109,"phases":11239,"primaryCompletion":577,"completion":577,"start":4320,"enrollment":2572,"conditions":11240,"interventions":11241},[88],[15,8194],[11209,11221,11222,11223],{"trials":11243,"activeCount":99},[],{"trials":11245,"activeCount":99},[],{"trials":11247,"activeCount":99},[],{"trials":11249,"activeCount":99},[],{"intervention":11222,"totalTrials":151,"cells":11251},{"EARLY_PHASE1":11252,"PHASE1":11254,"PHASE2":11260,"PHASE3":11262,"PHASE4":11264,"NA":11266},{"trials":11253,"activeCount":99},[],{"trials":11255,"activeCount":99},[11256],{"nctId":11216,"briefTitle":11217,"status":109,"phases":11257,"primaryCompletion":577,"completion":577,"start":4320,"enrollment":2572,"conditions":11258,"interventions":11259},[88],[15,8194],[11209,11221,11222,11223],{"trials":11261,"activeCount":99},[],{"trials":11263,"activeCount":99},[],{"trials":11265,"activeCount":99},[],{"trials":11267,"activeCount":99},[],{"intervention":11223,"totalTrials":151,"cells":11269},{"EARLY_PHASE1":11270,"PHASE1":11272,"PHASE2":11278,"PHASE3":11280,"PHASE4":11282,"NA":11284},{"trials":11271,"activeCount":99},[],{"trials":11273,"activeCount":99},[11274],{"nctId":11216,"briefTitle":11217,"status":109,"phases":11275,"primaryCompletion":577,"completion":577,"start":4320,"enrollment":2572,"conditions":11276,"interventions":11277},[88],[15,8194],[11209,11221,11222,11223],{"trials":11279,"activeCount":99},[],{"trials":11281,"activeCount":99},[],{"trials":11283,"activeCount":99},[],{"trials":11285,"activeCount":99},[],{"intervention":11287,"totalTrials":151,"cells":11288},"Viroflu® and MVA-NP+M1",{"EARLY_PHASE1":11289,"PHASE1":11291,"PHASE2":11301,"PHASE3":11303,"PHASE4":11305,"NA":11307},{"trials":11290,"activeCount":99},[],{"trials":11292,"activeCount":99},[11293],{"nctId":11294,"briefTitle":11295,"status":795,"phases":11296,"primaryCompletion":3653,"completion":3653,"start":11297,"enrollment":95,"conditions":11298,"interventions":11299},"NCT02014168","Safety and Immunogenicity of Co-administration of Candidate Influenza Vaccine MVA-NP+M1 and Viroflu® Seasonal Influenza Vaccine",[88],"2014-01",[30],[11287,11300],"Viroflu® and saline placebo",{"trials":11302,"activeCount":99},[],{"trials":11304,"activeCount":99},[],{"trials":11306,"activeCount":99},[],{"trials":11308,"activeCount":99},[],{"intervention":11300,"totalTrials":151,"cells":11310},{"EARLY_PHASE1":11311,"PHASE1":11313,"PHASE2":11319,"PHASE3":11321,"PHASE4":11323,"NA":11325},{"trials":11312,"activeCount":99},[],{"trials":11314,"activeCount":99},[11315],{"nctId":11294,"briefTitle":11295,"status":795,"phases":11316,"primaryCompletion":3653,"completion":3653,"start":11297,"enrollment":95,"conditions":11317,"interventions":11318},[88],[30],[11287,11300],{"trials":11320,"activeCount":99},[],{"trials":11322,"activeCount":99},[],{"trials":11324,"activeCount":99},[],{"trials":11326,"activeCount":99},[],{"intervention":11328,"totalTrials":151,"cells":11329},"PF-02341066",{"EARLY_PHASE1":11330,"PHASE1":11332,"PHASE2":11345,"PHASE3":11347,"PHASE4":11349,"NA":11351},{"trials":11331,"activeCount":99},[],{"trials":11333,"activeCount":99},[11334],{"nctId":11335,"briefTitle":11336,"status":109,"phases":11337,"primaryCompletion":11338,"completion":11338,"start":11339,"enrollment":7398,"conditions":11340,"interventions":11342},"NCT02510001","MEK and MET Inhibition in Colorectal Cancer",[88],"2018-12-03","2014-11",[6299,11341],"Colorectal Cancer",[11328,11343,11344],"PD-0325901","Binimetinib",{"trials":11346,"activeCount":99},[],{"trials":11348,"activeCount":99},[],{"trials":11350,"activeCount":99},[],{"trials":11352,"activeCount":99},[],{"intervention":11343,"totalTrials":151,"cells":11354},{"EARLY_PHASE1":11355,"PHASE1":11357,"PHASE2":11363,"PHASE3":11365,"PHASE4":11367,"NA":11369},{"trials":11356,"activeCount":99},[],{"trials":11358,"activeCount":99},[11359],{"nctId":11335,"briefTitle":11336,"status":109,"phases":11360,"primaryCompletion":11338,"completion":11338,"start":11339,"enrollment":7398,"conditions":11361,"interventions":11362},[88],[6299,11341],[11328,11343,11344],{"trials":11364,"activeCount":99},[],{"trials":11366,"activeCount":99},[],{"trials":11368,"activeCount":99},[],{"trials":11370,"activeCount":99},[],{"intervention":11344,"totalTrials":151,"cells":11372},{"EARLY_PHASE1":11373,"PHASE1":11375,"PHASE2":11381,"PHASE3":11383,"PHASE4":11385,"NA":11387},{"trials":11374,"activeCount":99},[],{"trials":11376,"activeCount":99},[11377],{"nctId":11335,"briefTitle":11336,"status":109,"phases":11378,"primaryCompletion":11338,"completion":11338,"start":11339,"enrollment":7398,"conditions":11379,"interventions":11380},[88],[6299,11341],[11328,11343,11344],{"trials":11382,"activeCount":99},[],{"trials":11384,"activeCount":99},[],{"trials":11386,"activeCount":99},[],{"trials":11388,"activeCount":99},[],{"intervention":6312,"totalTrials":151,"cells":11390},{"EARLY_PHASE1":11391,"PHASE1":11393,"PHASE2":11399,"PHASE3":11401,"PHASE4":11403,"NA":11405},{"trials":11392,"activeCount":99},[],{"trials":11394,"activeCount":99},[11395],{"nctId":6304,"briefTitle":6305,"status":109,"phases":11396,"primaryCompletion":6307,"completion":6307,"start":6308,"enrollment":31,"conditions":11397,"interventions":11398},[88],[6310],[6312,6284],{"trials":11400,"activeCount":99},[],{"trials":11402,"activeCount":99},[],{"trials":11404,"activeCount":99},[],{"trials":11406,"activeCount":99},[],{"intervention":6086,"totalTrials":151,"cells":11408},{"EARLY_PHASE1":11409,"PHASE1":11411,"PHASE2":11417,"PHASE3":11419,"PHASE4":11421,"NA":11423},{"trials":11410,"activeCount":99},[],{"trials":11412,"activeCount":99},[11413],{"nctId":6079,"briefTitle":6080,"status":109,"phases":11414,"primaryCompletion":6082,"completion":6082,"start":6083,"enrollment":19,"conditions":11415,"interventions":11416},[88],[18],[6086,6000],{"trials":11418,"activeCount":99},[],{"trials":11420,"activeCount":99},[],{"trials":11422,"activeCount":99},[],{"trials":11424,"activeCount":99},[],{"intervention":9441,"totalTrials":151,"cells":11426},{"EARLY_PHASE1":11427,"PHASE1":11429,"PHASE2":11435,"PHASE3":11437,"PHASE4":11439,"NA":11441},{"trials":11428,"activeCount":99},[],{"trials":11430,"activeCount":99},[11431],{"nctId":9435,"briefTitle":9436,"status":795,"phases":11432,"primaryCompletion":9438,"completion":9438,"start":576,"enrollment":168,"conditions":11433,"interventions":11434},[88],[18],[9421,9441,9442,9443],{"trials":11436,"activeCount":99},[],{"trials":11438,"activeCount":99},[],{"trials":11440,"activeCount":99},[],{"trials":11442,"activeCount":99},[],{"intervention":9442,"totalTrials":151,"cells":11444},{"EARLY_PHASE1":11445,"PHASE1":11447,"PHASE2":11453,"PHASE3":11455,"PHASE4":11457,"NA":11459},{"trials":11446,"activeCount":99},[],{"trials":11448,"activeCount":99},[11449],{"nctId":9435,"briefTitle":9436,"status":795,"phases":11450,"primaryCompletion":9438,"completion":9438,"start":576,"enrollment":168,"conditions":11451,"interventions":11452},[88],[18],[9421,9441,9442,9443],{"trials":11454,"activeCount":99},[],{"trials":11456,"activeCount":99},[],{"trials":11458,"activeCount":99},[],{"trials":11460,"activeCount":99},[],{"intervention":9443,"totalTrials":151,"cells":11462},{"EARLY_PHASE1":11463,"PHASE1":11465,"PHASE2":11471,"PHASE3":11473,"PHASE4":11475,"NA":11477},{"trials":11464,"activeCount":99},[],{"trials":11466,"activeCount":99},[11467],{"nctId":9435,"briefTitle":9436,"status":795,"phases":11468,"primaryCompletion":9438,"completion":9438,"start":576,"enrollment":168,"conditions":11469,"interventions":11470},[88],[18],[9421,9441,9442,9443],{"trials":11472,"activeCount":99},[],{"trials":11474,"activeCount":99},[],{"trials":11476,"activeCount":99},[],{"trials":11478,"activeCount":99},[],{"intervention":11480,"totalTrials":151,"cells":11481},"AdCh63 AMA1 + MVA AMA1 + AMA1-C1\u002FAlhydrogel®+ CPG 7909",{"EARLY_PHASE1":11482,"PHASE1":11484,"PHASE2":11497,"PHASE3":11499,"PHASE4":11501,"NA":11503},{"trials":11483,"activeCount":99},[],{"trials":11485,"activeCount":99},[11486],{"nctId":11487,"briefTitle":11488,"status":109,"phases":11489,"primaryCompletion":3655,"completion":3655,"start":590,"enrollment":11490,"conditions":11491,"interventions":11492},"NCT01351948","Safety and Immunogenicity of Malaria Vaccines AdCh63 AMA1, MVA AMA1 and AMA1-C1\u002FAlhydrogel®+\u002F- CPG 7909",[88],35,[15],[11480,11493,11494,11495,11496],"AdCh63 AMA1 + AMA1-C1\u002FAlhydrogel®+ CPG 7909","AdCh63 AMA1 + AMA1-C1\u002FAlhydrogel®","AdCh63 AMA1 AMA1-C1\u002FAlhydrogel®+ CPG 7909","AdCh63 AMA1 + MVA AMA1",{"trials":11498,"activeCount":99},[],{"trials":11500,"activeCount":99},[],{"trials":11502,"activeCount":99},[],{"trials":11504,"activeCount":99},[],{"intervention":11493,"totalTrials":151,"cells":11506},{"EARLY_PHASE1":11507,"PHASE1":11509,"PHASE2":11515,"PHASE3":11517,"PHASE4":11519,"NA":11521},{"trials":11508,"activeCount":99},[],{"trials":11510,"activeCount":99},[11511],{"nctId":11487,"briefTitle":11488,"status":109,"phases":11512,"primaryCompletion":3655,"completion":3655,"start":590,"enrollment":11490,"conditions":11513,"interventions":11514},[88],[15],[11480,11493,11494,11495,11496],{"trials":11516,"activeCount":99},[],{"trials":11518,"activeCount":99},[],{"trials":11520,"activeCount":99},[],{"trials":11522,"activeCount":99},[],{"intervention":11494,"totalTrials":151,"cells":11524},{"EARLY_PHASE1":11525,"PHASE1":11527,"PHASE2":11533,"PHASE3":11535,"PHASE4":11537,"NA":11539},{"trials":11526,"activeCount":99},[],{"trials":11528,"activeCount":99},[11529],{"nctId":11487,"briefTitle":11488,"status":109,"phases":11530,"primaryCompletion":3655,"completion":3655,"start":590,"enrollment":11490,"conditions":11531,"interventions":11532},[88],[15],[11480,11493,11494,11495,11496],{"trials":11534,"activeCount":99},[],{"trials":11536,"activeCount":99},[],{"trials":11538,"activeCount":99},[],{"trials":11540,"activeCount":99},[],{"intervention":11495,"totalTrials":151,"cells":11542},{"EARLY_PHASE1":11543,"PHASE1":11545,"PHASE2":11551,"PHASE3":11553,"PHASE4":11555,"NA":11557},{"trials":11544,"activeCount":99},[],{"trials":11546,"activeCount":99},[11547],{"nctId":11487,"briefTitle":11488,"status":109,"phases":11548,"primaryCompletion":3655,"completion":3655,"start":590,"enrollment":11490,"conditions":11549,"interventions":11550},[88],[15],[11480,11493,11494,11495,11496],{"trials":11552,"activeCount":99},[],{"trials":11554,"activeCount":99},[],{"trials":11556,"activeCount":99},[],{"trials":11558,"activeCount":99},[],{"intervention":11496,"totalTrials":151,"cells":11560},{"EARLY_PHASE1":11561,"PHASE1":11563,"PHASE2":11569,"PHASE3":11571,"PHASE4":11573,"NA":11575},{"trials":11562,"activeCount":99},[],{"trials":11564,"activeCount":99},[11565],{"nctId":11487,"briefTitle":11488,"status":109,"phases":11566,"primaryCompletion":3655,"completion":3655,"start":590,"enrollment":11490,"conditions":11567,"interventions":11568},[88],[15],[11480,11493,11494,11495,11496],{"trials":11570,"activeCount":99},[],{"trials":11572,"activeCount":99},[],{"trials":11574,"activeCount":99},[],{"trials":11576,"activeCount":99},[],{"intervention":11578,"totalTrials":151,"cells":11579},"ChAdOx2 HAV",{"EARLY_PHASE1":11580,"PHASE1":11582,"PHASE2":11595,"PHASE3":11597,"PHASE4":11599,"NA":11601},{"trials":11581,"activeCount":99},[],{"trials":11583,"activeCount":99},[11584],{"nctId":11585,"briefTitle":11586,"status":109,"phases":11587,"primaryCompletion":11588,"completion":11588,"start":11589,"enrollment":3743,"conditions":11590,"interventions":11593},"NCT03027193","A Study to Determine the Safety and Immunogenicity of a Candidate MAP Vaccines ChAdOx2 HAV and MVA in Healthy Adult Volunteers",[88],"2020-01-16","2017-03-15",[11591,11592],"Crohn Disease","Mycobacterium Avium Subspecies Paratuberculosis",[11578,11594],"MVA HAV",{"trials":11596,"activeCount":99},[],{"trials":11598,"activeCount":99},[],{"trials":11600,"activeCount":99},[],{"trials":11602,"activeCount":99},[],{"intervention":11594,"totalTrials":151,"cells":11604},{"EARLY_PHASE1":11605,"PHASE1":11607,"PHASE2":11613,"PHASE3":11615,"PHASE4":11617,"NA":11619},{"trials":11606,"activeCount":99},[],{"trials":11608,"activeCount":99},[11609],{"nctId":11585,"briefTitle":11586,"status":109,"phases":11610,"primaryCompletion":11588,"completion":11588,"start":11589,"enrollment":3743,"conditions":11611,"interventions":11612},[88],[11591,11592],[11578,11594],{"trials":11614,"activeCount":99},[],{"trials":11616,"activeCount":99},[],{"trials":11618,"activeCount":99},[],{"trials":11620,"activeCount":99},[],{"intervention":11622,"totalTrials":151,"cells":11623},"ChAdOx1.5T4",{"EARLY_PHASE1":11624,"PHASE1":11626,"PHASE2":11639,"PHASE3":11641,"PHASE4":11643,"NA":11645},{"trials":11625,"activeCount":99},[],{"trials":11627,"activeCount":99},[11628],{"nctId":11629,"briefTitle":11630,"status":109,"phases":11631,"primaryCompletion":11632,"completion":11633,"start":5378,"enrollment":1530,"conditions":11634,"interventions":11636},"NCT02390063","Vaccination in Prostate Cancer (VANCE)",[88],"2018-05-15","2019-05-15",[11635],"Prostate Cancer",[11622,11637,11638],"MVA.5T4","Cyclophosphamide",{"trials":11640,"activeCount":99},[],{"trials":11642,"activeCount":99},[],{"trials":11644,"activeCount":99},[],{"trials":11646,"activeCount":99},[],{"intervention":11637,"totalTrials":151,"cells":11648},{"EARLY_PHASE1":11649,"PHASE1":11651,"PHASE2":11657,"PHASE3":11659,"PHASE4":11661,"NA":11663},{"trials":11650,"activeCount":99},[],{"trials":11652,"activeCount":99},[11653],{"nctId":11629,"briefTitle":11630,"status":109,"phases":11654,"primaryCompletion":11632,"completion":11633,"start":5378,"enrollment":1530,"conditions":11655,"interventions":11656},[88],[11635],[11622,11637,11638],{"trials":11658,"activeCount":99},[],{"trials":11660,"activeCount":99},[],{"trials":11662,"activeCount":99},[],{"trials":11664,"activeCount":99},[],{"intervention":11638,"totalTrials":151,"cells":11666},{"EARLY_PHASE1":11667,"PHASE1":11669,"PHASE2":11675,"PHASE3":11677,"PHASE4":11679,"NA":11681},{"trials":11668,"activeCount":99},[],{"trials":11670,"activeCount":99},[11671],{"nctId":11629,"briefTitle":11630,"status":109,"phases":11672,"primaryCompletion":11632,"completion":11633,"start":5378,"enrollment":1530,"conditions":11673,"interventions":11674},[88],[11635],[11622,11637,11638],{"trials":11676,"activeCount":99},[],{"trials":11678,"activeCount":99},[],{"trials":11680,"activeCount":99},[],{"trials":11682,"activeCount":99},[],{"intervention":11684,"totalTrials":151,"cells":11685},"AdCh63 AMA1",{"EARLY_PHASE1":11686,"PHASE1":11688,"PHASE2":11697,"PHASE3":11699,"PHASE4":11701,"NA":11703},{"trials":11687,"activeCount":99},[],{"trials":11689,"activeCount":99},[11690],{"nctId":11691,"briefTitle":11692,"status":109,"phases":11693,"primaryCompletion":5421,"completion":5421,"start":4104,"enrollment":578,"conditions":11694,"interventions":11695},"NCT01095055","A Study of AdCh63 AMA1 Alone and With MVA AMA1",[88],[15],[11684,11696],"AdCh63 AMa1 and MVA AMA1",{"trials":11698,"activeCount":99},[],{"trials":11700,"activeCount":99},[],{"trials":11702,"activeCount":99},[],{"trials":11704,"activeCount":99},[],{"intervention":11696,"totalTrials":151,"cells":11706},{"EARLY_PHASE1":11707,"PHASE1":11709,"PHASE2":11715,"PHASE3":11717,"PHASE4":11719,"NA":11721},{"trials":11708,"activeCount":99},[],{"trials":11710,"activeCount":99},[11711],{"nctId":11691,"briefTitle":11692,"status":109,"phases":11712,"primaryCompletion":5421,"completion":5421,"start":4104,"enrollment":578,"conditions":11713,"interventions":11714},[88],[15],[11684,11696],{"trials":11716,"activeCount":99},[],{"trials":11718,"activeCount":99},[],{"trials":11720,"activeCount":99},[],{"trials":11722,"activeCount":99},[],{"intervention":6425,"totalTrials":151,"cells":11724},{"EARLY_PHASE1":11725,"PHASE1":11727,"PHASE2":11733,"PHASE3":11735,"PHASE4":11737,"NA":11739},{"trials":11726,"activeCount":99},[],{"trials":11728,"activeCount":99},[11729],{"nctId":6418,"briefTitle":6419,"status":109,"phases":11730,"primaryCompletion":6421,"completion":4518,"start":5768,"enrollment":6422,"conditions":11731,"interventions":11732},[88],[15],[6193,6425],{"trials":11734,"activeCount":99},[],{"trials":11736,"activeCount":99},[],{"trials":11738,"activeCount":99},[],{"trials":11740,"activeCount":99},[],{"intervention":11742,"totalTrials":151,"cells":11743},"Doxorubicin",{"EARLY_PHASE1":11744,"PHASE1":11746,"PHASE2":11761,"PHASE3":11763,"PHASE4":11765,"NA":11767},{"trials":11745,"activeCount":99},[],{"trials":11747,"activeCount":99},[11748],{"nctId":11749,"briefTitle":11750,"status":183,"phases":11751,"primaryCompletion":11752,"completion":11752,"start":11753,"enrollment":99,"conditions":11754,"interventions":11759},"NCT04852367","PanDox: Targeted Doxorubicin in Pancreatic Tumours",[88],"2023-03-30","2021-06-16",[11755,11756,11757,11758],"Pancreatic Ductal Adenocarcinoma","Pancreatic Cancer Stage IV","Pancreatic Cancer Non-resectable","Pancreatic Cancer Metastatic",[11742,11760],"ThermoDox",{"trials":11762,"activeCount":99},[],{"trials":11764,"activeCount":99},[],{"trials":11766,"activeCount":99},[],{"trials":11768,"activeCount":99},[],{"intervention":11760,"totalTrials":151,"cells":11770},{"EARLY_PHASE1":11771,"PHASE1":11773,"PHASE2":11779,"PHASE3":11781,"PHASE4":11783,"NA":11785},{"trials":11772,"activeCount":99},[],{"trials":11774,"activeCount":99},[11775],{"nctId":11749,"briefTitle":11750,"status":183,"phases":11776,"primaryCompletion":11752,"completion":11752,"start":11753,"enrollment":99,"conditions":11777,"interventions":11778},[88],[11755,11756,11757,11758],[11742,11760],{"trials":11780,"activeCount":99},[],{"trials":11782,"activeCount":99},[],{"trials":11784,"activeCount":99},[],{"trials":11786,"activeCount":99},[],{"intervention":11788,"totalTrials":151,"cells":11789},"Regimens",{"EARLY_PHASE1":11790,"PHASE1":11792,"PHASE2":11802,"PHASE3":11804,"PHASE4":11806,"NA":11808},{"trials":11791,"activeCount":99},[],{"trials":11793,"activeCount":99},[11794],{"nctId":11795,"briefTitle":11796,"status":109,"phases":11797,"primaryCompletion":6230,"completion":6230,"start":3829,"enrollment":1674,"conditions":11798,"interventions":11801},"NCT01668433","Pharmacokinetic and in Vitro Transmission Blocking Activities Study of Primaquine Compare to Methylene Blue in Healthy Volunteer Both G6PD Normal and G6PD Deficiency",[88],[11799,11800,24],"G6PD Normal","G6PD Deficient",[11788],{"trials":11803,"activeCount":99},[],{"trials":11805,"activeCount":99},[],{"trials":11807,"activeCount":99},[],{"trials":11809,"activeCount":99},[],{"intervention":11811,"totalTrials":151,"cells":11812},"ChAd63 CS",{"EARLY_PHASE1":11813,"PHASE1":11815,"PHASE2":11825,"PHASE3":11827,"PHASE4":11829,"NA":11831},{"trials":11814,"activeCount":99},[],{"trials":11816,"activeCount":99},[11817],{"nctId":11818,"briefTitle":11819,"status":109,"phases":11820,"primaryCompletion":527,"completion":527,"start":9401,"enrollment":2572,"conditions":11821,"interventions":11822},"NCT01450280","Safety and Immunogenicity of New Malaria Vaccine Candidate ChAd63 CS Administered Alone and With MVA CS",[88],[15],[11811,11823,11811,11824],"ChAd63 CS, MVA CS","ChAd63, MVA CS",{"trials":11826,"activeCount":99},[],{"trials":11828,"activeCount":99},[],{"trials":11830,"activeCount":99},[],{"trials":11832,"activeCount":99},[],{"intervention":11823,"totalTrials":151,"cells":11834},{"EARLY_PHASE1":11835,"PHASE1":11837,"PHASE2":11843,"PHASE3":11845,"PHASE4":11847,"NA":11849},{"trials":11836,"activeCount":99},[],{"trials":11838,"activeCount":99},[11839],{"nctId":11818,"briefTitle":11819,"status":109,"phases":11840,"primaryCompletion":527,"completion":527,"start":9401,"enrollment":2572,"conditions":11841,"interventions":11842},[88],[15],[11811,11823,11811,11824],{"trials":11844,"activeCount":99},[],{"trials":11846,"activeCount":99},[],{"trials":11848,"activeCount":99},[],{"trials":11850,"activeCount":99},[],{"intervention":11824,"totalTrials":151,"cells":11852},{"EARLY_PHASE1":11853,"PHASE1":11855,"PHASE2":11861,"PHASE3":11863,"PHASE4":11865,"NA":11867},{"trials":11854,"activeCount":99},[],{"trials":11856,"activeCount":99},[11857],{"nctId":11818,"briefTitle":11819,"status":109,"phases":11858,"primaryCompletion":527,"completion":527,"start":9401,"enrollment":2572,"conditions":11859,"interventions":11860},[88],[15],[11811,11823,11811,11824],{"trials":11862,"activeCount":99},[],{"trials":11864,"activeCount":99},[],{"trials":11866,"activeCount":99},[],{"trials":11868,"activeCount":99},[],{"intervention":2508,"totalTrials":151,"cells":11870},{"EARLY_PHASE1":11871,"PHASE1":11873,"PHASE2":11879,"PHASE3":11881,"PHASE4":11883,"NA":11885},{"trials":11872,"activeCount":99},[],{"trials":11874,"activeCount":99},[11875],{"nctId":2500,"briefTitle":2501,"status":109,"phases":11876,"primaryCompletion":2503,"completion":2503,"start":2504,"enrollment":1674,"conditions":11877,"interventions":11878},[88],[2506],[634,2508],{"trials":11880,"activeCount":99},[],{"trials":11882,"activeCount":99},[],{"trials":11884,"activeCount":99},[],{"trials":11886,"activeCount":99},[],{"intervention":11888,"totalTrials":151,"cells":11889},"ChAdOx1 Zika",{"EARLY_PHASE1":11890,"PHASE1":11892,"PHASE2":11902,"PHASE3":11904,"PHASE4":11906,"NA":11908},{"trials":11891,"activeCount":99},[],{"trials":11893,"activeCount":99},[11894],{"nctId":11895,"briefTitle":11896,"status":109,"phases":11897,"primaryCompletion":11898,"completion":11898,"start":11899,"enrollment":2572,"conditions":11900,"interventions":11901},"NCT04015648","Safety and Immunogenicity of a Candidate ZIKV Vaccine (ZIKA001)",[88],"2022-03-10","2019-10-21",[10728],[11888],{"trials":11903,"activeCount":99},[],{"trials":11905,"activeCount":99},[],{"trials":11907,"activeCount":99},[],{"trials":11909,"activeCount":99},[],{"intervention":11911,"totalTrials":151,"cells":11912},"IVM, IVM and PQ, IVM and DHA-PQP, IVM and DHA-PQP and PQ",{"EARLY_PHASE1":11913,"PHASE1":11915,"PHASE2":11927,"PHASE3":11929,"PHASE4":11931,"NA":11933},{"trials":11914,"activeCount":99},[],{"trials":11916,"activeCount":99},[11917],{"nctId":11918,"briefTitle":11919,"status":109,"phases":11920,"primaryCompletion":11921,"completion":11921,"start":6199,"enrollment":578,"conditions":11922,"interventions":11924},"NCT02568098","Pharmacokinetic and Mosquito-Lethal Effects of Ivermectin (IVM), Primaquine (PQ), Dihydroartemisinin-Piperaquine (DHA-PQP) and Albendazole (ABZ) in Healthy Subjects",[88],"2016-12",[1288,11923,24],"Pharmacokinetics",[11911,11925,11926],"PQ and DHA-PQP and PQ","DHA-PQP",{"trials":11928,"activeCount":99},[],{"trials":11930,"activeCount":99},[],{"trials":11932,"activeCount":99},[],{"trials":11934,"activeCount":99},[],{"intervention":11925,"totalTrials":151,"cells":11936},{"EARLY_PHASE1":11937,"PHASE1":11939,"PHASE2":11945,"PHASE3":11947,"PHASE4":11949,"NA":11951},{"trials":11938,"activeCount":99},[],{"trials":11940,"activeCount":99},[11941],{"nctId":11918,"briefTitle":11919,"status":109,"phases":11942,"primaryCompletion":11921,"completion":11921,"start":6199,"enrollment":578,"conditions":11943,"interventions":11944},[88],[1288,11923,24],[11911,11925,11926],{"trials":11946,"activeCount":99},[],{"trials":11948,"activeCount":99},[],{"trials":11950,"activeCount":99},[],{"trials":11952,"activeCount":99},[],{"intervention":11926,"totalTrials":151,"cells":11954},{"EARLY_PHASE1":11955,"PHASE1":11957,"PHASE2":11963,"PHASE3":11965,"PHASE4":11967,"NA":11969},{"trials":11956,"activeCount":99},[],{"trials":11958,"activeCount":99},[11959],{"nctId":11918,"briefTitle":11919,"status":109,"phases":11960,"primaryCompletion":11921,"completion":11921,"start":6199,"enrollment":578,"conditions":11961,"interventions":11962},[88],[1288,11923,24],[11911,11925,11926],{"trials":11964,"activeCount":99},[],{"trials":11966,"activeCount":99},[],{"trials":11968,"activeCount":99},[],{"trials":11970,"activeCount":99},[],{"intervention":11972,"totalTrials":151,"cells":11973},"SARS-CoV-2 virus",{"EARLY_PHASE1":11974,"PHASE1":11976,"PHASE2":11986,"PHASE3":11988,"PHASE4":11990,"NA":11992},{"trials":11975,"activeCount":99},[],{"trials":11977,"activeCount":99},[11978],{"nctId":11979,"briefTitle":11980,"status":2901,"phases":11981,"primaryCompletion":10665,"completion":10665,"start":11982,"enrollment":11983,"conditions":11984,"interventions":11985},"NCT04864548","COV-CHIM01: SARS-CoV-2 (COVID-19) Dose Finding Infection Study",[88],"2021-05-27",132,[4539],[11972],{"trials":11987,"activeCount":99},[],{"trials":11989,"activeCount":99},[],{"trials":11991,"activeCount":99},[],{"trials":11993,"activeCount":99},[],{"intervention":11995,"totalTrials":151,"cells":11996},"Plasmodium falciparum sporozoite",{"EARLY_PHASE1":11997,"PHASE1":11999,"PHASE2":12008,"PHASE3":12010,"PHASE4":12012,"NA":12014},{"trials":11998,"activeCount":99},[],{"trials":12000,"activeCount":99},[12001],{"nctId":12002,"briefTitle":12003,"status":2901,"phases":12004,"primaryCompletion":12005,"completion":3252,"start":3654,"enrollment":6585,"conditions":12006,"interventions":12007},"NCT02739763","Controlled Human Malaria Infection in Semi-Immune Kenyan Adults. (CHMI-SIKA)",[88],"2020-01",[15],[11995],{"trials":12009,"activeCount":99},[],{"trials":12011,"activeCount":99},[],{"trials":12013,"activeCount":99},[],{"trials":12015,"activeCount":99},[],{"intervention":12017,"totalTrials":151,"cells":12018},"R21\u002FMatrix-M - single vial formulation",{"EARLY_PHASE1":12019,"PHASE1":12021,"PHASE2":12040,"PHASE3":12042,"PHASE4":12044,"NA":12046},{"trials":12020,"activeCount":99},[],{"trials":12022,"activeCount":99},[12023],{"nctId":12024,"briefTitle":12025,"status":109,"phases":12026,"primaryCompletion":12027,"completion":12027,"start":12028,"enrollment":12029,"conditions":12030,"interventions":12031},"NCT05155579","Assessment of Safety and Immunogenicity of a Single Vial Presentation of R21\u002FMatrix-M and Co-Administration With EPI Vaccines",[88],"2025-05-27","2022-05-14",594,[15],[12017,12032,12033,12034,12035,12036,12037,12038,12039],"R21\u002FMatrix-M - two vial formulation","Licensed vaccine - Measles-rubella","Licensed vaccine - Yellow fever","Licensed vaccine - Pentavalent","Licensed vaccine - Oral Polio Vaccine","Licensed vaccine - Rotavirus","Licensed vaccine - Pneumococcal vaccine","Licensed vaccine - Inactivated Polio Vaccine",{"trials":12041,"activeCount":99},[],{"trials":12043,"activeCount":99},[],{"trials":12045,"activeCount":99},[],{"trials":12047,"activeCount":99},[],{"intervention":12032,"totalTrials":151,"cells":12049},{"EARLY_PHASE1":12050,"PHASE1":12052,"PHASE2":12058,"PHASE3":12060,"PHASE4":12062,"NA":12064},{"trials":12051,"activeCount":99},[],{"trials":12053,"activeCount":99},[12054],{"nctId":12024,"briefTitle":12025,"status":109,"phases":12055,"primaryCompletion":12027,"completion":12027,"start":12028,"enrollment":12029,"conditions":12056,"interventions":12057},[88],[15],[12017,12032,12033,12034,12035,12036,12037,12038,12039],{"trials":12059,"activeCount":99},[],{"trials":12061,"activeCount":99},[],{"trials":12063,"activeCount":99},[],{"trials":12065,"activeCount":99},[],{"intervention":12033,"totalTrials":151,"cells":12067},{"EARLY_PHASE1":12068,"PHASE1":12070,"PHASE2":12076,"PHASE3":12078,"PHASE4":12080,"NA":12082},{"trials":12069,"activeCount":99},[],{"trials":12071,"activeCount":99},[12072],{"nctId":12024,"briefTitle":12025,"status":109,"phases":12073,"primaryCompletion":12027,"completion":12027,"start":12028,"enrollment":12029,"conditions":12074,"interventions":12075},[88],[15],[12017,12032,12033,12034,12035,12036,12037,12038,12039],{"trials":12077,"activeCount":99},[],{"trials":12079,"activeCount":99},[],{"trials":12081,"activeCount":99},[],{"trials":12083,"activeCount":99},[],{"intervention":12034,"totalTrials":151,"cells":12085},{"EARLY_PHASE1":12086,"PHASE1":12088,"PHASE2":12094,"PHASE3":12096,"PHASE4":12098,"NA":12100},{"trials":12087,"activeCount":99},[],{"trials":12089,"activeCount":99},[12090],{"nctId":12024,"briefTitle":12025,"status":109,"phases":12091,"primaryCompletion":12027,"completion":12027,"start":12028,"enrollment":12029,"conditions":12092,"interventions":12093},[88],[15],[12017,12032,12033,12034,12035,12036,12037,12038,12039],{"trials":12095,"activeCount":99},[],{"trials":12097,"activeCount":99},[],{"trials":12099,"activeCount":99},[],{"trials":12101,"activeCount":99},[],{"intervention":12035,"totalTrials":151,"cells":12103},{"EARLY_PHASE1":12104,"PHASE1":12106,"PHASE2":12112,"PHASE3":12114,"PHASE4":12116,"NA":12118},{"trials":12105,"activeCount":99},[],{"trials":12107,"activeCount":99},[12108],{"nctId":12024,"briefTitle":12025,"status":109,"phases":12109,"primaryCompletion":12027,"completion":12027,"start":12028,"enrollment":12029,"conditions":12110,"interventions":12111},[88],[15],[12017,12032,12033,12034,12035,12036,12037,12038,12039],{"trials":12113,"activeCount":99},[],{"trials":12115,"activeCount":99},[],{"trials":12117,"activeCount":99},[],{"trials":12119,"activeCount":99},[],{"intervention":12036,"totalTrials":151,"cells":12121},{"EARLY_PHASE1":12122,"PHASE1":12124,"PHASE2":12130,"PHASE3":12132,"PHASE4":12134,"NA":12136},{"trials":12123,"activeCount":99},[],{"trials":12125,"activeCount":99},[12126],{"nctId":12024,"briefTitle":12025,"status":109,"phases":12127,"primaryCompletion":12027,"completion":12027,"start":12028,"enrollment":12029,"conditions":12128,"interventions":12129},[88],[15],[12017,12032,12033,12034,12035,12036,12037,12038,12039],{"trials":12131,"activeCount":99},[],{"trials":12133,"activeCount":99},[],{"trials":12135,"activeCount":99},[],{"trials":12137,"activeCount":99},[],{"intervention":12037,"totalTrials":151,"cells":12139},{"EARLY_PHASE1":12140,"PHASE1":12142,"PHASE2":12148,"PHASE3":12150,"PHASE4":12152,"NA":12154},{"trials":12141,"activeCount":99},[],{"trials":12143,"activeCount":99},[12144],{"nctId":12024,"briefTitle":12025,"status":109,"phases":12145,"primaryCompletion":12027,"completion":12027,"start":12028,"enrollment":12029,"conditions":12146,"interventions":12147},[88],[15],[12017,12032,12033,12034,12035,12036,12037,12038,12039],{"trials":12149,"activeCount":99},[],{"trials":12151,"activeCount":99},[],{"trials":12153,"activeCount":99},[],{"trials":12155,"activeCount":99},[],{"intervention":12038,"totalTrials":151,"cells":12157},{"EARLY_PHASE1":12158,"PHASE1":12160,"PHASE2":12166,"PHASE3":12168,"PHASE4":12170,"NA":12172},{"trials":12159,"activeCount":99},[],{"trials":12161,"activeCount":99},[12162],{"nctId":12024,"briefTitle":12025,"status":109,"phases":12163,"primaryCompletion":12027,"completion":12027,"start":12028,"enrollment":12029,"conditions":12164,"interventions":12165},[88],[15],[12017,12032,12033,12034,12035,12036,12037,12038,12039],{"trials":12167,"activeCount":99},[],{"trials":12169,"activeCount":99},[],{"trials":12171,"activeCount":99},[],{"trials":12173,"activeCount":99},[],{"intervention":12039,"totalTrials":151,"cells":12175},{"EARLY_PHASE1":12176,"PHASE1":12178,"PHASE2":12184,"PHASE3":12186,"PHASE4":12188,"NA":12190},{"trials":12177,"activeCount":99},[],{"trials":12179,"activeCount":99},[12180],{"nctId":12024,"briefTitle":12025,"status":109,"phases":12181,"primaryCompletion":12027,"completion":12027,"start":12028,"enrollment":12029,"conditions":12182,"interventions":12183},[88],[15],[12017,12032,12033,12034,12035,12036,12037,12038,12039],{"trials":12185,"activeCount":99},[],{"trials":12187,"activeCount":99},[],{"trials":12189,"activeCount":99},[],{"trials":12191,"activeCount":99},[],{"intervention":12193,"totalTrials":151,"cells":12194},"TIV and MVA-NP+M1",{"EARLY_PHASE1":12195,"PHASE1":12197,"PHASE2":12206,"PHASE3":12208,"PHASE4":12210,"NA":12212},{"trials":12196,"activeCount":99},[],{"trials":12198,"activeCount":99},[12199],{"nctId":12200,"briefTitle":12201,"status":109,"phases":12202,"primaryCompletion":1458,"completion":1458,"start":3378,"enrollment":2572,"conditions":12203,"interventions":12204},"NCT01465035","A Study to Determine the Safety and Immunogenicity of Co-administration of the Candidate Influenza Vaccine MVA-NP+M1 and Seasonal Influenza Vaccine",[88],[30],[12193,12205],"Saline placebo and seasonal influenza vaccine TIV",{"trials":12207,"activeCount":99},[],{"trials":12209,"activeCount":99},[],{"trials":12211,"activeCount":99},[],{"trials":12213,"activeCount":99},[],{"intervention":12205,"totalTrials":151,"cells":12215},{"EARLY_PHASE1":12216,"PHASE1":12218,"PHASE2":12224,"PHASE3":12226,"PHASE4":12228,"NA":12230},{"trials":12217,"activeCount":99},[],{"trials":12219,"activeCount":99},[12220],{"nctId":12200,"briefTitle":12201,"status":109,"phases":12221,"primaryCompletion":1458,"completion":1458,"start":3378,"enrollment":2572,"conditions":12222,"interventions":12223},[88],[30],[12193,12205],{"trials":12225,"activeCount":99},[],{"trials":12227,"activeCount":99},[],{"trials":12229,"activeCount":99},[],{"trials":12231,"activeCount":99},[],{"intervention":12233,"totalTrials":151,"cells":12234},"R21 with ASO1B",{"EARLY_PHASE1":12235,"PHASE1":12237,"PHASE2":12247,"PHASE3":12249,"PHASE4":12251,"NA":12253},{"trials":12236,"activeCount":99},[],{"trials":12238,"activeCount":99},[12239],{"nctId":12240,"briefTitle":12241,"status":109,"phases":12242,"primaryCompletion":12243,"completion":12243,"start":12244,"enrollment":1674,"conditions":12245,"interventions":12246},"NCT02600975","A Study to Assess the Safety and Immunogenicity of a Malaria Vaccine Candidate, R21, Administered With AS01B",[88],"2017-01-19","2015-12-08",[15],[12233],{"trials":12248,"activeCount":99},[],{"trials":12250,"activeCount":99},[],{"trials":12252,"activeCount":99},[],{"trials":12254,"activeCount":99},[],{"intervention":12256,"totalTrials":151,"cells":12257},"RH5.1\u002FMatrix-M",{"EARLY_PHASE1":12258,"PHASE1":12260,"PHASE2":12270,"PHASE3":12272,"PHASE4":12274,"NA":12276},{"trials":12259,"activeCount":99},[],{"trials":12261,"activeCount":99},[12262],{"nctId":12263,"briefTitle":12264,"status":109,"phases":12265,"primaryCompletion":12266,"completion":12266,"start":12267,"enrollment":16,"conditions":12268,"interventions":12269},"NCT04318002","Safety and Immunogenicity of RH5.1\u002FMatrix-M in Adults and Infants Living in Tanzania",[88],"2023-08-27","2021-01-21",[27],[12256],{"trials":12271,"activeCount":99},[],{"trials":12273,"activeCount":99},[],{"trials":12275,"activeCount":99},[],{"trials":12277,"activeCount":99},[],{"intervention":12279,"totalTrials":151,"cells":12280},"ChAd3-hliNSmut",{"EARLY_PHASE1":12281,"PHASE1":12283,"PHASE2":12297,"PHASE3":12299,"PHASE4":12301,"NA":12303},{"trials":12282,"activeCount":99},[],{"trials":12284,"activeCount":99},[12285],{"nctId":12286,"briefTitle":12287,"status":109,"phases":12288,"primaryCompletion":12289,"completion":12290,"start":12291,"enrollment":12292,"conditions":12293,"interventions":12295},"NCT03688061","Class II Invariant Chain HCV Vaccine Study",[88],"2019-08-04","2022-08-04","2017-12-04",25,[12294],"Hepatitis C",[12279,12296],"MVA-hliNSmut",{"trials":12298,"activeCount":99},[],{"trials":12300,"activeCount":99},[],{"trials":12302,"activeCount":99},[],{"trials":12304,"activeCount":99},[],{"intervention":12296,"totalTrials":151,"cells":12306},{"EARLY_PHASE1":12307,"PHASE1":12309,"PHASE2":12315,"PHASE3":12317,"PHASE4":12319,"NA":12321},{"trials":12308,"activeCount":99},[],{"trials":12310,"activeCount":99},[12311],{"nctId":12286,"briefTitle":12287,"status":109,"phases":12312,"primaryCompletion":12289,"completion":12290,"start":12291,"enrollment":12292,"conditions":12313,"interventions":12314},[88],[12294],[12279,12296],{"trials":12316,"activeCount":99},[],{"trials":12318,"activeCount":99},[],{"trials":12320,"activeCount":99},[],{"trials":12322,"activeCount":99},[],{"intervention":12324,"totalTrials":151,"cells":12325},"Pfs48\u002F45 in Matrix-M",{"EARLY_PHASE1":12326,"PHASE1":12336,"PHASE2":12338,"PHASE3":12340,"PHASE4":12342,"NA":12344},{"trials":12327,"activeCount":99},[12328],{"nctId":12329,"briefTitle":12330,"status":795,"phases":12331,"primaryCompletion":12332,"completion":12332,"start":12333,"enrollment":1300,"conditions":12334,"interventions":12335},"NCT05400746","A Study of the Plasmodium Falciparum Malaria Vaccine Candidate Pfs48\u002F45 in Matrix-M Adjuvant in the UK",[87],"2023-10-19","2022-11-02",[15,1315],[12324],{"trials":12337,"activeCount":99},[],{"trials":12339,"activeCount":99},[],{"trials":12341,"activeCount":99},[],{"trials":12343,"activeCount":99},[],{"trials":12345,"activeCount":99},[],{"intervention":12347,"totalTrials":151,"cells":12348},"P. vivax infected inoculum",{"EARLY_PHASE1":12349,"PHASE1":12359,"PHASE2":12361,"PHASE3":12363,"PHASE4":12365,"NA":12367},{"trials":12350,"activeCount":99},[12351],{"nctId":12352,"briefTitle":12353,"status":109,"phases":12354,"primaryCompletion":12355,"completion":12355,"start":12356,"enrollment":10268,"conditions":12357,"interventions":12358},"NCT03797989","VAC069: A Study of Blood-stage Controlled Human P. Vivax Infection",[87],"2022-12-20","2019-01-10",[8170],[12347],{"trials":12360,"activeCount":99},[],{"trials":12362,"activeCount":99},[],{"trials":12364,"activeCount":99},[],{"trials":12366,"activeCount":99},[],{"trials":12368,"activeCount":99},[],{"intervention":12370,"totalTrials":151,"cells":12371},"Xentuzumab",{"EARLY_PHASE1":12372,"PHASE1":12383,"PHASE2":12385,"PHASE3":12387,"PHASE4":12389,"NA":12391},{"trials":12373,"activeCount":99},[12374],{"nctId":12375,"briefTitle":12376,"status":109,"phases":12377,"primaryCompletion":12378,"completion":12379,"start":12380,"enrollment":6457,"conditions":12381,"interventions":12382},"NCT05110495","IGF Inhibition With Xentuzumab Prior to Radical Prostatectomy",[87],"2023-03-20","2023-05-27","2021-12-17",[11635],[12370],{"trials":12384,"activeCount":99},[],{"trials":12386,"activeCount":99},[],{"trials":12388,"activeCount":99},[],{"trials":12390,"activeCount":99},[],{"trials":12392,"activeCount":99},[],{"intervention":12394,"totalTrials":151,"cells":12395},"Atovaquone",{"EARLY_PHASE1":12396,"PHASE1":12406,"PHASE2":12408,"PHASE3":12410,"PHASE4":12412,"NA":12414},{"trials":12397,"activeCount":99},[12398],{"nctId":12399,"briefTitle":12400,"status":109,"phases":12401,"primaryCompletion":12402,"completion":12403,"start":3654,"enrollment":7618,"conditions":12404,"interventions":12405},"NCT02628080","Atovaquone as Tumour HypOxia Modifier",[87],"2018-10","2018-12",[3583],[12394],{"trials":12407,"activeCount":99},[],{"trials":12409,"activeCount":99},[],{"trials":12411,"activeCount":99},[],{"trials":12413,"activeCount":99},[],{"trials":12415,"activeCount":99},[],{"intervention":12417,"totalTrials":151,"cells":12418},"Fluorescent Lectin Application",{"EARLY_PHASE1":12419,"PHASE1":12430,"PHASE2":12432,"PHASE3":12434,"PHASE4":12436,"NA":12438},{"trials":12420,"activeCount":99},[12421],{"nctId":12422,"briefTitle":12423,"status":2901,"phases":12424,"primaryCompletion":2869,"completion":2869,"start":12425,"enrollment":2337,"conditions":12426,"interventions":12429},"NCT03070613","Investigating the Use of Fluorescent Lectins to Identify Dysplasia and Cancer During Endoscopy and Surgery",[87],"2017-04-23",[11341,12427,12428],"Colorectal Neoplasms","Colorectal Polyp",[12417],{"trials":12431,"activeCount":99},[],{"trials":12433,"activeCount":99},[],{"trials":12435,"activeCount":99},[],{"trials":12437,"activeCount":99},[],{"trials":12439,"activeCount":99},[],{"intervention":12441,"totalTrials":151,"cells":12442},"Pvs25-IMX313\u002FMatrix-M1",{"EARLY_PHASE1":12443,"PHASE1":12453,"PHASE2":12455,"PHASE3":12457,"PHASE4":12459,"NA":12461},{"trials":12444,"activeCount":99},[12445],{"nctId":12446,"briefTitle":12447,"status":795,"phases":12448,"primaryCompletion":12449,"completion":12449,"start":12450,"enrollment":12292,"conditions":12451,"interventions":12452},"NCT05270265","Safety and Immunogenicity of Pvs25-IMX313\u002FMatrix-M1 Vaccine",[87],"2023-07-31","2022-02-09",[8170],[12441],{"trials":12454,"activeCount":99},[],{"trials":12456,"activeCount":99},[],{"trials":12458,"activeCount":99},[],{"trials":12460,"activeCount":99},[],{"trials":12462,"activeCount":99},[],{"intervention":190,"totalTrials":1285,"cells":12464},{"EARLY_PHASE1":12465,"PHASE1":12467,"PHASE2":12483,"PHASE3":12493,"PHASE4":12495,"NA":12510},{"trials":12466,"activeCount":99},[],{"trials":12468,"activeCount":99},[12469,12475],{"nctId":12470,"briefTitle":12471,"status":109,"phases":12472,"primaryCompletion":577,"completion":680,"start":681,"enrollment":1674,"conditions":12473,"interventions":12474},"NCT01780753","Primaquine Pharmacokinetics in Lactating Women and Their Infants",[88],[531],[190],{"nctId":12476,"briefTitle":12477,"status":109,"phases":12478,"primaryCompletion":12479,"completion":681,"start":6421,"enrollment":34,"conditions":12480,"interventions":12482},"NCT02789566","Pharmacokinetic Study of Primaquine in Healthy Obese Thai Adult Subjects",[88],"2011-11",[12481],"Obese",[190],{"trials":12484,"activeCount":99},[12485,12489],{"nctId":1295,"briefTitle":1296,"status":795,"phases":12486,"primaryCompletion":1298,"completion":1298,"start":1299,"enrollment":1300,"conditions":12487,"interventions":12488},[88,89],[1287,1288,24],[1272,1290,1272,1291,190,1303,1304,1303],{"nctId":2580,"briefTitle":2581,"status":2582,"phases":12490,"primaryCompletion":393,"completion":2584,"start":2585,"enrollment":2586,"conditions":12491,"interventions":12492},[88,89],[27],[2589,2590,2559,2591,190],{"trials":12494,"activeCount":99},[],{"trials":12496,"activeCount":99},[12497,12506],{"nctId":12498,"briefTitle":12499,"status":109,"phases":12500,"primaryCompletion":12501,"completion":12501,"start":12502,"enrollment":31,"conditions":12503,"interventions":12505},"NCT06191458","Postpartum Primaquine in Breast Milk",[91],"2025-02-23","2024-07-09",[12504],"Postpartum Women",[190],{"nctId":181,"briefTitle":182,"status":183,"phases":12507,"primaryCompletion":185,"completion":185,"start":186,"enrollment":99,"conditions":12508,"interventions":12509},[91],[188],[190,167],{"trials":12511,"activeCount":99},[12512,12520],{"nctId":12513,"briefTitle":12514,"status":109,"phases":12515,"primaryCompletion":12516,"completion":12516,"start":4426,"enrollment":12517,"conditions":12518,"interventions":12519},"NCT01076868","Incidence of Vivax Along the Thai Burma Border",[92],"2014-09-02",403,[531],[190],{"nctId":12521,"briefTitle":12522,"status":109,"phases":12523,"primaryCompletion":12524,"completion":12524,"start":577,"enrollment":12525,"conditions":12526,"interventions":12528},"NCT01814683","IMPROV (Improving the Radical Cure of Vivax Malaria)",[92],"2018-02-28",2388,[12527],"Uncomplicated Vivax Malaria",[190,190],{"intervention":6115,"totalTrials":2935,"cells":12530},{"EARLY_PHASE1":12531,"PHASE1":12533,"PHASE2":12566,"PHASE3":12572,"PHASE4":12574,"NA":12576},{"trials":12532,"activeCount":99},[],{"trials":12534,"activeCount":99},[12535,12543,12550,12558],{"nctId":12536,"briefTitle":12537,"status":109,"phases":12538,"primaryCompletion":12539,"completion":12539,"start":12540,"enrollment":3379,"conditions":12541,"interventions":12542},"NCT00654316","Study of the Safety and Immunogenicity of Bacille Calmette Guerin (BCG) Vaccine",[88],"2005-11","2004-02",[9228],[6115],{"nctId":12544,"briefTitle":12545,"status":109,"phases":12546,"primaryCompletion":4157,"completion":4157,"start":12547,"enrollment":1530,"conditions":12548,"interventions":12549},"NCT00653627","A Study to Quantify Bacille Calmette Guerin (BCG) and Characterise the Immune Response After BCG Vaccination",[88],"2007-08",[18],[6115],{"nctId":12551,"briefTitle":12552,"status":109,"phases":12553,"primaryCompletion":12554,"completion":12554,"start":12555,"enrollment":7618,"conditions":12556,"interventions":12557},"NCT02709278","Aerosol BCG Challenge Trial in Healthy UK Adults",[88],"2019-05-09","2016-03-07",[18],[6115,6115],{"nctId":12559,"briefTitle":12560,"status":109,"phases":12561,"completion":12562,"start":12563,"enrollment":3379,"conditions":12564,"interventions":12565},"NCT00480688","A Study of the Immunogenicity of M. Bovis BCG, Delivered Intradermally in Healthy Volunteers",[88],"2002-05","2001-11",[9228],[6115],{"trials":12567,"activeCount":99},[12568],{"nctId":6104,"briefTitle":6105,"status":109,"phases":12569,"primaryCompletion":6107,"completion":6107,"start":6108,"enrollment":6109,"conditions":12570,"interventions":12571},[88,89],[6111,6112],[6114,6000,6115],{"trials":12573,"activeCount":99},[],{"trials":12575,"activeCount":99},[],{"trials":12577,"activeCount":99},[12578],{"nctId":12579,"briefTitle":12580,"status":109,"phases":12581,"completion":12582,"start":6075,"enrollment":34,"conditions":12583,"interventions":12584},"NCT00480714","A Study of the Immunogenicity of BCG, Delivered Intradermally in Healthy Volunteers",[92],"2003-09",[9228],[6115],{"intervention":545,"totalTrials":1273,"cells":12586},{"EARLY_PHASE1":12587,"PHASE1":12589,"PHASE2":12591,"PHASE3":12597,"PHASE4":12607,"NA":12613},{"trials":12588,"activeCount":99},[],{"trials":12590,"activeCount":99},[],{"trials":12592,"activeCount":99},[12593],{"nctId":8188,"briefTitle":8189,"status":109,"phases":12594,"primaryCompletion":8191,"completion":8191,"start":8192,"enrollment":2104,"conditions":12595,"interventions":12596},[88,89],[8194],[581,8179],{"trials":12598,"activeCount":99},[12599,12603],{"nctId":5003,"briefTitle":5004,"status":109,"phases":12600,"primaryCompletion":5006,"completion":5006,"start":5007,"enrollment":5008,"conditions":12601,"interventions":12602},[90],[15],[5011,4992,5012],{"nctId":536,"briefTitle":537,"status":109,"phases":12604,"primaryCompletion":539,"completion":540,"start":541,"enrollment":542,"conditions":12605,"interventions":12606},[90],[531],[545,545,202,202],{"trials":12608,"activeCount":99},[12609],{"nctId":573,"briefTitle":574,"status":109,"phases":12610,"primaryCompletion":576,"completion":576,"start":577,"enrollment":578,"conditions":12611,"interventions":12612},[91],[24],[202,581],{"trials":12614,"activeCount":99},[12615],{"nctId":12616,"briefTitle":12617,"status":795,"phases":12618,"primaryCompletion":10140,"completion":12619,"start":3604,"enrollment":2803,"conditions":12620,"interventions":12622},"NCT01640587","Compare the Effectiveness Between Existing Treatment and New Treatment",[92],"2017-03-30",[12621],"P. Falciparum Malaria",[12623,545],"Mefloquine+Artesunate",{"intervention":3285,"totalTrials":595,"cells":12625},{"EARLY_PHASE1":12626,"PHASE1":12628,"PHASE2":12630,"PHASE3":12636,"PHASE4":12638,"NA":12648},{"trials":12627,"activeCount":99},[],{"trials":12629,"activeCount":99},[],{"trials":12631,"activeCount":99},[12632],{"nctId":7149,"briefTitle":7150,"status":109,"phases":12633,"primaryCompletion":680,"completion":3787,"start":3899,"enrollment":7152,"conditions":12634,"interventions":12635},[89],[5812,7154],[7140,3285],{"trials":12637,"activeCount":99},[],{"trials":12639,"activeCount":99},[12640,12644],{"nctId":3303,"briefTitle":3304,"status":109,"phases":12641,"primaryCompletion":3306,"completion":3306,"start":3307,"enrollment":151,"conditions":12642,"interventions":12643},[91],[3283],[3285,3286,3287,3310,3311],{"nctId":3276,"briefTitle":3277,"status":109,"phases":12645,"primaryCompletion":3279,"completion":3279,"start":3280,"enrollment":3281,"conditions":12646,"interventions":12647},[91],[3283],[3285,3286,3287,3240],{"trials":12649,"activeCount":99},[12650],{"nctId":12651,"briefTitle":12652,"status":109,"phases":12653,"primaryCompletion":12654,"completion":12654,"start":4402,"enrollment":12655,"conditions":12656,"interventions":12657},"NCT03531073","Multicentre ObservatioNal Initiative in Treat to Target Outcomes in Psoriatic Arthritis",[],"2024-12-31",446,[3283],[3285],{"intervention":533,"totalTrials":595,"cells":12659},{"EARLY_PHASE1":12660,"PHASE1":12662,"PHASE2":12664,"PHASE3":12666,"PHASE4":12676,"NA":12682},{"trials":12661,"activeCount":99},[],{"trials":12663,"activeCount":99},[],{"trials":12665,"activeCount":99},[],{"trials":12667,"activeCount":99},[12668,12672],{"nctId":524,"briefTitle":525,"status":109,"phases":12669,"primaryCompletion":527,"completion":527,"start":528,"enrollment":529,"conditions":12670,"interventions":12671},[90],[531],[533,202,534],{"nctId":5990,"briefTitle":5991,"status":183,"phases":12673,"primaryCompletion":5421,"completion":5421,"start":5421,"enrollment":99,"conditions":12674,"interventions":12675},[89,90],[5380],[5979,533],{"trials":12677,"activeCount":99},[12678],{"nctId":3550,"briefTitle":3551,"status":109,"phases":12679,"primaryCompletion":3553,"completion":3553,"start":3554,"enrollment":3555,"conditions":12680,"interventions":12681},[91],[3557],[3559,3537],{"trials":12683,"activeCount":99},[12684],{"nctId":12685,"briefTitle":12686,"status":109,"phases":12687,"primaryCompletion":6126,"completion":6126,"start":12688,"enrollment":1530,"conditions":12689,"interventions":12690},"NCT00493363","Clinical Investigation of In-vivo Susceptibility of P.Falciparum to Artesunate in Western Cambodia",[92],"2007-06",[3902],[533,12691],"Artesunate + Mefloquine",{"intervention":12693,"totalTrials":95,"cells":12694},"Prucalopride",{"EARLY_PHASE1":12695,"PHASE1":12697,"PHASE2":12699,"PHASE3":12701,"PHASE4":12703,"NA":12705},{"trials":12696,"activeCount":99},[],{"trials":12698,"activeCount":99},[],{"trials":12700,"activeCount":99},[],{"trials":12702,"activeCount":99},[],{"trials":12704,"activeCount":99},[],{"trials":12706,"activeCount":99},[12707,12716,12724],{"nctId":12708,"briefTitle":12709,"status":109,"phases":12710,"primaryCompletion":12711,"completion":12711,"start":12712,"enrollment":2337,"conditions":12713,"interventions":12715},"NCT05220228","Prucalopride and Cognition in Recovered Depression",[92],"2023-11-13","2022-01-04",[12714],"Depression in Remission",[12693],{"nctId":12717,"briefTitle":12718,"status":109,"phases":12719,"primaryCompletion":12720,"completion":12720,"start":12721,"enrollment":2104,"conditions":12722,"interventions":12723},"NCT03863366","Effects of Acute Prucalopride Administration in Healthy Volunteers",[92],"2017-08-08","2017-02-07",[3006,21,2977,2999,2978,2979,2980],[12693],{"nctId":12725,"briefTitle":12726,"status":109,"phases":12727,"primaryCompletion":12728,"completion":12728,"start":12729,"enrollment":2337,"conditions":12730,"interventions":12732},"NCT03572790","Effects of Seven Day Prucalopride Administration in Healthy Volunteers",[92],"2019-05-17","2018-06-11",[3006,21,2977,2999,12731,2979,2980],"Mental Disorders",[12693],{"intervention":10442,"totalTrials":95,"cells":12734},{"EARLY_PHASE1":12735,"PHASE1":12737,"PHASE2":12743,"PHASE3":12753,"PHASE4":12755,"NA":12757},{"trials":12736,"activeCount":99},[],{"trials":12738,"activeCount":99},[12739],{"nctId":10436,"briefTitle":10437,"status":109,"phases":12740,"primaryCompletion":3788,"completion":3553,"start":2987,"enrollment":31,"conditions":12741,"interventions":12742},[88],[10440],[10429,10442],{"trials":12744,"activeCount":99},[12745],{"nctId":12746,"briefTitle":12747,"status":183,"phases":12748,"enrollment":99,"conditions":12749,"interventions":12751},"NCT00960921","Study of the Effects of Iron on Lung Blood Pressure at High Altitude",[89],[12750],"Hypertension, Pulmonary",[12752,10442],"Iron sucrose",{"trials":12754,"activeCount":99},[],{"trials":12756,"activeCount":99},[],{"trials":12758,"activeCount":99},[12759],{"nctId":12760,"briefTitle":12761,"status":109,"phases":12762,"primaryCompletion":12763,"completion":12763,"start":12764,"enrollment":6231,"conditions":12765,"interventions":12768},"NCT00952302","Study of the Effects of Iron Levels on the Lungs at High Altitude",[92],"2008-11","2008-10",[12766,12767],"Pulmonary Hypertension","Mountain Sickness",[12752,10442,12752,10442],{"intervention":12770,"totalTrials":95,"cells":12771},"d-cycloserine",{"EARLY_PHASE1":12772,"PHASE1":12781,"PHASE2":12783,"PHASE3":12785,"PHASE4":12795,"NA":12797},{"trials":12773,"activeCount":99},[12774],{"nctId":12775,"briefTitle":12776,"status":2901,"phases":12777,"primaryCompletion":12403,"completion":7218,"start":3604,"enrollment":2947,"conditions":12778,"interventions":12780},"NCT01985750","Understanding the Importance of Plasticity in the Brain Mechanisms of Dyspnoea Perception",[87],[12779],"Chronic Obstructive Pulmonary Disease",[12770],{"trials":12782,"activeCount":99},[],{"trials":12784,"activeCount":99},[],{"trials":12786,"activeCount":99},[12787],{"nctId":12788,"briefTitle":12789,"status":795,"phases":12790,"primaryCompletion":6229,"completion":12791,"start":527,"enrollment":6231,"conditions":12792,"interventions":12794},"NCT01680107","D-cycloserine Augmented CBT for Panic Disorder",[90],"2018-04-30",[12793],"Panic Disorder",[12770],{"trials":12796,"activeCount":99},[],{"trials":12798,"activeCount":99},[12799],{"nctId":12800,"briefTitle":12801,"status":109,"phases":12802,"primaryCompletion":12803,"completion":12803,"start":12804,"enrollment":1530,"conditions":12805,"interventions":12808},"NCT03961464","The Effect of D-cycloserine on Emotional Processing",[92],"2018-12-05","2018-08-10",[12806,12807],"Cycloserine","Healthy Volunteer",[12770],{"intervention":12810,"totalTrials":168,"cells":12811},"Ketamine Hydrochloride",{"EARLY_PHASE1":12812,"PHASE1":12814,"PHASE2":12816,"PHASE3":12818,"PHASE4":12820,"NA":12822},{"trials":12813,"activeCount":99},[],{"trials":12815,"activeCount":99},[],{"trials":12817,"activeCount":99},[],{"trials":12819,"activeCount":99},[],{"trials":12821,"activeCount":99},[],{"trials":12823,"activeCount":99},[12824,12834],{"nctId":12825,"briefTitle":12826,"status":2901,"phases":12827,"primaryCompletion":12828,"completion":12829,"start":12830,"enrollment":16,"conditions":12831,"interventions":12833},"NCT05809609","Glutamate Emotion Memory Study",[92],"2024-11-28","2024-12-28","2022-07-01",[9515,21,12832],"Major Depressive Disorder",[12810],{"nctId":12835,"briefTitle":12836,"status":2901,"phases":12837,"primaryCompletion":12838,"completion":12838,"start":12839,"enrollment":2657,"conditions":12840,"interventions":12841},"NCT04850911","Reward Emotion Learning and Ketamine Study",[92],"2023-05","2021-08-25",[21,12832,9515],[12810],{"intervention":12843,"totalTrials":168,"cells":12844},"Folic Acid",{"EARLY_PHASE1":12845,"PHASE1":12847,"PHASE2":12849,"PHASE3":12859,"PHASE4":12861,"NA":12863},{"trials":12846,"activeCount":99},[],{"trials":12848,"activeCount":99},[],{"trials":12850,"activeCount":99},[12851],{"nctId":12852,"briefTitle":12853,"status":2901,"phases":12854,"primaryCompletion":12855,"start":12856,"enrollment":16,"conditions":12857,"interventions":12858},"NCT00300352","Effect of Folic Acid Treatment in Coronary Artery Disease",[89],"2006-05","2004-05",[7994],[12843],{"trials":12860,"activeCount":99},[],{"trials":12862,"activeCount":99},[],{"trials":12864,"activeCount":99},[12865],{"nctId":12866,"briefTitle":12867,"status":109,"phases":12868,"primaryCompletion":590,"completion":9401,"start":2526,"enrollment":7009,"conditions":12869,"interventions":12870},"NCT00459264","Prevention of Mood Disorders by Folic Acid Supplementation",[92],[21,6358],[12843],{"intervention":12872,"totalTrials":168,"cells":12873},"Ferric carboxymaltose",{"EARLY_PHASE1":12874,"PHASE1":12876,"PHASE2":12878,"PHASE3":12880,"PHASE4":12882,"NA":12895},{"trials":12875,"activeCount":99},[],{"trials":12877,"activeCount":99},[],{"trials":12879,"activeCount":99},[],{"trials":12881,"activeCount":99},[],{"trials":12883,"activeCount":99},[12884],{"nctId":12885,"briefTitle":12886,"status":109,"phases":12887,"primaryCompletion":12888,"completion":12889,"start":12890,"enrollment":1674,"conditions":12891,"interventions":12894},"NCT03632525","Intravenous Iron in Adults With Cystic Fibrosis",[91],"2020-03-27","2021-10-26","2019-02-22",[12892,12893],"Cystic Fibrosis","Iron-deficiency",[12872],{"trials":12896,"activeCount":99},[12897],{"nctId":12898,"briefTitle":12899,"status":109,"phases":12900,"primaryCompletion":540,"completion":4929,"start":6230,"enrollment":22,"conditions":12901,"interventions":12903},"NCT02308449","Iron Status and Human Metabolism",[92],[12902],"Iron Deficiency",[12872,12904],"Sodium chloride",{"intervention":12904,"totalTrials":168,"cells":12906},{"EARLY_PHASE1":12907,"PHASE1":12909,"PHASE2":12911,"PHASE3":12913,"PHASE4":12915,"NA":12921},{"trials":12908,"activeCount":99},[],{"trials":12910,"activeCount":99},[],{"trials":12912,"activeCount":99},[],{"trials":12914,"activeCount":99},[],{"trials":12916,"activeCount":99},[12917],{"nctId":4101,"briefTitle":4102,"status":109,"phases":12918,"primaryCompletion":3553,"completion":3787,"start":4104,"enrollment":4105,"conditions":12919,"interventions":12920},[91],[4107],[4088,4109],{"trials":12922,"activeCount":99},[12923],{"nctId":12898,"briefTitle":12899,"status":109,"phases":12924,"primaryCompletion":540,"completion":4929,"start":6230,"enrollment":22,"conditions":12925,"interventions":12926},[92],[12902],[12872,12904],{"intervention":4567,"totalTrials":168,"cells":12928},{"EARLY_PHASE1":12929,"PHASE1":12931,"PHASE2":12933,"PHASE3":12939,"PHASE4":12941,"NA":12943},{"trials":12930,"activeCount":99},[],{"trials":12932,"activeCount":99},[],{"trials":12934,"activeCount":99},[12935],{"nctId":4555,"briefTitle":4556,"status":109,"phases":12936,"primaryCompletion":4558,"completion":4558,"start":4559,"enrollment":4560,"conditions":12937,"interventions":12938},[88,89],[4539],[4526,4563,4564,4565,4566,4567,4568,4569,4569],{"trials":12940,"activeCount":99},[],{"trials":12942,"activeCount":99},[],{"trials":12944,"activeCount":99},[12945],{"nctId":12946,"briefTitle":12947,"status":109,"phases":12948,"primaryCompletion":12949,"completion":12950,"start":12951,"enrollment":368,"conditions":12952,"interventions":12953},"NCT01641289","Paracetamol Effect on Oxidative Stress and Renal Function in Severe Malaria",[92],"2014-09-13","2014-09-21","2012-07-10",[15],[4567,12954],"No Paracetamol",{"intervention":12956,"totalTrials":168,"cells":12957},"Simvastatin 20mg",{"EARLY_PHASE1":12958,"PHASE1":12960,"PHASE2":12962,"PHASE3":12972,"PHASE4":12974,"NA":12976},{"trials":12959,"activeCount":99},[],{"trials":12961,"activeCount":99},[],{"trials":12963,"activeCount":99},[12964],{"nctId":12965,"briefTitle":12966,"status":109,"phases":12967,"primaryCompletion":12968,"completion":12968,"start":12969,"enrollment":2870,"conditions":12970,"interventions":12971},"NCT04652089","7-day Simvastatin and Emotional Processing",[88,89],"2021-09-01","2020-12-03",[21,8465],[12956],{"trials":12973,"activeCount":99},[],{"trials":12975,"activeCount":99},[],{"trials":12977,"activeCount":99},[12978],{"nctId":12979,"briefTitle":12980,"status":109,"phases":12981,"primaryCompletion":51,"completion":51,"start":12982,"enrollment":12983,"conditions":12984,"interventions":12985},"NCT04973800","Simvastatin and Emotional Processing (OxSTEP)",[92],"2021-07-05",101,[21,8465],[12956],{"intervention":12987,"totalTrials":168,"cells":12988},"BCG SSI",{"EARLY_PHASE1":12989,"PHASE1":12991,"PHASE2":12993,"PHASE3":12995,"PHASE4":12997,"NA":12999},{"trials":12990,"activeCount":99},[],{"trials":12992,"activeCount":99},[],{"trials":12994,"activeCount":99},[],{"trials":12996,"activeCount":99},[],{"trials":12998,"activeCount":99},[],{"trials":13000,"activeCount":99},[13001,13008],{"nctId":13002,"briefTitle":13003,"status":109,"phases":13004,"primaryCompletion":3788,"completion":3788,"start":5258,"enrollment":7756,"conditions":13005,"interventions":13006},"NCT02088892","A Clinical Challenge Study of BCG in Healthy Volunteers",[92],[18],[12987,13007],"BCG Tice",{"nctId":13009,"briefTitle":13010,"status":109,"phases":13011,"primaryCompletion":588,"completion":588,"start":6667,"enrollment":1848,"conditions":13012,"interventions":13013},"NCT02380508","Heterologous Effects of BCG in Healthy UK Adults",[92],[18],[12987,13014],"BCG Sii",{"intervention":12752,"totalTrials":168,"cells":13016},{"EARLY_PHASE1":13017,"PHASE1":13019,"PHASE2":13021,"PHASE3":13027,"PHASE4":13029,"NA":13031},{"trials":13018,"activeCount":99},[],{"trials":13020,"activeCount":99},[],{"trials":13022,"activeCount":99},[13023],{"nctId":12746,"briefTitle":12747,"status":183,"phases":13024,"enrollment":99,"conditions":13025,"interventions":13026},[89],[12750],[12752,10442],{"trials":13028,"activeCount":99},[],{"trials":13030,"activeCount":99},[],{"trials":13032,"activeCount":99},[13033],{"nctId":12760,"briefTitle":12761,"status":109,"phases":13034,"primaryCompletion":12763,"completion":12763,"start":12764,"enrollment":6231,"conditions":13035,"interventions":13036},[92],[12766,12767],[12752,10442,12752,10442],{"intervention":3259,"totalTrials":168,"cells":13038},{"EARLY_PHASE1":13039,"PHASE1":13041,"PHASE2":13043,"PHASE3":13049,"PHASE4":13051,"NA":13053},{"trials":13040,"activeCount":99},[],{"trials":13042,"activeCount":99},[],{"trials":13044,"activeCount":99},[13045],{"nctId":3249,"briefTitle":3250,"status":109,"phases":13046,"primaryCompletion":3252,"completion":3253,"start":3254,"enrollment":3255,"conditions":13047,"interventions":13048},[89],[3257],[3240,3259],{"trials":13050,"activeCount":99},[],{"trials":13052,"activeCount":99},[],{"trials":13054,"activeCount":99},[13055],{"nctId":13056,"briefTitle":13057,"status":2901,"phases":13058,"primaryCompletion":13059,"completion":13060,"start":13061,"enrollment":9968,"conditions":13062,"interventions":13063},"NCT05876195","KLH Challenge to Explore the Human Immune Response",[92],"2023-10","2024-02","2023-03-01",[3747],[13064,3259,13065,13066],"Keyhole-Limpet Hemocyanin","Montanide ISA 51 VG","Alhydrogel",{"intervention":13068,"totalTrials":151,"cells":13069},"Chloroquine or Hydroxychloroquine",{"EARLY_PHASE1":13070,"PHASE1":13072,"PHASE2":13074,"PHASE3":13076,"PHASE4":13078,"NA":13080},{"trials":13071,"activeCount":99},[],{"trials":13073,"activeCount":99},[],{"trials":13075,"activeCount":99},[],{"trials":13077,"activeCount":99},[],{"trials":13079,"activeCount":99},[],{"trials":13081,"activeCount":99},[13082],{"nctId":13083,"briefTitle":13084,"status":109,"phases":13085,"primaryCompletion":13086,"completion":13086,"start":13087,"enrollment":13088,"conditions":13089,"interventions":13092},"NCT04303507","Chloroquine\u002F Hydroxychloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting",[92],"2022-03-22","2020-04-29",4652,[13090,4539,13091],"COVID19","Acute Respiratory Illnesses",[13068],{"intervention":13094,"totalTrials":151,"cells":13095},"Esketamine nasal spray",{"EARLY_PHASE1":13096,"PHASE1":13098,"PHASE2":13100,"PHASE3":13102,"PHASE4":13104,"NA":13106},{"trials":13097,"activeCount":99},[],{"trials":13099,"activeCount":99},[],{"trials":13101,"activeCount":99},[],{"trials":13103,"activeCount":99},[],{"trials":13105,"activeCount":99},[],{"trials":13107,"activeCount":99},[13108],{"nctId":13109,"briefTitle":13110,"status":109,"phases":13111,"primaryCompletion":13112,"completion":13112,"start":13113,"enrollment":578,"conditions":13114,"interventions":13115},"NCT06432322","(GluEsk) Glutamate and Esketamine",[92],"2025-03-26","2024-06-14",[21],[13094],{"intervention":13117,"totalTrials":151,"cells":13118},"Antimalarials",{"EARLY_PHASE1":13119,"PHASE1":13121,"PHASE2":13123,"PHASE3":13125,"PHASE4":13127,"NA":13129},{"trials":13120,"activeCount":99},[],{"trials":13122,"activeCount":99},[],{"trials":13124,"activeCount":99},[],{"trials":13126,"activeCount":99},[],{"trials":13128,"activeCount":99},[],{"trials":13130,"activeCount":99},[13131],{"nctId":13132,"briefTitle":13133,"status":109,"phases":13134,"primaryCompletion":13135,"completion":4619,"start":13136,"enrollment":13137,"conditions":13138,"interventions":13139},"NCT04093765","Mass Screening and Treatment for Reduction of Falciparum Malaria",[92],"2019-12-31","2018-11-01",5542,[33],[13117],{"intervention":13141,"totalTrials":151,"cells":13142},"4CMenB (Bexsero®) vaccine",{"EARLY_PHASE1":13143,"PHASE1":13145,"PHASE2":13147,"PHASE3":13149,"PHASE4":13151,"NA":13153},{"trials":13144,"activeCount":99},[],{"trials":13146,"activeCount":99},[],{"trials":13148,"activeCount":99},[],{"trials":13150,"activeCount":99},[],{"trials":13152,"activeCount":99},[],{"trials":13154,"activeCount":99},[13155],{"nctId":13156,"briefTitle":13157,"status":109,"phases":13158,"primaryCompletion":13159,"completion":13160,"start":13161,"enrollment":2337,"conditions":13162,"interventions":13164},"NCT04297436","Gonococcal Vaccine Study in Key Populations in Kenya",[92],"2022-02-05","2022-02-28","2021-05-31",[13163],"Gonorrhea",[13141],{"intervention":3031,"totalTrials":151,"cells":13166},{"EARLY_PHASE1":13167,"PHASE1":13169,"PHASE2":13171,"PHASE3":13173,"PHASE4":13175,"NA":13177},{"trials":13168,"activeCount":99},[],{"trials":13170,"activeCount":99},[],{"trials":13172,"activeCount":99},[],{"trials":13174,"activeCount":99},[],{"trials":13176,"activeCount":99},[],{"trials":13178,"activeCount":99},[13179],{"nctId":3024,"briefTitle":3025,"status":109,"phases":13180,"primaryCompletion":3027,"completion":3027,"start":541,"enrollment":2337,"conditions":13181,"interventions":13182},[92],[3029],[3031,3009],{"intervention":13007,"totalTrials":151,"cells":13184},{"EARLY_PHASE1":13185,"PHASE1":13187,"PHASE2":13189,"PHASE3":13191,"PHASE4":13193,"NA":13195},{"trials":13186,"activeCount":99},[],{"trials":13188,"activeCount":99},[],{"trials":13190,"activeCount":99},[],{"trials":13192,"activeCount":99},[],{"trials":13194,"activeCount":99},[],{"trials":13196,"activeCount":99},[13197],{"nctId":13002,"briefTitle":13003,"status":109,"phases":13198,"primaryCompletion":3788,"completion":3788,"start":5258,"enrollment":7756,"conditions":13199,"interventions":13200},[92],[18],[12987,13007],{"intervention":13202,"totalTrials":151,"cells":13203},"Previously exposed to Ebola vaccine",{"EARLY_PHASE1":13204,"PHASE1":13206,"PHASE2":13208,"PHASE3":13210,"PHASE4":13212,"NA":13214},{"trials":13205,"activeCount":99},[],{"trials":13207,"activeCount":99},[],{"trials":13209,"activeCount":99},[],{"trials":13211,"activeCount":99},[],{"trials":13213,"activeCount":99},[],{"trials":13215,"activeCount":99},[13216],{"nctId":13217,"briefTitle":13218,"status":109,"phases":13219,"primaryCompletion":13220,"completion":13220,"start":13221,"enrollment":13222,"conditions":13223,"interventions":13224},"NCT03140774","Persistence of the Immune Response After Immunisation With Ebola Virus Vaccines",[],"2020-07-10","2017-05-17",126,[9348],[13202],{"intervention":13226,"totalTrials":151,"cells":13227},"Combivir and efavirenz",{"EARLY_PHASE1":13228,"PHASE1":13230,"PHASE2":13232,"PHASE3":13234,"PHASE4":13236,"NA":13238},{"trials":13229,"activeCount":99},[],{"trials":13231,"activeCount":99},[],{"trials":13233,"activeCount":99},[],{"trials":13235,"activeCount":99},[],{"trials":13237,"activeCount":99},[],{"trials":13239,"activeCount":99},[13240],{"nctId":13241,"briefTitle":13242,"status":2901,"phases":13243,"primaryCompletion":13244,"completion":13244,"start":13245,"enrollment":13246,"conditions":13247,"interventions":13249},"NCT00433719","Immediate Versus Deferred Antiretroviral Therapy for HIV-Associated Tuberculous Meningitis",[92],"2008-12","2005-09",253,[6046,13248],"Tuberculous Meningitis",[13226],{"intervention":13251,"totalTrials":151,"cells":13252},"Steroid",{"EARLY_PHASE1":13253,"PHASE1":13255,"PHASE2":13257,"PHASE3":13259,"PHASE4":13261,"NA":13263},{"trials":13254,"activeCount":99},[],{"trials":13256,"activeCount":99},[],{"trials":13258,"activeCount":99},[],{"trials":13260,"activeCount":99},[],{"trials":13262,"activeCount":99},[],{"trials":13264,"activeCount":99},[13265],{"nctId":13266,"briefTitle":13267,"status":2901,"phases":13268,"primaryCompletion":13269,"completion":286,"start":13270,"enrollment":13271,"conditions":13272,"interventions":13279},"NCT05859412","Mechanisms of Neurodynamic Treatments",[92],"2025-02","2023-05-17",108,[13273,13274,13275,13276,13277,13278],"Carpal Tunnel Syndrome","Neurodynamic Treatment","Nerve Mobilisation","Diffusion MRI","Physiotherapy","Mechanistic Trial",[13251],{"intervention":13281,"totalTrials":151,"cells":13282},"4CMenB (Bexsero®) - Novartis Vaccines and Diagnostics",{"EARLY_PHASE1":13283,"PHASE1":13285,"PHASE2":13287,"PHASE3":13289,"PHASE4":13291,"NA":13293},{"trials":13284,"activeCount":99},[],{"trials":13286,"activeCount":99},[],{"trials":13288,"activeCount":99},[],{"trials":13290,"activeCount":99},[],{"trials":13292,"activeCount":99},[],{"trials":13294,"activeCount":99},[13295],{"nctId":13296,"briefTitle":13297,"status":109,"phases":13298,"primaryCompletion":7617,"completion":13299,"start":3553,"enrollment":28,"conditions":13300,"interventions":13305},"NCT02398396","Investigating Meningococcal Vaccines in Adults",[92],"2019-06-13",[13301,13302,13303,13304],"Meningococcal Vaccines","Meningococcal Infections","Neisseria Meningitidis","Factor H-binding Protein, Neisseria Meningitidi",[13281],{"intervention":13307,"totalTrials":151,"cells":13308},"malaria elimination using DP and low-dose primaquine",{"EARLY_PHASE1":13309,"PHASE1":13311,"PHASE2":13313,"PHASE3":13315,"PHASE4":13317,"NA":13319},{"trials":13310,"activeCount":99},[],{"trials":13312,"activeCount":99},[],{"trials":13314,"activeCount":99},[],{"trials":13316,"activeCount":99},[],{"trials":13318,"activeCount":99},[],{"trials":13320,"activeCount":99},[13321],{"nctId":13322,"briefTitle":13323,"status":109,"phases":13324,"primaryCompletion":13325,"completion":13325,"start":4320,"enrollment":13326,"conditions":13327,"interventions":13328},"NCT01872702","Targeted Chemo-elimination (TCE) of Malaria",[92],"2017-07",8000,[33],[13307],{"intervention":13330,"totalTrials":151,"cells":13331},"Intravenous administration of ferric carboxymaltose",{"EARLY_PHASE1":13332,"PHASE1":13334,"PHASE2":13336,"PHASE3":13338,"PHASE4":13340,"NA":13342},{"trials":13333,"activeCount":99},[],{"trials":13335,"activeCount":99},[],{"trials":13337,"activeCount":99},[],{"trials":13339,"activeCount":99},[],{"trials":13341,"activeCount":99},[],{"trials":13343,"activeCount":99},[13344],{"nctId":13345,"briefTitle":13346,"status":109,"phases":13347,"primaryCompletion":3653,"completion":3653,"start":1434,"enrollment":19,"conditions":13348,"interventions":13351},"NCT01847352","Iron Status and Hypoxic Pulmonary Vascular Responses",[92],[13349,13350,12902],"Lung Hypoxia","Pulmonary Arterial Hypertension",[13330],{"intervention":13353,"totalTrials":151,"cells":13354},"Salmonella enterica serovar Paratyphi A",{"EARLY_PHASE1":13355,"PHASE1":13357,"PHASE2":13359,"PHASE3":13361,"PHASE4":13363,"NA":13365},{"trials":13356,"activeCount":99},[],{"trials":13358,"activeCount":99},[],{"trials":13360,"activeCount":99},[],{"trials":13362,"activeCount":99},[],{"trials":13364,"activeCount":99},[],{"trials":13366,"activeCount":99},[13367],{"nctId":13368,"briefTitle":13369,"status":109,"phases":13370,"primaryCompletion":4929,"completion":13371,"start":5258,"enrollment":799,"conditions":13372,"interventions":13374},"NCT02100397","Understanding Paratyphoid Infection",[92],"2022-03-09",[13373],"Enteric Fever Caused by Salmonella Enterica Serovar Paratyphi A",[13353],{"intervention":13376,"totalTrials":151,"cells":13377},"Semaglutide, 0.5 mg\u002FmL",{"EARLY_PHASE1":13378,"PHASE1":13380,"PHASE2":13382,"PHASE3":13384,"PHASE4":13386,"NA":13388},{"trials":13379,"activeCount":99},[],{"trials":13381,"activeCount":99},[],{"trials":13383,"activeCount":99},[],{"trials":13385,"activeCount":99},[],{"trials":13387,"activeCount":99},[],{"trials":13389,"activeCount":99},[13390],{"nctId":13391,"briefTitle":13392,"status":109,"phases":13393,"primaryCompletion":13394,"completion":13394,"start":13395,"enrollment":2657,"conditions":13396,"interventions":13398},"NCT06363487","Semaglutide and Cognition in Healthy Volunteers",[92],"2024-12-11","2024-06-06",[13397],"Cognitive Change",[13376],{"intervention":13400,"totalTrials":151,"cells":13401},"Artesunate + Sulphadoxine-pyrimethamine",{"EARLY_PHASE1":13402,"PHASE1":13404,"PHASE2":13406,"PHASE3":13408,"PHASE4":13410,"NA":13412},{"trials":13403,"activeCount":99},[],{"trials":13405,"activeCount":99},[],{"trials":13407,"activeCount":99},[],{"trials":13409,"activeCount":99},[],{"trials":13411,"activeCount":99},[],{"trials":13413,"activeCount":99},[13414],{"nctId":13415,"briefTitle":13416,"status":109,"phases":13417,"primaryCompletion":11297,"completion":11297,"start":527,"enrollment":7219,"conditions":13418,"interventions":13420},"NCT01707199","SPK Study in Afghanistan",[92],[13419],"Uncomplicated P. Falciparum Malaria",[13400],{"intervention":13422,"totalTrials":151,"cells":13423},"Fenofibrate",{"EARLY_PHASE1":13424,"PHASE1":13426,"PHASE2":13428,"PHASE3":13430,"PHASE4":13432,"NA":13434},{"trials":13425,"activeCount":99},[],{"trials":13427,"activeCount":99},[],{"trials":13429,"activeCount":99},[],{"trials":13431,"activeCount":99},[],{"trials":13433,"activeCount":99},[],{"trials":13435,"activeCount":99},[13436],{"nctId":13437,"briefTitle":13438,"status":2901,"phases":13439,"primaryCompletion":2878,"completion":2878,"start":13440,"enrollment":13441,"conditions":13442,"interventions":13444},"NCT05256758","Oxford - Fibrates in Aortic Stenosis",[92],"2019-05-29",67,[13443],"Aortic Valve Stenosis",[13422,13445],"Placental Lactogen",{"intervention":13445,"totalTrials":151,"cells":13447},{"EARLY_PHASE1":13448,"PHASE1":13450,"PHASE2":13452,"PHASE3":13454,"PHASE4":13456,"NA":13458},{"trials":13449,"activeCount":99},[],{"trials":13451,"activeCount":99},[],{"trials":13453,"activeCount":99},[],{"trials":13455,"activeCount":99},[],{"trials":13457,"activeCount":99},[],{"trials":13459,"activeCount":99},[13460],{"nctId":13437,"briefTitle":13438,"status":2901,"phases":13461,"primaryCompletion":2878,"completion":2878,"start":13440,"enrollment":13441,"conditions":13462,"interventions":13463},[92],[13443],[13422,13445],{"intervention":13465,"totalTrials":151,"cells":13466},"Typhoid Vaccine",{"EARLY_PHASE1":13467,"PHASE1":13469,"PHASE2":13471,"PHASE3":13473,"PHASE4":13475,"NA":13477},{"trials":13468,"activeCount":99},[],{"trials":13470,"activeCount":99},[],{"trials":13472,"activeCount":99},[],{"trials":13474,"activeCount":99},[],{"trials":13476,"activeCount":99},[],{"trials":13478,"activeCount":99},[13479],{"nctId":13480,"briefTitle":13481,"status":109,"phases":13482,"primaryCompletion":539,"completion":539,"start":6667,"enrollment":578,"conditions":13483,"interventions":13485},"NCT02628054","Investigating the Effects of Typhoid Vaccine on Sleep in Healthy Volunteers",[92],[13484],"Typhoid Vaccine on Sleep",[13465],{"intervention":13487,"totalTrials":151,"cells":13488},"Intravenous Artesunate as part of standard medical practice",{"EARLY_PHASE1":13489,"PHASE1":13491,"PHASE2":13493,"PHASE3":13495,"PHASE4":13497,"NA":13499},{"trials":13490,"activeCount":99},[],{"trials":13492,"activeCount":99},[],{"trials":13494,"activeCount":99},[],{"trials":13496,"activeCount":99},[],{"trials":13498,"activeCount":99},[],{"trials":13500,"activeCount":99},[13501],{"nctId":13502,"briefTitle":13503,"status":183,"phases":13504,"primaryCompletion":9130,"completion":9130,"start":6199,"enrollment":99,"conditions":13505,"interventions":13506},"NCT02640495","Artemisinin Resistance In Malaria Treated With IV Artesunate",[],[15],[13487],{"intervention":13508,"totalTrials":151,"cells":13509},"Atorvastatin 20mg",{"EARLY_PHASE1":13510,"PHASE1":13512,"PHASE2":13514,"PHASE3":13516,"PHASE4":13518,"NA":13520},{"trials":13511,"activeCount":99},[],{"trials":13513,"activeCount":99},[],{"trials":13515,"activeCount":99},[],{"trials":13517,"activeCount":99},[],{"trials":13519,"activeCount":99},[],{"trials":13521,"activeCount":99},[13522],{"nctId":13523,"briefTitle":13524,"status":109,"phases":13525,"primaryCompletion":13526,"completion":13526,"start":13527,"enrollment":2337,"conditions":13528,"interventions":13529},"NCT03966859","7-day Atorvastatin and Emotional Processing",[92],"2020-02-01","2019-06-19",[24],[13508],{"intervention":13531,"totalTrials":151,"cells":13532},"Mosquito bites",{"EARLY_PHASE1":13533,"PHASE1":13535,"PHASE2":13537,"PHASE3":13539,"PHASE4":13541,"NA":13543},{"trials":13534,"activeCount":99},[],{"trials":13536,"activeCount":99},[],{"trials":13538,"activeCount":99},[],{"trials":13540,"activeCount":99},[],{"trials":13542,"activeCount":99},[],{"trials":13544,"activeCount":99},[13545],{"nctId":13546,"briefTitle":13547,"status":109,"phases":13548,"primaryCompletion":13549,"completion":13549,"start":12267,"enrollment":13550,"conditions":13551,"interventions":13553},"NCT04478370","Characterizing Humoral Immune Response to Mosquito Bites",[92],"2025-07-23",147,[15,13552],"Dengue",[13531],{"intervention":13555,"totalTrials":151,"cells":13556},"Meropenem",{"EARLY_PHASE1":13557,"PHASE1":13559,"PHASE2":13561,"PHASE3":13563,"PHASE4":13565,"NA":13567},{"trials":13558,"activeCount":99},[],{"trials":13560,"activeCount":99},[],{"trials":13562,"activeCount":99},[],{"trials":13564,"activeCount":99},[],{"trials":13566,"activeCount":99},[],{"trials":13568,"activeCount":99},[13569],{"nctId":13570,"briefTitle":13571,"status":2901,"phases":13572,"primaryCompletion":4180,"completion":4180,"start":13573,"enrollment":13574,"conditions":13575,"interventions":13577},"NCT00579956","A Randomized Double Blinded Comparison of Ceftazidime and Meropenem in Severe Melioidosis",[92],"2007-12",750,[13576],"Melioidosis",[13555,13578],"Ceftazidime",{"intervention":13578,"totalTrials":151,"cells":13580},{"EARLY_PHASE1":13581,"PHASE1":13583,"PHASE2":13585,"PHASE3":13587,"PHASE4":13589,"NA":13591},{"trials":13582,"activeCount":99},[],{"trials":13584,"activeCount":99},[],{"trials":13586,"activeCount":99},[],{"trials":13588,"activeCount":99},[],{"trials":13590,"activeCount":99},[],{"trials":13592,"activeCount":99},[13593],{"nctId":13570,"briefTitle":13571,"status":2901,"phases":13594,"primaryCompletion":4180,"completion":4180,"start":13573,"enrollment":13574,"conditions":13595,"interventions":13596},[92],[13576],[13555,13578],{"intervention":13598,"totalTrials":151,"cells":13599},"Bupropion",{"EARLY_PHASE1":13600,"PHASE1":13602,"PHASE2":13604,"PHASE3":13606,"PHASE4":13608,"NA":13610},{"trials":13601,"activeCount":99},[],{"trials":13603,"activeCount":99},[],{"trials":13605,"activeCount":99},[],{"trials":13607,"activeCount":99},[],{"trials":13609,"activeCount":99},[],{"trials":13611,"activeCount":99},[13612],{"nctId":13613,"briefTitle":13614,"status":109,"phases":13615,"primaryCompletion":3654,"completion":3654,"start":11297,"enrollment":799,"conditions":13616,"interventions":13617},"NCT02104128","Effects of Bupropion in Depression",[92],[21],[13598],{"intervention":13619,"totalTrials":151,"cells":13620},"Ivabradine",{"EARLY_PHASE1":13621,"PHASE1":13623,"PHASE2":13625,"PHASE3":13627,"PHASE4":13629,"NA":13631},{"trials":13622,"activeCount":99},[],{"trials":13624,"activeCount":99},[],{"trials":13626,"activeCount":99},[],{"trials":13628,"activeCount":99},[],{"trials":13630,"activeCount":99},[],{"trials":13632,"activeCount":99},[13633],{"nctId":13634,"briefTitle":13635,"status":109,"phases":13636,"primaryCompletion":11297,"completion":11297,"start":9401,"enrollment":13637,"conditions":13638,"interventions":13640},"NCT02354573","The Role of Chronotropic Incompetence in Heart Failure With Normal Ejection Fraction (HFNEF)",[92],121,[13639],"Heart Failure",[13619],{"intervention":13642,"totalTrials":151,"cells":13643},"Losartan",{"EARLY_PHASE1":13644,"PHASE1":13646,"PHASE2":13648,"PHASE3":13650,"PHASE4":13652,"NA":13654},{"trials":13645,"activeCount":99},[],{"trials":13647,"activeCount":99},[],{"trials":13649,"activeCount":99},[],{"trials":13651,"activeCount":99},[],{"trials":13653,"activeCount":99},[],{"trials":13655,"activeCount":99},[13656],{"nctId":13657,"briefTitle":13658,"status":109,"phases":13659,"primaryCompletion":13660,"completion":13660,"start":6960,"enrollment":1699,"conditions":13661,"interventions":13662},"NCT03434054","The Effect of Losartan on Emotional Processing in Healthy Volunteers",[92],"2017-06-30",[10440],[13642],{"intervention":13664,"totalTrials":151,"cells":13665},"Blood-stage controlled human P. falciparum malaria infection",{"EARLY_PHASE1":13666,"PHASE1":13668,"PHASE2":13670,"PHASE3":13672,"PHASE4":13674,"NA":13676},{"trials":13667,"activeCount":99},[],{"trials":13669,"activeCount":99},[],{"trials":13671,"activeCount":99},[],{"trials":13673,"activeCount":99},[],{"trials":13675,"activeCount":99},[],{"trials":13677,"activeCount":99},[13678],{"nctId":13679,"briefTitle":13680,"status":109,"phases":13681,"primaryCompletion":13682,"completion":13682,"start":13683,"enrollment":3379,"conditions":13684,"interventions":13685},"NCT03906474","VAC063C: A Study to Assess Repeat Blood-stage P. Falciparum Infection",[92],"2019-02-14","2018-11-06",[15],[13664],{"intervention":13687,"totalTrials":151,"cells":13688},"Estrogen-bazedoxifene",{"EARLY_PHASE1":13689,"PHASE1":13691,"PHASE2":13693,"PHASE3":13695,"PHASE4":13697,"NA":13699},{"trials":13690,"activeCount":99},[],{"trials":13692,"activeCount":99},[],{"trials":13694,"activeCount":99},[],{"trials":13696,"activeCount":99},[],{"trials":13698,"activeCount":99},[],{"trials":13700,"activeCount":99},[13701],{"nctId":13702,"briefTitle":13703,"status":109,"phases":13704,"primaryCompletion":13705,"completion":13706,"start":12554,"enrollment":3743,"conditions":13707,"interventions":13709},"NCT04036929","Can we Use Estrogen-containing Therapy to Improve Pain in Women After Menopause With Hand Osteoarthritis?",[92],"2021-08-19","2021-12-10",[13708],"Hand Osteoarthritis",[13687],{"intervention":13711,"totalTrials":151,"cells":13712},"artesunate plus sulfadoxine-pyrimethamine",{"EARLY_PHASE1":13713,"PHASE1":13715,"PHASE2":13717,"PHASE3":13719,"PHASE4":13721,"NA":13723},{"trials":13714,"activeCount":99},[],{"trials":13716,"activeCount":99},[],{"trials":13718,"activeCount":99},[],{"trials":13720,"activeCount":99},[],{"trials":13722,"activeCount":99},[],{"trials":13724,"activeCount":99},[13725],{"nctId":13726,"briefTitle":13727,"status":109,"phases":13728,"primaryCompletion":6669,"completion":694,"start":4104,"enrollment":4158,"conditions":13729,"interventions":13730},"NCT01115439","Artesunate+Sulfadoxine-Pyrimethamine for the Treatment of Uncomplicated Falciparum Malaria",[],[3902],[13711],{"intervention":13064,"totalTrials":151,"cells":13732},{"EARLY_PHASE1":13733,"PHASE1":13735,"PHASE2":13737,"PHASE3":13739,"PHASE4":13741,"NA":13743},{"trials":13734,"activeCount":99},[],{"trials":13736,"activeCount":99},[],{"trials":13738,"activeCount":99},[],{"trials":13740,"activeCount":99},[],{"trials":13742,"activeCount":99},[],{"trials":13744,"activeCount":99},[13745],{"nctId":13056,"briefTitle":13057,"status":2901,"phases":13746,"primaryCompletion":13059,"completion":13060,"start":13061,"enrollment":9968,"conditions":13747,"interventions":13748},[92],[3747],[13064,3259,13065,13066],{"intervention":13065,"totalTrials":151,"cells":13750},{"EARLY_PHASE1":13751,"PHASE1":13753,"PHASE2":13755,"PHASE3":13757,"PHASE4":13759,"NA":13761},{"trials":13752,"activeCount":99},[],{"trials":13754,"activeCount":99},[],{"trials":13756,"activeCount":99},[],{"trials":13758,"activeCount":99},[],{"trials":13760,"activeCount":99},[],{"trials":13762,"activeCount":99},[13763],{"nctId":13056,"briefTitle":13057,"status":2901,"phases":13764,"primaryCompletion":13059,"completion":13060,"start":13061,"enrollment":9968,"conditions":13765,"interventions":13766},[92],[3747],[13064,3259,13065,13066],{"intervention":13066,"totalTrials":151,"cells":13768},{"EARLY_PHASE1":13769,"PHASE1":13771,"PHASE2":13773,"PHASE3":13775,"PHASE4":13777,"NA":13779},{"trials":13770,"activeCount":99},[],{"trials":13772,"activeCount":99},[],{"trials":13774,"activeCount":99},[],{"trials":13776,"activeCount":99},[],{"trials":13778,"activeCount":99},[],{"trials":13780,"activeCount":99},[13781],{"nctId":13056,"briefTitle":13057,"status":2901,"phases":13782,"primaryCompletion":13059,"completion":13060,"start":13061,"enrollment":9968,"conditions":13783,"interventions":13784},[92],[3747],[13064,3259,13065,13066],{"intervention":13786,"totalTrials":151,"cells":13787},"Plasmodium falciparum sporozoites 2sites",{"EARLY_PHASE1":13788,"PHASE1":13790,"PHASE2":13792,"PHASE3":13794,"PHASE4":13796,"NA":13798},{"trials":13789,"activeCount":99},[],{"trials":13791,"activeCount":99},[],{"trials":13793,"activeCount":99},[],{"trials":13795,"activeCount":99},[],{"trials":13797,"activeCount":99},[],{"trials":13799,"activeCount":99},[13800],{"nctId":13801,"briefTitle":13802,"status":109,"phases":13803,"primaryCompletion":541,"completion":1434,"start":3378,"enrollment":1511,"conditions":13804,"interventions":13805},"NCT01465048","Optimisation of Controlled Human Malaria Infection Using Sporozoites Administered by Needle and Syringe",[92],[15,1315],[13786,13806,13807],"Plasmodium falciparum sporozoites 1 site","Plasmodium falciparum sporozoites 1site",{"intervention":13806,"totalTrials":151,"cells":13809},{"EARLY_PHASE1":13810,"PHASE1":13812,"PHASE2":13814,"PHASE3":13816,"PHASE4":13818,"NA":13820},{"trials":13811,"activeCount":99},[],{"trials":13813,"activeCount":99},[],{"trials":13815,"activeCount":99},[],{"trials":13817,"activeCount":99},[],{"trials":13819,"activeCount":99},[],{"trials":13821,"activeCount":99},[13822],{"nctId":13801,"briefTitle":13802,"status":109,"phases":13823,"primaryCompletion":541,"completion":1434,"start":3378,"enrollment":1511,"conditions":13824,"interventions":13825},[92],[15,1315],[13786,13806,13807],{"intervention":13807,"totalTrials":151,"cells":13827},{"EARLY_PHASE1":13828,"PHASE1":13830,"PHASE2":13832,"PHASE3":13834,"PHASE4":13836,"NA":13838},{"trials":13829,"activeCount":99},[],{"trials":13831,"activeCount":99},[],{"trials":13833,"activeCount":99},[],{"trials":13835,"activeCount":99},[],{"trials":13837,"activeCount":99},[],{"trials":13839,"activeCount":99},[13840],{"nctId":13801,"briefTitle":13802,"status":109,"phases":13841,"primaryCompletion":541,"completion":1434,"start":3378,"enrollment":1511,"conditions":13842,"interventions":13843},[92],[15,1315],[13786,13806,13807],{"intervention":13845,"totalTrials":151,"cells":13846},"Selegiline Hydrochloride 10 MG",{"EARLY_PHASE1":13847,"PHASE1":13849,"PHASE2":13851,"PHASE3":13853,"PHASE4":13855,"NA":13857},{"trials":13848,"activeCount":99},[],{"trials":13850,"activeCount":99},[],{"trials":13852,"activeCount":99},[],{"trials":13854,"activeCount":99},[],{"trials":13856,"activeCount":99},[],{"trials":13858,"activeCount":99},[13859],{"nctId":13860,"briefTitle":13861,"status":2901,"phases":13862,"primaryCompletion":13863,"completion":13863,"start":13864,"enrollment":6422,"conditions":13865,"interventions":13866},"NCT04130087","Selegiline and Reward Processing",[92],"2020-09-10","2019-09-18",[24],[13845],{"intervention":13868,"totalTrials":151,"cells":13869},"Multiple",{"EARLY_PHASE1":13870,"PHASE1":13872,"PHASE2":13874,"PHASE3":13876,"PHASE4":13878,"NA":13880},{"trials":13871,"activeCount":99},[],{"trials":13873,"activeCount":99},[],{"trials":13875,"activeCount":99},[],{"trials":13877,"activeCount":99},[],{"trials":13879,"activeCount":99},[],{"trials":13881,"activeCount":99},[13882],{"nctId":13883,"briefTitle":13884,"status":183,"phases":13885,"primaryCompletion":13886,"completion":13886,"start":13886,"enrollment":99,"conditions":13887,"interventions":13889},"NCT05140122","LEONIDaS Caregivers Study",[],"2023-10-26",[13888,21,2968],"Dravet Syndrome",[13868],{"intervention":13891,"totalTrials":151,"cells":13892},"Japanese encephalitis (JE) vaccine",{"EARLY_PHASE1":13893,"PHASE1":13895,"PHASE2":13897,"PHASE3":13899,"PHASE4":13901,"NA":13903},{"trials":13894,"activeCount":99},[],{"trials":13896,"activeCount":99},[],{"trials":13898,"activeCount":99},[],{"trials":13900,"activeCount":99},[],{"trials":13902,"activeCount":99},[],{"trials":13904,"activeCount":99},[13905],{"nctId":13906,"briefTitle":13907,"status":2901,"phases":13908,"primaryCompletion":13909,"completion":13910,"start":13911,"enrollment":5423,"conditions":13912,"interventions":13914},"NCT06027801","Iron Fortified Food to Improve Japanese Encephalitis and Typhoid Fever Vaccine Immunogenicity",[92],"2024-09-30","2024-12-30","2023-09-06",[13913],"Iron Deficiency Anemia",[13891,13915],"Typhoid Vi polysaccharide (Vi-PS) vaccine",{"intervention":13915,"totalTrials":151,"cells":13917},{"EARLY_PHASE1":13918,"PHASE1":13920,"PHASE2":13922,"PHASE3":13924,"PHASE4":13926,"NA":13928},{"trials":13919,"activeCount":99},[],{"trials":13921,"activeCount":99},[],{"trials":13923,"activeCount":99},[],{"trials":13925,"activeCount":99},[],{"trials":13927,"activeCount":99},[],{"trials":13929,"activeCount":99},[13930],{"nctId":13906,"briefTitle":13907,"status":2901,"phases":13931,"primaryCompletion":13909,"completion":13910,"start":13911,"enrollment":5423,"conditions":13932,"interventions":13933},[92],[13913],[13891,13915],{"intervention":13935,"totalTrials":151,"cells":13936},"N-acetyl cysteine",{"EARLY_PHASE1":13937,"PHASE1":13939,"PHASE2":13941,"PHASE3":13943,"PHASE4":13945,"NA":13947},{"trials":13938,"activeCount":99},[],{"trials":13940,"activeCount":99},[],{"trials":13942,"activeCount":99},[],{"trials":13944,"activeCount":99},[],{"trials":13946,"activeCount":99},[],{"trials":13948,"activeCount":99},[13949],{"nctId":13950,"briefTitle":13951,"status":109,"phases":13952,"primaryCompletion":10141,"completion":10141,"start":6320,"enrollment":25,"conditions":13953,"interventions":13956},"NCT02794389","Glutathione Levels and Compulsivity",[92],[13954,13955],"Anorexia Nervosa","Compulsive Behavior",[13935],{"intervention":13958,"totalTrials":151,"cells":13959},"P. falciparum infected erythrocytes",{"EARLY_PHASE1":13960,"PHASE1":13962,"PHASE2":13964,"PHASE3":13966,"PHASE4":13968,"NA":13970},{"trials":13961,"activeCount":99},[],{"trials":13963,"activeCount":99},[],{"trials":13965,"activeCount":99},[],{"trials":13967,"activeCount":99},[],{"trials":13969,"activeCount":99},[],{"trials":13971,"activeCount":99},[13972],{"nctId":13973,"briefTitle":13974,"status":109,"phases":13975,"primaryCompletion":6307,"completion":6307,"start":6584,"enrollment":31,"conditions":13976,"interventions":13977},"NCT04788862","A Study of Blood-stage Controlled Human Plasmodium Falciparum Malaria Infection in Tanzania",[92],[15,1315],[13958],{"intervention":13979,"totalTrials":151,"cells":13980},"Reboxetine",{"EARLY_PHASE1":13981,"PHASE1":13983,"PHASE2":13985,"PHASE3":13987,"PHASE4":13989,"NA":13991},{"trials":13982,"activeCount":99},[],{"trials":13984,"activeCount":99},[],{"trials":13986,"activeCount":99},[],{"trials":13988,"activeCount":99},[],{"trials":13990,"activeCount":99},[],{"trials":13992,"activeCount":99},[13993],{"nctId":13994,"briefTitle":13995,"status":109,"phases":13996,"primaryCompletion":13997,"completion":13997,"start":13998,"enrollment":10464,"conditions":13999,"interventions":14000},"NCT03957174","Noradrenaline, Acetylcholine and Dynamic Learning in Healthy Humans",[92],"2020-06-01","2019-06-01",[24],[13979,14001],"Rivastigmine",{"intervention":14001,"totalTrials":151,"cells":14003},{"EARLY_PHASE1":14004,"PHASE1":14006,"PHASE2":14008,"PHASE3":14010,"PHASE4":14012,"NA":14014},{"trials":14005,"activeCount":99},[],{"trials":14007,"activeCount":99},[],{"trials":14009,"activeCount":99},[],{"trials":14011,"activeCount":99},[],{"trials":14013,"activeCount":99},[],{"trials":14015,"activeCount":99},[14016],{"nctId":13994,"briefTitle":13995,"status":109,"phases":14017,"primaryCompletion":13997,"completion":13997,"start":13998,"enrollment":10464,"conditions":14018,"interventions":14019},[92],[24],[13979,14001],{"intervention":14021,"totalTrials":151,"cells":14022},"Salmonella Typhi",{"EARLY_PHASE1":14023,"PHASE1":14025,"PHASE2":14027,"PHASE3":14029,"PHASE4":14031,"NA":14033},{"trials":14024,"activeCount":99},[],{"trials":14026,"activeCount":99},[],{"trials":14028,"activeCount":99},[],{"trials":14030,"activeCount":99},[],{"trials":14032,"activeCount":99},[],{"trials":14034,"activeCount":99},[14035],{"nctId":14036,"briefTitle":14037,"status":109,"phases":14038,"primaryCompletion":14039,"completion":14040,"start":680,"enrollment":14041,"conditions":14042,"interventions":14044},"NCT02192008","Investigating Enteric Fever - Salmonella Typhi and Paratyphi Challenge Study",[92],"2018-09-22","2022-05-26",125,[7011,14043],"Paratyphoid Fever",[14021,14045],"Salmonella Paratyphi",{"intervention":14045,"totalTrials":151,"cells":14047},{"EARLY_PHASE1":14048,"PHASE1":14050,"PHASE2":14052,"PHASE3":14054,"PHASE4":14056,"NA":14058},{"trials":14049,"activeCount":99},[],{"trials":14051,"activeCount":99},[],{"trials":14053,"activeCount":99},[],{"trials":14055,"activeCount":99},[],{"trials":14057,"activeCount":99},[],{"trials":14059,"activeCount":99},[14060],{"nctId":14036,"briefTitle":14037,"status":109,"phases":14061,"primaryCompletion":14039,"completion":14040,"start":680,"enrollment":14041,"conditions":14062,"interventions":14063},[92],[7011,14043],[14021,14045],{"intervention":14065,"totalTrials":151,"cells":14066},"Seasonal Flu vaccine",{"EARLY_PHASE1":14067,"PHASE1":14069,"PHASE2":14071,"PHASE3":14073,"PHASE4":14075,"NA":14077},{"trials":14068,"activeCount":99},[],{"trials":14070,"activeCount":99},[],{"trials":14072,"activeCount":99},[],{"trials":14074,"activeCount":99},[],{"trials":14076,"activeCount":99},[],{"trials":14078,"activeCount":99},[14079],{"nctId":14080,"briefTitle":14081,"status":109,"phases":14082,"primaryCompletion":4155,"completion":4155,"start":2987,"enrollment":14083,"conditions":14084,"interventions":14085},"NCT01239537","Swine Flu (Influenza A H1N1) Follow on Vaccine Study",[],560,[30],[14065],{"intervention":14087,"totalTrials":151,"cells":14088},"Pramipexole",{"EARLY_PHASE1":14089,"PHASE1":14091,"PHASE2":14093,"PHASE3":14095,"PHASE4":14097,"NA":14099},{"trials":14090,"activeCount":99},[],{"trials":14092,"activeCount":99},[],{"trials":14094,"activeCount":99},[],{"trials":14096,"activeCount":99},[],{"trials":14098,"activeCount":99},[],{"trials":14100,"activeCount":99},[14101],{"nctId":14102,"briefTitle":14103,"status":109,"phases":14104,"primaryCompletion":14105,"completion":14105,"start":14106,"enrollment":6670,"conditions":14107,"interventions":14112},"NCT03681509","Pramipexole and Emotional Processing",[92],"2019-11-01","2018-09-01",[14108,14109,14110,14111],"Emotions","Motivation","Reward","Dopamine",[14087],{"intervention":14114,"totalTrials":151,"cells":14115},"Niaspan",{"EARLY_PHASE1":14116,"PHASE1":14118,"PHASE2":14120,"PHASE3":14122,"PHASE4":14124,"NA":14126},{"trials":14117,"activeCount":99},[],{"trials":14119,"activeCount":99},[],{"trials":14121,"activeCount":99},[],{"trials":14123,"activeCount":99},[],{"trials":14125,"activeCount":99},[],{"trials":14127,"activeCount":99},[14128],{"nctId":14129,"briefTitle":14130,"status":2901,"phases":14131,"completion":3580,"start":14132,"enrollment":2657,"conditions":14133,"interventions":14135},"NCT00232531","Oxford Niaspan Study: Effects of Niaspan on Atherosclerosis and Endothelial Function",[92],"2004-09",[14134],"Atherosclerosis",[14114],{"intervention":14137,"totalTrials":151,"cells":14138},"Lithium",{"EARLY_PHASE1":14139,"PHASE1":14141,"PHASE2":14143,"PHASE3":14145,"PHASE4":14147,"NA":14149},{"trials":14140,"activeCount":99},[],{"trials":14142,"activeCount":99},[],{"trials":14144,"activeCount":99},[],{"trials":14146,"activeCount":99},[],{"trials":14148,"activeCount":99},[],{"trials":14150,"activeCount":99},[14151],{"nctId":14152,"briefTitle":14153,"status":109,"phases":14154,"primaryCompletion":14155,"completion":14155,"start":14156,"enrollment":6019,"conditions":14157,"interventions":14158},"NCT03965247","Lithium Effects on Reward Processing and Reappraisal in Healthy Volunteers",[92],"2012-09-04","2011-10-31",[24],[14137],{"intervention":14160,"totalTrials":151,"cells":14161},"Lamotrigine",{"EARLY_PHASE1":14162,"PHASE1":14164,"PHASE2":14166,"PHASE3":14168,"PHASE4":14170,"NA":14172},{"trials":14163,"activeCount":99},[],{"trials":14165,"activeCount":99},[],{"trials":14167,"activeCount":99},[],{"trials":14169,"activeCount":99},[],{"trials":14171,"activeCount":99},[],{"trials":14173,"activeCount":99},[14174],{"nctId":14175,"briefTitle":14176,"status":109,"phases":14177,"primaryCompletion":14178,"completion":14179,"start":14180,"enrollment":1848,"conditions":14181,"interventions":14182},"NCT04396938","The Effect of a Single Dose of Lamotrigine on Brain Function in Healthy Volunteers",[92],"2018-11-29","2019-08-30","2017-05-10",[24],[14160,14183],"Placebos",{"intervention":14183,"totalTrials":151,"cells":14185},{"EARLY_PHASE1":14186,"PHASE1":14188,"PHASE2":14190,"PHASE3":14192,"PHASE4":14194,"NA":14196},{"trials":14187,"activeCount":99},[],{"trials":14189,"activeCount":99},[],{"trials":14191,"activeCount":99},[],{"trials":14193,"activeCount":99},[],{"trials":14195,"activeCount":99},[],{"trials":14197,"activeCount":99},[14198],{"nctId":14175,"briefTitle":14176,"status":109,"phases":14199,"primaryCompletion":14178,"completion":14179,"start":14180,"enrollment":1848,"conditions":14200,"interventions":14201},[92],[24],[14160,14183],{"intervention":12954,"totalTrials":151,"cells":14203},{"EARLY_PHASE1":14204,"PHASE1":14206,"PHASE2":14208,"PHASE3":14210,"PHASE4":14212,"NA":14214},{"trials":14205,"activeCount":99},[],{"trials":14207,"activeCount":99},[],{"trials":14209,"activeCount":99},[],{"trials":14211,"activeCount":99},[],{"trials":14213,"activeCount":99},[],{"trials":14215,"activeCount":99},[14216],{"nctId":12946,"briefTitle":12947,"status":109,"phases":14217,"primaryCompletion":12949,"completion":12950,"start":12951,"enrollment":368,"conditions":14218,"interventions":14219},[92],[15],[4567,12954],{"intervention":12623,"totalTrials":151,"cells":14221},{"EARLY_PHASE1":14222,"PHASE1":14224,"PHASE2":14226,"PHASE3":14228,"PHASE4":14230,"NA":14232},{"trials":14223,"activeCount":99},[],{"trials":14225,"activeCount":99},[],{"trials":14227,"activeCount":99},[],{"trials":14229,"activeCount":99},[],{"trials":14231,"activeCount":99},[],{"trials":14233,"activeCount":99},[14234],{"nctId":12616,"briefTitle":12617,"status":795,"phases":14235,"primaryCompletion":10140,"completion":12619,"start":3604,"enrollment":2803,"conditions":14236,"interventions":14237},[92],[12621],[12623,545],{"intervention":12691,"totalTrials":151,"cells":14239},{"EARLY_PHASE1":14240,"PHASE1":14242,"PHASE2":14244,"PHASE3":14246,"PHASE4":14248,"NA":14250},{"trials":14241,"activeCount":99},[],{"trials":14243,"activeCount":99},[],{"trials":14245,"activeCount":99},[],{"trials":14247,"activeCount":99},[],{"trials":14249,"activeCount":99},[],{"trials":14251,"activeCount":99},[14252],{"nctId":12685,"briefTitle":12686,"status":109,"phases":14253,"primaryCompletion":6126,"completion":6126,"start":12688,"enrollment":1530,"conditions":14254,"interventions":14255},[92],[3902],[533,12691],{"intervention":14257,"totalTrials":151,"cells":14258},"Intravenous Methylene blue",{"EARLY_PHASE1":14259,"PHASE1":14261,"PHASE2":14263,"PHASE3":14265,"PHASE4":14267,"NA":14269},{"trials":14260,"activeCount":99},[],{"trials":14262,"activeCount":99},[],{"trials":14264,"activeCount":99},[],{"trials":14266,"activeCount":99},[],{"trials":14268,"activeCount":99},[],{"trials":14270,"activeCount":99},[14271],{"nctId":14272,"briefTitle":14273,"status":2901,"phases":14274,"primaryCompletion":14275,"completion":14275,"start":14276,"enrollment":1530,"conditions":14277,"interventions":14279},"NCT03386201","FLuorescence Cholangiography Using Methylene Blue",[92],"2018-06-01","2018-01-01",[14278],"Bile Duct Injury",[14257],{"intervention":14281,"totalTrials":151,"cells":14282},"Salmonella Typhi challenge",{"EARLY_PHASE1":14283,"PHASE1":14285,"PHASE2":14287,"PHASE3":14289,"PHASE4":14291,"NA":14293},{"trials":14284,"activeCount":99},[],{"trials":14286,"activeCount":99},[],{"trials":14288,"activeCount":99},[],{"trials":14290,"activeCount":99},[],{"trials":14292,"activeCount":99},[],{"trials":14294,"activeCount":99},[14295],{"nctId":14296,"briefTitle":14297,"status":109,"phases":14298,"primaryCompletion":9325,"completion":9325,"start":14299,"enrollment":3379,"conditions":14300,"interventions":14302},"NCT03889067","Understanding How Salmonella Typhi Infects Humans (Bottlenecks)",[92],"2019-05-30",[14301],"Salmonella Typhi Infection",[14281],{"intervention":14304,"totalTrials":151,"cells":14305},"Minocycline",{"EARLY_PHASE1":14306,"PHASE1":14308,"PHASE2":14310,"PHASE3":14312,"PHASE4":14314,"NA":14316},{"trials":14307,"activeCount":99},[],{"trials":14309,"activeCount":99},[],{"trials":14311,"activeCount":99},[],{"trials":14313,"activeCount":99},[],{"trials":14315,"activeCount":99},[],{"trials":14317,"activeCount":99},[14318],{"nctId":14319,"briefTitle":14320,"status":109,"phases":14321,"primaryCompletion":14322,"completion":14322,"start":14323,"enrollment":1530,"conditions":14324,"interventions":14325},"NCT03768557","The Effect of Acute Minocycline Administration on Emotional Processing and Cognition in Healthy Volunteers",[92],"2018-10-25","2017-04-26",[2805,13397],[14304],{"intervention":14327,"totalTrials":151,"cells":14328},"EmbryoGlue®",{"EARLY_PHASE1":14329,"PHASE1":14331,"PHASE2":14333,"PHASE3":14335,"PHASE4":14337,"NA":14339},{"trials":14330,"activeCount":99},[],{"trials":14332,"activeCount":99},[],{"trials":14334,"activeCount":99},[],{"trials":14336,"activeCount":99},[],{"trials":14338,"activeCount":99},[],{"trials":14340,"activeCount":99},[14341],{"nctId":14342,"briefTitle":14343,"status":2901,"phases":14344,"primaryCompletion":14345,"completion":14345,"start":14346,"enrollment":1459,"conditions":14347,"interventions":14348},"NCT03332680","EmbryoGlue as an Embryo Transfer Medium",[92],"2019-11-30","2017-06-16",[3719],[14327,14349],"Standard control medium",{"intervention":14349,"totalTrials":151,"cells":14351},{"EARLY_PHASE1":14352,"PHASE1":14354,"PHASE2":14356,"PHASE3":14358,"PHASE4":14360,"NA":14362},{"trials":14353,"activeCount":99},[],{"trials":14355,"activeCount":99},[],{"trials":14357,"activeCount":99},[],{"trials":14359,"activeCount":99},[],{"trials":14361,"activeCount":99},[],{"trials":14363,"activeCount":99},[14364],{"nctId":14342,"briefTitle":14343,"status":2901,"phases":14365,"primaryCompletion":14345,"completion":14345,"start":14346,"enrollment":1459,"conditions":14366,"interventions":14367},[92],[3719],[14327,14349],{"intervention":14369,"totalTrials":151,"cells":14370},"Caffeine",{"EARLY_PHASE1":14371,"PHASE1":14373,"PHASE2":14375,"PHASE3":14377,"PHASE4":14379,"NA":14381},{"trials":14372,"activeCount":99},[],{"trials":14374,"activeCount":99},[],{"trials":14376,"activeCount":99},[],{"trials":14378,"activeCount":99},[],{"trials":14380,"activeCount":99},[],{"trials":14382,"activeCount":99},[14383],{"nctId":14384,"briefTitle":14385,"status":2901,"phases":14386,"primaryCompletion":14387,"completion":14387,"start":14388,"enrollment":1699,"conditions":14389,"interventions":14391},"NCT06416956","Baby-CINO: CaffeINe Treatment Optimisation in Premature Infants",[],"2024-09-01","2023-12-11",[14390,14369],"Infant,Premature",[14369],{"intervention":14393,"totalTrials":151,"cells":14394},"Pitolisant 17.8 MG [Wakix]",{"EARLY_PHASE1":14395,"PHASE1":14397,"PHASE2":14399,"PHASE3":14401,"PHASE4":14403,"NA":14405},{"trials":14396,"activeCount":99},[],{"trials":14398,"activeCount":99},[],{"trials":14400,"activeCount":99},[],{"trials":14402,"activeCount":99},[],{"trials":14404,"activeCount":99},[],{"trials":14406,"activeCount":99},[14407],{"nctId":14408,"briefTitle":14409,"status":109,"phases":14410,"primaryCompletion":14411,"completion":14412,"start":14413,"enrollment":2314,"conditions":14414,"interventions":14415},"NCT05849675","Pitolisant Effects on Affect and Cognition Exploratory Study (PEACE Study)",[92],"2024-02-18","2024-05-08","2023-04-01",[8081,4299],[14393],{"intervention":14417,"totalTrials":151,"cells":14418},"Engerix B®, a recombinant hepatitis B vaccine",{"EARLY_PHASE1":14419,"PHASE1":14421,"PHASE2":14423,"PHASE3":14425,"PHASE4":14427,"NA":14429},{"trials":14420,"activeCount":99},[],{"trials":14422,"activeCount":99},[],{"trials":14424,"activeCount":99},[],{"trials":14426,"activeCount":99},[],{"trials":14428,"activeCount":99},[],{"trials":14430,"activeCount":99},[14431],{"nctId":14432,"briefTitle":14433,"status":109,"phases":14434,"primaryCompletion":3942,"completion":3942,"start":3580,"enrollment":3743,"conditions":14435,"interventions":14436},"NCT00873652","Observational Study of Immune Response to Hepatitis B Childhood Booster",[],[24],[14417],{"intervention":13014,"totalTrials":151,"cells":14438},{"EARLY_PHASE1":14439,"PHASE1":14441,"PHASE2":14443,"PHASE3":14445,"PHASE4":14447,"NA":14449},{"trials":14440,"activeCount":99},[],{"trials":14442,"activeCount":99},[],{"trials":14444,"activeCount":99},[],{"trials":14446,"activeCount":99},[],{"trials":14448,"activeCount":99},[],{"trials":14450,"activeCount":99},[14451],{"nctId":13009,"briefTitle":13010,"status":109,"phases":14452,"primaryCompletion":588,"completion":588,"start":6667,"enrollment":1848,"conditions":14453,"interventions":14454},[92],[18],[12987,13014]]